[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fEXGvNAL2LSOOEg5-XgEc8EgKZwh9Q10rQndE0HxVVUQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":87,"rows":94},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",[4],577,false,110,8,36336,109,137,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Prostate Cancer",56,{"name":18,"count":19},"Breast Cancer",43,{"name":21,"count":22},"Pancreatic Cancer",37,{"name":24,"count":25},"Brain and Central Nervous System Tumors",36,{"name":27,"count":28},"Leukemia",35,{"name":30,"count":31},"Lymphoma",28,{"name":33,"count":34},"Myelodysplastic Syndromes",19,{"name":36,"count":37},"Head and Neck Cancer",16,[39,44,49,54,59,64,69,74,78,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT00616967","Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer","2014-06","carboplatin",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT01937117","Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer","2018-03-20","Trastuzumab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT02923180","Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer","2020-08-11","Enoblituzumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT04386746","Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer","2022-10-04","Gemcitabine",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT02259621","Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC","2022-10-14","Nivolumab",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT03961971","Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM","2022-11-16","MBG453",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT03047135","Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis","2023-05-24","Olaparib",{"nctId":75,"briefTitle":76,"date":77,"intervention":63},"NCT02989636","Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma","2024-04-24",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT01088789","Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer","2024-07-17","Cyclophosphamide",{"nctId":84,"briefTitle":85,"date":86,"intervention":63},"NCT04658147","Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)","2025-09-02",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,507,611,1289,1424,1542,1616,1654,1718,1817,1915,1991,2096,2163,2193,2238,2264,2461,2545,2607,2659,2731,2767,2801,2823,2845,2875,2902,2953,3027,3135,3183,3243,3293,3326,3352,3378,3404,3426,3444,3467,3493,3511,3529,3547,3565,3589,3607,3625,3643,3661,3679,3704,3722,3740,3758,3776,3794,3819,3837,3871,3889,3907,3925,3943,3968,3986,4004,4022,4040,4058,4082,4100,4118,4136,4154,4172,4190,4208,4253,4328,4356,4394,4416,4446,4469,4487,4512,4530,4556,4574,4599,4623,4641,4659,4679,4702,4726,4751,4769,4794,4812,4838,4864,4888,4943,4961,4984,5002,5030,5076,5105,5140,5167,5189,5207,5229,5247,5265,5289,5307,5325,5420,5493,5572,5610,5652,5685,5720,5750,5787,5817,5847,5887,5932,5980,6006,6041,6084,6121,6147,6173,6203,6229,6263,6300,6330,6361,6387,6428,6461,6487,6523,6545,6569,6591,6617,6654,6678,6709,6731,6757,6782,6804,6826,6852,6876,6898,6920,6942,6964,6986,7008,7030,7062,7094,7116,7148,7176,7198,7224,7246,7268,7290,7319,7341,7363,7385,7407,7441,7459,7477,7495,7513,7537,7555,7573,7597,7615,7641,7659,7682,7708,7730,7754,7786,7804,7822,7840,7858,7882,7900,7918,7936,7954,7976,7994,8020,8042,8060,8083,8101,8119,8148,8166,8184,8202,8220,8242,8265,8283,8306,8331,8349,8367,8385,8403,8421,8439,8457,8475,8498,8519,8537,8555,8580,8605,8623,8645,8663,8681,8699,8717,8741,8759,8781,8802,8827,8853,8871,8889,8907,8925,8949,8970,8988,9012,9030,9048,9066,9090,9108,9132,9150,9168,9186,9211,9229,9247,9265,9288,9306,9324,9342,9360,9378,9402,9426,9444,9462,9484,9509,9532,9550,9568,9586,9604,9622,9645,9663,9685,9703,9728,9749,9767,9785,9803,9826,9844,9862,9880,9902,9925,9943,9961,9979,10001,10019,10045,10075,10100,10122,10153,10190,10208,10233,10251,10269,10287,10312,10330,10354,10372,10394,10418,10436,10454,10472,10490,10508,10526,10544,10562,10586,10608,10632,10656,10674,10692,10710,10728,10746,10770,10788,10810,10834,10852,10877,10902,10920,10944,10962,10984,11007,11025,11043,11061,11079,11101,11126,11148,11172,11190,11215,11238,11261,11279,11297,11320,11338,11356,11379,11405,11423,11441,11464,11493,11511,11529,11547,11565,11583,11601,11626,11644,11662,11680,11698,11724,11752,11775,11793,11811,11834,11860,11878,11900,11918,11942,11968,11986,12007,12032,12056,12077,12099,12122,12143,12164,12186,12204,12239,12270,12299,12329,12355,12382,12404,12422,12445,12467,12485,12503,12524,12542,12564,12587,12611,12634,12652,12674,12692,12713,12735,12759,12777,12795],{"intervention":63,"totalTrials":96,"cells":97},34,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":232,"PHASE3":501,"PHASE4":503,"NA":505},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":231,"soonestReadout":77},[103,112,124,136,149,161,177,186,194,206,216],{"nctId":75,"briefTitle":76,"status":104,"phases":105,"primaryCompletion":77,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":111},"ACTIVE_NOT_RECRUITING",[89],"2026-11","2017-03-10",21,[110],"Chordoma",[63],{"nctId":113,"briefTitle":114,"status":104,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":121},"NCT04117087","Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer",[89],"2027-06-01","2020-05-28",27,[120,21],"Colorectal Cancer",[122,63,123],"KRAS peptide vaccine","Ipilimumab",{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":16,"conditions":132,"interventions":134},"NCT04248569","DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma","RECRUITING",[89],"2029-03-01","2034-03-01","2020-04-20",[133],"Fibrolamellar Hepatocellular Carcinoma (FLC)",[135,63,123],"DNAJB1-PRKACA peptide vaccine",{"nctId":137,"briefTitle":138,"status":139,"phases":140,"primaryCompletion":141,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":148},"NCT02716948","SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine","COMPLETED",[89],"2021-08-27","2016-06-23",17,[145,146,147],"Metastatic Malignant Neoplasm in the Brain","Metastatic Malignant Neoplasm in the Spine","Stage IV Skin Melanoma",[63],{"nctId":150,"briefTitle":151,"status":139,"phases":152,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},"NCT03299946","Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)",[89],"2019-12-09","2021-10-01","2018-05-14",15,[158],"Locally Advanced Hepatocellular Carcinoma",[160,63],"Cabozantinib",{"nctId":162,"briefTitle":163,"status":104,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":173},"NCT03044613","Nivolumab +\u002F- Relatlimab Prior to Chemoradiation With II\u002FIII Gastro\u002FEsophageal Cancer",[89],"2027-03","2027-08","2017-07-11",32,[170,171,172],"Gastric Cancer","Esophageal Cancer","GastroEsophageal Cancer",[63,174,175,176],"Relatlimab","Carboplatin","Paclitaxel",{"nctId":178,"briefTitle":179,"status":139,"phases":180,"primaryCompletion":181,"completion":181,"start":182,"enrollment":143,"conditions":183,"interventions":185},"NCT02575222","Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma",[89],"2020-06-09","2016-02",[184],"Clear Cell Renal Cell Carcinoma",[63],{"nctId":84,"briefTitle":85,"status":104,"phases":187,"primaryCompletion":86,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},[89],"2030-06-01","2021-05-28",31,[192],"Hepatocellular Carcinoma",[63,174],{"nctId":195,"briefTitle":196,"status":197,"phases":198,"primaryCompletion":199,"completion":199,"start":200,"enrollment":118,"conditions":201,"interventions":203},"NCT07430202","A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","NOT_YET_RECRUITING",[89],"2030-08","2026-08",[202],"Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))",[204,205,63,123],"DNAJB1-PRKACA Peptide Vaccine","DRP-104",{"nctId":207,"briefTitle":208,"status":139,"phases":209,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":215},"NCT04465643","Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor",[89],"2025-07-30","2021-06-08",13,[214],"Nerve Sheath Tumors",[63,123],{"nctId":217,"briefTitle":218,"status":219,"phases":220,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":228},"NCT03707457","Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma","TERMINATED",[89],"2019-11-30","2020-06-18","2019-03-22",3,[226,227],"Glioblastoma","Glioblastoma Multiforme",[63,229,230,123],"Anti-GITR Monoclonal Antibody MK-4166","IDO1 inhibitor INCB024360",6,{"trials":233,"activeCount":361,"soonestReadout":62},[234,247,259,271,284,295,306,317,331,345,355,366,377,389,399,413,424,433,445,458,470,476,487],{"nctId":235,"briefTitle":236,"status":139,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":245},"NCT03554317","COMbination of Bipolar Androgen Therapy and Nivolumab",[90],"2022-10-27","2023-01-06","2018-09-05",45,[243,244,15],"Castration-resistant Prostate Cancer","Metastatic Prostate Cancer",[246,63],"Testosterone cypionate",{"nctId":248,"briefTitle":249,"status":139,"phases":250,"primaryCompletion":251,"completion":252,"start":253,"enrollment":168,"conditions":254,"interventions":257},"NCT02601014","Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7",[90],"2020-12-03","2021-10-06","2016-03-15",[15,255,256],"Recurrent Prostate Carcinoma","Stage IV Prostate Adenocarcinoma",[123,63,258],"Enzalutamide",{"nctId":260,"briefTitle":261,"status":104,"phases":262,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":269},"NCT04848116","Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca",[90],"2027-04","2030-11","2021-04-24",24,[268],"Head and Neck Squamous Cell Carcinoma",[63,270],"HuMax-IL8",{"nctId":272,"briefTitle":273,"status":127,"phases":274,"primaryCompletion":275,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":283},"NCT03465592","Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma",[89,90],"2027-01","2029-03","2018-05-01",39,[280,281,282],"Sarcoma","Solid Tumor, Adult","Solid Tumor, Childhood",[63],{"nctId":285,"briefTitle":286,"status":104,"phases":287,"primaryCompletion":288,"completion":289,"start":290,"enrollment":108,"conditions":291,"interventions":294},"NCT03610711","REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer",[89,90],"2026-12","2027-12","2019-03-06",[292,293],"Gastroesophageal Cancer","Immune Checkpoint Inhibition",[63,174],{"nctId":296,"briefTitle":297,"status":104,"phases":298,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":305},"NCT03607890","Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor",[90],"2026-10","2018-11-16",38,[303,304],"Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy","MSI-H Tumors",[63,174,63,174,63,174],{"nctId":307,"briefTitle":308,"status":104,"phases":309,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":316},"NCT03918252","Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma",[90],"2026-06","2027-06","2019-10-02",30,[315],"Mesothelioma",[63,123],{"nctId":318,"briefTitle":319,"status":139,"phases":320,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":327},"NCT01928576","Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.",[90],"2023-04-04","2013-11-06",143,[325,326],"Non-Small Cell Lung Cancer","Epigenetic Therapy",[328,329,63,330],"Azacitidine","Entinostat","CC-486 300",{"nctId":332,"briefTitle":333,"status":139,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":340},"NCT02243371","GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab",[90],"2017-07-21","2015-01-02",93,[339],"Previously Treated Metastatic Adenocarcinoma of the Pancreas",[341,341,342,343,344],"CRS-207","nivolumab","GVAX","CY",{"nctId":346,"briefTitle":347,"status":139,"phases":348,"primaryCompletion":349,"completion":350,"start":351,"enrollment":9,"conditions":352,"interventions":354},"NCT04019964","Nivolumab in Biochemically Recurrent dMMR Prostate Cancer",[90],"2025-04-23","2025-07-03","2020-01-13",[15,353],"Recurrent Prostate Cancer",[63],{"nctId":356,"briefTitle":357,"status":219,"phases":358,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":365},"NCT03420521","Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors",[90],"2021-11-24","2018-03-09",9,[363,364],"Neuroendocrine Tumors","Carcinoid Tumor",[63,123],{"nctId":367,"briefTitle":368,"status":139,"phases":369,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":375},"NCT03190265","Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer",[90],"2022-08-03","2023-08-23","2017-12-14",61,[21],[82,63,123,376,341,341],"GVAX Pancreas Vaccine",{"nctId":378,"briefTitle":379,"status":139,"phases":380,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":388},"NCT03642067","Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer",[90],"2024-02-23","2024-09-18","2019-02-12",59,[386,387],"Microsatellite Stable (MSS) Colorectal Adenocarcinomas","Colorectal Adenocarcinoma",[63,174],{"nctId":390,"briefTitle":391,"status":219,"phases":392,"primaryCompletion":393,"completion":394,"start":395,"enrollment":231,"conditions":396,"interventions":398},"NCT02864316","Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure",[90],"2018-08","2018-09","2016-12",[397],"Solid Tumors Induced by Prior Radiation Exposure",[63],{"nctId":400,"briefTitle":401,"status":127,"phases":402,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":406,"interventions":407},"NCT06941857","NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer",[90],"2028-12","2025-09-04",20,[21],[408,409,410,411,412,63,123],"Oxaliplatin","Irinotecan","Folinic Acid","5-Fluorouracil","NC410",{"nctId":414,"briefTitle":415,"status":416,"phases":417,"primaryCompletion":418,"completion":418,"start":419,"enrollment":100,"conditions":420,"interventions":422},"NCT03768531","Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer","WITHDRAWN",[90],"2023-01","2019-06-14",[421],"Resectable Biliary Tract Cancer",[63,423],"Cabrilizumab",{"nctId":425,"briefTitle":426,"status":139,"phases":427,"primaryCompletion":428,"completion":429,"start":430,"enrollment":190,"conditions":431,"interventions":432},"NCT03161379","GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer",[90],"2024-02-20","2024-02-28","2018-02-02",[21],[82,63,376],{"nctId":434,"briefTitle":435,"status":139,"phases":436,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":443},"NCT03767582","Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.",[89,90],"2025-02-01","2019-12-12",22,[441,442],"Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Ductal Adenocarcinoma",[63,444,343],"CCR2\u002FCCR5 dual antagonist",{"nctId":446,"briefTitle":447,"status":139,"phases":448,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":456},"NCT03711058","Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed\u002FRefractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer",[89,90],"2022-06-14","2025-06-30","2019-01-17",48,[454,455],"Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor","Microsatellite Stable (MSS) Colon Cancer",[457,63],"Copanlisib",{"nctId":459,"briefTitle":460,"status":104,"phases":461,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":466},"NCT02451982","Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas",[90],"2026-09-30","2016-03-28",76,[21],[82,467,63,468,469],"GVAX pancreatic cancer","Urelumab","BMS-986253",{"nctId":60,"briefTitle":61,"status":104,"phases":471,"primaryCompletion":62,"completion":472,"start":473,"enrollment":278,"conditions":474,"interventions":475},[90],"2027-10","2014-09",[325],[63,175,176,123],{"nctId":477,"briefTitle":478,"status":127,"phases":479,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":484,"interventions":486},"NCT03521830","Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma",[90],"2027-07","2032-07","2018-11-27",57,[485],"Basal Cell Carcinoma",[63,123,174],{"nctId":488,"briefTitle":489,"status":139,"phases":490,"primaryCompletion":491,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":500},"NCT03250273","A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma",[90],"2020-11-20","2017-11-06",44,[495,496,21,497,498,499],"Metastatic Cholangiocarcinoma","Cholangiocarcinoma","Metastatic Pancreatic Cancer","Unresectable Pancreatic Cancer","Unresectable Cholangiocarcinoma",[329,63,329,63],{"trials":502,"activeCount":100},[],{"trials":504,"activeCount":100},[],{"trials":506,"activeCount":100},[],{"intervention":123,"totalTrials":37,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":552,"PHASE3":605,"PHASE4":607,"NA":609},{"trials":510,"activeCount":100},[],{"trials":512,"activeCount":224,"soonestReadout":116},[513,522,526,530,540,544,548],{"nctId":514,"briefTitle":515,"status":139,"phases":516,"primaryCompletion":517,"completion":517,"start":518,"enrollment":313,"conditions":519,"interventions":520},"NCT00836407","Ipilimumab +\u002F- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer",[89],"2012-07","2009-02",[21],[123,521],"Pancreatic Cancer Vaccine",{"nctId":113,"briefTitle":114,"status":104,"phases":523,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":524,"interventions":525},[89],[120,21],[122,63,123],{"nctId":125,"briefTitle":126,"status":127,"phases":527,"primaryCompletion":129,"completion":130,"start":131,"enrollment":16,"conditions":528,"interventions":529},[89],[133],[135,63,123],{"nctId":531,"briefTitle":532,"status":219,"phases":533,"primaryCompletion":534,"start":535,"enrollment":536,"conditions":537,"interventions":539},"NCT01950195","SRS (Stereotactic Radiosurgery) Plus Ipilimumab",[89],"2016-09","2013-09",4,[538],"Newly Diagnosed Melanoma Metastases in the Brain and Spine",[123],{"nctId":195,"briefTitle":196,"status":197,"phases":541,"primaryCompletion":199,"completion":199,"start":200,"enrollment":118,"conditions":542,"interventions":543},[89],[202],[204,205,63,123],{"nctId":207,"briefTitle":208,"status":139,"phases":545,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":546,"interventions":547},[89],[214],[63,123],{"nctId":217,"briefTitle":218,"status":219,"phases":549,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":550,"interventions":551},[89],[226,227],[63,229,230,123],{"trials":553,"activeCount":536,"soonestReadout":62},[554,558,570,581,585,589,593,597,601],{"nctId":248,"briefTitle":249,"status":139,"phases":555,"primaryCompletion":251,"completion":252,"start":253,"enrollment":168,"conditions":556,"interventions":557},[90],[15,255,256],[123,63,258],{"nctId":559,"briefTitle":560,"status":139,"phases":561,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":567},"NCT01896869","FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer",[90],"2019-05-03","2013-11",83,[566],"Metastatic Pancreatic Adenocarcinoma",[123,568,569],"Vaccine","FOLFIRINOX",{"nctId":571,"briefTitle":572,"status":139,"phases":573,"primaryCompletion":574,"completion":575,"start":576,"enrollment":143,"conditions":577,"interventions":578},"NCT05014776","Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer",[90],"2024-04-03","2025-06-19","2022-08-22",[21],[579,580,123,341],"Tadalafil","Pembrolizumab",{"nctId":307,"briefTitle":308,"status":104,"phases":582,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":583,"interventions":584},[90],[315],[63,123],{"nctId":356,"briefTitle":357,"status":219,"phases":586,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":587,"interventions":588},[90],[363,364],[63,123],{"nctId":367,"briefTitle":368,"status":139,"phases":590,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":591,"interventions":592},[90],[21],[82,63,123,376,341,341],{"nctId":400,"briefTitle":401,"status":127,"phases":594,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":595,"interventions":596},[90],[21],[408,409,410,411,412,63,123],{"nctId":60,"briefTitle":61,"status":104,"phases":598,"primaryCompletion":62,"completion":472,"start":473,"enrollment":278,"conditions":599,"interventions":600},[90],[325],[63,175,176,123],{"nctId":477,"briefTitle":478,"status":127,"phases":602,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":603,"interventions":604},[90],[485],[63,123,174],{"trials":606,"activeCount":100},[],{"trials":608,"activeCount":100},[],{"trials":610,"activeCount":100},[],{"intervention":82,"totalTrials":612,"cells":613},62,{"EARLY_PHASE1":614,"PHASE1":651,"PHASE2":821,"PHASE3":1272,"PHASE4":1285,"NA":1287},{"trials":615,"activeCount":100},[616,627,640],{"nctId":617,"briefTitle":618,"status":139,"phases":619,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":624,"interventions":625},"NCT03153410","Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas",[88],"2022-03-09","2023-08-29","2018-09-27",11,[21],[82,376,580,626],"IMC-CS4",{"nctId":628,"briefTitle":629,"status":219,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":231,"conditions":633,"interventions":635},"NCT02212574","Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma",[88],"2018-11-09","2017-04-04",[634],"Medulloblastoma",[636,637,638,82,639,637],"Lomustine","Vincristine","Cisplatin","Mesna",{"nctId":641,"briefTitle":642,"status":219,"phases":643,"primaryCompletion":644,"completion":645,"start":646,"enrollment":34,"conditions":647,"interventions":649},"NCT00499733","Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer",[88],"2010-07","2013-01-09","2007-06",[648],"Cancer",[650],"cyclophosphamide",{"trials":652,"activeCount":100},[653,664,682,694,705,717,727,737,748,759,771,790,798,808],{"nctId":654,"briefTitle":655,"status":139,"phases":656,"primaryCompletion":657,"completion":658,"start":659,"enrollment":361,"conditions":660,"interventions":662},"NCT00656123","Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer",[89],"2011-08","2013-01","2008-03",[120,661],"Metastatic Cancer",[663,650],"Colon GVAX",{"nctId":665,"briefTitle":666,"status":139,"phases":667,"primaryCompletion":668,"completion":668,"start":657,"enrollment":669,"conditions":670,"interventions":675},"NCT01342289","Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide",[89],"2018-03",127,[671,27,672,673,674],"Hodgkin's Lymphoma","Myelodysplastic Syndrome(MDS)","Multiple Myeloma","Non Hodgkin's Lymphoma",[82,676,677,678,679,680,681],"Fludarabine","Mycophenolate Mofetil","Tacrolimus 60","Tacrolimus 90","Tacrolimus 120","Bone marrow transplant",{"nctId":683,"briefTitle":684,"status":219,"phases":685,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":691},"NCT00245115","Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia",[89],"2007-12","2012-01","2005-10",7,[27],[692,693,650],"filgrastim","busulfan",{"nctId":695,"briefTitle":696,"status":139,"phases":697,"primaryCompletion":698,"start":699,"enrollment":700,"conditions":701,"interventions":702},"NCT00093834","Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer",[89],"2008-08","2004-01",60,[18],[703,650,704],"allogeneic GM-CSF-secreting breast cancer vaccine","doxorubicin hydrochloride",{"nctId":706,"briefTitle":707,"status":139,"phases":708,"start":709,"conditions":710,"interventions":712},"NCT00003243","Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer",[89],"1998-01",[27,30,33,711],"Myelodysplastic\u002FMyeloproliferative Diseases",[713,692,714,650,715,716],"aldesleukin","therapeutic allogeneic lymphocytes","etoposide","pegylated liposomal doxorubicin hydrochloride",{"nctId":718,"briefTitle":719,"status":219,"phases":720,"primaryCompletion":721,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":725},"NCT00356928","Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies",[89],"2011-05","2006-10",14,[27,33],[82,726],"Donor T cells",{"nctId":728,"briefTitle":729,"status":219,"phases":730,"primaryCompletion":731,"completion":731,"start":732,"enrollment":733,"conditions":734,"interventions":735},"NCT01493154","Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients",[89],"2015-10","2012-04",2,[36],[736,82],"DNA Vaccine",{"nctId":738,"briefTitle":739,"status":139,"phases":740,"primaryCompletion":741,"start":742,"enrollment":743,"conditions":744,"interventions":746},"NCT00293410","Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders",[89],"2010-04","2005-11",70,[745,27,711],"Chronic Myeloproliferative Disorders",[747,650],"clofarabine",{"nctId":749,"briefTitle":750,"status":139,"phases":751,"start":752,"conditions":753,"interventions":755},"NCT00006042","Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",[89],"1999-12",[27,30,754,33,711],"Multiple Myeloma and Plasma Cell Neoplasm",[692,650,756,757,758],"fludarabine phosphate","mycophenolate mofetil","tacrolimus",{"nctId":760,"briefTitle":761,"status":139,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":770},"NCT00002600","Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer",[89],"2001-07-25","1994-10-21",23,[767,768,769],"Fallopian Tube Cancer","Ovarian Cancer","Primary Peritoneal Cavity Cancer",[692,43,650],{"nctId":772,"briefTitle":773,"status":219,"phases":774,"primaryCompletion":775,"completion":775,"start":776,"enrollment":28,"conditions":777,"interventions":788},"NCT00852709","Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias",[89],"2009-11-20","2007-09-01",[778,779,780,781,782,783,784,785,786,787],"Myelodysplastic Syndrome","Acute Myeloid Leukemia","Myeloproliferative Disorders","Acute Lymphocytic Leukemia","Acute Promyelocytic Leukemia","Acute Leukemia","Chronic Myelogenous Leukemia","Myelofibrosis","Chronic Myelomonocytic Leukemia","Juvenile Myelomonocytic Leukemia",[789,82],"Clofarabine",{"nctId":791,"briefTitle":792,"status":139,"phases":793,"start":794,"enrollment":700,"conditions":795,"interventions":797},"NCT00255710","Cyclophosphamide and\u002For Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer",[89],"2002-07",[745,796,27,30,754,33,711],"Graft Versus Host Disease",[692,650,756,757,758],{"nctId":799,"briefTitle":800,"status":139,"phases":801,"primaryCompletion":658,"completion":802,"start":803,"enrollment":108,"conditions":804,"interventions":806},"NCT01435499","Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma",[89],"2016-03","2011-09",[805],"Melanoma",[807,82],"melanoma GVAX",{"nctId":809,"briefTitle":810,"status":139,"phases":811,"primaryCompletion":812,"completion":812,"start":813,"enrollment":108,"conditions":814,"interventions":820},"NCT00007813","Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors",[89],"2005-02-01","1997-05-31",[24,815,816,817,818,768,280,819],"Childhood Germ Cell Tumor","Extragonadal Germ Cell Tumor","Liver Cancer","Neuroblastoma","Testicular Germ Cell Tumor",[692,43,650,715],{"trials":822,"activeCount":231,"soonestReadout":81},[823,833,842,856,875,884,898,907,918,927,934,944,953,965,972,983,994,1015,1025,1037,1046,1057,1064,1072,1081,1092,1103,1115,1125,1137,1149,1163,1167,1179,1187,1196,1204,1208,1220,1230,1239,1248,1252,1265],{"nctId":824,"briefTitle":825,"status":139,"phases":826,"primaryCompletion":827,"completion":827,"start":828,"enrollment":700,"conditions":829,"interventions":830},"NCT00305760","Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer",[90],"2009-03","2005-12",[21],[831,832,82],"Cetuximab","Pancreatic tumor vaccine",{"nctId":834,"briefTitle":835,"status":139,"phases":836,"primaryCompletion":658,"completion":658,"start":742,"enrollment":190,"conditions":837,"interventions":838},"NCT00134082","Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma",[89,90],[30],[839,840,841,82],"KGEL vaccine","Filgrastim","Rituximab",{"nctId":843,"briefTitle":844,"status":139,"phases":845,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":852},"NCT02224872","Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia",[90],"2021-12","2014-08",18,[850,851],"Severe Aplastic Anemia","Bone Marrow Failure Syndromes",[853,676,82,639,854,855],"Thymoglobulin","Tacrolimus","Mycophenolic acid mofetil",{"nctId":857,"briefTitle":858,"status":139,"phases":859,"primaryCompletion":860,"completion":860,"start":861,"enrollment":862,"conditions":863,"interventions":873},"NCT02556931","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",[90],"2021-04","2015-12",117,[778,786,864,865,866,867,745,673,868,869,785,870,871,872],"Small Lymphocytic Lymphoma","Chronic Lymphocytic Leukemia","Prolymphocytic Leukemia","Chronic Myeloid Leukemia","Plasma Cell Neoplasm","Plasma Cell Dyscrasia","Polycythemia Vera","Essential Thrombocythemia","Plasma Cell Leukemia",[676,82,854,874],"Mycophenolate mofetil",{"nctId":876,"briefTitle":877,"status":139,"phases":878,"primaryCompletion":879,"completion":879,"start":880,"enrollment":108,"conditions":881,"interventions":882},"NCT00258206","Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma",[90],"2007-09-07","2004-12",[754],[883,650],"rituximab",{"nctId":885,"briefTitle":886,"status":219,"phases":887,"primaryCompletion":888,"completion":888,"start":889,"enrollment":118,"conditions":890,"interventions":892},"NCT00809341","R-ICE and High-Dose Cyclophosphamide With PET\u002FCT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma",[90],"2014-04","2009-01",[891],"Non-Hodgkin's Lymphoma",[841,82,893,637,894,895,175,896,897],"Doxorubicin","Prednisone","Ifosfamide","Etoposide","High-dose cyclophosphamide",{"nctId":899,"briefTitle":900,"status":416,"phases":901,"primaryCompletion":902,"completion":902,"start":903,"enrollment":100,"conditions":904,"interventions":905},"NCT00343447","Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia",[90],"2007-05","2006-08",[27],[906,883,650],"autologous tumor cell vaccine",{"nctId":908,"briefTitle":909,"status":127,"phases":910,"primaryCompletion":911,"completion":912,"start":913,"enrollment":313,"conditions":914,"interventions":916},"NCT06245889","PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC",[90],"2029-06","2030-06","2024-05-01",[915],"Triple Negative Breast Cancer",[176,175,580,893,82,73,917],"Capecitabine",{"nctId":919,"briefTitle":920,"status":139,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":25,"conditions":924,"interventions":925},"NCT00003960","Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",[90],"2001-09","1998-04",[27,754,33],[693,650,926],"methylprednisolone",{"nctId":928,"briefTitle":929,"status":139,"phases":930,"primaryCompletion":395,"completion":395,"start":931,"enrollment":118,"conditions":932,"interventions":933},"NCT00278109","Partial Breast Irradiation With Chemotherapy",[89,90],"2004-07",[18],[650,893],{"nctId":935,"briefTitle":936,"status":139,"phases":937,"primaryCompletion":938,"completion":938,"start":939,"enrollment":940,"conditions":941,"interventions":942},"NCT00134017","Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer",[90],"2010-02","2004-06",142,[745,27,30,754,33],[943,82],"Busulfan",{"nctId":945,"briefTitle":946,"status":416,"phases":947,"primaryCompletion":948,"completion":949,"start":473,"enrollment":100,"conditions":950,"interventions":951},"NCT02215876","Neoadjuvant Doxorubicin\u002FCyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer",[90],"2017-08","2020-03",[18],[893,82,952],"Eribulin",{"nctId":954,"briefTitle":955,"status":219,"phases":956,"primaryCompletion":957,"completion":957,"start":958,"enrollment":19,"conditions":959,"interventions":961},"NCT00489281","Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders",[90],"2018-12-29","2008-06-23",[960],"Sickle Cell Disease",[82,676,874,962,963,964],"Sirolimus","Levetiracetam","Anti-thymocyte globulin",{"nctId":966,"briefTitle":967,"status":139,"phases":968,"primaryCompletion":658,"completion":658,"start":902,"enrollment":969,"conditions":970,"interventions":971},"NCT00492921","High-Dose Cyclophosphamide for Steroid Refractory GVHD",[90],12,[796],[82],{"nctId":973,"briefTitle":974,"status":139,"phases":975,"primaryCompletion":948,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":981},"NCT01696877","A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer",[89,90],"2018-12-18","2013-01-18",29,[980],"Prostate Cancer Adenocarcinoma in Situ",[982,82,343],"degarelix acetate",{"nctId":984,"briefTitle":985,"status":139,"phases":986,"primaryCompletion":987,"completion":988,"start":989,"enrollment":990,"conditions":991,"interventions":992},"NCT00278161","Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma",[90],"2009-12","2011-07","2005-01",94,[27,30],[993,841,82],"Pegfilgrastim",{"nctId":995,"briefTitle":996,"status":127,"phases":997,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":118,"conditions":1001,"interventions":1012},"NCT04232085","Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures",[90],"2027-12-31","2028-12-31","2020-02-12",[1002,1003,1004,1005,1006,1007,1008,1009,1010,1011],"Primary Immune Deficiency Disorder","Immune Deficiency Disease","Bone Marrow Failure","Short Telomere Length","Fanconi Anemia","Non Fanconi DNA-DSB Repair Disorder","Hoyeraal-Hreidarsson Syndrome","Dyskeratosis Congenita","Telomere Biology Disorder","Short Telomere Syndrome",[1013,676,1014,82,854,677],"Alemtuzumab","Melphalan",{"nctId":1016,"briefTitle":1017,"status":139,"phases":1018,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":493,"conditions":1021,"interventions":1022},"NCT00242996","Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma",[90],"2007-04","2004-03",[30],[692,883,1023,1024,650,715],"sargramostim","carmustine",{"nctId":1026,"briefTitle":1027,"status":139,"phases":1028,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":1032,"conditions":1033,"interventions":1036},"NCT00004464","Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria",[90],"2007-03-01","2008-11-11","1996-02",69,[1034,1035],"Aplastic Anemia","Paroxysmal Hemoglobinuria, Nocturnal",[650,692],{"nctId":1038,"briefTitle":1039,"status":127,"phases":1040,"primaryCompletion":275,"completion":1041,"start":1042,"enrollment":700,"conditions":1043,"interventions":1045},"NCT01804634","Reduced Intensity Haploidentical BMT for High Risk Solid Tumors",[90],"2030-01","2013-03-27",[1044],"Refractory and\u002For Relapsed Metastatic Solid Tumors",[82,676,1014,854],{"nctId":1047,"briefTitle":1048,"status":416,"phases":1049,"primaryCompletion":1050,"completion":1050,"start":802,"enrollment":100,"conditions":1051,"interventions":1054},"NCT02702960","Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)",[90],"2018-01-03",[1052,1053,192],"Fibrolamellar Hepatocellular Carcinoma","Hepatocellular Carcinoma (Fibrolamellar Variant)",[82,639,840,854,757,894,1055,1056],"Antithymocyte globulin","fludarabine",{"nctId":79,"briefTitle":80,"status":104,"phases":1058,"primaryCompletion":81,"completion":200,"start":1059,"enrollment":1060,"conditions":1061,"interventions":1062},[90],"2010-04-20",71,[21],[82,1063,376],"Cyclophosphamide Pill",{"nctId":1065,"briefTitle":1066,"status":139,"phases":1067,"primaryCompletion":1068,"completion":1068,"start":534,"enrollment":108,"conditions":1069,"interventions":1071},"NCT02833805","NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia",[90],"2021-07",[850,1034,1004,1070],"Immunosuppression",[853,676,82,854,874],{"nctId":1073,"briefTitle":1074,"status":139,"phases":1075,"primaryCompletion":802,"completion":802,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1079},"NCT00971737","Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer",[90],"2009-07",63,[18],[703,1080,650],"trastuzumab",{"nctId":1082,"briefTitle":1083,"status":139,"phases":1084,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1090},"NCT03006302","Epacadostat, Pembrolizumab, and CRS-207, With or Without CY\u002FGVAX Pancreas in Patients With Metastatic Pancreas Cancer",[90],"2023-08-22","2024-08-05","2018-01-31",41,[566],[1091,580,341,82,376],"Epacadostat",{"nctId":1093,"briefTitle":1094,"status":139,"phases":1095,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":1100,"interventions":1101},"NCT00727441","Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery",[90],"2015-05","2019-02","2008-07-02",87,[21],[1102,650],"GVAX pancreatic cancer vaccine",{"nctId":1104,"briefTitle":1105,"status":139,"phases":1106,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":25,"conditions":1110,"interventions":1111},"NCT01045460","Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma",[90],"2014-12","2020-06","2010-01-15",[673],[1112,1113,82,840,1014,1114],"Activated marrow infiltrating lymphocytes","Allogeneic Myeloma Vaccine","Autologous stem cell transplant",{"nctId":1116,"briefTitle":1117,"status":139,"phases":1118,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":1121,"conditions":1122,"interventions":1123},"NCT02648282","Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer",[90],"2022-06-01","2016-07-18",58,[21],[82,1124,580],"GVAX Pancreatic Cancer Vaccine",{"nctId":1126,"briefTitle":1127,"status":139,"phases":1128,"primaryCompletion":657,"completion":1129,"start":1130,"enrollment":765,"conditions":1131,"interventions":1132},"NCT00133991","Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia",[90],"2013-08","2005-07",[27,30],[840,841,82,1133,1134,894,1135,637,1136],"Cytarabine","Methotrexate","Hydrocortisone","Leucovorin",{"nctId":1138,"briefTitle":1139,"status":139,"phases":1140,"primaryCompletion":42,"completion":1141,"start":1142,"enrollment":1143,"conditions":1144,"interventions":1148},"NCT00796562","Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy",[90],"2016-11","2008-12",107,[1145,1146,1147],"MDS","Leukemias","Lymphomas",[943,82],{"nctId":1150,"briefTitle":1151,"status":219,"phases":1152,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":1157,"interventions":1160},"NCT02080195","Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)",[89,90],"2017-03-28","2017-03-29","2016-09-13",1,[1158,1159],"Lupus Erythematosus","Graft-versus-host Disease",[82,676,854,677,1161,1162],"Rabbit antithymocyte globulin","Allogeneic bone marrow transplant",{"nctId":367,"briefTitle":368,"status":139,"phases":1164,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":1165,"interventions":1166},[90],[21],[82,63,123,376,341,341],{"nctId":1168,"briefTitle":1169,"status":139,"phases":1170,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":384,"conditions":1173,"interventions":1174},"NCT00238368","Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant",[90],"2007-09-17","2004-02",[30],[692,883,693,1175,650,1176,704,715,926,1177,1178],"cisplatin","cytarabine","prednisone","vincristine sulfate",{"nctId":1180,"briefTitle":1181,"status":219,"phases":1182,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":156,"conditions":1185,"interventions":1186},"NCT01135329","Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers",[90],"2012-05","2010-08",[30,27,778],[676,943,82,677,854],{"nctId":1188,"briefTitle":1189,"status":139,"phases":1190,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":1194,"interventions":1195},"NCT00134004","Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer",[90],"2015-01","2004-10",210,[745,27,30,754,33],[650,756,757,758],{"nctId":1197,"briefTitle":1198,"status":139,"phases":1199,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":34,"conditions":1202,"interventions":1203},"NCT01595321","Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas",[90],"2023-10-18","2012-10-29",[21],[82,376,569],{"nctId":425,"briefTitle":426,"status":139,"phases":1205,"primaryCompletion":428,"completion":429,"start":430,"enrollment":190,"conditions":1206,"interventions":1207},[90],[21],[82,63,376],{"nctId":1209,"briefTitle":1210,"status":219,"phases":1211,"primaryCompletion":1212,"completion":1213,"start":1076,"enrollment":1214,"conditions":1215,"interventions":1218},"NCT00946023","Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab",[90],"2013-07","2013-07-17",135,[30,1216,1217,865],"B-cell Lymphoma","Non Hodgkin Lymphoma",[676,82,854,677,841,1219],"Allogeneic Bone Marrow Transplant",{"nctId":1221,"briefTitle":1222,"status":127,"phases":1223,"primaryCompletion":403,"completion":403,"start":1224,"enrollment":301,"conditions":1225,"interventions":1226},"NCT06782932","Comparing Neoadjuvant\u002FAdjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer",[89,90],"2025-05-27",[21],[1227,1228,82,343,1227,1228,1229],"AGEN2373","Balstilimab","mKRASvax",{"nctId":1231,"briefTitle":1232,"status":139,"phases":1233,"primaryCompletion":1234,"completion":1234,"start":1235,"conditions":1236,"interventions":1237},"NCT00003340","Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia",[90],"2000-02","1997-11",[27],[650,1238],"topotecan hydrochloride",{"nctId":1240,"briefTitle":1241,"status":139,"phases":1242,"primaryCompletion":938,"completion":938,"start":1243,"enrollment":439,"conditions":1244,"interventions":1246},"NCT00399529","Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2\u002FNeu-Overexpressing Metastatic Breast Cancer",[90],"2006-09",[1245],"Breast Neoplasms",[1247,48,82],"Allogeneic GM-CSF-secreting breast cancer vaccine",{"nctId":459,"briefTitle":460,"status":104,"phases":1249,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":1250,"interventions":1251},[90],[21],[82,467,63,468,469],{"nctId":1253,"briefTitle":1254,"status":139,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":28,"conditions":1259,"interventions":1264},"NCT02120157","Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies",[90],"2018-06-15","2020-10-01","2015-07-02",[1260,1261,1262,1263],"Myeloablative Conditioning","HLA-mismatched Bone Marrow Transplantation","Graft Survival","Transplantation, Bone Marrow",[82,943,854,874],{"nctId":1266,"briefTitle":1267,"status":139,"phases":1268,"primaryCompletion":1269,"completion":1269,"start":1142,"enrollment":405,"conditions":1270,"interventions":1271},"NCT00847171","Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer",[90],"2013-06",[18],[703,1080,650],{"trials":1273,"activeCount":100},[1274],{"nctId":1275,"briefTitle":1276,"status":139,"phases":1277,"primaryCompletion":1278,"completion":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1282},"NCT00003414","Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease",[91],"2004-05","1997-10",50,[796,30],[713,1283,693,650,1284],"recombinant interferon gamma","cyclosporine",{"trials":1286,"activeCount":100},[],{"trials":1288,"activeCount":100},[],{"intervention":580,"totalTrials":156,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1297,"PHASE2":1299,"PHASE3":1408,"PHASE4":1410,"NA":1412},{"trials":1292,"activeCount":100},[1293],{"nctId":617,"briefTitle":618,"status":139,"phases":1294,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":1295,"interventions":1296},[88],[21],[82,376,580,626],{"trials":1298,"activeCount":100},[],{"trials":1300,"activeCount":231,"soonestReadout":1402},[1301,1310,1319,1323,1327,1338,1351,1359,1363,1372,1376,1388,1398],{"nctId":1302,"briefTitle":1303,"status":127,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":118,"conditions":1307,"interventions":1309},"NCT06001658","Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers",[90],"2028-06","2024-07-08",[1308],"Billiary Track Cancer",[58,638,580],{"nctId":1311,"briefTitle":1312,"status":104,"phases":1313,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":25,"conditions":1316,"interventions":1318},"NCT04209686","Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma",[90],"2028-09-01","2020-07-31",[1317],"Advanced Gastric Adenocarcinoma",[176,73,580],{"nctId":908,"briefTitle":909,"status":127,"phases":1320,"primaryCompletion":911,"completion":912,"start":913,"enrollment":313,"conditions":1321,"interventions":1322},[90],[915],[176,175,580,893,82,73,917],{"nctId":571,"briefTitle":572,"status":139,"phases":1324,"primaryCompletion":574,"completion":575,"start":576,"enrollment":143,"conditions":1325,"interventions":1326},[90],[21],[579,580,123,341],{"nctId":1328,"briefTitle":1329,"status":127,"phases":1330,"primaryCompletion":1305,"completion":911,"start":1331,"enrollment":405,"conditions":1332,"interventions":1336},"NCT05656235","Renal Retention in High Grade Upper Tract Urothelial Cancer",[90],"2024-11-25",[1333,1334,1335],"High Grade Urothelial Carcinoma","Bladder Cancer","Urothelial Carcinoma Bladder",[1337,580],"Enfortumab vedotin",{"nctId":1339,"briefTitle":1340,"status":416,"phases":1341,"primaryCompletion":1342,"completion":1343,"start":1344,"enrollment":100,"conditions":1345,"interventions":1348},"NCT06361810","PSMA Therapy and Immunotherapy in Kidney Cancer",[89,90],"2031-01","2032-01","2025-10-01",[1346,1347],"Metastatic Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma",[580,1349,1350],"177Lu-PNT2002","(F-18)-DCFPyL",{"nctId":1352,"briefTitle":1353,"status":139,"phases":1354,"primaryCompletion":47,"completion":47,"start":1355,"enrollment":143,"conditions":1356,"interventions":1358},"NCT02981524","Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer",[90],"2017-05-26",[1357],"Metastatic Colorectal Cancer",[344,343,580],{"nctId":1082,"briefTitle":1083,"status":139,"phases":1360,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1361,"interventions":1362},[90],[566],[1091,580,341,82,376],{"nctId":1364,"briefTitle":1365,"status":219,"phases":1366,"primaryCompletion":1367,"completion":1367,"start":1368,"enrollment":212,"conditions":1369,"interventions":1371},"NCT03091478","Pembrolizumab in Patients With Leptomeningeal Disease",[90],"2019-12-14","2017-04-12",[1370],"Patients With Leptomeningeal Disease",[580],{"nctId":1116,"briefTitle":1117,"status":139,"phases":1373,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":1121,"conditions":1374,"interventions":1375},[90],[21],[82,1124,580],{"nctId":1377,"briefTitle":1378,"status":139,"phases":1379,"primaryCompletion":1380,"completion":1381,"start":1382,"enrollment":1383,"conditions":1384,"interventions":1385},"NCT02845297","Study of Azacitidine in Combination With Pembrolizumab in R\u002FR AML Patients and in Newly Diagnosed Older Patients",[90],"2022-04","2022-12","2016-07",67,[779],[1386,1387],"pembrolizumab","Azacitadine",{"nctId":1389,"briefTitle":1390,"status":104,"phases":1391,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":301,"conditions":1395,"interventions":1396},"NCT04753879","Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.",[90],"2026-12-01","2029-12-01","2021-09-29",[497],[1397,58,638,409,917,580,73],"Nab-paclitaxel",{"nctId":1399,"briefTitle":1400,"status":127,"phases":1401,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":313,"conditions":1405,"interventions":1406},"NCT05977907","Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).",[90],"2026-10-16","2028-10-16","2023-12-14",[268],[580,1407],"IO102-103",{"trials":1409,"activeCount":100},[],{"trials":1411,"activeCount":100},[],{"trials":1413,"activeCount":100},[1414],{"nctId":1415,"briefTitle":1416,"status":139,"phases":1417,"primaryCompletion":1418,"completion":1418,"start":1419,"enrollment":969,"conditions":1420,"interventions":1422},"NCT02489357","Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer",[93],"2017-11-30","2015-12-11",[1421],"Stage IV Prostate Cancer",[1423,580],"Degarelix",{"intervention":175,"totalTrials":723,"cells":1425},{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1442,"PHASE3":1536,"PHASE4":1538,"NA":1540},{"trials":1427,"activeCount":100},[],{"trials":1429,"activeCount":1156,"soonestReadout":165},[1430,1434,1438],{"nctId":162,"briefTitle":163,"status":104,"phases":1431,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":1432,"interventions":1433},[89],[170,171,172],[63,174,175,176],{"nctId":760,"briefTitle":761,"status":139,"phases":1435,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":1436,"interventions":1437},[89],[767,768,769],[692,43,650],{"nctId":809,"briefTitle":810,"status":139,"phases":1439,"primaryCompletion":812,"completion":812,"start":813,"enrollment":108,"conditions":1440,"interventions":1441},[89],[24,815,816,817,818,768,280,819],[692,43,650,715],{"trials":1443,"activeCount":536,"soonestReadout":42},[1444,1454,1463,1467,1471,1480,1490,1501,1512,1523,1532],{"nctId":1445,"briefTitle":1446,"status":219,"phases":1447,"primaryCompletion":1141,"completion":1448,"start":1449,"enrollment":361,"conditions":1450,"interventions":1452},"NCT01732640","A Phase I\u002FII Study Afatinib\u002FCarboplatin\u002FPaclitaxel Induction Chemotherapy In HPV-Negative HNSCC.",[89,90],"2017-01","2012-12",[1451],"Squamous Cell Carcinoma of the Head and Neck",[1453,176,175,638],"Afatinib",{"nctId":1455,"briefTitle":1456,"status":219,"phases":1457,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":361,"conditions":1460,"interventions":1461},"NCT01009346","RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN",[89,90],"2011-03","2009-10",[36],[1462,831,638,175],"RAD001",{"nctId":885,"briefTitle":886,"status":219,"phases":1464,"primaryCompletion":888,"completion":888,"start":889,"enrollment":118,"conditions":1465,"interventions":1466},[90],[891],[841,82,893,637,894,895,175,896,897],{"nctId":908,"briefTitle":909,"status":127,"phases":1468,"primaryCompletion":911,"completion":912,"start":913,"enrollment":313,"conditions":1469,"interventions":1470},[90],[915],[176,175,580,893,82,73,917],{"nctId":40,"briefTitle":41,"status":104,"phases":1472,"primaryCompletion":42,"completion":1473,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1477},[90],"2027-02","2008-05",68,[18],[43,1478,1479],"paclitaxel albumin-stabilized nanoparticle formulation","vorinostat",{"nctId":1481,"briefTitle":1482,"status":127,"phases":1483,"primaryCompletion":472,"completion":1484,"start":1485,"enrollment":1077,"conditions":1486,"interventions":1488},"NCT05312671","Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer",[90],"2029-10","2022-06-27",[1487,1334,1335],"Small Cell Neuroendocrine Carcinoma of Bladder",[1489,175,638,896],"Atezolizumab",{"nctId":1491,"briefTitle":1492,"status":139,"phases":1493,"primaryCompletion":1494,"start":1130,"enrollment":1495,"conditions":1496,"interventions":1498},"NCT00276588","Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",[90],"2007-03",46,[1497],"Lung Cancer",[43,1499,1500],"gemcitabine hydrochloride","paclitaxel",{"nctId":1502,"briefTitle":1503,"status":139,"phases":1504,"primaryCompletion":1505,"completion":1506,"start":1507,"enrollment":1508,"conditions":1509,"interventions":1510},"NCT00287989","Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer",[90],"2007-08","2009-05","2004-11",86,[1497],[175,1511,176,1511],"erlotinib hydrochloride",{"nctId":1513,"briefTitle":1514,"status":219,"phases":1515,"primaryCompletion":1448,"completion":1448,"start":1183,"enrollment":1516,"conditions":1517,"interventions":1520},"NCT01578551","Study of Metformin Plus Paclitaxel\u002FCarboplatin\u002FBevacizumab in Patients With Adenocarcinoma.",[90],25,[1518,1519],"Carcinoma, Non-Small-Cell Lung","Lung Adenocarcinoma",[176,175,1521,1522],"Bevacizumab","Metformin",{"nctId":1524,"briefTitle":1525,"status":139,"phases":1526,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":700,"conditions":1529,"interventions":1531},"NCT01088802","Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx",[90],"2019-10","2010-03",[1530],"Squamous Cell Carcinoma of Oropharynx",[638,175],{"nctId":60,"briefTitle":61,"status":104,"phases":1533,"primaryCompletion":62,"completion":472,"start":473,"enrollment":278,"conditions":1534,"interventions":1535},[90],[325],[63,175,176,123],{"trials":1537,"activeCount":100},[],{"trials":1539,"activeCount":100},[],{"trials":1541,"activeCount":100},[],{"intervention":73,"totalTrials":9,"cells":1543},{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1567,"PHASE3":1610,"PHASE4":1612,"NA":1614},{"trials":1545,"activeCount":100},[],{"trials":1547,"activeCount":100},[1548,1558],{"nctId":1549,"briefTitle":1550,"status":219,"phases":1551,"primaryCompletion":1552,"completion":1552,"start":1553,"enrollment":266,"conditions":1554,"interventions":1556},"NCT02485990","Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",[89],"2020-03-05","2016-01-08",[1555],"Primary Peritoneal Carcinoma",[1557,73],"Tremelimumab",{"nctId":1559,"briefTitle":1560,"status":139,"phases":1561,"primaryCompletion":1562,"completion":182,"start":1563,"enrollment":848,"conditions":1564,"interventions":1565},"NCT01296763","Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer",[89],"2014-01","2011-01",[21],[409,638,73,73,1566],"Mitomycin-C",{"trials":1568,"activeCount":1609,"soonestReadout":72},[1569,1573,1577,1585,1593,1605],{"nctId":1311,"briefTitle":1312,"status":104,"phases":1570,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":25,"conditions":1571,"interventions":1572},[90],[1317],[176,73,580],{"nctId":908,"briefTitle":909,"status":127,"phases":1574,"primaryCompletion":911,"completion":912,"start":913,"enrollment":313,"conditions":1575,"interventions":1576},[90],[915],[176,175,580,893,82,73,917],{"nctId":70,"briefTitle":71,"status":104,"phases":1578,"primaryCompletion":72,"completion":1579,"start":1580,"enrollment":1581,"conditions":1582,"interventions":1584},[90],"2027-05-01","2017-03-01",51,[1583],"Prostate",[73],{"nctId":1586,"briefTitle":1587,"status":219,"phases":1588,"primaryCompletion":1589,"completion":1589,"start":1590,"enrollment":536,"conditions":1591,"interventions":1592},"NCT05501548","Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer",[90],"2024-10-14","2023-06-30",[15,243],[73],{"nctId":1594,"briefTitle":1595,"status":127,"phases":1596,"primaryCompletion":165,"completion":1597,"start":1598,"enrollment":405,"conditions":1599,"interventions":1604},"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",[90],"2028-03","2019-06-03",[1600,1346,1601,1602,1603],"Renal Cell Carcinoma","Kidney Cancer","Renal Carcinoma","Kidney Cancer Metastatic",[73],{"nctId":1389,"briefTitle":1390,"status":104,"phases":1606,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":301,"conditions":1607,"interventions":1608},[90],[497],[1397,58,638,409,917,580,73],5,{"trials":1611,"activeCount":100},[],{"trials":1613,"activeCount":100},[],{"trials":1615,"activeCount":100},[],{"intervention":174,"totalTrials":231,"cells":1617},{"EARLY_PHASE1":1618,"PHASE1":1620,"PHASE2":1630,"PHASE3":1648,"PHASE4":1650,"NA":1652},{"trials":1619,"activeCount":100},[],{"trials":1621,"activeCount":733,"soonestReadout":86},[1622,1626],{"nctId":162,"briefTitle":163,"status":104,"phases":1623,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":1624,"interventions":1625},[89],[170,171,172],[63,174,175,176],{"nctId":84,"briefTitle":85,"status":104,"phases":1627,"primaryCompletion":86,"completion":188,"start":189,"enrollment":190,"conditions":1628,"interventions":1629},[89],[192],[63,174],{"trials":1631,"activeCount":224,"soonestReadout":299},[1632,1636,1640,1644],{"nctId":285,"briefTitle":286,"status":104,"phases":1633,"primaryCompletion":288,"completion":289,"start":290,"enrollment":108,"conditions":1634,"interventions":1635},[89,90],[292,293],[63,174],{"nctId":296,"briefTitle":297,"status":104,"phases":1637,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":1638,"interventions":1639},[90],[303,304],[63,174,63,174,63,174],{"nctId":378,"briefTitle":379,"status":139,"phases":1641,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":1642,"interventions":1643},[90],[386,387],[63,174],{"nctId":477,"briefTitle":478,"status":127,"phases":1645,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":1646,"interventions":1647},[90],[485],[63,123,174],{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"trials":1653,"activeCount":100},[],{"intervention":176,"totalTrials":1655,"cells":1656},10,{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1665,"PHASE3":1712,"PHASE4":1714,"NA":1716},{"trials":1658,"activeCount":100},[],{"trials":1660,"activeCount":1156,"soonestReadout":165},[1661],{"nctId":162,"briefTitle":163,"status":104,"phases":1662,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":1663,"interventions":1664},[89],[170,171,172],[63,174,175,176],{"trials":1666,"activeCount":224,"soonestReadout":62},[1667,1671,1675,1679,1688,1696,1700,1704,1708],{"nctId":1445,"briefTitle":1446,"status":219,"phases":1668,"primaryCompletion":1141,"completion":1448,"start":1449,"enrollment":361,"conditions":1669,"interventions":1670},[89,90],[1451],[1453,176,175,638],{"nctId":1311,"briefTitle":1312,"status":104,"phases":1672,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":25,"conditions":1673,"interventions":1674},[90],[1317],[176,73,580],{"nctId":908,"briefTitle":909,"status":127,"phases":1676,"primaryCompletion":911,"completion":912,"start":913,"enrollment":313,"conditions":1677,"interventions":1678},[90],[915],[176,175,580,893,82,73,917],{"nctId":1680,"briefTitle":1681,"status":219,"phases":1682,"primaryCompletion":1683,"completion":1683,"start":1684,"enrollment":34,"conditions":1685,"interventions":1686},"NCT00493025","Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery",[90],"2013-03","2005-04",[171],[1175,1687,1500],"gefitinib",{"nctId":1689,"briefTitle":1690,"status":219,"phases":1691,"primaryCompletion":42,"completion":1692,"start":1693,"enrollment":190,"conditions":1694,"interventions":1695},"NCT01372202","CHFR Methylation Status Esophageal Cancer Study",[90],"2014-10-01","2011-06",[171],[176,638,408,411],{"nctId":1491,"briefTitle":1492,"status":139,"phases":1697,"primaryCompletion":1494,"start":1130,"enrollment":1495,"conditions":1698,"interventions":1699},[90],[1497],[43,1499,1500],{"nctId":1502,"briefTitle":1503,"status":139,"phases":1701,"primaryCompletion":1505,"completion":1506,"start":1507,"enrollment":1508,"conditions":1702,"interventions":1703},[90],[1497],[175,1511,176,1511],{"nctId":1513,"briefTitle":1514,"status":219,"phases":1705,"primaryCompletion":1448,"completion":1448,"start":1183,"enrollment":1516,"conditions":1706,"interventions":1707},[90],[1518,1519],[176,175,1521,1522],{"nctId":60,"briefTitle":61,"status":104,"phases":1709,"primaryCompletion":62,"completion":472,"start":473,"enrollment":278,"conditions":1710,"interventions":1711},[90],[325],[63,175,176,123],{"trials":1713,"activeCount":100},[],{"trials":1715,"activeCount":100},[],{"trials":1717,"activeCount":100},[],{"intervention":246,"totalTrials":361,"cells":1719},{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1734,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1721,"activeCount":100},[],{"trials":1723,"activeCount":100},[1724],{"nctId":1725,"briefTitle":1726,"status":219,"phases":1727,"primaryCompletion":1728,"completion":1728,"start":1729,"enrollment":224,"conditions":1730,"interventions":1731},"NCT02995330","Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer",[89],"2021-06-16","2017-02-09",[15],[1732,1733],"Cytoxan","testosterone cypionate",{"trials":1735,"activeCount":536,"soonestReadout":1755},[1736,1747,1751,1762,1773,1783,1792,1802],{"nctId":1737,"briefTitle":1738,"status":127,"phases":1739,"primaryCompletion":1740,"completion":1741,"start":1742,"enrollment":1280,"conditions":1743,"interventions":1744},"NCT06059118","Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer",[90],"2027-01-04","2029-11-30","2023-10-04",[15],[1745,1733,1746,258],"DFMO","Luteinizing hormone-releasing hormone (LHRH) analogue",{"nctId":235,"briefTitle":236,"status":139,"phases":1748,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":1749,"interventions":1750},[90],[243,244,15],[246,63],{"nctId":1752,"briefTitle":1753,"status":127,"phases":1754,"primaryCompletion":1755,"completion":480,"start":1756,"enrollment":1757,"conditions":1758,"interventions":1760},"NCT04363164","Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression",[90],"2026-07","2020-08-19",150,[1759],"Castration Resistant Metastatic Prostate Cancer",[246,258,1761],"Testosterone enanthate",{"nctId":1763,"briefTitle":1764,"status":139,"phases":1765,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1768,"conditions":1769,"interventions":1770},"NCT02090114","RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)",[90],"2021-11-11","2014-08-25",112,[15],[246,1771,1772,258],"Testosterone Enanthate","Abiraterone acetate",{"nctId":1774,"briefTitle":1775,"status":127,"phases":1776,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1280,"conditions":1779,"interventions":1781},"NCT06922318","The COSMYC Trial (COmbined Suppression of MYC)",[90],"2031-08-30","2025-08-19",[1780],"Metastatic Castration-resistant Prostate Cancer",[1782,246,258,1746],"ZEN-3694",{"nctId":1784,"briefTitle":1785,"status":139,"phases":1786,"primaryCompletion":1787,"completion":1788,"start":1191,"enrollment":1789,"conditions":1790,"interventions":1791},"NCT02286921","Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance",[90],"2018-10-26","2020-02-21",222,[1759],[246,258,1771],{"nctId":1793,"briefTitle":1794,"status":139,"phases":1795,"primaryCompletion":1796,"completion":1796,"start":658,"enrollment":1797,"conditions":1798,"interventions":1799},"NCT01750398","Bipolar Androgen-based Therapy for Prostate Cancer (BAT)",[90],"2015-06",33,[353],[246,1800,1801],"Goserelin","Leuprolide",{"nctId":1803,"briefTitle":1804,"status":127,"phases":1805,"primaryCompletion":188,"completion":1806,"start":1807,"enrollment":700,"conditions":1808,"interventions":1809},"NCT07142551","Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response",[90],"2034-06-01","2026-03-09",[1780],[246,1746,1810],"Darolutamide",{"trials":1812,"activeCount":100},[],{"trials":1814,"activeCount":100},[],{"trials":1816,"activeCount":100},[],{"intervention":917,"totalTrials":361,"cells":1818},{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1823,"PHASE3":1909,"PHASE4":1911,"NA":1913},{"trials":1820,"activeCount":100},[],{"trials":1822,"activeCount":100},[],{"trials":1824,"activeCount":536,"soonestReadout":1392},[1825,1829,1847,1858,1866,1876,1884,1893,1905],{"nctId":908,"briefTitle":909,"status":127,"phases":1826,"primaryCompletion":911,"completion":912,"start":913,"enrollment":313,"conditions":1827,"interventions":1828},[90],[915],[176,175,580,893,82,73,917],{"nctId":1830,"briefTitle":1831,"status":139,"phases":1832,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":452,"conditions":1835,"interventions":1846},"NCT03535727","A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer",[89,90],"2022-10-03","2018-06-21",[1836,1837,1838,1839,1840,1841,1842,1843,1844,1845],"Adenocarcinoma","Pancreatic Neoplasms","Neoplasm, Glandular","Neoplasms","Neoplasms Pancreatic","Digestive System Neoplasm","Endocrine Gland Neoplasms","Digestive System Disease","Pancreatic Diseases","Endocrine System Diseases",[1397,58,917,638,409,1397,58,917,638,409],{"nctId":1848,"briefTitle":1849,"status":197,"phases":1850,"primaryCompletion":1851,"completion":1851,"start":1755,"enrollment":1852,"conditions":1853,"interventions":1854},"NCT07281768","Capecitabine\u002FOxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer",[90],"2030-07",66,[120],[408,917,1855,1856,1857],"Cemiplimab","Fianlimab","REGN7075",{"nctId":1859,"briefTitle":1860,"status":197,"phases":1861,"primaryCompletion":1851,"completion":1851,"start":1755,"enrollment":313,"conditions":1862,"interventions":1864},"NCT07580339","Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer",[90],[1863],"Rectal Cancer",[1865,917,408],"DCSZ11",{"nctId":1867,"briefTitle":1868,"status":139,"phases":1869,"primaryCompletion":987,"completion":1870,"start":1871,"enrollment":1872,"conditions":1873,"interventions":1874},"NCT00274768","Capecitabine in Treating Patients With Metastatic Breast Cancer",[90],"2012-11","2004-04",26,[18],[1875],"capecitabine",{"nctId":1877,"briefTitle":1878,"status":139,"phases":1879,"primaryCompletion":1880,"start":828,"enrollment":1881,"conditions":1882,"interventions":1883},"NCT00303927","Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene",[90],"2007-09",65,[21],[1875],{"nctId":1885,"briefTitle":1886,"status":139,"phases":1887,"primaryCompletion":731,"completion":731,"start":1888,"enrollment":848,"conditions":1889,"interventions":1891},"NCT00414271","Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer",[90],"2006-01",[1890],"Stage T3-4NxM0 Gastric Cancer",[1892,917],"Docetaxel",{"nctId":1894,"briefTitle":1895,"status":219,"phases":1896,"primaryCompletion":741,"completion":741,"start":688,"enrollment":1897,"conditions":1898,"interventions":1899},"NCT00276744","Individualized Drug Treatment for Treating Patients With Pancreatic Cancer",[90],249,[21],[1900,1875,1901,1902,58,409,1903,1904],"cetuximab","docetaxel","Erlotinib","mitomycin C","rapamycin",{"nctId":1389,"briefTitle":1390,"status":104,"phases":1906,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":301,"conditions":1907,"interventions":1908},[90],[497],[1397,58,638,409,917,580,73],{"trials":1910,"activeCount":100},[],{"trials":1912,"activeCount":100},[],{"trials":1914,"activeCount":100},[],{"intervention":258,"totalTrials":1655,"cells":1916},{"EARLY_PHASE1":1917,"PHASE1":1919,"PHASE2":1921,"PHASE3":1974,"PHASE4":1976,"NA":1978},{"trials":1918,"activeCount":100},[],{"trials":1920,"activeCount":100},[],{"trials":1922,"activeCount":536,"soonestReadout":1960},[1923,1932,1936,1940,1944,1948,1952,1956,1965],{"nctId":1924,"briefTitle":1925,"status":139,"phases":1926,"primaryCompletion":1927,"completion":1927,"start":1928,"enrollment":156,"conditions":1929,"interventions":1930},"NCT05081193","Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer",[90],"2025-08-04","2022-03-07",[15,243,1780],[1931,258],"Testosterone Undecanoate",{"nctId":1737,"briefTitle":1738,"status":127,"phases":1933,"primaryCompletion":1740,"completion":1741,"start":1742,"enrollment":1280,"conditions":1934,"interventions":1935},[90],[15],[1745,1733,1746,258],{"nctId":248,"briefTitle":249,"status":139,"phases":1937,"primaryCompletion":251,"completion":252,"start":253,"enrollment":168,"conditions":1938,"interventions":1939},[90],[15,255,256],[123,63,258],{"nctId":1752,"briefTitle":1753,"status":127,"phases":1941,"primaryCompletion":1755,"completion":480,"start":1756,"enrollment":1757,"conditions":1942,"interventions":1943},[90],[1759],[246,258,1761],{"nctId":1763,"briefTitle":1764,"status":139,"phases":1945,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1768,"conditions":1946,"interventions":1947},[90],[15],[246,1771,1772,258],{"nctId":1774,"briefTitle":1775,"status":127,"phases":1949,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1280,"conditions":1950,"interventions":1951},[90],[1780],[1782,246,258,1746],{"nctId":1784,"briefTitle":1785,"status":139,"phases":1953,"primaryCompletion":1787,"completion":1788,"start":1191,"enrollment":1789,"conditions":1954,"interventions":1955},[90],[1759],[246,258,1771],{"nctId":1957,"briefTitle":1958,"status":104,"phases":1959,"primaryCompletion":1960,"completion":288,"start":1961,"enrollment":700,"conditions":1962,"interventions":1963},"NCT02452008","Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer",[90],"2025-12-08","2016-05-03",[15],[258,1964],"LY2157299",{"nctId":1966,"briefTitle":1967,"status":139,"phases":1968,"primaryCompletion":1969,"completion":1969,"start":1970,"enrollment":1508,"conditions":1971,"interventions":1973},"NCT02203695","Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy",[90],"2022-12-31","2015-03-28",[1972],"Adenocarcinoma of the Prostate",[258],{"trials":1975,"activeCount":100},[],{"trials":1977,"activeCount":100},[],{"trials":1979,"activeCount":100},[1980],{"nctId":1981,"briefTitle":1982,"status":219,"phases":1983,"primaryCompletion":668,"completion":668,"start":1984,"enrollment":1609,"conditions":1985,"interventions":1989},"NCT02491411","Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel",[93],"2015-09",[1986,1987,1988,1421],"Hormone-Resistant Prostate Cancer","Metastatic Prostate Carcinoma","Prostate Adenocarcinoma",[1990,258],"Dexamethasone",{"intervention":638,"totalTrials":143,"cells":1992},{"EARLY_PHASE1":1993,"PHASE1":1999,"PHASE2":2012,"PHASE3":2090,"PHASE4":2092,"NA":2094},{"trials":1994,"activeCount":100},[1995],{"nctId":628,"briefTitle":629,"status":219,"phases":1996,"primaryCompletion":631,"completion":631,"start":632,"enrollment":231,"conditions":1997,"interventions":1998},[88],[634],[636,637,638,82,639,637],{"trials":2000,"activeCount":100},[2001,2005],{"nctId":1559,"briefTitle":1560,"status":139,"phases":2002,"primaryCompletion":1562,"completion":182,"start":1563,"enrollment":848,"conditions":2003,"interventions":2004},[89],[21],[409,638,73,73,1566],{"nctId":2006,"briefTitle":2007,"status":219,"phases":2008,"primaryCompletion":182,"completion":182,"start":1076,"enrollment":439,"conditions":2009,"interventions":2010},"NCT00882583","A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC",[89],[36],[831,2011,638],"Dasatinib",{"trials":2013,"activeCount":224,"soonestReadout":1392},[2014,2018,2022,2026,2030,2042,2050,2054,2058,2062,2071,2075,2082,2086],{"nctId":1445,"briefTitle":1446,"status":219,"phases":2015,"primaryCompletion":1141,"completion":1448,"start":1449,"enrollment":361,"conditions":2016,"interventions":2017},[89,90],[1451],[1453,176,175,638],{"nctId":1302,"briefTitle":1303,"status":127,"phases":2019,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":118,"conditions":2020,"interventions":2021},[90],[1308],[58,638,580],{"nctId":1455,"briefTitle":1456,"status":219,"phases":2023,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":361,"conditions":2024,"interventions":2025},[89,90],[36],[1462,831,638,175],{"nctId":1481,"briefTitle":1482,"status":127,"phases":2027,"primaryCompletion":472,"completion":1484,"start":1485,"enrollment":1077,"conditions":2028,"interventions":2029},[90],[1487,1334,1335],[1489,175,638,896],{"nctId":2031,"briefTitle":2032,"status":139,"phases":2033,"primaryCompletion":2034,"completion":2035,"start":2036,"enrollment":2037,"conditions":2038,"interventions":2039},"NCT02324543","Study of Gemcitabine\u002FTaxotere\u002FXeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer",[89,90],"2019-06","2020-02","2015-02",47,[566],[58,2040,2041,638,409],"Taxotere","Xeloda",{"nctId":2043,"briefTitle":2044,"status":139,"phases":2045,"primaryCompletion":646,"completion":2046,"start":2047,"enrollment":1280,"conditions":2048,"interventions":2049},"NCT00281970","Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery",[90],"2009-06","2004-08",[1497],[1175,1901],{"nctId":1830,"briefTitle":1831,"status":139,"phases":2051,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":452,"conditions":2052,"interventions":2053},[89,90],[1836,1837,1838,1839,1840,1841,1842,1843,1844,1845],[1397,58,917,638,409,1397,58,917,638,409],{"nctId":1680,"briefTitle":1681,"status":219,"phases":2055,"primaryCompletion":1683,"completion":1683,"start":1684,"enrollment":34,"conditions":2056,"interventions":2057},[90],[171],[1175,1687,1500],{"nctId":1168,"briefTitle":1169,"status":139,"phases":2059,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":384,"conditions":2060,"interventions":2061},[90],[30],[692,883,693,1175,650,1176,704,715,926,1177,1178],{"nctId":2063,"briefTitle":2064,"status":139,"phases":2065,"primaryCompletion":1796,"completion":2066,"start":1449,"enrollment":118,"conditions":2067,"interventions":2069},"NCT01715233","Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.",[90],"2017-04",[2068,292,170],"Metastatic Esophageal Cancer",[1892,1136,2070,638],"Fluorouracil",{"nctId":1689,"briefTitle":1690,"status":219,"phases":2072,"primaryCompletion":42,"completion":1692,"start":1693,"enrollment":190,"conditions":2073,"interventions":2074},[90],[171],[176,638,408,411],{"nctId":2076,"briefTitle":2077,"status":139,"phases":2078,"primaryCompletion":1141,"completion":1141,"start":2079,"enrollment":493,"conditions":2080,"interventions":2081},"NCT01459614","Gemcitabine\u002FTaxotere\u002FXeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer",[90],"2011-11",[21],[58,2040,2041,638],{"nctId":1524,"briefTitle":1525,"status":139,"phases":2083,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":700,"conditions":2084,"interventions":2085},[90],[1530],[638,175],{"nctId":1389,"briefTitle":1390,"status":104,"phases":2087,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":301,"conditions":2088,"interventions":2089},[90],[497],[1397,58,638,409,917,580,73],{"trials":2091,"activeCount":100},[],{"trials":2093,"activeCount":100},[],{"trials":2095,"activeCount":100},[],{"intervention":58,"totalTrials":361,"cells":2097},{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2157,"PHASE4":2159,"NA":2161},{"trials":2099,"activeCount":100},[],{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":224,"soonestReadout":57},[2104,2108,2112,2116,2122,2133,2137,2141,2145],{"nctId":1302,"briefTitle":1303,"status":127,"phases":2105,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":118,"conditions":2106,"interventions":2107},[90],[1308],[58,638,580],{"nctId":2031,"briefTitle":2032,"status":139,"phases":2109,"primaryCompletion":2034,"completion":2035,"start":2036,"enrollment":2037,"conditions":2110,"interventions":2111},[89,90],[566],[58,2040,2041,638,409],{"nctId":1830,"briefTitle":1831,"status":139,"phases":2113,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":452,"conditions":2114,"interventions":2115},[89,90],[1836,1837,1838,1839,1840,1841,1842,1843,1844,1845],[1397,58,917,638,409,1397,58,917,638,409],{"nctId":55,"briefTitle":56,"status":104,"phases":2117,"primaryCompletion":57,"completion":2118,"start":2119,"enrollment":118,"conditions":2120,"interventions":2121},[90],"2026-11-30","2020-07-29",[1335,1334],[58,1892],{"nctId":2123,"briefTitle":2124,"status":219,"phases":2125,"primaryCompletion":2126,"completion":2127,"start":2128,"enrollment":231,"conditions":2129,"interventions":2131},"NCT01639131","Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma",[90],"2016-10-03","2019-03-11","2012-09-10",[2130],"Metastatic Colorectal Adenocarcinoma",[58,1892,2132],"Filgrastim or Pegfilgrastim",{"nctId":1894,"briefTitle":1895,"status":219,"phases":2134,"primaryCompletion":741,"completion":741,"start":688,"enrollment":1897,"conditions":2135,"interventions":2136},[90],[21],[1900,1875,1901,1902,58,409,1903,1904],{"nctId":2076,"briefTitle":2077,"status":139,"phases":2138,"primaryCompletion":1141,"completion":1141,"start":2079,"enrollment":493,"conditions":2139,"interventions":2140},[90],[21],[58,2040,2041,638],{"nctId":1389,"briefTitle":1390,"status":104,"phases":2142,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":301,"conditions":2143,"interventions":2144},[90],[497],[1397,58,638,409,917,580,73],{"nctId":2146,"briefTitle":2147,"status":219,"phases":2148,"primaryCompletion":2149,"completion":2149,"start":2150,"enrollment":765,"conditions":2151,"interventions":2152},"NCT01431794","Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma",[89,90],"2018-11-05","2011-12-27",[442],[2153,58,2154,2155,2156],"LDE225-600mg","nab-paclitaxel","LDE225-400mg","LDE225-800mg",{"trials":2158,"activeCount":100},[],{"trials":2160,"activeCount":100},[],{"trials":2162,"activeCount":100},[],{"intervention":408,"totalTrials":536,"cells":2164},{"EARLY_PHASE1":2165,"PHASE1":2167,"PHASE2":2169,"PHASE3":2187,"PHASE4":2189,"NA":2191},{"trials":2166,"activeCount":100},[],{"trials":2168,"activeCount":100},[],{"trials":2170,"activeCount":224,"soonestReadout":403},[2171,2175,2179,2183],{"nctId":1848,"briefTitle":1849,"status":197,"phases":2172,"primaryCompletion":1851,"completion":1851,"start":1755,"enrollment":1852,"conditions":2173,"interventions":2174},[90],[120],[408,917,1855,1856,1857],{"nctId":1859,"briefTitle":1860,"status":197,"phases":2176,"primaryCompletion":1851,"completion":1851,"start":1755,"enrollment":313,"conditions":2177,"interventions":2178},[90],[1863],[1865,917,408],{"nctId":1689,"briefTitle":1690,"status":219,"phases":2180,"primaryCompletion":42,"completion":1692,"start":1693,"enrollment":190,"conditions":2181,"interventions":2182},[90],[171],[176,638,408,411],{"nctId":400,"briefTitle":401,"status":127,"phases":2184,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":2185,"interventions":2186},[90],[21],[408,409,410,411,412,63,123],{"trials":2188,"activeCount":100},[],{"trials":2190,"activeCount":100},[],{"trials":2192,"activeCount":100},[],{"intervention":1855,"totalTrials":536,"cells":2194},{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2232,"PHASE4":2234,"NA":2236},{"trials":2196,"activeCount":100},[],{"trials":2198,"activeCount":100},[],{"trials":2200,"activeCount":224,"soonestReadout":2227},[2201,2205,2213,2223],{"nctId":1848,"briefTitle":1849,"status":197,"phases":2202,"primaryCompletion":1851,"completion":1851,"start":1755,"enrollment":1852,"conditions":2203,"interventions":2204},[90],[120],[408,917,1855,1856,1857],{"nctId":2206,"briefTitle":2207,"status":127,"phases":2208,"primaryCompletion":2209,"completion":2209,"start":2210,"enrollment":493,"conditions":2211,"interventions":2212},"NCT06205836","Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer",[90],"2030-05","2024-06-13",[120],[1855,1856],{"nctId":2214,"briefTitle":2215,"status":139,"phases":2216,"primaryCompletion":2217,"completion":2218,"start":2219,"enrollment":1516,"conditions":2220,"interventions":2221},"NCT04177810","Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer",[90],"2023-03-29","2023-05-19","2020-11-16",[497],[1855,2222],"Plerixafor",{"nctId":2224,"briefTitle":2225,"status":127,"phases":2226,"primaryCompletion":2227,"completion":289,"start":2228,"enrollment":168,"conditions":2229,"interventions":2231},"NCT04988074","Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w\u002FHPV H&N Ca",[90],"2027-06-30","2021-12-13",[2230],"HPV-Related Squamous Cell Carcinoma",[1855],{"trials":2233,"activeCount":100},[],{"trials":2235,"activeCount":100},[],{"trials":2237,"activeCount":100},[],{"intervention":1746,"totalTrials":224,"cells":2239},{"EARLY_PHASE1":2240,"PHASE1":2242,"PHASE2":2244,"PHASE3":2258,"PHASE4":2260,"NA":2262},{"trials":2241,"activeCount":100},[],{"trials":2243,"activeCount":100},[],{"trials":2245,"activeCount":224,"soonestReadout":1740},[2246,2250,2254],{"nctId":1737,"briefTitle":1738,"status":127,"phases":2247,"primaryCompletion":1740,"completion":1741,"start":1742,"enrollment":1280,"conditions":2248,"interventions":2249},[90],[15],[1745,1733,1746,258],{"nctId":1774,"briefTitle":1775,"status":127,"phases":2251,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1280,"conditions":2252,"interventions":2253},[90],[1780],[1782,246,258,1746],{"nctId":1803,"briefTitle":1804,"status":127,"phases":2255,"primaryCompletion":188,"completion":1806,"start":1807,"enrollment":700,"conditions":2256,"interventions":2257},[90],[1780],[246,1746,1810],{"trials":2259,"activeCount":100},[],{"trials":2261,"activeCount":100},[],{"trials":2263,"activeCount":100},[],{"intervention":2265,"totalTrials":34,"cells":2266},"temozolomide",{"EARLY_PHASE1":2267,"PHASE1":2286,"PHASE2":2349,"PHASE3":2443,"PHASE4":2445,"NA":2447},{"trials":2268,"activeCount":100},[2269,2277],{"nctId":2270,"briefTitle":2271,"status":139,"phases":2272,"primaryCompletion":1756,"completion":1756,"start":2273,"enrollment":224,"conditions":2274,"interventions":2275},"NCT03291990","5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme",[88],"2017-10-18",[227],[2276],"Temozolomide",{"nctId":2278,"briefTitle":2279,"status":139,"phases":2280,"primaryCompletion":182,"completion":2281,"start":2036,"enrollment":231,"conditions":2282,"interventions":2284},"NCT02389738","Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration",[88],"2018-02-01",[2283],"Blood Brain Barrier Defect",[2285,2276],"Regadenoson",{"trials":2287,"activeCount":1156,"soonestReadout":2343},[2288,2298,2309,2318,2329,2339],{"nctId":2289,"briefTitle":2290,"status":139,"phases":2291,"primaryCompletion":2292,"completion":2293,"start":2294,"conditions":2295,"interventions":2296},"NCT00006025","Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma",[89],"2005-01-10","2007-12-01","2001-01-05",[24],[2297,2265],"irinotecan hydrochloride",{"nctId":2299,"briefTitle":2300,"status":139,"phases":2301,"primaryCompletion":2046,"start":2302,"enrollment":1280,"conditions":2303,"interventions":2304},"NCT00390403","Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[89],"2007-02",[24],[2305,2265,2306,2307,2308],"R-(-)-gossypol acetic acid","gene expression analysis","mutation analysis","protein expression analysis",{"nctId":2310,"briefTitle":2311,"status":139,"phases":2312,"primaryCompletion":2313,"completion":2314,"start":2315,"conditions":2316,"interventions":2317},"NCT00027625","Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma",[89],"2005-03-17","2005-11-01","2002-01-28",[24],[1687,2265],{"nctId":2319,"briefTitle":2320,"status":139,"phases":2321,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":266,"conditions":2324,"interventions":2325},"NCT00770471","ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[89],"2012-03-01","2009-07-13",[24],[2265,2326,2327,2306,2307,2328],"veliparib","DNA methylation analysis","proteomic profiling",{"nctId":2330,"briefTitle":2331,"status":139,"phases":2332,"primaryCompletion":2333,"completion":2334,"start":2335,"enrollment":31,"conditions":2336,"interventions":2337},"NCT01480050","Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma",[89],"2015-08","2017-06-01","2012-05-31",[24],[2265,2338],"Mibefradil",{"nctId":2340,"briefTitle":2341,"status":127,"phases":2342,"primaryCompletion":2343,"completion":2344,"start":2345,"enrollment":1280,"conditions":2346,"interventions":2347},"NCT05083754","Carmustine Wafer in Combination With Retifanlimab and Radiation With\u002FWithout Temozolomide in Subjects With Glioblastoma",[89],"2028-01","2029-01","2022-08-31",[227],[2348,2276],"Retifanlimab",{"trials":2350,"activeCount":733,"soonestReadout":310},[2351,2361,2369,2378,2385,2395,2402,2416,2425,2435],{"nctId":2352,"briefTitle":2353,"status":139,"phases":2354,"primaryCompletion":2355,"completion":2356,"start":2357,"enrollment":493,"conditions":2358,"interventions":2359},"NCT00006358","Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor",[90],"2003-01-23","2006-07-20","2000-06-13",[24],[2265,2360],"thalidomide",{"nctId":2362,"briefTitle":2363,"status":139,"phases":2364,"primaryCompletion":846,"completion":1381,"start":2365,"enrollment":190,"conditions":2366,"interventions":2368},"NCT01466686","Low Dose Radiation Therapy for Glioblastoma Multiforme",[90],"2012-09",[2367],"High Grade Glioma",[2276],{"nctId":2370,"briefTitle":2371,"status":139,"phases":2372,"primaryCompletion":2373,"completion":741,"start":1888,"enrollment":2374,"conditions":2375,"interventions":2376},"NCT00262730","Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM",[90],"2009-08",97,[227],[2377,2265],"poly ICLC",{"nctId":2379,"briefTitle":2380,"status":219,"phases":2381,"primaryCompletion":2365,"completion":2365,"start":2382,"enrollment":37,"conditions":2383,"interventions":2384},"NCT00248534","Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma",[90],"2005-09",[30],[883,926,2265],{"nctId":2386,"briefTitle":2387,"status":127,"phases":2388,"primaryCompletion":472,"completion":2389,"start":2390,"enrollment":848,"conditions":2391,"interventions":2393},"NCT06617923","Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer",[90],"2029-12","2025-02-06",[2392,767,769],"Ovary Cancer",[2394,2276],"Senaparib",{"nctId":2396,"briefTitle":2397,"status":104,"phases":2398,"primaryCompletion":310,"completion":311,"start":2399,"enrollment":700,"conditions":2400,"interventions":2401},"NCT02177578","Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme",[90],"2014-07-08",[227],[2276],{"nctId":2403,"briefTitle":2404,"status":139,"phases":2405,"primaryCompletion":2406,"completion":2406,"start":2407,"enrollment":1383,"conditions":2408,"interventions":2414},"NCT03914742","BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1\u002F2 Mutations",[89,90],"2023-10-31","2020-02-16",[2409,2410,2411,2412,2413],"IDH1 Mutation","IDH2 Mutation","Recurrent Glioblastoma","Recurrent WHO Grade II Glioma","Recurrent WHO Grade III Glioma",[2415,2276],"PARP Inhibitor BGB-290",{"nctId":2417,"briefTitle":2418,"status":139,"phases":2419,"primaryCompletion":1269,"completion":1562,"start":2420,"enrollment":2421,"conditions":2422,"interventions":2423},"NCT00486603","Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[89,90],"2007-10-29",92,[24],[2424,2265],"hydroxychloroquine",{"nctId":2426,"briefTitle":2427,"status":139,"phases":2428,"primaryCompletion":2429,"completion":2430,"start":2431,"enrollment":2432,"conditions":2433,"interventions":2434},"NCT00003176","Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma",[90],"2001-12-03","2004-01-06","1998-03-25",82,[24],[1024,2265],{"nctId":2436,"briefTitle":2437,"status":219,"phases":2438,"primaryCompletion":2439,"completion":2439,"start":2440,"enrollment":156,"conditions":2441,"interventions":2442},"NCT00238277","Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme",[90],"2007-12-11","2005-02-15",[24],[2265],{"trials":2444,"activeCount":100},[],{"trials":2446,"activeCount":100},[],{"trials":2448,"activeCount":100},[2449],{"nctId":2450,"briefTitle":2451,"status":219,"phases":2452,"primaryCompletion":2453,"completion":2454,"start":2455,"enrollment":1655,"conditions":2456,"interventions":2458},"NCT00471653","Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy",[],"2008-11-12","2009-08-18","2006-11-11",[24,2457],"Thrombocytopenia",[2265,2459,2460],"comparative genomic hybridization","polymorphism analysis",{"intervention":854,"totalTrials":156,"cells":2462},{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2475,"PHASE3":2539,"PHASE4":2541,"NA":2543},{"trials":2464,"activeCount":100},[],{"trials":2466,"activeCount":100},[2467,2471],{"nctId":749,"briefTitle":750,"status":139,"phases":2468,"start":752,"conditions":2469,"interventions":2470},[89],[27,30,754,33,711],[692,650,756,757,758],{"nctId":791,"briefTitle":792,"status":139,"phases":2472,"start":794,"enrollment":700,"conditions":2473,"interventions":2474},[89],[745,796,27,30,754,33,711],[692,650,756,757,758],{"trials":2476,"activeCount":733,"soonestReadout":275},[2477,2481,2485,2489,2498,2502,2506,2510,2519,2523,2527,2531,2535],{"nctId":843,"briefTitle":844,"status":139,"phases":2478,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":2479,"interventions":2480},[90],[850,851],[853,676,82,639,854,855],{"nctId":857,"briefTitle":858,"status":139,"phases":2482,"primaryCompletion":860,"completion":860,"start":861,"enrollment":862,"conditions":2483,"interventions":2484},[90],[778,786,864,865,866,867,745,673,868,869,785,870,871,872],[676,82,854,874],{"nctId":995,"briefTitle":996,"status":127,"phases":2486,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":118,"conditions":2487,"interventions":2488},[90],[1002,1003,1004,1005,1006,1007,1008,1009,1010,1011],[1013,676,1014,82,854,677],{"nctId":2490,"briefTitle":2491,"status":139,"phases":2492,"primaryCompletion":2493,"completion":2493,"start":2494,"enrollment":405,"conditions":2495,"interventions":2496},"NCT00003572","Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers",[90],"2002-04","1998-08",[27,30,754,33],[2497,757,758],"peripheral blood lymphocyte therapy",{"nctId":1038,"briefTitle":1039,"status":127,"phases":2499,"primaryCompletion":275,"completion":1041,"start":1042,"enrollment":700,"conditions":2500,"interventions":2501},[90],[1044],[82,676,1014,854],{"nctId":1047,"briefTitle":1048,"status":416,"phases":2503,"primaryCompletion":1050,"completion":1050,"start":802,"enrollment":100,"conditions":2504,"interventions":2505},[90],[1052,1053,192],[82,639,840,854,757,894,1055,1056],{"nctId":1065,"briefTitle":1066,"status":139,"phases":2507,"primaryCompletion":1068,"completion":1068,"start":534,"enrollment":108,"conditions":2508,"interventions":2509},[90],[850,1034,1004,1070],[853,676,82,854,874],{"nctId":2511,"briefTitle":2512,"status":139,"phases":2513,"primaryCompletion":2514,"completion":2514,"start":2515,"enrollment":1099,"conditions":2516,"interventions":2518},"NCT01203722","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",[89,90],"2024-05-28","2010-09",[2517],"Hematologic Malignancies",[676,1732,677,962,854],{"nctId":1150,"briefTitle":1151,"status":219,"phases":2520,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":2521,"interventions":2522},[89,90],[1158,1159],[82,676,854,677,1161,1162],{"nctId":1180,"briefTitle":1181,"status":219,"phases":2524,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":156,"conditions":2525,"interventions":2526},[90],[30,27,778],[676,943,82,677,854],{"nctId":1188,"briefTitle":1189,"status":139,"phases":2528,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":2529,"interventions":2530},[90],[745,27,30,754,33],[650,756,757,758],{"nctId":1209,"briefTitle":1210,"status":219,"phases":2532,"primaryCompletion":1212,"completion":1213,"start":1076,"enrollment":1214,"conditions":2533,"interventions":2534},[90],[30,1216,1217,865],[676,82,854,677,841,1219],{"nctId":1253,"briefTitle":1254,"status":139,"phases":2536,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":28,"conditions":2537,"interventions":2538},[90],[1260,1261,1262,1263],[82,943,854,874],{"trials":2540,"activeCount":100},[],{"trials":2542,"activeCount":100},[],{"trials":2544,"activeCount":100},[],{"intervention":676,"totalTrials":969,"cells":2546},{"EARLY_PHASE1":2547,"PHASE1":2549,"PHASE2":2555,"PHASE3":2601,"PHASE4":2603,"NA":2605},{"trials":2548,"activeCount":100},[],{"trials":2550,"activeCount":100},[2551],{"nctId":665,"briefTitle":666,"status":139,"phases":2552,"primaryCompletion":668,"completion":668,"start":657,"enrollment":669,"conditions":2553,"interventions":2554},[89],[671,27,672,673,674],[82,676,677,678,679,680,681],{"trials":2556,"activeCount":733,"soonestReadout":275},[2557,2561,2565,2569,2573,2577,2581,2585,2589,2593,2597],{"nctId":843,"briefTitle":844,"status":139,"phases":2558,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":2559,"interventions":2560},[90],[850,851],[853,676,82,639,854,855],{"nctId":857,"briefTitle":858,"status":139,"phases":2562,"primaryCompletion":860,"completion":860,"start":861,"enrollment":862,"conditions":2563,"interventions":2564},[90],[778,786,864,865,866,867,745,673,868,869,785,870,871,872],[676,82,854,874],{"nctId":954,"briefTitle":955,"status":219,"phases":2566,"primaryCompletion":957,"completion":957,"start":958,"enrollment":19,"conditions":2567,"interventions":2568},[90],[960],[82,676,874,962,963,964],{"nctId":995,"briefTitle":996,"status":127,"phases":2570,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":118,"conditions":2571,"interventions":2572},[90],[1002,1003,1004,1005,1006,1007,1008,1009,1010,1011],[1013,676,1014,82,854,677],{"nctId":1038,"briefTitle":1039,"status":127,"phases":2574,"primaryCompletion":275,"completion":1041,"start":1042,"enrollment":700,"conditions":2575,"interventions":2576},[90],[1044],[82,676,1014,854],{"nctId":1047,"briefTitle":1048,"status":416,"phases":2578,"primaryCompletion":1050,"completion":1050,"start":802,"enrollment":100,"conditions":2579,"interventions":2580},[90],[1052,1053,192],[82,639,840,854,757,894,1055,1056],{"nctId":1065,"briefTitle":1066,"status":139,"phases":2582,"primaryCompletion":1068,"completion":1068,"start":534,"enrollment":108,"conditions":2583,"interventions":2584},[90],[850,1034,1004,1070],[853,676,82,854,874],{"nctId":2511,"briefTitle":2512,"status":139,"phases":2586,"primaryCompletion":2514,"completion":2514,"start":2515,"enrollment":1099,"conditions":2587,"interventions":2588},[89,90],[2517],[676,1732,677,962,854],{"nctId":1150,"briefTitle":1151,"status":219,"phases":2590,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":2591,"interventions":2592},[89,90],[1158,1159],[82,676,854,677,1161,1162],{"nctId":1180,"briefTitle":1181,"status":219,"phases":2594,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":156,"conditions":2595,"interventions":2596},[90],[30,27,778],[676,943,82,677,854],{"nctId":1209,"briefTitle":1210,"status":219,"phases":2598,"primaryCompletion":1212,"completion":1213,"start":1076,"enrollment":1214,"conditions":2599,"interventions":2600},[90],[30,1216,1217,865],[676,82,854,677,841,1219],{"trials":2602,"activeCount":100},[],{"trials":2604,"activeCount":100},[],{"trials":2606,"activeCount":100},[],{"intervention":409,"totalTrials":689,"cells":2608},{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2617,"PHASE3":2653,"PHASE4":2655,"NA":2657},{"trials":2610,"activeCount":100},[],{"trials":2612,"activeCount":100},[2613],{"nctId":1559,"briefTitle":1560,"status":139,"phases":2614,"primaryCompletion":1562,"completion":182,"start":1563,"enrollment":848,"conditions":2615,"interventions":2616},[89],[21],[409,638,73,73,1566],{"trials":2618,"activeCount":733,"soonestReadout":1392},[2619,2623,2637,2641,2645,2649],{"nctId":2031,"briefTitle":2032,"status":139,"phases":2620,"primaryCompletion":2034,"completion":2035,"start":2036,"enrollment":2037,"conditions":2621,"interventions":2622},[89,90],[566],[58,2040,2041,638,409],{"nctId":2624,"briefTitle":2625,"status":139,"phases":2626,"primaryCompletion":2627,"completion":2627,"start":2628,"enrollment":2629,"conditions":2630,"interventions":2632},"NCT01896856","Phase I\u002FII Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer",[89,90],"2019-08-26","2013-10-23",118,[2631],"Previously Treated Metastatic Colorectal Cancer",[2633,2634,2635,2636,409],"SGI-110 Dose Escalation","Regorafenib","TAS-102","SGI-110",{"nctId":1830,"briefTitle":1831,"status":139,"phases":2638,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":452,"conditions":2639,"interventions":2640},[89,90],[1836,1837,1838,1839,1840,1841,1842,1843,1844,1845],[1397,58,917,638,409,1397,58,917,638,409],{"nctId":400,"briefTitle":401,"status":127,"phases":2642,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":2643,"interventions":2644},[90],[21],[408,409,410,411,412,63,123],{"nctId":1894,"briefTitle":1895,"status":219,"phases":2646,"primaryCompletion":741,"completion":741,"start":688,"enrollment":1897,"conditions":2647,"interventions":2648},[90],[21],[1900,1875,1901,1902,58,409,1903,1904],{"nctId":1389,"briefTitle":1390,"status":104,"phases":2650,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":301,"conditions":2651,"interventions":2652},[90],[497],[1397,58,638,409,917,580,73],{"trials":2654,"activeCount":100},[],{"trials":2656,"activeCount":100},[],{"trials":2658,"activeCount":100},[],{"intervention":2660,"totalTrials":231,"cells":2661},"Durvalumab",{"EARLY_PHASE1":2662,"PHASE1":2664,"PHASE2":2674,"PHASE3":2725,"PHASE4":2727,"NA":2729},{"trials":2663,"activeCount":100},[],{"trials":2665,"activeCount":1156,"soonestReadout":276},[2666],{"nctId":2667,"briefTitle":2668,"status":127,"phases":2669,"primaryCompletion":276,"completion":276,"start":1224,"enrollment":1516,"conditions":2670,"interventions":2672},"NCT06564623","Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)",[89],[2671],"Biliary Tract Cancers",[2673,2660,1557],"mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]",{"trials":2675,"activeCount":1156,"soonestReadout":1314},[2676,2684,2695,2703,2715],{"nctId":2677,"briefTitle":2678,"status":139,"phases":2679,"primaryCompletion":2680,"completion":2680,"start":312,"enrollment":108,"conditions":2681,"interventions":2683},"NCT03638141","CTLA-4 \u002FPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab",[90],"2024-08-20",[2682,192],"Intermediate Stage of Hepatocellular Carcinoma",[2660,1557],{"nctId":2685,"briefTitle":2686,"status":139,"phases":2687,"primaryCompletion":2688,"completion":2689,"start":2690,"enrollment":1609,"conditions":2691,"interventions":2693},"NCT04301778","Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma",[90],"2022-11-04","2024-02-06","2021-08-24",[2692],"Unresectable Intrahepatic Cholangiocarcinoma",[2660,2694],"SNDX-6352",{"nctId":2696,"briefTitle":2697,"status":127,"phases":2698,"primaryCompletion":1314,"completion":2699,"start":2700,"enrollment":118,"conditions":2701,"interventions":2702},"NCT06027086","DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)",[89,90],"2033-09-01","2024-02-12",[1052],[2660,205],{"nctId":2704,"briefTitle":2705,"status":416,"phases":2706,"primaryCompletion":2707,"completion":2707,"start":2708,"enrollment":100,"conditions":2709,"interventions":2713},"NCT04001413","Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients",[90],"2021-03-25","2019-09-17",[2710,2711,2712],"HPV Positive Oropharyngeal Squamous Cell Carcinoma","Oropharynx Cancer","HPV-Related Carcinoma",[2714,2660],"MEDI0457",{"nctId":2716,"briefTitle":2717,"status":219,"phases":2718,"primaryCompletion":2719,"completion":2720,"start":2721,"enrollment":361,"conditions":2722,"interventions":2723},"NCT03237377","Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer",[90],"2021-11-04","2024-05-23","2017-12-12",[325],[2660,1557,2724],"Standard of care adjuvant chemotherapy",{"trials":2726,"activeCount":100},[],{"trials":2728,"activeCount":100},[],{"trials":2730,"activeCount":100},[],{"intervention":1014,"totalTrials":536,"cells":2732},{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2737,"PHASE3":2761,"PHASE4":2763,"NA":2765},{"trials":2734,"activeCount":100},[],{"trials":2736,"activeCount":100},[],{"trials":2738,"activeCount":733,"soonestReadout":275},[2739,2743,2747,2751],{"nctId":995,"briefTitle":996,"status":127,"phases":2740,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":118,"conditions":2741,"interventions":2742},[90],[1002,1003,1004,1005,1006,1007,1008,1009,1010,1011],[1013,676,1014,82,854,677],{"nctId":1038,"briefTitle":1039,"status":127,"phases":2744,"primaryCompletion":275,"completion":1041,"start":1042,"enrollment":700,"conditions":2745,"interventions":2746},[90],[1044],[82,676,1014,854],{"nctId":1104,"briefTitle":1105,"status":139,"phases":2748,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":25,"conditions":2749,"interventions":2750},[90],[673],[1112,1113,82,840,1014,1114],{"nctId":2752,"briefTitle":2753,"status":139,"phases":2754,"primaryCompletion":42,"completion":2755,"start":2756,"enrollment":1872,"conditions":2757,"interventions":2758},"NCT00566098","Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma",[89,90],"2018-10","2007-11",[754],[2759,1014,2760],"MILs","PCV13",{"trials":2762,"activeCount":100},[],{"trials":2764,"activeCount":100},[],{"trials":2766,"activeCount":100},[],{"intervention":2768,"totalTrials":733,"cells":2769},"Palbociclib",{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2774,"PHASE3":2795,"PHASE4":2797,"NA":2799},{"trials":2771,"activeCount":100},[],{"trials":2773,"activeCount":100},[],{"trials":2775,"activeCount":733,"soonestReadout":310},[2776,2785],{"nctId":2777,"briefTitle":2778,"status":104,"phases":2779,"primaryCompletion":310,"completion":310,"start":2780,"enrollment":700,"conditions":2781,"interventions":2783},"NCT02738866","Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor",[90],"2016-10-25",[2782],"Metastatic Breast Cancer",[2768,2784],"Fulvestrant",{"nctId":2786,"briefTitle":2787,"status":104,"phases":2788,"primaryCompletion":462,"completion":2789,"start":2790,"enrollment":1797,"conditions":2791,"interventions":2792},"NCT03573648","Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer",[90],"2026-12-30","2018-11-13",[18],[2793,2794,2768],"Avelumab","Endocrine therapy",{"trials":2796,"activeCount":100},[],{"trials":2798,"activeCount":100},[],{"trials":2800,"activeCount":100},[],{"intervention":1856,"totalTrials":733,"cells":2802},{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2807,"PHASE3":2817,"PHASE4":2819,"NA":2821},{"trials":2804,"activeCount":100},[],{"trials":2806,"activeCount":100},[],{"trials":2808,"activeCount":733,"soonestReadout":2209},[2809,2813],{"nctId":1848,"briefTitle":1849,"status":197,"phases":2810,"primaryCompletion":1851,"completion":1851,"start":1755,"enrollment":1852,"conditions":2811,"interventions":2812},[90],[120],[408,917,1855,1856,1857],{"nctId":2206,"briefTitle":2207,"status":127,"phases":2814,"primaryCompletion":2209,"completion":2209,"start":2210,"enrollment":493,"conditions":2815,"interventions":2816},[90],[120],[1855,1856],{"trials":2818,"activeCount":100},[],{"trials":2820,"activeCount":100},[],{"trials":2822,"activeCount":100},[],{"intervention":205,"totalTrials":733,"cells":2824},{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2833,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2826,"activeCount":100},[],{"trials":2828,"activeCount":1156,"soonestReadout":199},[2829],{"nctId":195,"briefTitle":196,"status":197,"phases":2830,"primaryCompletion":199,"completion":199,"start":200,"enrollment":118,"conditions":2831,"interventions":2832},[89],[202],[204,205,63,123],{"trials":2834,"activeCount":1156,"soonestReadout":1314},[2835],{"nctId":2696,"briefTitle":2697,"status":127,"phases":2836,"primaryCompletion":1314,"completion":2699,"start":2700,"enrollment":118,"conditions":2837,"interventions":2838},[89,90],[1052],[2660,205],{"trials":2840,"activeCount":100},[],{"trials":2842,"activeCount":100},[],{"trials":2844,"activeCount":100},[],{"intervention":1228,"totalTrials":733,"cells":2846},{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2863,"PHASE3":2869,"PHASE4":2871,"NA":2873},{"trials":2848,"activeCount":100},[],{"trials":2850,"activeCount":1156,"soonestReadout":2855},[2851],{"nctId":2852,"briefTitle":2853,"status":127,"phases":2854,"primaryCompletion":2855,"completion":2856,"start":2857,"enrollment":2858,"conditions":2859,"interventions":2860},"NCT06411691","KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer",[89],"2028-03-01","2029-07-01","2025-06-24",54,[120,21],[2861,1228,2862],"KRAS Vaccine with Poly-ICLC adjuvant","Botensilimab",{"trials":2864,"activeCount":1156,"soonestReadout":403},[2865],{"nctId":1221,"briefTitle":1222,"status":127,"phases":2866,"primaryCompletion":403,"completion":403,"start":1224,"enrollment":301,"conditions":2867,"interventions":2868},[89,90],[21],[1227,1228,82,343,1227,1228,1229],{"trials":2870,"activeCount":100},[],{"trials":2872,"activeCount":100},[],{"trials":2874,"activeCount":100},[],{"intervention":53,"totalTrials":733,"cells":2876},{"EARLY_PHASE1":2877,"PHASE1":2879,"PHASE2":2881,"PHASE3":2896,"PHASE4":2898,"NA":2900},{"trials":2878,"activeCount":100},[],{"trials":2880,"activeCount":100},[],{"trials":2882,"activeCount":733,"soonestReadout":52},[2883,2891],{"nctId":2884,"briefTitle":2885,"status":127,"phases":2886,"primaryCompletion":129,"completion":129,"start":2887,"enrollment":2888,"conditions":2889,"interventions":2890},"NCT06014255","Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer",[90],"2024-02-16",219,[15],[53],{"nctId":50,"briefTitle":51,"status":104,"phases":2892,"primaryCompletion":52,"completion":1755,"start":2893,"enrollment":1797,"conditions":2894,"interventions":2895},[90],"2017-02-14",[15],[53],{"trials":2897,"activeCount":100},[],{"trials":2899,"activeCount":100},[],{"trials":2901,"activeCount":100},[],{"intervention":1990,"totalTrials":536,"cells":2903},{"EARLY_PHASE1":2904,"PHASE1":2906,"PHASE2":2908,"PHASE3":2943,"PHASE4":2945,"NA":2947},{"trials":2905,"activeCount":100},[],{"trials":2907,"activeCount":100},[],{"trials":2909,"activeCount":733,"soonestReadout":2914},[2910,2924,2935],{"nctId":2911,"briefTitle":2912,"status":104,"phases":2913,"primaryCompletion":2914,"completion":2914,"start":2915,"enrollment":493,"conditions":2916,"interventions":2920},"NCT03114865","A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance",[89,90],"2026-06-30","2017-09-05",[2917,2918,2919],"Acute Lymphoblastic Leukemia","B-cell Non Hodgkin Lymphoma","Pre B-Cell Acute Lymphoblastic Leukaemia",[2921,2922,2923,1990],"Blinatumomab 9ug","Blinatumomab 28 ug","Blinatumomab",{"nctId":2925,"briefTitle":2926,"status":127,"phases":2927,"primaryCompletion":2928,"completion":2929,"start":2930,"enrollment":1121,"conditions":2931,"interventions":2933},"NCT06616597","Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer",[90],"2031-03-30","2032-03-30","2025-02-13",[2932,244],"Prostate Cancer (Adenocarcinoma)",[1772,1990,2934],"Metronidazole",{"nctId":2936,"briefTitle":2937,"status":219,"phases":2938,"primaryCompletion":1562,"completion":1562,"start":732,"enrollment":723,"conditions":2939,"interventions":2940},"NCT01374217","Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma",[90],[673],[579,2941,1990,2942],"Lenalidomide","Clarithromycin",{"trials":2944,"activeCount":100},[],{"trials":2946,"activeCount":100},[],{"trials":2948,"activeCount":100},[2949],{"nctId":1981,"briefTitle":1982,"status":219,"phases":2950,"primaryCompletion":668,"completion":668,"start":1984,"enrollment":1609,"conditions":2951,"interventions":2952},[93],[1986,1987,1988,1421],[1990,258],{"intervention":677,"totalTrials":156,"cells":2954},{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2971,"PHASE3":3021,"PHASE4":3023,"NA":3025},{"trials":2956,"activeCount":100},[],{"trials":2958,"activeCount":100},[2959,2963,2967],{"nctId":665,"briefTitle":666,"status":139,"phases":2960,"primaryCompletion":668,"completion":668,"start":657,"enrollment":669,"conditions":2961,"interventions":2962},[89],[671,27,672,673,674],[82,676,677,678,679,680,681],{"nctId":749,"briefTitle":750,"status":139,"phases":2964,"start":752,"conditions":2965,"interventions":2966},[89],[27,30,754,33,711],[692,650,756,757,758],{"nctId":791,"briefTitle":792,"status":139,"phases":2968,"start":794,"enrollment":700,"conditions":2969,"interventions":2970},[89],[745,796,27,30,754,33,711],[692,650,756,757,758],{"trials":2972,"activeCount":1156,"soonestReadout":998},[2973,2977,2981,2985,2989,2993,2997,3001,3005,3009,3013,3017],{"nctId":857,"briefTitle":858,"status":139,"phases":2974,"primaryCompletion":860,"completion":860,"start":861,"enrollment":862,"conditions":2975,"interventions":2976},[90],[778,786,864,865,866,867,745,673,868,869,785,870,871,872],[676,82,854,874],{"nctId":954,"briefTitle":955,"status":219,"phases":2978,"primaryCompletion":957,"completion":957,"start":958,"enrollment":19,"conditions":2979,"interventions":2980},[90],[960],[82,676,874,962,963,964],{"nctId":995,"briefTitle":996,"status":127,"phases":2982,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":118,"conditions":2983,"interventions":2984},[90],[1002,1003,1004,1005,1006,1007,1008,1009,1010,1011],[1013,676,1014,82,854,677],{"nctId":2490,"briefTitle":2491,"status":139,"phases":2986,"primaryCompletion":2493,"completion":2493,"start":2494,"enrollment":405,"conditions":2987,"interventions":2988},[90],[27,30,754,33],[2497,757,758],{"nctId":1047,"briefTitle":1048,"status":416,"phases":2990,"primaryCompletion":1050,"completion":1050,"start":802,"enrollment":100,"conditions":2991,"interventions":2992},[90],[1052,1053,192],[82,639,840,854,757,894,1055,1056],{"nctId":1065,"briefTitle":1066,"status":139,"phases":2994,"primaryCompletion":1068,"completion":1068,"start":534,"enrollment":108,"conditions":2995,"interventions":2996},[90],[850,1034,1004,1070],[853,676,82,854,874],{"nctId":2511,"briefTitle":2512,"status":139,"phases":2998,"primaryCompletion":2514,"completion":2514,"start":2515,"enrollment":1099,"conditions":2999,"interventions":3000},[89,90],[2517],[676,1732,677,962,854],{"nctId":1150,"briefTitle":1151,"status":219,"phases":3002,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":3003,"interventions":3004},[89,90],[1158,1159],[82,676,854,677,1161,1162],{"nctId":1180,"briefTitle":1181,"status":219,"phases":3006,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":156,"conditions":3007,"interventions":3008},[90],[30,27,778],[676,943,82,677,854],{"nctId":1188,"briefTitle":1189,"status":139,"phases":3010,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":3011,"interventions":3012},[90],[745,27,30,754,33],[650,756,757,758],{"nctId":1209,"briefTitle":1210,"status":219,"phases":3014,"primaryCompletion":1212,"completion":1213,"start":1076,"enrollment":1214,"conditions":3015,"interventions":3016},[90],[30,1216,1217,865],[676,82,854,677,841,1219],{"nctId":1253,"briefTitle":1254,"status":139,"phases":3018,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":28,"conditions":3019,"interventions":3020},[90],[1260,1261,1262,1263],[82,943,854,874],{"trials":3022,"activeCount":100},[],{"trials":3024,"activeCount":100},[],{"trials":3026,"activeCount":100},[],{"intervention":1892,"totalTrials":723,"cells":3028},{"EARLY_PHASE1":3029,"PHASE1":3031,"PHASE2":3067,"PHASE3":3129,"PHASE4":3131,"NA":3133},{"trials":3030,"activeCount":100},[],{"trials":3032,"activeCount":100},[3033,3042,3051,3058],{"nctId":3034,"briefTitle":3035,"status":219,"phases":3036,"primaryCompletion":3037,"completion":3037,"start":1382,"enrollment":224,"conditions":3038,"interventions":3039},"NCT02478125","Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer",[89],"2017-05",[15],[3040,1892,3041],"Burixafor Hydrobromide","G-CSF",{"nctId":3043,"briefTitle":3044,"status":219,"phases":3045,"primaryCompletion":3046,"completion":3046,"start":3047,"enrollment":536,"conditions":3048,"interventions":3049},"NCT03043989","Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin",[89],"2019-07-26","2017-03-21",[15],[1892,3050,2942],"Cabazitaxel",{"nctId":3052,"briefTitle":3053,"status":139,"phases":3054,"primaryCompletion":3055,"completion":3055,"start":880,"enrollment":212,"conditions":3056,"interventions":3057},"NCT00559429","Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer",[89],"2008-10",[15],[1892,1892,1892,1892],{"nctId":3059,"briefTitle":3060,"status":139,"phases":3061,"primaryCompletion":3062,"completion":1563,"start":3063,"enrollment":969,"conditions":3064,"interventions":3065},"NCT00080665","Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer",[89],"2007-01","2003-12",[18],[1901,3066],"imatinib mesylate",{"trials":3068,"activeCount":1156,"soonestReadout":57},[3069,3078,3082,3091,3095,3099,3108,3112,3116,3120],{"nctId":3070,"briefTitle":3071,"status":139,"phases":3072,"primaryCompletion":1380,"completion":1380,"start":3073,"enrollment":1872,"conditions":3074,"interventions":3075},"NCT02716974","A Study of Definitive Therapy to Treat Prostate Cancer",[90],"2016-06",[15],[3076,3077,1892],"Leuprolide Acetate","Bicalutamide",{"nctId":2043,"briefTitle":2044,"status":139,"phases":3079,"primaryCompletion":646,"completion":2046,"start":2047,"enrollment":1280,"conditions":3080,"interventions":3081},[90],[1497],[1175,1901],{"nctId":3083,"briefTitle":3084,"status":219,"phases":3085,"primaryCompletion":3086,"completion":3086,"start":3087,"enrollment":34,"conditions":3088,"interventions":3089},"NCT00080626","Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer",[90],"2006-05-01","2003-08-11",[18],[3090,1901],"pegfilgrastim",{"nctId":55,"briefTitle":56,"status":104,"phases":3092,"primaryCompletion":57,"completion":2118,"start":2119,"enrollment":118,"conditions":3093,"interventions":3094},[90],[1335,1334],[58,1892],{"nctId":2123,"briefTitle":2124,"status":219,"phases":3096,"primaryCompletion":2126,"completion":2127,"start":2128,"enrollment":231,"conditions":3097,"interventions":3098},[90],[2130],[58,1892,2132],{"nctId":3100,"briefTitle":3101,"status":219,"phases":3102,"primaryCompletion":3103,"completion":3104,"start":3105,"enrollment":1280,"conditions":3106,"interventions":3107},"NCT02516670","Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer",[90],"2021-07-31","2021-10-14","2016-06-20",[1986,1987,1421],[1892],{"nctId":2063,"briefTitle":2064,"status":139,"phases":3109,"primaryCompletion":1796,"completion":2066,"start":1449,"enrollment":118,"conditions":3110,"interventions":3111},[90],[2068,292,170],[1892,1136,2070,638],{"nctId":1885,"briefTitle":1886,"status":139,"phases":3113,"primaryCompletion":731,"completion":731,"start":1888,"enrollment":848,"conditions":3114,"interventions":3115},[90],[1890],[1892,917],{"nctId":1894,"briefTitle":1895,"status":219,"phases":3117,"primaryCompletion":741,"completion":741,"start":688,"enrollment":1897,"conditions":3118,"interventions":3119},[90],[21],[1900,1875,1901,1902,58,409,1903,1904],{"nctId":3121,"briefTitle":3122,"status":139,"phases":3123,"primaryCompletion":3124,"completion":3124,"start":3125,"enrollment":1872,"conditions":3126,"interventions":3127},"NCT03043807","A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy",[90],"2022-10-17","2017-02-22",[15],[3076,1892,3077,3128],"Abiraterone Acetate",{"trials":3130,"activeCount":100},[],{"trials":3132,"activeCount":100},[],{"trials":3134,"activeCount":100},[],{"intervention":376,"totalTrials":689,"cells":3136},{"EARLY_PHASE1":3137,"PHASE1":3143,"PHASE2":3145,"PHASE3":3177,"PHASE4":3179,"NA":3181},{"trials":3138,"activeCount":100},[3139],{"nctId":617,"briefTitle":618,"status":139,"phases":3140,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":3141,"interventions":3142},[88],[21],[82,376,580,626],{"trials":3144,"activeCount":100},[],{"trials":3146,"activeCount":1156,"soonestReadout":81},[3147,3157,3161,3165,3169,3173],{"nctId":3148,"briefTitle":3149,"status":139,"phases":3150,"primaryCompletion":3151,"completion":3152,"start":3153,"enrollment":16,"conditions":3154,"interventions":3155},"NCT00389610","Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer",[90],"2021-10-11","2022-12-10","2006-09-11",[21],[3156],"GVAX pancreas vaccine",{"nctId":79,"briefTitle":80,"status":104,"phases":3158,"primaryCompletion":81,"completion":200,"start":1059,"enrollment":1060,"conditions":3159,"interventions":3160},[90],[21],[82,1063,376],{"nctId":1082,"briefTitle":1083,"status":139,"phases":3162,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":3163,"interventions":3164},[90],[566],[1091,580,341,82,376],{"nctId":367,"briefTitle":368,"status":139,"phases":3166,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":3167,"interventions":3168},[90],[21],[82,63,123,376,341,341],{"nctId":1197,"briefTitle":1198,"status":139,"phases":3170,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":34,"conditions":3171,"interventions":3172},[90],[21],[82,376,569],{"nctId":425,"briefTitle":426,"status":139,"phases":3174,"primaryCompletion":428,"completion":429,"start":430,"enrollment":190,"conditions":3175,"interventions":3176},[90],[21],[82,63,376],{"trials":3178,"activeCount":100},[],{"trials":3180,"activeCount":100},[],{"trials":3182,"activeCount":100},[],{"intervention":893,"totalTrials":689,"cells":3184},{"EARLY_PHASE1":3185,"PHASE1":3187,"PHASE2":3189,"PHASE3":3237,"PHASE4":3239,"NA":3241},{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":100},[],{"trials":3190,"activeCount":1156,"soonestReadout":911},[3191,3195,3206,3216,3220,3224,3228],{"nctId":885,"briefTitle":886,"status":219,"phases":3192,"primaryCompletion":888,"completion":888,"start":889,"enrollment":118,"conditions":3193,"interventions":3194},[90],[891],[841,82,893,637,894,895,175,896,897],{"nctId":3196,"briefTitle":3197,"status":139,"phases":3198,"primaryCompletion":3199,"completion":3199,"start":3200,"enrollment":1581,"conditions":3201,"interventions":3202},"NCT00369681","Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma",[90],"2014-10","2006-05",[30],[3203,841,3204,893,3205],"Bleomycin","Dacarbazine","Vinblastine",{"nctId":3207,"briefTitle":3208,"status":219,"phases":3209,"primaryCompletion":2515,"completion":3210,"start":3211,"enrollment":536,"conditions":3212,"interventions":3214},"NCT00755261","Phase II Study of Doxorubicin and Avastin® in Sarcoma.",[90],"2010-11","2008-09",[280,3213],"Soft Tissue Sarcoma",[3215,893],"Avastin",{"nctId":908,"briefTitle":909,"status":127,"phases":3217,"primaryCompletion":911,"completion":912,"start":913,"enrollment":313,"conditions":3218,"interventions":3219},[90],[915],[176,175,580,893,82,73,917],{"nctId":928,"briefTitle":929,"status":139,"phases":3221,"primaryCompletion":395,"completion":395,"start":931,"enrollment":118,"conditions":3222,"interventions":3223},[89,90],[18],[650,893],{"nctId":945,"briefTitle":946,"status":416,"phases":3225,"primaryCompletion":948,"completion":949,"start":473,"enrollment":100,"conditions":3226,"interventions":3227},[90],[18],[893,82,952],{"nctId":3229,"briefTitle":3230,"status":219,"phases":3231,"primaryCompletion":3232,"completion":3232,"start":3233,"enrollment":361,"conditions":3234,"interventions":3236},"NCT00484601","Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma",[90],"2007-11-07","2004-04-15",[3235],"Refractory Nasopharyngeal Carcinoma",[895,893],{"trials":3238,"activeCount":100},[],{"trials":3240,"activeCount":100},[],{"trials":3242,"activeCount":100},[],{"intervention":343,"totalTrials":689,"cells":3244},{"EARLY_PHASE1":3245,"PHASE1":3247,"PHASE2":3257,"PHASE3":3287,"PHASE4":3289,"NA":3291},{"trials":3246,"activeCount":100},[],{"trials":3248,"activeCount":100},[3249],{"nctId":3250,"briefTitle":3251,"status":139,"phases":3252,"primaryCompletion":3253,"completion":3253,"start":3254,"enrollment":848,"conditions":3255,"interventions":3256},"NCT01966289","SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)",[89],"2020-06-06","2014-04-14",[1357],[344,343,2636],{"trials":3258,"activeCount":1156,"soonestReadout":403},[3259,3263,3267,3271,3275,3279],{"nctId":973,"briefTitle":974,"status":139,"phases":3260,"primaryCompletion":948,"completion":976,"start":977,"enrollment":978,"conditions":3261,"interventions":3262},[89,90],[980],[982,82,343],{"nctId":1352,"briefTitle":1353,"status":139,"phases":3264,"primaryCompletion":47,"completion":47,"start":1355,"enrollment":143,"conditions":3265,"interventions":3266},[90],[1357],[344,343,580],{"nctId":332,"briefTitle":333,"status":139,"phases":3268,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":3269,"interventions":3270},[90],[339],[341,341,342,343,344],{"nctId":1221,"briefTitle":1222,"status":127,"phases":3272,"primaryCompletion":403,"completion":403,"start":1224,"enrollment":301,"conditions":3273,"interventions":3274},[89,90],[21],[1227,1228,82,343,1227,1228,1229],{"nctId":434,"briefTitle":435,"status":139,"phases":3276,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":3277,"interventions":3278},[89,90],[441,442],[63,444,343],{"nctId":3280,"briefTitle":3281,"status":139,"phases":3282,"primaryCompletion":880,"completion":3283,"start":3284,"enrollment":31,"conditions":3285,"interventions":3286},"NCT00024466","Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma",[89,90],"2009-04","2001-04",[673],[343],{"trials":3288,"activeCount":100},[],{"trials":3290,"activeCount":100},[],{"trials":3292,"activeCount":100},[],{"intervention":1080,"totalTrials":536,"cells":3294},{"EARLY_PHASE1":3295,"PHASE1":3297,"PHASE2":3299,"PHASE3":3320,"PHASE4":3322,"NA":3324},{"trials":3296,"activeCount":100},[],{"trials":3298,"activeCount":100},[],{"trials":3300,"activeCount":1156,"soonestReadout":47},[3301,3305,3309,3316],{"nctId":1073,"briefTitle":1074,"status":139,"phases":3302,"primaryCompletion":802,"completion":802,"start":1076,"enrollment":1077,"conditions":3303,"interventions":3304},[90],[18],[703,1080,650],{"nctId":1240,"briefTitle":1241,"status":139,"phases":3306,"primaryCompletion":938,"completion":938,"start":1243,"enrollment":439,"conditions":3307,"interventions":3308},[90],[1245],[1247,48,82],{"nctId":45,"briefTitle":46,"status":104,"phases":3310,"primaryCompletion":47,"completion":310,"start":3311,"enrollment":3312,"conditions":3313,"interventions":3314},[90],"2014-01-30",88,[18],[48,3315],"Pertuzumab",{"nctId":1266,"briefTitle":1267,"status":139,"phases":3317,"primaryCompletion":1269,"completion":1269,"start":1142,"enrollment":405,"conditions":3318,"interventions":3319},[90],[18],[703,1080,650],{"trials":3321,"activeCount":100},[],{"trials":3323,"activeCount":100},[],{"trials":3325,"activeCount":100},[],{"intervention":1771,"totalTrials":224,"cells":3327},{"EARLY_PHASE1":3328,"PHASE1":3330,"PHASE2":3332,"PHASE3":3346,"PHASE4":3348,"NA":3350},{"trials":3329,"activeCount":100},[],{"trials":3331,"activeCount":100},[],{"trials":3333,"activeCount":1156,"soonestReadout":1755},[3334,3338,3342],{"nctId":1752,"briefTitle":1753,"status":127,"phases":3335,"primaryCompletion":1755,"completion":480,"start":1756,"enrollment":1757,"conditions":3336,"interventions":3337},[90],[1759],[246,258,1761],{"nctId":1763,"briefTitle":1764,"status":139,"phases":3339,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1768,"conditions":3340,"interventions":3341},[90],[15],[246,1771,1772,258],{"nctId":1784,"briefTitle":1785,"status":139,"phases":3343,"primaryCompletion":1787,"completion":1788,"start":1191,"enrollment":1789,"conditions":3344,"interventions":3345},[90],[1759],[246,258,1771],{"trials":3347,"activeCount":100},[],{"trials":3349,"activeCount":100},[],{"trials":3351,"activeCount":100},[],{"intervention":1772,"totalTrials":224,"cells":3353},{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3358,"PHASE3":3372,"PHASE4":3374,"NA":3376},{"trials":3355,"activeCount":100},[],{"trials":3357,"activeCount":100},[],{"trials":3359,"activeCount":1156,"soonestReadout":2928},[3360,3364,3368],{"nctId":1763,"briefTitle":1764,"status":139,"phases":3361,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1768,"conditions":3362,"interventions":3363},[90],[15],[246,1771,1772,258],{"nctId":2925,"briefTitle":2926,"status":127,"phases":3365,"primaryCompletion":2928,"completion":2929,"start":2930,"enrollment":1121,"conditions":3366,"interventions":3367},[90],[2932,244],[1772,1990,2934],{"nctId":3121,"briefTitle":3122,"status":139,"phases":3369,"primaryCompletion":3124,"completion":3124,"start":3125,"enrollment":1872,"conditions":3370,"interventions":3371},[90],[15],[3076,1892,3077,3128],{"trials":3373,"activeCount":100},[],{"trials":3375,"activeCount":100},[],{"trials":3377,"activeCount":100},[],{"intervention":1397,"totalTrials":224,"cells":3379},{"EARLY_PHASE1":3380,"PHASE1":3382,"PHASE2":3384,"PHASE3":3398,"PHASE4":3400,"NA":3402},{"trials":3381,"activeCount":100},[],{"trials":3383,"activeCount":100},[],{"trials":3385,"activeCount":1156,"soonestReadout":1392},[3386,3390,3394],{"nctId":1830,"briefTitle":1831,"status":139,"phases":3387,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":452,"conditions":3388,"interventions":3389},[89,90],[1836,1837,1838,1839,1840,1841,1842,1843,1844,1845],[1397,58,917,638,409,1397,58,917,638,409],{"nctId":1389,"briefTitle":1390,"status":104,"phases":3391,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":301,"conditions":3392,"interventions":3393},[90],[497],[1397,58,638,409,917,580,73],{"nctId":2146,"briefTitle":2147,"status":219,"phases":3395,"primaryCompletion":2149,"completion":2149,"start":2150,"enrollment":765,"conditions":3396,"interventions":3397},[89,90],[442],[2153,58,2154,2155,2156],{"trials":3399,"activeCount":100},[],{"trials":3401,"activeCount":100},[],{"trials":3403,"activeCount":100},[],{"intervention":411,"totalTrials":733,"cells":3405},{"EARLY_PHASE1":3406,"PHASE1":3408,"PHASE2":3410,"PHASE3":3420,"PHASE4":3422,"NA":3424},{"trials":3407,"activeCount":100},[],{"trials":3409,"activeCount":100},[],{"trials":3411,"activeCount":1156,"soonestReadout":403},[3412,3416],{"nctId":1689,"briefTitle":1690,"status":219,"phases":3413,"primaryCompletion":42,"completion":1692,"start":1693,"enrollment":190,"conditions":3414,"interventions":3415},[90],[171],[176,638,408,411],{"nctId":400,"briefTitle":401,"status":127,"phases":3417,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":3418,"interventions":3419},[90],[21],[408,409,410,411,412,63,123],{"trials":3421,"activeCount":100},[],{"trials":3423,"activeCount":100},[],{"trials":3425,"activeCount":100},[],{"intervention":1745,"totalTrials":1156,"cells":3427},{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3432,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3429,"activeCount":100},[],{"trials":3431,"activeCount":100},[],{"trials":3433,"activeCount":1156,"soonestReadout":1740},[3434],{"nctId":1737,"briefTitle":1738,"status":127,"phases":3435,"primaryCompletion":1740,"completion":1741,"start":1742,"enrollment":1280,"conditions":3436,"interventions":3437},[90],[15],[1745,1733,1746,258],{"trials":3439,"activeCount":100},[],{"trials":3441,"activeCount":100},[],{"trials":3443,"activeCount":100},[],{"intervention":3445,"totalTrials":1156,"cells":3446},"pBI-11",{"EARLY_PHASE1":3447,"PHASE1":3449,"PHASE2":3451,"PHASE3":3461,"PHASE4":3463,"NA":3465},{"trials":3448,"activeCount":100},[],{"trials":3450,"activeCount":100},[],{"trials":3452,"activeCount":1156,"soonestReadout":276},[3453],{"nctId":3454,"briefTitle":3455,"status":197,"phases":3456,"primaryCompletion":276,"completion":3457,"start":1755,"enrollment":452,"conditions":3458,"interventions":3460},"NCT06210854","Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16\u002F18+",[90],"2030-03",[3459],"HPV Infection",[3445,3445],{"trials":3462,"activeCount":100},[],{"trials":3464,"activeCount":100},[],{"trials":3466,"activeCount":100},[],{"intervention":3468,"totalTrials":1156,"cells":3469},"Bipolar Androgen Therapy",{"EARLY_PHASE1":3470,"PHASE1":3472,"PHASE2":3474,"PHASE3":3487,"PHASE4":3489,"NA":3491},{"trials":3471,"activeCount":100},[],{"trials":3473,"activeCount":100},[],{"trials":3475,"activeCount":1156,"soonestReadout":3480},[3476],{"nctId":3477,"briefTitle":3478,"status":127,"phases":3479,"primaryCompletion":3480,"completion":3481,"start":3482,"enrollment":2037,"conditions":3483,"interventions":3486},"NCT04704505","Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)",[90],"2028-02","2029-02","2022-04-28",[1988,3484,3485],"Metastatic Prostate Adenocarcinoma","Castration-resistant",[3468],{"trials":3488,"activeCount":100},[],{"trials":3490,"activeCount":100},[],{"trials":3492,"activeCount":100},[],{"intervention":270,"totalTrials":1156,"cells":3494},{"EARLY_PHASE1":3495,"PHASE1":3497,"PHASE2":3499,"PHASE3":3505,"PHASE4":3507,"NA":3509},{"trials":3496,"activeCount":100},[],{"trials":3498,"activeCount":100},[],{"trials":3500,"activeCount":1156,"soonestReadout":263},[3501],{"nctId":260,"briefTitle":261,"status":104,"phases":3502,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":3503,"interventions":3504},[90],[268],[63,270],{"trials":3506,"activeCount":100},[],{"trials":3508,"activeCount":100},[],{"trials":3510,"activeCount":100},[],{"intervention":1337,"totalTrials":1156,"cells":3512},{"EARLY_PHASE1":3513,"PHASE1":3515,"PHASE2":3517,"PHASE3":3523,"PHASE4":3525,"NA":3527},{"trials":3514,"activeCount":100},[],{"trials":3516,"activeCount":100},[],{"trials":3518,"activeCount":1156,"soonestReadout":1305},[3519],{"nctId":1328,"briefTitle":1329,"status":127,"phases":3520,"primaryCompletion":1305,"completion":911,"start":1331,"enrollment":405,"conditions":3521,"interventions":3522},[90],[1333,1334,1335],[1337,580],{"trials":3524,"activeCount":100},[],{"trials":3526,"activeCount":100},[],{"trials":3528,"activeCount":100},[],{"intervention":1478,"totalTrials":1156,"cells":3530},{"EARLY_PHASE1":3531,"PHASE1":3533,"PHASE2":3535,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3532,"activeCount":100},[],{"trials":3534,"activeCount":100},[],{"trials":3536,"activeCount":1156,"soonestReadout":42},[3537],{"nctId":40,"briefTitle":41,"status":104,"phases":3538,"primaryCompletion":42,"completion":1473,"start":1474,"enrollment":1475,"conditions":3539,"interventions":3540},[90],[18],[43,1478,1479],{"trials":3542,"activeCount":100},[],{"trials":3544,"activeCount":100},[],{"trials":3546,"activeCount":100},[],{"intervention":1479,"totalTrials":1156,"cells":3548},{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3559,"PHASE4":3561,"NA":3563},{"trials":3550,"activeCount":100},[],{"trials":3552,"activeCount":100},[],{"trials":3554,"activeCount":1156,"soonestReadout":42},[3555],{"nctId":40,"briefTitle":41,"status":104,"phases":3556,"primaryCompletion":42,"completion":1473,"start":1474,"enrollment":1475,"conditions":3557,"interventions":3558},[90],[18],[43,1478,1479],{"trials":3560,"activeCount":100},[],{"trials":3562,"activeCount":100},[],{"trials":3564,"activeCount":100},[],{"intervention":3566,"totalTrials":1156,"cells":3567},"CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16",{"EARLY_PHASE1":3568,"PHASE1":3570,"PHASE2":3572,"PHASE3":3583,"PHASE4":3585,"NA":3587},{"trials":3569,"activeCount":100},[],{"trials":3571,"activeCount":100},[],{"trials":3573,"activeCount":1156,"soonestReadout":3578},[3574],{"nctId":3575,"briefTitle":3576,"status":104,"phases":3577,"primaryCompletion":3578,"completion":3578,"start":1200,"enrollment":266,"conditions":3579,"interventions":3581},"NCT04713046","Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers",[89,90],"2026-10-01",[3580],"HPV 16+ Recurrent or Metastatic Cancer",[3566,3582],"Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16",{"trials":3584,"activeCount":100},[],{"trials":3586,"activeCount":100},[],{"trials":3588,"activeCount":100},[],{"intervention":3582,"totalTrials":1156,"cells":3590},{"EARLY_PHASE1":3591,"PHASE1":3593,"PHASE2":3595,"PHASE3":3601,"PHASE4":3603,"NA":3605},{"trials":3592,"activeCount":100},[],{"trials":3594,"activeCount":100},[],{"trials":3596,"activeCount":1156,"soonestReadout":3578},[3597],{"nctId":3575,"briefTitle":3576,"status":104,"phases":3598,"primaryCompletion":3578,"completion":3578,"start":1200,"enrollment":266,"conditions":3599,"interventions":3600},[89,90],[3580],[3566,3582],{"trials":3602,"activeCount":100},[],{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[],{"intervention":1489,"totalTrials":1156,"cells":3608},{"EARLY_PHASE1":3609,"PHASE1":3611,"PHASE2":3613,"PHASE3":3619,"PHASE4":3621,"NA":3623},{"trials":3610,"activeCount":100},[],{"trials":3612,"activeCount":100},[],{"trials":3614,"activeCount":1156,"soonestReadout":472},[3615],{"nctId":1481,"briefTitle":1482,"status":127,"phases":3616,"primaryCompletion":472,"completion":1484,"start":1485,"enrollment":1077,"conditions":3617,"interventions":3618},[90],[1487,1334,1335],[1489,175,638,896],{"trials":3620,"activeCount":100},[],{"trials":3622,"activeCount":100},[],{"trials":3624,"activeCount":100},[],{"intervention":1013,"totalTrials":1156,"cells":3626},{"EARLY_PHASE1":3627,"PHASE1":3629,"PHASE2":3631,"PHASE3":3637,"PHASE4":3639,"NA":3641},{"trials":3628,"activeCount":100},[],{"trials":3630,"activeCount":100},[],{"trials":3632,"activeCount":1156,"soonestReadout":998},[3633],{"nctId":995,"briefTitle":996,"status":127,"phases":3634,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":118,"conditions":3635,"interventions":3636},[90],[1002,1003,1004,1005,1006,1007,1008,1009,1010,1011],[1013,676,1014,82,854,677],{"trials":3638,"activeCount":100},[],{"trials":3640,"activeCount":100},[],{"trials":3642,"activeCount":100},[],{"intervention":2394,"totalTrials":1156,"cells":3644},{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3649,"PHASE3":3655,"PHASE4":3657,"NA":3659},{"trials":3646,"activeCount":100},[],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":1156,"soonestReadout":472},[3651],{"nctId":2386,"briefTitle":2387,"status":127,"phases":3652,"primaryCompletion":472,"completion":2389,"start":2390,"enrollment":848,"conditions":3653,"interventions":3654},[90],[2392,767,769],[2394,2276],{"trials":3656,"activeCount":100},[],{"trials":3658,"activeCount":100},[],{"trials":3660,"activeCount":100},[],{"intervention":2784,"totalTrials":1156,"cells":3662},{"EARLY_PHASE1":3663,"PHASE1":3665,"PHASE2":3667,"PHASE3":3673,"PHASE4":3675,"NA":3677},{"trials":3664,"activeCount":100},[],{"trials":3666,"activeCount":100},[],{"trials":3668,"activeCount":1156,"soonestReadout":310},[3669],{"nctId":2777,"briefTitle":2778,"status":104,"phases":3670,"primaryCompletion":310,"completion":310,"start":2780,"enrollment":700,"conditions":3671,"interventions":3672},[90],[2782],[2768,2784],{"trials":3674,"activeCount":100},[],{"trials":3676,"activeCount":100},[],{"trials":3678,"activeCount":100},[],{"intervention":3680,"totalTrials":1156,"cells":3681},"EBRT + 6 mo ADT + 177Lu-PSMA-617",{"EARLY_PHASE1":3682,"PHASE1":3684,"PHASE2":3686,"PHASE3":3698,"PHASE4":3700,"NA":3702},{"trials":3683,"activeCount":100},[],{"trials":3685,"activeCount":100},[],{"trials":3687,"activeCount":1156,"soonestReadout":3692},[3688],{"nctId":3689,"briefTitle":3690,"status":197,"phases":3691,"primaryCompletion":3692,"completion":3693,"start":3694,"enrollment":700,"conditions":3695,"interventions":3697},"NCT07550517","PSMA-High: EBRT\u002F PSMA617\u002F ADT vs. EBRT\u002F ADT",[90],"2032-04","2033-04","2026-04",[3696],"High-Risk Localized Prostate Cancer",[3680],{"trials":3699,"activeCount":100},[],{"trials":3701,"activeCount":100},[],{"trials":3703,"activeCount":100},[],{"intervention":1857,"totalTrials":1156,"cells":3705},{"EARLY_PHASE1":3706,"PHASE1":3708,"PHASE2":3710,"PHASE3":3716,"PHASE4":3718,"NA":3720},{"trials":3707,"activeCount":100},[],{"trials":3709,"activeCount":100},[],{"trials":3711,"activeCount":1156,"soonestReadout":1851},[3712],{"nctId":1848,"briefTitle":1849,"status":197,"phases":3713,"primaryCompletion":1851,"completion":1851,"start":1755,"enrollment":1852,"conditions":3714,"interventions":3715},[90],[120],[408,917,1855,1856,1857],{"trials":3717,"activeCount":100},[],{"trials":3719,"activeCount":100},[],{"trials":3721,"activeCount":100},[],{"intervention":1782,"totalTrials":1156,"cells":3723},{"EARLY_PHASE1":3724,"PHASE1":3726,"PHASE2":3728,"PHASE3":3734,"PHASE4":3736,"NA":3738},{"trials":3725,"activeCount":100},[],{"trials":3727,"activeCount":100},[],{"trials":3729,"activeCount":1156,"soonestReadout":1777},[3730],{"nctId":1774,"briefTitle":1775,"status":127,"phases":3731,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1280,"conditions":3732,"interventions":3733},[90],[1780],[1782,246,258,1746],{"trials":3735,"activeCount":100},[],{"trials":3737,"activeCount":100},[],{"trials":3739,"activeCount":100},[],{"intervention":1865,"totalTrials":1156,"cells":3741},{"EARLY_PHASE1":3742,"PHASE1":3744,"PHASE2":3746,"PHASE3":3752,"PHASE4":3754,"NA":3756},{"trials":3743,"activeCount":100},[],{"trials":3745,"activeCount":100},[],{"trials":3747,"activeCount":1156,"soonestReadout":1851},[3748],{"nctId":1859,"briefTitle":1860,"status":197,"phases":3749,"primaryCompletion":1851,"completion":1851,"start":1755,"enrollment":313,"conditions":3750,"interventions":3751},[90],[1863],[1865,917,408],{"trials":3753,"activeCount":100},[],{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"intervention":1964,"totalTrials":1156,"cells":3759},{"EARLY_PHASE1":3760,"PHASE1":3762,"PHASE2":3764,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3761,"activeCount":100},[],{"trials":3763,"activeCount":100},[],{"trials":3765,"activeCount":1156,"soonestReadout":1960},[3766],{"nctId":1957,"briefTitle":1958,"status":104,"phases":3767,"primaryCompletion":1960,"completion":288,"start":1961,"enrollment":700,"conditions":3768,"interventions":3769},[90],[15],[258,1964],{"trials":3771,"activeCount":100},[],{"trials":3773,"activeCount":100},[],{"trials":3775,"activeCount":100},[],{"intervention":1063,"totalTrials":1156,"cells":3777},{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3788,"PHASE4":3790,"NA":3792},{"trials":3779,"activeCount":100},[],{"trials":3781,"activeCount":100},[],{"trials":3783,"activeCount":1156,"soonestReadout":81},[3784],{"nctId":79,"briefTitle":80,"status":104,"phases":3785,"primaryCompletion":81,"completion":200,"start":1059,"enrollment":1060,"conditions":3786,"interventions":3787},[90],[21],[82,1063,376],{"trials":3789,"activeCount":100},[],{"trials":3791,"activeCount":100},[],{"trials":3793,"activeCount":100},[],{"intervention":3795,"totalTrials":1156,"cells":3796},"Nivolumab in combination with Urelumab",{"EARLY_PHASE1":3797,"PHASE1":3799,"PHASE2":3801,"PHASE3":3813,"PHASE4":3815,"NA":3817},{"trials":3798,"activeCount":100},[],{"trials":3800,"activeCount":100},[],{"trials":3802,"activeCount":1156,"soonestReadout":3807},[3803],{"nctId":3804,"briefTitle":3805,"status":104,"phases":3806,"primaryCompletion":3807,"completion":289,"start":3808,"enrollment":156,"conditions":3809,"interventions":3811},"NCT02845323","Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder",[90],"2027-07-31","2017-05-16",[3810,1334],"Urothelial Carcinoma",[3795,3812],"Nivolumab monotherapy",{"trials":3814,"activeCount":100},[],{"trials":3816,"activeCount":100},[],{"trials":3818,"activeCount":100},[],{"intervention":3812,"totalTrials":1156,"cells":3820},{"EARLY_PHASE1":3821,"PHASE1":3823,"PHASE2":3825,"PHASE3":3831,"PHASE4":3833,"NA":3835},{"trials":3822,"activeCount":100},[],{"trials":3824,"activeCount":100},[],{"trials":3826,"activeCount":1156,"soonestReadout":3807},[3827],{"nctId":3804,"briefTitle":3805,"status":104,"phases":3828,"primaryCompletion":3807,"completion":289,"start":3808,"enrollment":156,"conditions":3829,"interventions":3830},[90],[3810,1334],[3795,3812],{"trials":3832,"activeCount":100},[],{"trials":3834,"activeCount":100},[],{"trials":3836,"activeCount":100},[],{"intervention":3838,"totalTrials":1156,"cells":3839},"Toripalimab + Chemotherapy",{"EARLY_PHASE1":3840,"PHASE1":3842,"PHASE2":3844,"PHASE3":3865,"PHASE4":3867,"NA":3869},{"trials":3841,"activeCount":100},[],{"trials":3843,"activeCount":100},[],{"trials":3845,"activeCount":1156,"soonestReadout":3850},[3846],{"nctId":3847,"briefTitle":3848,"status":127,"phases":3849,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":3853,"conditions":3854,"interventions":3863},"NCT07209189","Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)",[90],"2030-10-01","2030-12-01","2026-02-18",75,[36,3855,3856,3857,3858,3859,3860,3861,3862],"Squamous Cell Carcinoma","Oral Cavity Cancer","Oropharyngeal Cancer","Laryngeal Cancer","Sinonasal Squamous Cell Carcinoma","HPV (Human Papillomavirus)-Associated Carcinoma","Skull Base Tumors","HPV 16 Positive Oropharyngeal Tumors (OPC)",[3838,3864],"Toripalimab",{"trials":3866,"activeCount":100},[],{"trials":3868,"activeCount":100},[],{"trials":3870,"activeCount":100},[],{"intervention":3864,"totalTrials":1156,"cells":3872},{"EARLY_PHASE1":3873,"PHASE1":3875,"PHASE2":3877,"PHASE3":3883,"PHASE4":3885,"NA":3887},{"trials":3874,"activeCount":100},[],{"trials":3876,"activeCount":100},[],{"trials":3878,"activeCount":1156,"soonestReadout":3850},[3879],{"nctId":3847,"briefTitle":3848,"status":127,"phases":3880,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":3853,"conditions":3881,"interventions":3882},[90],[36,3855,3856,3857,3858,3859,3860,3861,3862],[3838,3864],{"trials":3884,"activeCount":100},[],{"trials":3886,"activeCount":100},[],{"trials":3888,"activeCount":100},[],{"intervention":2921,"totalTrials":1156,"cells":3890},{"EARLY_PHASE1":3891,"PHASE1":3893,"PHASE2":3895,"PHASE3":3901,"PHASE4":3903,"NA":3905},{"trials":3892,"activeCount":100},[],{"trials":3894,"activeCount":100},[],{"trials":3896,"activeCount":1156,"soonestReadout":2914},[3897],{"nctId":2911,"briefTitle":2912,"status":104,"phases":3898,"primaryCompletion":2914,"completion":2914,"start":2915,"enrollment":493,"conditions":3899,"interventions":3900},[89,90],[2917,2918,2919],[2921,2922,2923,1990],{"trials":3902,"activeCount":100},[],{"trials":3904,"activeCount":100},[],{"trials":3906,"activeCount":100},[],{"intervention":2922,"totalTrials":1156,"cells":3908},{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3913,"PHASE3":3919,"PHASE4":3921,"NA":3923},{"trials":3910,"activeCount":100},[],{"trials":3912,"activeCount":100},[],{"trials":3914,"activeCount":1156,"soonestReadout":2914},[3915],{"nctId":2911,"briefTitle":2912,"status":104,"phases":3916,"primaryCompletion":2914,"completion":2914,"start":2915,"enrollment":493,"conditions":3917,"interventions":3918},[89,90],[2917,2918,2919],[2921,2922,2923,1990],{"trials":3920,"activeCount":100},[],{"trials":3922,"activeCount":100},[],{"trials":3924,"activeCount":100},[],{"intervention":2923,"totalTrials":1156,"cells":3926},{"EARLY_PHASE1":3927,"PHASE1":3929,"PHASE2":3931,"PHASE3":3937,"PHASE4":3939,"NA":3941},{"trials":3928,"activeCount":100},[],{"trials":3930,"activeCount":100},[],{"trials":3932,"activeCount":1156,"soonestReadout":2914},[3933],{"nctId":2911,"briefTitle":2912,"status":104,"phases":3934,"primaryCompletion":2914,"completion":2914,"start":2915,"enrollment":493,"conditions":3935,"interventions":3936},[89,90],[2917,2918,2919],[2921,2922,2923,1990],{"trials":3938,"activeCount":100},[],{"trials":3940,"activeCount":100},[],{"trials":3942,"activeCount":100},[],{"intervention":3944,"totalTrials":1156,"cells":3945},"Peptide vaccine",{"EARLY_PHASE1":3946,"PHASE1":3948,"PHASE2":3950,"PHASE3":3962,"PHASE4":3964,"NA":3966},{"trials":3947,"activeCount":100},[],{"trials":3949,"activeCount":100},[],{"trials":3951,"activeCount":1156,"soonestReadout":1755},[3952],{"nctId":3953,"briefTitle":3954,"status":127,"phases":3955,"primaryCompletion":1755,"completion":3956,"start":3957,"enrollment":969,"conditions":3958,"interventions":3961},"NCT05950139","Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC",[89,90],"2029-07","2024-05-13",[3959,3960],"NSCLC Stage IV","ALK Fusion Protein Expression",[3944],{"trials":3963,"activeCount":100},[],{"trials":3965,"activeCount":100},[],{"trials":3967,"activeCount":100},[],{"intervention":410,"totalTrials":1156,"cells":3969},{"EARLY_PHASE1":3970,"PHASE1":3972,"PHASE2":3974,"PHASE3":3980,"PHASE4":3982,"NA":3984},{"trials":3971,"activeCount":100},[],{"trials":3973,"activeCount":100},[],{"trials":3975,"activeCount":1156,"soonestReadout":403},[3976],{"nctId":400,"briefTitle":401,"status":127,"phases":3977,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":3978,"interventions":3979},[90],[21],[408,409,410,411,412,63,123],{"trials":3981,"activeCount":100},[],{"trials":3983,"activeCount":100},[],{"trials":3985,"activeCount":100},[],{"intervention":412,"totalTrials":1156,"cells":3987},{"EARLY_PHASE1":3988,"PHASE1":3990,"PHASE2":3992,"PHASE3":3998,"PHASE4":4000,"NA":4002},{"trials":3989,"activeCount":100},[],{"trials":3991,"activeCount":100},[],{"trials":3993,"activeCount":1156,"soonestReadout":403},[3994],{"nctId":400,"briefTitle":401,"status":127,"phases":3995,"primaryCompletion":403,"completion":403,"start":404,"enrollment":405,"conditions":3996,"interventions":3997},[90],[21],[408,409,410,411,412,63,123],{"trials":3999,"activeCount":100},[],{"trials":4001,"activeCount":100},[],{"trials":4003,"activeCount":100},[],{"intervention":2934,"totalTrials":1156,"cells":4005},{"EARLY_PHASE1":4006,"PHASE1":4008,"PHASE2":4010,"PHASE3":4016,"PHASE4":4018,"NA":4020},{"trials":4007,"activeCount":100},[],{"trials":4009,"activeCount":100},[],{"trials":4011,"activeCount":1156,"soonestReadout":2928},[4012],{"nctId":2925,"briefTitle":2926,"status":127,"phases":4013,"primaryCompletion":2928,"completion":2929,"start":2930,"enrollment":1121,"conditions":4014,"interventions":4015},[90],[2932,244],[1772,1990,2934],{"trials":4017,"activeCount":100},[],{"trials":4019,"activeCount":100},[],{"trials":4021,"activeCount":100},[],{"intervention":1227,"totalTrials":1156,"cells":4023},{"EARLY_PHASE1":4024,"PHASE1":4026,"PHASE2":4028,"PHASE3":4034,"PHASE4":4036,"NA":4038},{"trials":4025,"activeCount":100},[],{"trials":4027,"activeCount":100},[],{"trials":4029,"activeCount":1156,"soonestReadout":403},[4030],{"nctId":1221,"briefTitle":1222,"status":127,"phases":4031,"primaryCompletion":403,"completion":403,"start":1224,"enrollment":301,"conditions":4032,"interventions":4033},[89,90],[21],[1227,1228,82,343,1227,1228,1229],{"trials":4035,"activeCount":100},[],{"trials":4037,"activeCount":100},[],{"trials":4039,"activeCount":100},[],{"intervention":1229,"totalTrials":1156,"cells":4041},{"EARLY_PHASE1":4042,"PHASE1":4044,"PHASE2":4046,"PHASE3":4052,"PHASE4":4054,"NA":4056},{"trials":4043,"activeCount":100},[],{"trials":4045,"activeCount":100},[],{"trials":4047,"activeCount":1156,"soonestReadout":403},[4048],{"nctId":1221,"briefTitle":1222,"status":127,"phases":4049,"primaryCompletion":403,"completion":403,"start":1224,"enrollment":301,"conditions":4050,"interventions":4051},[89,90],[21],[1227,1228,82,343,1227,1228,1229],{"trials":4053,"activeCount":100},[],{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[],{"intervention":4059,"totalTrials":1156,"cells":4060},"Endocrine Therapy and a CDK 4\u002F6 inhibitor",{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4065,"PHASE3":4076,"PHASE4":4078,"NA":4080},{"trials":4062,"activeCount":100},[],{"trials":4064,"activeCount":100},[],{"trials":4066,"activeCount":1156,"soonestReadout":4071},[4067],{"nctId":4068,"briefTitle":4069,"status":104,"phases":4070,"primaryCompletion":4071,"completion":4072,"start":4073,"enrollment":241,"conditions":4074,"interventions":4075},"NCT03439735","Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4\u002F6) Inhibitor for HR+ MBC",[90],"2026-08-01","2026-11-01","2018-07-20",[18],[4059,4059],{"trials":4077,"activeCount":100},[],{"trials":4079,"activeCount":100},[],{"trials":4081,"activeCount":100},[],{"intervention":2793,"totalTrials":1156,"cells":4083},{"EARLY_PHASE1":4084,"PHASE1":4086,"PHASE2":4088,"PHASE3":4094,"PHASE4":4096,"NA":4098},{"trials":4085,"activeCount":100},[],{"trials":4087,"activeCount":100},[],{"trials":4089,"activeCount":1156,"soonestReadout":462},[4090],{"nctId":2786,"briefTitle":2787,"status":104,"phases":4091,"primaryCompletion":462,"completion":2789,"start":2790,"enrollment":1797,"conditions":4092,"interventions":4093},[90],[18],[2793,2794,2768],{"trials":4095,"activeCount":100},[],{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[],{"intervention":3315,"totalTrials":1156,"cells":4101},{"EARLY_PHASE1":4102,"PHASE1":4104,"PHASE2":4106,"PHASE3":4112,"PHASE4":4114,"NA":4116},{"trials":4103,"activeCount":100},[],{"trials":4105,"activeCount":100},[],{"trials":4107,"activeCount":1156,"soonestReadout":47},[4108],{"nctId":45,"briefTitle":46,"status":104,"phases":4109,"primaryCompletion":47,"completion":310,"start":3311,"enrollment":3312,"conditions":4110,"interventions":4111},[90],[18],[48,3315],{"trials":4113,"activeCount":100},[],{"trials":4115,"activeCount":100},[],{"trials":4117,"activeCount":100},[],{"intervention":467,"totalTrials":1156,"cells":4119},{"EARLY_PHASE1":4120,"PHASE1":4122,"PHASE2":4124,"PHASE3":4130,"PHASE4":4132,"NA":4134},{"trials":4121,"activeCount":100},[],{"trials":4123,"activeCount":100},[],{"trials":4125,"activeCount":1156,"soonestReadout":462},[4126],{"nctId":459,"briefTitle":460,"status":104,"phases":4127,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":4128,"interventions":4129},[90],[21],[82,467,63,468,469],{"trials":4131,"activeCount":100},[],{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":100},[],{"intervention":468,"totalTrials":1156,"cells":4137},{"EARLY_PHASE1":4138,"PHASE1":4140,"PHASE2":4142,"PHASE3":4148,"PHASE4":4150,"NA":4152},{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[],{"trials":4143,"activeCount":1156,"soonestReadout":462},[4144],{"nctId":459,"briefTitle":460,"status":104,"phases":4145,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":4146,"interventions":4147},[90],[21],[82,467,63,468,469],{"trials":4149,"activeCount":100},[],{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":100},[],{"intervention":469,"totalTrials":1156,"cells":4155},{"EARLY_PHASE1":4156,"PHASE1":4158,"PHASE2":4160,"PHASE3":4166,"PHASE4":4168,"NA":4170},{"trials":4157,"activeCount":100},[],{"trials":4159,"activeCount":100},[],{"trials":4161,"activeCount":1156,"soonestReadout":462},[4162],{"nctId":459,"briefTitle":460,"status":104,"phases":4163,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":4164,"interventions":4165},[90],[21],[82,467,63,468,469],{"trials":4167,"activeCount":100},[],{"trials":4169,"activeCount":100},[],{"trials":4171,"activeCount":100},[],{"intervention":1810,"totalTrials":1156,"cells":4173},{"EARLY_PHASE1":4174,"PHASE1":4176,"PHASE2":4178,"PHASE3":4184,"PHASE4":4186,"NA":4188},{"trials":4175,"activeCount":100},[],{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":1156,"soonestReadout":188},[4180],{"nctId":1803,"briefTitle":1804,"status":127,"phases":4181,"primaryCompletion":188,"completion":1806,"start":1807,"enrollment":700,"conditions":4182,"interventions":4183},[90],[1780],[246,1746,1810],{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[],{"trials":4189,"activeCount":100},[],{"intervention":1407,"totalTrials":1156,"cells":4191},{"EARLY_PHASE1":4192,"PHASE1":4194,"PHASE2":4196,"PHASE3":4202,"PHASE4":4204,"NA":4206},{"trials":4193,"activeCount":100},[],{"trials":4195,"activeCount":100},[],{"trials":4197,"activeCount":1156,"soonestReadout":1402},[4198],{"nctId":1399,"briefTitle":1400,"status":127,"phases":4199,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":313,"conditions":4200,"interventions":4201},[90],[268],[580,1407],{"trials":4203,"activeCount":100},[],{"trials":4205,"activeCount":100},[],{"trials":4207,"activeCount":100},[],{"intervention":715,"totalTrials":689,"cells":4209},{"EARLY_PHASE1":4210,"PHASE1":4212,"PHASE2":4222,"PHASE3":4240,"PHASE4":4242,"NA":4244},{"trials":4211,"activeCount":100},[],{"trials":4213,"activeCount":100},[4214,4218],{"nctId":706,"briefTitle":707,"status":139,"phases":4215,"start":709,"conditions":4216,"interventions":4217},[89],[27,30,33,711],[713,692,714,650,715,716],{"nctId":809,"briefTitle":810,"status":139,"phases":4219,"primaryCompletion":812,"completion":812,"start":813,"enrollment":108,"conditions":4220,"interventions":4221},[89],[24,815,816,817,818,768,280,819],[692,43,650,715],{"trials":4223,"activeCount":1156,"soonestReadout":472},[4224,4228,4232,4236],{"nctId":885,"briefTitle":886,"status":219,"phases":4225,"primaryCompletion":888,"completion":888,"start":889,"enrollment":118,"conditions":4226,"interventions":4227},[90],[891],[841,82,893,637,894,895,175,896,897],{"nctId":1481,"briefTitle":1482,"status":127,"phases":4229,"primaryCompletion":472,"completion":1484,"start":1485,"enrollment":1077,"conditions":4230,"interventions":4231},[90],[1487,1334,1335],[1489,175,638,896],{"nctId":1016,"briefTitle":1017,"status":139,"phases":4233,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":493,"conditions":4234,"interventions":4235},[90],[30],[692,883,1023,1024,650,715],{"nctId":1168,"briefTitle":1169,"status":139,"phases":4237,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":384,"conditions":4238,"interventions":4239},[90],[30],[692,883,693,1175,650,1176,704,715,926,1177,1178],{"trials":4241,"activeCount":100},[],{"trials":4243,"activeCount":100},[],{"trials":4245,"activeCount":100},[4246],{"nctId":4247,"briefTitle":4248,"status":139,"phases":4249,"primaryCompletion":3199,"completion":3199,"start":1528,"enrollment":37,"conditions":4250,"interventions":4251},"NCT01084759","A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer",[93],[15],[4252,896],"Testosterone",{"intervention":4254,"totalTrials":689,"cells":4255},"18F-DCFPyL",{"EARLY_PHASE1":4256,"PHASE1":4258,"PHASE2":4295,"PHASE3":4305,"PHASE4":4315,"NA":4317},{"trials":4257,"activeCount":100},[],{"trials":4259,"activeCount":100},[4260,4270,4279,4288],{"nctId":4261,"briefTitle":4262,"status":139,"phases":4263,"primaryCompletion":4264,"completion":4264,"start":4265,"enrollment":301,"conditions":4266,"interventions":4269},"NCT03542773","Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET",[89],"2022-05-01","2015-02-06",[4267,4268],"Schwannomas","Malignant Tumors",[4254],{"nctId":4271,"briefTitle":4272,"status":139,"phases":4273,"primaryCompletion":4274,"completion":4275,"start":4276,"enrollment":765,"conditions":4277,"interventions":4278},"NCT03793543","Test-Retest Reproducibility of 18F-DCFPyL PET\u002FCT in the Evaluation of Patients With Metastatic Prostate Cancer",[89],"2020-03-06","2021-10-15","2019-03-27",[15],[4254],{"nctId":4280,"briefTitle":4281,"status":139,"phases":4282,"primaryCompletion":4283,"completion":4283,"start":4284,"enrollment":1516,"conditions":4285,"interventions":4286},"NCT03497377","Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.",[89],"2020-04","2016-05-16",[244],[4254,4287],"18F-NaF",{"nctId":4289,"briefTitle":4290,"status":139,"phases":4291,"primaryCompletion":4283,"completion":4283,"start":4292,"enrollment":22,"conditions":4293,"interventions":4294},"NCT02151760","Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer",[89],"2014-05",[244],[4254],{"trials":4296,"activeCount":1156,"soonestReadout":4301},[4297],{"nctId":4298,"briefTitle":4299,"status":104,"phases":4300,"primaryCompletion":4301,"completion":4301,"start":4302,"enrollment":1757,"conditions":4303,"interventions":4304},"NCT03471650","Study of PSMA-targeted 18F-DCFPyL PET\u002FCT for the Detection of Clinically Significant Prostate Cancer",[90],"2028-03-07","2018-03-29",[15],[4254],{"trials":4306,"activeCount":100},[4307],{"nctId":4308,"briefTitle":4309,"status":416,"phases":4310,"primaryCompletion":4311,"completion":4311,"start":4312,"enrollment":100,"conditions":4313,"interventions":4314},"NCT03800784","Study of 18F-DCFPyL PET\u002FCT Imaging in Patients With Prostate Cancer",[90,91],"2021-10-21","2019-10-01",[15],[4254],{"trials":4316,"activeCount":100},[],{"trials":4318,"activeCount":100},[4319],{"nctId":4320,"briefTitle":4321,"status":139,"phases":4322,"primaryCompletion":4323,"completion":4324,"start":4325,"enrollment":1280,"conditions":4326,"interventions":4327},"NCT02523924","Pilot Study of 18F-DCFPyL PET\u002FCT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy",[93],"2016-11-04","2019-03-04","2015-06-02",[1972],[4254],{"intervention":4329,"totalTrials":733,"cells":4330},"endocrine therapy",{"EARLY_PHASE1":4331,"PHASE1":4333,"PHASE2":4335,"PHASE3":4341,"PHASE4":4343,"NA":4345},{"trials":4332,"activeCount":100},[],{"trials":4334,"activeCount":100},[],{"trials":4336,"activeCount":1156,"soonestReadout":462},[4337],{"nctId":2786,"briefTitle":2787,"status":104,"phases":4338,"primaryCompletion":462,"completion":2789,"start":2790,"enrollment":1797,"conditions":4339,"interventions":4340},[90],[18],[2793,2794,2768],{"trials":4342,"activeCount":100},[],{"trials":4344,"activeCount":100},[],{"trials":4346,"activeCount":100},[4347],{"nctId":4348,"briefTitle":4349,"status":139,"phases":4350,"primaryCompletion":518,"completion":4351,"start":3200,"enrollment":28,"conditions":4352,"interventions":4353},"NCT00373191","Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery",[],"2013-12",[18],[4354,4329,2327,4355],"chemotherapy","protein analysis",{"intervention":2348,"totalTrials":224,"cells":4357},{"EARLY_PHASE1":4358,"PHASE1":4370,"PHASE2":4386,"PHASE3":4388,"PHASE4":4390,"NA":4392},{"trials":4359,"activeCount":1156,"soonestReadout":2227},[4360],{"nctId":4361,"briefTitle":4362,"status":127,"phases":4363,"primaryCompletion":2227,"completion":4364,"start":4365,"enrollment":266,"conditions":4366,"interventions":4368},"NCT06610682","A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma",[88],"2028-06-30","2025-04-07",[4367],"BRAF V600E Mutation",[4369,2348],"Plixorafenib",{"trials":4371,"activeCount":1156,"soonestReadout":2343},[4372,4382],{"nctId":4373,"briefTitle":4374,"status":416,"phases":4375,"primaryCompletion":4376,"completion":4376,"start":4376,"enrollment":100,"conditions":4377,"interventions":4380},"NCT04799431","Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer",[89],"2023-05-03",[4378,4379],"Pancreatic Cancer Metastatic","Colorectal Cancer Metastatic",[4381,2348],"Neoantigen Vaccine with Poly-ICLC adjuvant",{"nctId":2340,"briefTitle":2341,"status":127,"phases":4383,"primaryCompletion":2343,"completion":2344,"start":2345,"enrollment":1280,"conditions":4384,"interventions":4385},[89],[227],[2348,2276],{"trials":4387,"activeCount":100},[],{"trials":4389,"activeCount":100},[],{"trials":4391,"activeCount":100},[],{"trials":4393,"activeCount":100},[],{"intervention":135,"totalTrials":733,"cells":4395},{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4408,"PHASE3":4410,"PHASE4":4412,"NA":4414},{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":733,"soonestReadout":129},[4400,4404],{"nctId":125,"briefTitle":126,"status":127,"phases":4401,"primaryCompletion":129,"completion":130,"start":131,"enrollment":16,"conditions":4402,"interventions":4403},[89],[133],[135,63,123],{"nctId":195,"briefTitle":196,"status":197,"phases":4405,"primaryCompletion":199,"completion":199,"start":200,"enrollment":118,"conditions":4406,"interventions":4407},[89],[202],[204,205,63,123],{"trials":4409,"activeCount":100},[],{"trials":4411,"activeCount":100},[],{"trials":4413,"activeCount":100},[],{"trials":4415,"activeCount":100},[],{"intervention":1557,"totalTrials":536,"cells":4417},{"EARLY_PHASE1":4418,"PHASE1":4420,"PHASE2":4430,"PHASE3":4440,"PHASE4":4442,"NA":4444},{"trials":4419,"activeCount":100},[],{"trials":4421,"activeCount":1156,"soonestReadout":276},[4422,4426],{"nctId":1549,"briefTitle":1550,"status":219,"phases":4423,"primaryCompletion":1552,"completion":1552,"start":1553,"enrollment":266,"conditions":4424,"interventions":4425},[89],[1555],[1557,73],{"nctId":2667,"briefTitle":2668,"status":127,"phases":4427,"primaryCompletion":276,"completion":276,"start":1224,"enrollment":1516,"conditions":4428,"interventions":4429},[89],[2671],[2673,2660,1557],{"trials":4431,"activeCount":100},[4432,4436],{"nctId":2677,"briefTitle":2678,"status":139,"phases":4433,"primaryCompletion":2680,"completion":2680,"start":312,"enrollment":108,"conditions":4434,"interventions":4435},[90],[2682,192],[2660,1557],{"nctId":2716,"briefTitle":2717,"status":219,"phases":4437,"primaryCompletion":2719,"completion":2720,"start":2721,"enrollment":361,"conditions":4438,"interventions":4439},[90],[325],[2660,1557,2724],{"trials":4441,"activeCount":100},[],{"trials":4443,"activeCount":100},[],{"trials":4445,"activeCount":100},[],{"intervention":4447,"totalTrials":1156,"cells":4448},"111In-XYIMSR-01",{"EARLY_PHASE1":4449,"PHASE1":4451,"PHASE2":4461,"PHASE3":4463,"PHASE4":4465,"NA":4467},{"trials":4450,"activeCount":100},[],{"trials":4452,"activeCount":1156,"soonestReadout":480},[4453],{"nctId":4454,"briefTitle":4455,"status":127,"phases":4456,"primaryCompletion":480,"completion":3956,"start":4457,"enrollment":231,"conditions":4458,"interventions":4460},"NCT07062549","Study of 111In-XYIMSR-01 SPECT\u002FCT in Patients With Metastatic Clear Cell Renal Cell",[89],"2022-01-26",[4459],"Renal Cell Carcinoma (Kidney Cancer)",[4447],{"trials":4462,"activeCount":100},[],{"trials":4464,"activeCount":100},[],{"trials":4466,"activeCount":100},[],{"trials":4468,"activeCount":100},[],{"intervention":122,"totalTrials":1156,"cells":4470},{"EARLY_PHASE1":4471,"PHASE1":4473,"PHASE2":4479,"PHASE3":4481,"PHASE4":4483,"NA":4485},{"trials":4472,"activeCount":100},[],{"trials":4474,"activeCount":1156,"soonestReadout":116},[4475],{"nctId":113,"briefTitle":114,"status":104,"phases":4476,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":4477,"interventions":4478},[89],[120,21],[122,63,123],{"trials":4480,"activeCount":100},[],{"trials":4482,"activeCount":100},[],{"trials":4484,"activeCount":100},[],{"trials":4486,"activeCount":100},[],{"intervention":4488,"totalTrials":1156,"cells":4489},"Dose Escalation -tagraxofusp-erzs",{"EARLY_PHASE1":4490,"PHASE1":4492,"PHASE2":4504,"PHASE3":4506,"PHASE4":4508,"NA":4510},{"trials":4491,"activeCount":100},[],{"trials":4493,"activeCount":1156,"soonestReadout":4498},[4494],{"nctId":4495,"briefTitle":4496,"status":104,"phases":4497,"primaryCompletion":4498,"completion":4499,"start":4500,"enrollment":25,"conditions":4501,"interventions":4502},"NCT05716009","Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed\u002FRefractory AML",[89],"2027-12-25","2028-12-25","2023-11-20",[779],[4488,4503],"Dose Expansion at RP2D -tagraxofusp-erzs",{"trials":4505,"activeCount":100},[],{"trials":4507,"activeCount":100},[],{"trials":4509,"activeCount":100},[],{"trials":4511,"activeCount":100},[],{"intervention":4503,"totalTrials":1156,"cells":4513},{"EARLY_PHASE1":4514,"PHASE1":4516,"PHASE2":4522,"PHASE3":4524,"PHASE4":4526,"NA":4528},{"trials":4515,"activeCount":100},[],{"trials":4517,"activeCount":1156,"soonestReadout":4498},[4518],{"nctId":4495,"briefTitle":4496,"status":104,"phases":4519,"primaryCompletion":4498,"completion":4499,"start":4500,"enrollment":25,"conditions":4520,"interventions":4521},[89],[779],[4488,4503],{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":100},[],{"trials":4529,"activeCount":100},[],{"intervention":4531,"totalTrials":1156,"cells":4532},"Cohort A: Patients at high risk of developing pancreatic cancer.",{"EARLY_PHASE1":4533,"PHASE1":4535,"PHASE2":4548,"PHASE3":4550,"PHASE4":4552,"NA":4554},{"trials":4534,"activeCount":100},[],{"trials":4536,"activeCount":1156,"soonestReadout":4541},[4537],{"nctId":4538,"briefTitle":4539,"status":127,"phases":4540,"primaryCompletion":4541,"completion":4542,"start":4543,"enrollment":22,"conditions":4544,"interventions":4546},"NCT05013216","Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer",[89],"2027-10-01","2031-05-01","2022-04-11",[4545,21],"High Risk Cancer",[4531,4547],"Cohort B: Patients must have evidence of a pancreatic cystic neoplasm",{"trials":4549,"activeCount":100},[],{"trials":4551,"activeCount":100},[],{"trials":4553,"activeCount":100},[],{"trials":4555,"activeCount":100},[],{"intervention":4547,"totalTrials":1156,"cells":4557},{"EARLY_PHASE1":4558,"PHASE1":4560,"PHASE2":4566,"PHASE3":4568,"PHASE4":4570,"NA":4572},{"trials":4559,"activeCount":100},[],{"trials":4561,"activeCount":1156,"soonestReadout":4541},[4562],{"nctId":4538,"briefTitle":4539,"status":127,"phases":4563,"primaryCompletion":4541,"completion":4542,"start":4543,"enrollment":22,"conditions":4564,"interventions":4565},[89],[4545,21],[4531,4547],{"trials":4567,"activeCount":100},[],{"trials":4569,"activeCount":100},[],{"trials":4571,"activeCount":100},[],{"trials":4573,"activeCount":100},[],{"intervention":4575,"totalTrials":1156,"cells":4576},"Ruxolitinib",{"EARLY_PHASE1":4577,"PHASE1":4579,"PHASE2":4591,"PHASE3":4593,"PHASE4":4595,"NA":4597},{"trials":4578,"activeCount":100},[],{"trials":4580,"activeCount":1156,"soonestReadout":4585},[4581],{"nctId":4582,"briefTitle":4583,"status":197,"phases":4584,"primaryCompletion":4585,"completion":4586,"start":4587,"enrollment":37,"conditions":4588,"interventions":4590},"NCT07424222","Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)",[89],"2028-06-01","2029-01-01","2026-06-01",[4589],"Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)",[4575],{"trials":4592,"activeCount":100},[],{"trials":4594,"activeCount":100},[],{"trials":4596,"activeCount":100},[],{"trials":4598,"activeCount":100},[],{"intervention":4600,"totalTrials":1156,"cells":4601},"[18F]DK222 radiotracer",{"EARLY_PHASE1":4602,"PHASE1":4604,"PHASE2":4615,"PHASE3":4617,"PHASE4":4619,"NA":4621},{"trials":4603,"activeCount":100},[],{"trials":4605,"activeCount":1156,"soonestReadout":4610},[4606],{"nctId":4607,"briefTitle":4608,"status":127,"phases":4609,"primaryCompletion":4610,"completion":4610,"start":4611,"enrollment":231,"conditions":4612,"interventions":4614},"NCT07140315","DK222 Study at Hopkins",[89],"2027-07-01","2026-07-01",[325,4613],"Urothelial Cancer",[4600],{"trials":4616,"activeCount":100},[],{"trials":4618,"activeCount":100},[],{"trials":4620,"activeCount":100},[],{"trials":4622,"activeCount":100},[],{"intervention":2861,"totalTrials":1156,"cells":4624},{"EARLY_PHASE1":4625,"PHASE1":4627,"PHASE2":4633,"PHASE3":4635,"PHASE4":4637,"NA":4639},{"trials":4626,"activeCount":100},[],{"trials":4628,"activeCount":1156,"soonestReadout":2855},[4629],{"nctId":2852,"briefTitle":2853,"status":127,"phases":4630,"primaryCompletion":2855,"completion":2856,"start":2857,"enrollment":2858,"conditions":4631,"interventions":4632},[89],[120,21],[2861,1228,2862],{"trials":4634,"activeCount":100},[],{"trials":4636,"activeCount":100},[],{"trials":4638,"activeCount":100},[],{"trials":4640,"activeCount":100},[],{"intervention":2862,"totalTrials":1156,"cells":4642},{"EARLY_PHASE1":4643,"PHASE1":4645,"PHASE2":4651,"PHASE3":4653,"PHASE4":4655,"NA":4657},{"trials":4644,"activeCount":100},[],{"trials":4646,"activeCount":1156,"soonestReadout":2855},[4647],{"nctId":2852,"briefTitle":2853,"status":127,"phases":4648,"primaryCompletion":2855,"completion":2856,"start":2857,"enrollment":2858,"conditions":4649,"interventions":4650},[89],[120,21],[2861,1228,2862],{"trials":4652,"activeCount":100},[],{"trials":4654,"activeCount":100},[],{"trials":4656,"activeCount":100},[],{"trials":4658,"activeCount":100},[],{"intervention":68,"totalTrials":1156,"cells":4660},{"EARLY_PHASE1":4661,"PHASE1":4663,"PHASE2":4671,"PHASE3":4673,"PHASE4":4675,"NA":4677},{"trials":4662,"activeCount":100},[],{"trials":4664,"activeCount":1156,"soonestReadout":67},[4665],{"nctId":65,"briefTitle":66,"status":104,"phases":4666,"primaryCompletion":67,"completion":4667,"start":4668,"enrollment":37,"conditions":4669,"interventions":4670},[89],"2026-09","2020-02-18",[227],[68],{"trials":4672,"activeCount":100},[],{"trials":4674,"activeCount":100},[],{"trials":4676,"activeCount":100},[],{"trials":4678,"activeCount":100},[],{"intervention":4680,"totalTrials":1156,"cells":4681},"Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides",{"EARLY_PHASE1":4682,"PHASE1":4684,"PHASE2":4694,"PHASE3":4696,"PHASE4":4698,"NA":4700},{"trials":4683,"activeCount":100},[],{"trials":4685,"activeCount":1156,"soonestReadout":4690},[4686],{"nctId":4687,"briefTitle":4688,"status":127,"phases":4689,"primaryCompletion":4690,"completion":4690,"start":4691,"enrollment":969,"conditions":4692,"interventions":4693},"NCT05254184","KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC",[89],"2027-04-01","2022-11-01",[325],[4680],{"trials":4695,"activeCount":100},[],{"trials":4697,"activeCount":100},[],{"trials":4699,"activeCount":100},[],{"trials":4701,"activeCount":100},[],{"intervention":4703,"totalTrials":1156,"cells":4704},"PVX7",{"EARLY_PHASE1":4705,"PHASE1":4707,"PHASE2":4718,"PHASE3":4720,"PHASE4":4722,"NA":4724},{"trials":4706,"activeCount":100},[],{"trials":4708,"activeCount":1156,"soonestReadout":4713},[4709],{"nctId":4710,"briefTitle":4711,"status":127,"phases":4712,"primaryCompletion":4713,"completion":3692,"start":4714,"enrollment":168,"conditions":4715,"interventions":4717},"NCT06315257","A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients",[89],"2030-02","2025-07-23",[4716],"Cervical Cancer",[4703],{"trials":4719,"activeCount":100},[],{"trials":4721,"activeCount":100},[],{"trials":4723,"activeCount":100},[],{"trials":4725,"activeCount":100},[],{"intervention":4727,"totalTrials":1156,"cells":4728},"Decitabine",{"EARLY_PHASE1":4729,"PHASE1":4731,"PHASE2":4743,"PHASE3":4745,"PHASE4":4747,"NA":4749},{"trials":4730,"activeCount":100},[],{"trials":4732,"activeCount":1156,"soonestReadout":4737},[4733],{"nctId":4734,"briefTitle":4735,"status":104,"phases":4736,"primaryCompletion":4737,"completion":4610,"start":4738,"enrollment":28,"conditions":4739,"interventions":4741},"NCT03875287","Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors",[89],"2026-09-02","2019-04-17",[4740],"Solid Tumor",[4727,4742],"Cedazuridine",{"trials":4744,"activeCount":100},[],{"trials":4746,"activeCount":100},[],{"trials":4748,"activeCount":100},[],{"trials":4750,"activeCount":100},[],{"intervention":4742,"totalTrials":1156,"cells":4752},{"EARLY_PHASE1":4753,"PHASE1":4755,"PHASE2":4761,"PHASE3":4763,"PHASE4":4765,"NA":4767},{"trials":4754,"activeCount":100},[],{"trials":4756,"activeCount":1156,"soonestReadout":4737},[4757],{"nctId":4734,"briefTitle":4735,"status":104,"phases":4758,"primaryCompletion":4737,"completion":4610,"start":4738,"enrollment":28,"conditions":4759,"interventions":4760},[89],[4740],[4727,4742],{"trials":4762,"activeCount":100},[],{"trials":4764,"activeCount":100},[],{"trials":4766,"activeCount":100},[],{"trials":4768,"activeCount":100},[],{"intervention":4770,"totalTrials":1156,"cells":4771},"pNGVL4aCRTE6E7L2",{"EARLY_PHASE1":4772,"PHASE1":4774,"PHASE2":4786,"PHASE3":4788,"PHASE4":4790,"NA":4792},{"trials":4773,"activeCount":100},[],{"trials":4775,"activeCount":1156,"soonestReadout":1392},[4776],{"nctId":4777,"briefTitle":4778,"status":127,"phases":4779,"primaryCompletion":1392,"completion":4585,"start":4780,"enrollment":452,"conditions":4781,"interventions":4785},"NCT04131413","HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia",[89],"2020-09-14",[4782,4783,4784],"Human Papillomavirus Type 16","Cervical Intraepithelial Neoplasia Grade II","Cervical Intraepithelial Neoplasia, Grade III",[4770],{"trials":4787,"activeCount":100},[],{"trials":4789,"activeCount":100},[],{"trials":4791,"activeCount":100},[],{"trials":4793,"activeCount":100},[],{"intervention":2673,"totalTrials":1156,"cells":4795},{"EARLY_PHASE1":4796,"PHASE1":4798,"PHASE2":4804,"PHASE3":4806,"PHASE4":4808,"NA":4810},{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":1156,"soonestReadout":276},[4800],{"nctId":2667,"briefTitle":2668,"status":127,"phases":4801,"primaryCompletion":276,"completion":276,"start":1224,"enrollment":1516,"conditions":4802,"interventions":4803},[89],[2671],[2673,2660,1557],{"trials":4805,"activeCount":100},[],{"trials":4807,"activeCount":100},[],{"trials":4809,"activeCount":100},[],{"trials":4811,"activeCount":100},[],{"intervention":4813,"totalTrials":1156,"cells":4814},"pNGVL4a-Sig\u002FE7(detox)\u002FHSP70 plasmid DNA; TA-HPV vaccinia virus",{"EARLY_PHASE1":4815,"PHASE1":4817,"PHASE2":4830,"PHASE3":4832,"PHASE4":4834,"NA":4836},{"trials":4816,"activeCount":100},[],{"trials":4818,"activeCount":1156,"soonestReadout":4824},[4819],{"nctId":4820,"briefTitle":4821,"status":4822,"phases":4823,"primaryCompletion":4824,"completion":4825,"start":1200,"enrollment":266,"conditions":4826,"interventions":4829},"NCT06508138","Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig\u002FE7(Detox)\u002FHSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection","ENROLLING_BY_INVITATION",[89],"2027-04-18","2027-10-18",[4827,2712,4828,661],"HPV 16 Infection","Recurrence",[4813],{"trials":4831,"activeCount":100},[],{"trials":4833,"activeCount":100},[],{"trials":4835,"activeCount":100},[],{"trials":4837,"activeCount":100},[],{"intervention":4839,"totalTrials":1156,"cells":4840},"Itacitinib",{"EARLY_PHASE1":4841,"PHASE1":4843,"PHASE2":4856,"PHASE3":4858,"PHASE4":4860,"NA":4862},{"trials":4842,"activeCount":100},[],{"trials":4844,"activeCount":1156,"soonestReadout":1597},[4845],{"nctId":4846,"briefTitle":4847,"status":104,"phases":4848,"primaryCompletion":1597,"completion":3457,"start":4849,"enrollment":168,"conditions":4850,"interventions":4855},"NCT05823571","Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients",[89],"2023-07-06",[4851,33,4852,4853,4854,780,673,872],"Leukemia, Acute","Myelomonocytic Leukemia, Chronic","T-cell Prolymphocytic Leukemia","CML",[4839],{"trials":4857,"activeCount":100},[],{"trials":4859,"activeCount":100},[],{"trials":4861,"activeCount":100},[],{"trials":4863,"activeCount":100},[],{"intervention":4865,"totalTrials":1156,"cells":4866},"Combination treatment",{"EARLY_PHASE1":4867,"PHASE1":4869,"PHASE2":4880,"PHASE3":4882,"PHASE4":4884,"NA":4886},{"trials":4868,"activeCount":100},[],{"trials":4870,"activeCount":1156,"soonestReadout":289},[4871],{"nctId":4872,"briefTitle":4873,"status":127,"phases":4874,"primaryCompletion":289,"completion":4875,"start":4876,"enrollment":452,"conditions":4877,"interventions":4879},"NCT04892303","Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer",[89],"2030-12","2021-03-17",[4878],"Recurrent Thyroid Cancer",[4865],{"trials":4881,"activeCount":100},[],{"trials":4883,"activeCount":100},[],{"trials":4885,"activeCount":100},[],{"trials":4887,"activeCount":100},[],{"intervention":328,"totalTrials":1609,"cells":4889},{"EARLY_PHASE1":4890,"PHASE1":4904,"PHASE2":4924,"PHASE3":4937,"PHASE4":4939,"NA":4941},{"trials":4891,"activeCount":1156,"soonestReadout":4896},[4892],{"nctId":4893,"briefTitle":4894,"status":127,"phases":4895,"primaryCompletion":4896,"completion":4897,"start":4898,"enrollment":848,"conditions":4899,"interventions":4902},"NCT07071155","Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes\u002FMyeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia",[88],"2028-03-05","2028-07-30","2026-03-19",[786,33,4900,4901],"Myeloproliferative Overlap Neoplasms","Chronic Neutrophilic Leukemia",[4903,328],"Momelotinib",{"trials":4905,"activeCount":100},[4906,4916],{"nctId":4907,"briefTitle":4908,"status":139,"phases":4909,"primaryCompletion":1130,"completion":1130,"start":4910,"enrollment":96,"conditions":4911,"interventions":4914},"NCT00005639","Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment",[89],"2000-03",[30,4912,4913],"Small Intestine Cancer","Unspecified Adult Solid Tumor, Protocol Specific",[328,4915],"sodium phenylbutyrate",{"nctId":4917,"briefTitle":4918,"status":139,"phases":4919,"start":4920,"conditions":4921,"interventions":4922},"NCT00004871","Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome",[89],"2000-05",[27,33,711],[4923,4915],"azacitidine",{"trials":4925,"activeCount":100},[4926,4930],{"nctId":318,"briefTitle":319,"status":139,"phases":4927,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":4928,"interventions":4929},[90],[325,326],[328,329,63,330],{"nctId":4931,"briefTitle":4932,"status":139,"phases":4933,"primaryCompletion":1108,"completion":1108,"start":1269,"enrollment":1516,"conditions":4934,"interventions":4935},"NCT01700673","Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS",[90],[779,778],[328,4936],"Sargramostim",{"trials":4938,"activeCount":100},[],{"trials":4940,"activeCount":100},[],{"trials":4942,"activeCount":100},[],{"intervention":4903,"totalTrials":1156,"cells":4944},{"EARLY_PHASE1":4945,"PHASE1":4951,"PHASE2":4953,"PHASE3":4955,"PHASE4":4957,"NA":4959},{"trials":4946,"activeCount":1156,"soonestReadout":4896},[4947],{"nctId":4893,"briefTitle":4894,"status":127,"phases":4948,"primaryCompletion":4896,"completion":4897,"start":4898,"enrollment":848,"conditions":4949,"interventions":4950},[88],[786,33,4900,4901],[4903,328],{"trials":4952,"activeCount":100},[],{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[],{"trials":4958,"activeCount":100},[],{"trials":4960,"activeCount":100},[],{"intervention":4962,"totalTrials":1156,"cells":4963},"(18F)DCFPyL",{"EARLY_PHASE1":4964,"PHASE1":4974,"PHASE2":4976,"PHASE3":4978,"PHASE4":4980,"NA":4982},{"trials":4965,"activeCount":1156,"soonestReadout":403},[4966],{"nctId":4967,"briefTitle":4968,"status":127,"phases":4969,"primaryCompletion":403,"completion":4970,"start":4971,"enrollment":405,"conditions":4972,"interventions":4973},"NCT03861676","Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET\u002FCT",[88],"2033-12","2023-08-03",[15],[4962],{"trials":4975,"activeCount":100},[],{"trials":4977,"activeCount":100},[],{"trials":4979,"activeCount":100},[],{"trials":4981,"activeCount":100},[],{"trials":4983,"activeCount":100},[],{"intervention":4369,"totalTrials":1156,"cells":4985},{"EARLY_PHASE1":4986,"PHASE1":4992,"PHASE2":4994,"PHASE3":4996,"PHASE4":4998,"NA":5000},{"trials":4987,"activeCount":1156,"soonestReadout":2227},[4988],{"nctId":4361,"briefTitle":4362,"status":127,"phases":4989,"primaryCompletion":2227,"completion":4364,"start":4365,"enrollment":266,"conditions":4990,"interventions":4991},[88],[4367],[4369,2348],{"trials":4993,"activeCount":100},[],{"trials":4995,"activeCount":100},[],{"trials":4997,"activeCount":100},[],{"trials":4999,"activeCount":100},[],{"trials":5001,"activeCount":100},[],{"intervention":5003,"totalTrials":1156,"cells":5004},"Darzalex Faspro",{"EARLY_PHASE1":5005,"PHASE1":5020,"PHASE2":5022,"PHASE3":5024,"PHASE4":5026,"NA":5028},{"trials":5006,"activeCount":1156,"soonestReadout":4667},[5007],{"nctId":5008,"briefTitle":5009,"status":127,"phases":5010,"primaryCompletion":4667,"completion":165,"start":5011,"enrollment":9,"conditions":5012,"interventions":5019},"NCT06398457","Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies",[88],"2024-09-19",[5013,5014,5015,5016,5017,673,1034,30,1217,5018,867,785],"Hematologic Malignancy","Bone Marrow Transplant Rejection","Acute Myeloid Leukemia (AML)","Myelodysplastic Syndromes (MDS)","Acute Lymphoblastic Leukemia (ALL), Adult","Hodgkin Lymphoma",[5003],{"trials":5021,"activeCount":100},[],{"trials":5023,"activeCount":100},[],{"trials":5025,"activeCount":100},[],{"trials":5027,"activeCount":100},[],{"trials":5029,"activeCount":100},[],{"intervention":693,"totalTrials":9,"cells":5031},{"EARLY_PHASE1":5032,"PHASE1":5034,"PHASE2":5040,"PHASE3":5066,"PHASE4":5072,"NA":5074},{"trials":5033,"activeCount":100},[],{"trials":5035,"activeCount":100},[5036],{"nctId":683,"briefTitle":684,"status":219,"phases":5037,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":5038,"interventions":5039},[89],[27],[692,693,650],{"trials":5041,"activeCount":100},[5042,5046,5050,5054,5058,5062],{"nctId":919,"briefTitle":920,"status":139,"phases":5043,"primaryCompletion":922,"completion":922,"start":923,"enrollment":25,"conditions":5044,"interventions":5045},[90],[27,754,33],[693,650,926],{"nctId":935,"briefTitle":936,"status":139,"phases":5047,"primaryCompletion":938,"completion":938,"start":939,"enrollment":940,"conditions":5048,"interventions":5049},[90],[745,27,30,754,33],[943,82],{"nctId":1138,"briefTitle":1139,"status":139,"phases":5051,"primaryCompletion":42,"completion":1141,"start":1142,"enrollment":1143,"conditions":5052,"interventions":5053},[90],[1145,1146,1147],[943,82],{"nctId":1168,"briefTitle":1169,"status":139,"phases":5055,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":384,"conditions":5056,"interventions":5057},[90],[30],[692,883,693,1175,650,1176,704,715,926,1177,1178],{"nctId":1180,"briefTitle":1181,"status":219,"phases":5059,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":156,"conditions":5060,"interventions":5061},[90],[30,27,778],[676,943,82,677,854],{"nctId":1253,"briefTitle":1254,"status":139,"phases":5063,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":28,"conditions":5064,"interventions":5065},[90],[1260,1261,1262,1263],[82,943,854,874],{"trials":5067,"activeCount":100},[5068],{"nctId":1275,"briefTitle":1276,"status":139,"phases":5069,"primaryCompletion":1278,"completion":1278,"start":1279,"enrollment":1280,"conditions":5070,"interventions":5071},[91],[796,30],[713,1283,693,650,1284],{"trials":5073,"activeCount":100},[],{"trials":5075,"activeCount":100},[],{"intervention":713,"totalTrials":224,"cells":5077},{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5093,"PHASE3":5095,"PHASE4":5101,"NA":5103},{"trials":5079,"activeCount":100},[],{"trials":5081,"activeCount":100},[5082,5089],{"nctId":5083,"briefTitle":5084,"status":139,"phases":5085,"primaryCompletion":5086,"completion":5086,"start":923,"conditions":5087,"interventions":5088},"NCT00003962","Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",[89],"2000-06",[27,30,754],[713],{"nctId":706,"briefTitle":707,"status":139,"phases":5090,"start":709,"conditions":5091,"interventions":5092},[89],[27,30,33,711],[713,692,714,650,715,716],{"trials":5094,"activeCount":100},[],{"trials":5096,"activeCount":100},[5097],{"nctId":1275,"briefTitle":1276,"status":139,"phases":5098,"primaryCompletion":1278,"completion":1278,"start":1279,"enrollment":1280,"conditions":5099,"interventions":5100},[91],[796,30],[713,1283,693,650,1284],{"trials":5102,"activeCount":100},[],{"trials":5104,"activeCount":100},[],{"intervention":5106,"totalTrials":733,"cells":5107},"Placebos",{"EARLY_PHASE1":5108,"PHASE1":5110,"PHASE2":5112,"PHASE3":5124,"PHASE4":5136,"NA":5138},{"trials":5109,"activeCount":100},[],{"trials":5111,"activeCount":100},[],{"trials":5113,"activeCount":100},[5114],{"nctId":5115,"briefTitle":5116,"status":139,"phases":5117,"primaryCompletion":5118,"completion":5118,"start":5119,"enrollment":5120,"conditions":5121,"interventions":5122},"NCT00022399","Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer",[90],"2005-01-31","2002-04-25",73,[15],[5123,5106],"celecoxib",{"trials":5125,"activeCount":100},[5126],{"nctId":5127,"briefTitle":5128,"status":219,"phases":5129,"primaryCompletion":5130,"completion":5131,"start":5132,"enrollment":384,"conditions":5133,"interventions":5134},"NCT03535675","Muscadine Plus (MPX) In Men With Prostate Cancer",[91],"2022-07-06","2022-11-03","2018-10-30",[1972],[5135,5106],"Muscadine Plus",{"trials":5137,"activeCount":100},[],{"trials":5139,"activeCount":100},[],{"intervention":5141,"totalTrials":1156,"cells":5142},"Liposomal bupivacaine",{"EARLY_PHASE1":5143,"PHASE1":5145,"PHASE2":5147,"PHASE3":5149,"PHASE4":5163,"NA":5165},{"trials":5144,"activeCount":100},[],{"trials":5146,"activeCount":100},[],{"trials":5148,"activeCount":100},[],{"trials":5150,"activeCount":100},[5151],{"nctId":5152,"briefTitle":5153,"status":139,"phases":5154,"primaryCompletion":5155,"completion":5156,"start":5157,"enrollment":5158,"conditions":5159,"interventions":5162},"NCT04117074","Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery",[91],"2025-03-03","2025-03-17","2021-04-14",106,[5160,5161],"Surgery","Analgesia",[5141],{"trials":5164,"activeCount":100},[],{"trials":5166,"activeCount":100},[],{"intervention":5168,"totalTrials":1156,"cells":5169},"Cytarabine consolidation",{"EARLY_PHASE1":5170,"PHASE1":5172,"PHASE2":5174,"PHASE3":5176,"PHASE4":5185,"NA":5187},{"trials":5171,"activeCount":100},[],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[],{"trials":5177,"activeCount":100},[5178],{"nctId":5179,"briefTitle":5180,"status":219,"phases":5181,"primaryCompletion":2066,"completion":2066,"start":4351,"enrollment":1655,"conditions":5182,"interventions":5183},"NCT01588951","Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior",[90,91],[779],[5168,5184],"Allogeneic transplant",{"trials":5186,"activeCount":100},[],{"trials":5188,"activeCount":100},[],{"intervention":5184,"totalTrials":1156,"cells":5190},{"EARLY_PHASE1":5191,"PHASE1":5193,"PHASE2":5195,"PHASE3":5197,"PHASE4":5203,"NA":5205},{"trials":5192,"activeCount":100},[],{"trials":5194,"activeCount":100},[],{"trials":5196,"activeCount":100},[],{"trials":5198,"activeCount":100},[5199],{"nctId":5179,"briefTitle":5180,"status":219,"phases":5200,"primaryCompletion":2066,"completion":2066,"start":4351,"enrollment":1655,"conditions":5201,"interventions":5202},[90,91],[779],[5168,5184],{"trials":5204,"activeCount":100},[],{"trials":5206,"activeCount":100},[],{"intervention":5208,"totalTrials":1156,"cells":5209},"Cobimetinib",{"EARLY_PHASE1":5210,"PHASE1":5212,"PHASE2":5214,"PHASE3":5216,"PHASE4":5225,"NA":5227},{"trials":5211,"activeCount":100},[],{"trials":5213,"activeCount":100},[],{"trials":5215,"activeCount":100},[],{"trials":5217,"activeCount":100},[5218],{"nctId":5219,"briefTitle":5220,"status":416,"phases":5221,"primaryCompletion":1141,"completion":1141,"start":2333,"enrollment":100,"conditions":5222,"interventions":5223},"NCT02427893","Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma",[91],[805],[5208,5224],"Vemurafenib",{"trials":5226,"activeCount":100},[],{"trials":5228,"activeCount":100},[],{"intervention":5224,"totalTrials":1156,"cells":5230},{"EARLY_PHASE1":5231,"PHASE1":5233,"PHASE2":5235,"PHASE3":5237,"PHASE4":5243,"NA":5245},{"trials":5232,"activeCount":100},[],{"trials":5234,"activeCount":100},[],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[5239],{"nctId":5219,"briefTitle":5220,"status":416,"phases":5240,"primaryCompletion":1141,"completion":1141,"start":2333,"enrollment":100,"conditions":5241,"interventions":5242},[91],[805],[5208,5224],{"trials":5244,"activeCount":100},[],{"trials":5246,"activeCount":100},[],{"intervention":5135,"totalTrials":1156,"cells":5248},{"EARLY_PHASE1":5249,"PHASE1":5251,"PHASE2":5253,"PHASE3":5255,"PHASE4":5261,"NA":5263},{"trials":5250,"activeCount":100},[],{"trials":5252,"activeCount":100},[],{"trials":5254,"activeCount":100},[],{"trials":5256,"activeCount":100},[5257],{"nctId":5127,"briefTitle":5128,"status":219,"phases":5258,"primaryCompletion":5130,"completion":5131,"start":5132,"enrollment":384,"conditions":5259,"interventions":5260},[91],[1972],[5135,5106],{"trials":5262,"activeCount":100},[],{"trials":5264,"activeCount":100},[],{"intervention":5266,"totalTrials":1156,"cells":5267},"Modafinil",{"EARLY_PHASE1":5268,"PHASE1":5270,"PHASE2":5272,"PHASE3":5274,"PHASE4":5285,"NA":5287},{"trials":5269,"activeCount":100},[],{"trials":5271,"activeCount":100},[],{"trials":5273,"activeCount":100},[],{"trials":5275,"activeCount":100},[5276],{"nctId":5277,"briefTitle":5278,"status":219,"phases":5279,"completion":5280,"start":1888,"enrollment":5281,"conditions":5282,"interventions":5284},"NCT00267332","Modafinil in Opioid Induced Sedation",[91],"2006-12",90,[648,5283],"Pain",[5266],{"trials":5286,"activeCount":100},[],{"trials":5288,"activeCount":100},[],{"intervention":1283,"totalTrials":1156,"cells":5290},{"EARLY_PHASE1":5291,"PHASE1":5293,"PHASE2":5295,"PHASE3":5297,"PHASE4":5303,"NA":5305},{"trials":5292,"activeCount":100},[],{"trials":5294,"activeCount":100},[],{"trials":5296,"activeCount":100},[],{"trials":5298,"activeCount":100},[5299],{"nctId":1275,"briefTitle":1276,"status":139,"phases":5300,"primaryCompletion":1278,"completion":1278,"start":1279,"enrollment":1280,"conditions":5301,"interventions":5302},[91],[796,30],[713,1283,693,650,1284],{"trials":5304,"activeCount":100},[],{"trials":5306,"activeCount":100},[],{"intervention":1284,"totalTrials":1156,"cells":5308},{"EARLY_PHASE1":5309,"PHASE1":5311,"PHASE2":5313,"PHASE3":5315,"PHASE4":5321,"NA":5323},{"trials":5310,"activeCount":100},[],{"trials":5312,"activeCount":100},[],{"trials":5314,"activeCount":100},[],{"trials":5316,"activeCount":100},[5317],{"nctId":1275,"briefTitle":1276,"status":139,"phases":5318,"primaryCompletion":1278,"completion":1278,"start":1279,"enrollment":1280,"conditions":5319,"interventions":5320},[91],[796,30],[713,1283,693,650,1284],{"trials":5322,"activeCount":100},[],{"trials":5324,"activeCount":100},[],{"intervention":841,"totalTrials":156,"cells":5326},{"EARLY_PHASE1":5327,"PHASE1":5329,"PHASE2":5339,"PHASE3":5414,"PHASE4":5416,"NA":5418},{"trials":5328,"activeCount":100},[],{"trials":5330,"activeCount":100},[5331],{"nctId":5332,"briefTitle":5333,"status":219,"phases":5334,"primaryCompletion":5335,"completion":5335,"start":42,"enrollment":231,"conditions":5336,"interventions":5337},"NCT01900496","Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma",[89],"2017-07",[30],[5338,841],"Brentuximab vedotin",{"trials":5340,"activeCount":100},[5341,5345,5349,5353,5357,5361,5365,5369,5373,5388,5392,5396,5400,5407],{"nctId":834,"briefTitle":835,"status":139,"phases":5342,"primaryCompletion":658,"completion":658,"start":742,"enrollment":190,"conditions":5343,"interventions":5344},[89,90],[30],[839,840,841,82],{"nctId":876,"briefTitle":877,"status":139,"phases":5346,"primaryCompletion":879,"completion":879,"start":880,"enrollment":108,"conditions":5347,"interventions":5348},[90],[754],[883,650],{"nctId":885,"briefTitle":886,"status":219,"phases":5350,"primaryCompletion":888,"completion":888,"start":889,"enrollment":118,"conditions":5351,"interventions":5352},[90],[891],[841,82,893,637,894,895,175,896,897],{"nctId":3196,"briefTitle":3197,"status":139,"phases":5354,"primaryCompletion":3199,"completion":3199,"start":3200,"enrollment":1581,"conditions":5355,"interventions":5356},[90],[30],[3203,841,3204,893,3205],{"nctId":899,"briefTitle":900,"status":416,"phases":5358,"primaryCompletion":902,"completion":902,"start":903,"enrollment":100,"conditions":5359,"interventions":5360},[90],[27],[906,883,650],{"nctId":2379,"briefTitle":2380,"status":219,"phases":5362,"primaryCompletion":2365,"completion":2365,"start":2382,"enrollment":37,"conditions":5363,"interventions":5364},[90],[30],[883,926,2265],{"nctId":984,"briefTitle":985,"status":139,"phases":5366,"primaryCompletion":987,"completion":988,"start":989,"enrollment":990,"conditions":5367,"interventions":5368},[90],[27,30],[993,841,82],{"nctId":1016,"briefTitle":1017,"status":139,"phases":5370,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":493,"conditions":5371,"interventions":5372},[90],[30],[692,883,1023,1024,650,715],{"nctId":5374,"briefTitle":5375,"status":139,"phases":5376,"primaryCompletion":5377,"completion":5378,"start":2365,"enrollment":16,"conditions":5379,"interventions":5386},"NCT01665768","Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma",[90],"2017-10","2020-08",[5380,5381,5382,5383,5384,5385],"CD20+, B-cell Lymphomas","Mantle Cell Lymphoma","Non-Mantle Cell Low Grade B Cell Lymphomas (SLL\u002FCLL)","Transformed Lymphoma\u002FDLBCL\u002FPMBCL","Hodgkin's Disease","Gray Zone Lymphoma",[5387,841],"Everolimus",{"nctId":1126,"briefTitle":1127,"status":139,"phases":5389,"primaryCompletion":657,"completion":1129,"start":1130,"enrollment":765,"conditions":5390,"interventions":5391},[90],[27,30],[840,841,82,1133,1134,894,1135,637,1136],{"nctId":1168,"briefTitle":1169,"status":139,"phases":5393,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":384,"conditions":5394,"interventions":5395},[90],[30],[692,883,693,1175,650,1176,704,715,926,1177,1178],{"nctId":1209,"briefTitle":1210,"status":219,"phases":5397,"primaryCompletion":1212,"completion":1213,"start":1076,"enrollment":1214,"conditions":5398,"interventions":5399},[90],[30,1216,1217,865],[676,82,854,677,841,1219],{"nctId":5401,"briefTitle":5402,"status":219,"phases":5403,"primaryCompletion":827,"completion":5404,"start":1278,"enrollment":969,"conditions":5405,"interventions":5406},"NCT00072449","Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma",[90],"2010-06",[30],[883],{"nctId":5408,"briefTitle":5409,"status":219,"phases":5410,"primaryCompletion":5411,"completion":5411,"start":1130,"conditions":5412,"interventions":5413},"NCT00265915","Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia",[90],"2006-03",[27],[883,1023],{"trials":5415,"activeCount":100},[],{"trials":5417,"activeCount":100},[],{"trials":5419,"activeCount":100},[],{"intervention":692,"totalTrials":723,"cells":5421},{"EARLY_PHASE1":5422,"PHASE1":5424,"PHASE2":5450,"PHASE3":5487,"PHASE4":5489,"NA":5491},{"trials":5423,"activeCount":100},[],{"trials":5425,"activeCount":100},[5426,5430,5434,5438,5442,5446],{"nctId":683,"briefTitle":684,"status":219,"phases":5427,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":5428,"interventions":5429},[89],[27],[692,693,650],{"nctId":706,"briefTitle":707,"status":139,"phases":5431,"start":709,"conditions":5432,"interventions":5433},[89],[27,30,33,711],[713,692,714,650,715,716],{"nctId":749,"briefTitle":750,"status":139,"phases":5435,"start":752,"conditions":5436,"interventions":5437},[89],[27,30,754,33,711],[692,650,756,757,758],{"nctId":760,"briefTitle":761,"status":139,"phases":5439,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":5440,"interventions":5441},[89],[767,768,769],[692,43,650],{"nctId":791,"briefTitle":792,"status":139,"phases":5443,"start":794,"enrollment":700,"conditions":5444,"interventions":5445},[89],[745,796,27,30,754,33,711],[692,650,756,757,758],{"nctId":809,"briefTitle":810,"status":139,"phases":5447,"primaryCompletion":812,"completion":812,"start":813,"enrollment":108,"conditions":5448,"interventions":5449},[89],[24,815,816,817,818,768,280,819],[692,43,650,715],{"trials":5451,"activeCount":100},[5452,5456,5463,5467,5471,5475,5479,5483],{"nctId":834,"briefTitle":835,"status":139,"phases":5453,"primaryCompletion":658,"completion":658,"start":742,"enrollment":190,"conditions":5454,"interventions":5455},[89,90],[30],[839,840,841,82],{"nctId":5457,"briefTitle":5458,"status":139,"phases":5459,"primaryCompletion":3055,"completion":827,"start":1192,"enrollment":623,"conditions":5460,"interventions":5461},"NCT00245011","Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma",[90],[280],[692,5462],"ifosfamide",{"nctId":1016,"briefTitle":1017,"status":139,"phases":5464,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":493,"conditions":5465,"interventions":5466},[90],[30],[692,883,1023,1024,650,715],{"nctId":1026,"briefTitle":1027,"status":139,"phases":5468,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":1032,"conditions":5469,"interventions":5470},[90],[1034,1035],[650,692],{"nctId":1047,"briefTitle":1048,"status":416,"phases":5472,"primaryCompletion":1050,"completion":1050,"start":802,"enrollment":100,"conditions":5473,"interventions":5474},[90],[1052,1053,192],[82,639,840,854,757,894,1055,1056],{"nctId":1104,"briefTitle":1105,"status":139,"phases":5476,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":25,"conditions":5477,"interventions":5478},[90],[673],[1112,1113,82,840,1014,1114],{"nctId":1126,"briefTitle":1127,"status":139,"phases":5480,"primaryCompletion":657,"completion":1129,"start":1130,"enrollment":765,"conditions":5481,"interventions":5482},[90],[27,30],[840,841,82,1133,1134,894,1135,637,1136],{"nctId":1168,"briefTitle":1169,"status":139,"phases":5484,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":384,"conditions":5485,"interventions":5486},[90],[30],[692,883,693,1175,650,1176,704,715,926,1177,1178],{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[],{"trials":5492,"activeCount":100},[],{"intervention":1023,"totalTrials":361,"cells":5494},{"EARLY_PHASE1":5495,"PHASE1":5497,"PHASE2":5499,"PHASE3":5566,"PHASE4":5568,"NA":5570},{"trials":5496,"activeCount":100},[],{"trials":5498,"activeCount":100},[],{"trials":5500,"activeCount":100},[5501,5505,5516,5525,5532,5540,5549,5558,5562],{"nctId":1016,"briefTitle":1017,"status":139,"phases":5502,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":493,"conditions":5503,"interventions":5504},[90],[30],[692,883,1023,1024,650,715],{"nctId":5506,"briefTitle":5507,"status":139,"phases":5508,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":1872,"conditions":5511,"interventions":5512},"NCT00425477","Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia",[90],"2016-09-30","2006-11",[27,33,711],[1023,5513,5514,5515],"bexarotene","cytogenetic analysis","fluorescence in situ hybridization",{"nctId":5517,"briefTitle":5518,"status":219,"phases":5519,"primaryCompletion":5520,"completion":1184,"start":5521,"enrollment":452,"conditions":5522,"interventions":5523},"NCT00003561","Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",[90],"2001-10","1998-02",[27],[5524,1023],"recombinant interferon alfa",{"nctId":5526,"briefTitle":5527,"status":139,"phases":5528,"primaryCompletion":686,"completion":686,"start":5529,"conditions":5530,"interventions":5531},"NCT00003961","Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome",[90],"1999-04",[27,33,711],[1023],{"nctId":5533,"briefTitle":5534,"status":139,"phases":5535,"primaryCompletion":5536,"completion":5536,"start":5537,"conditions":5538,"interventions":5539},"NCT00011934","Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia",[90],"2002-08","1998-05",[27],[5524,1023],{"nctId":5541,"briefTitle":5542,"status":219,"phases":5543,"primaryCompletion":5544,"completion":644,"start":5545,"enrollment":5546,"conditions":5547,"interventions":5548},"NCT00002778","Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia",[90],"2005-02","1995-02",40,[27],[1023,714],{"nctId":5550,"briefTitle":5551,"status":139,"phases":5552,"primaryCompletion":5553,"completion":5553,"start":1243,"enrollment":25,"conditions":5554,"interventions":5555},"NCT00363649","Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI",[90],"2017-09",[27],[5556,5557,4936],"GM-K562 cell vaccine","Interferon alfa",{"nctId":4931,"briefTitle":4932,"status":139,"phases":5559,"primaryCompletion":1108,"completion":1108,"start":1269,"enrollment":1516,"conditions":5560,"interventions":5561},[90],[779,778],[328,4936],{"nctId":5408,"briefTitle":5409,"status":219,"phases":5563,"primaryCompletion":5411,"completion":5411,"start":1130,"conditions":5564,"interventions":5565},[90],[27],[883,1023],{"trials":5567,"activeCount":100},[],{"trials":5569,"activeCount":100},[],{"trials":5571,"activeCount":100},[],{"intervention":831,"totalTrials":1609,"cells":5573},{"EARLY_PHASE1":5574,"PHASE1":5576,"PHASE2":5582,"PHASE3":5604,"PHASE4":5606,"NA":5608},{"trials":5575,"activeCount":100},[],{"trials":5577,"activeCount":100},[5578],{"nctId":2006,"briefTitle":2007,"status":219,"phases":5579,"primaryCompletion":182,"completion":182,"start":1076,"enrollment":439,"conditions":5580,"interventions":5581},[89],[36],[831,2011,638],{"trials":5583,"activeCount":100},[5584,5588,5592,5600],{"nctId":824,"briefTitle":825,"status":139,"phases":5585,"primaryCompletion":827,"completion":827,"start":828,"enrollment":700,"conditions":5586,"interventions":5587},[90],[21],[831,832,82],{"nctId":1455,"briefTitle":1456,"status":219,"phases":5589,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":361,"conditions":5590,"interventions":5591},[89,90],[36],[1462,831,638,175],{"nctId":5593,"briefTitle":5594,"status":139,"phases":5595,"primaryCompletion":5596,"completion":5596,"start":902,"enrollment":28,"conditions":5597,"interventions":5599},"NCT00524017","Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract",[90],"2011-12",[36,5598],"Precancerous Condition",[1900],{"nctId":1894,"briefTitle":1895,"status":219,"phases":5601,"primaryCompletion":741,"completion":741,"start":688,"enrollment":1897,"conditions":5602,"interventions":5603},[90],[21],[1900,1875,1901,1902,58,409,1903,1904],{"trials":5605,"activeCount":100},[],{"trials":5607,"activeCount":100},[],{"trials":5609,"activeCount":100},[],{"intervention":2297,"totalTrials":536,"cells":5611},{"EARLY_PHASE1":5612,"PHASE1":5614,"PHASE2":5628,"PHASE3":5646,"PHASE4":5648,"NA":5650},{"trials":5613,"activeCount":100},[],{"trials":5615,"activeCount":100},[5616,5620],{"nctId":2289,"briefTitle":2290,"status":139,"phases":5617,"primaryCompletion":2292,"completion":2293,"start":2294,"conditions":5618,"interventions":5619},[89],[24],[2297,2265],{"nctId":5621,"briefTitle":5622,"status":139,"phases":5623,"primaryCompletion":5624,"start":5536,"enrollment":313,"conditions":5625,"interventions":5626},"NCT00047242","UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors",[89],"2006-02",[4913],[5627,2297],"7-hydroxystaurosporine",{"trials":5629,"activeCount":100},[5630,5637],{"nctId":5631,"briefTitle":5632,"status":219,"phases":5633,"primaryCompletion":5634,"completion":5634,"start":1507,"enrollment":231,"conditions":5635,"interventions":5636},"NCT00100828","Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer",[90],"2008-11",[36],[2297],{"nctId":5638,"briefTitle":5639,"status":139,"phases":5640,"primaryCompletion":5641,"completion":5642,"start":5643,"conditions":5644,"interventions":5645},"NCT00003616","Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma",[89,90],"2002-05-17","2005-12-20","1998-10-22",[24],[2297],{"trials":5647,"activeCount":100},[],{"trials":5649,"activeCount":100},[],{"trials":5651,"activeCount":100},[],{"intervention":756,"totalTrials":536,"cells":5653},{"EARLY_PHASE1":5654,"PHASE1":5656,"PHASE2":5673,"PHASE3":5679,"PHASE4":5681,"NA":5683},{"trials":5655,"activeCount":100},[],{"trials":5657,"activeCount":100},[5658,5665,5669],{"nctId":5659,"briefTitle":5660,"status":139,"phases":5661,"start":699,"conditions":5662,"interventions":5663},"NCT00077558","3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome",[89],[27,33,711],[756,5664],"triapine",{"nctId":749,"briefTitle":750,"status":139,"phases":5666,"start":752,"conditions":5667,"interventions":5668},[89],[27,30,754,33,711],[692,650,756,757,758],{"nctId":791,"briefTitle":792,"status":139,"phases":5670,"start":794,"enrollment":700,"conditions":5671,"interventions":5672},[89],[745,796,27,30,754,33,711],[692,650,756,757,758],{"trials":5674,"activeCount":100},[5675],{"nctId":1188,"briefTitle":1189,"status":139,"phases":5676,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":5677,"interventions":5678},[90],[745,27,30,754,33],[650,756,757,758],{"trials":5680,"activeCount":100},[],{"trials":5682,"activeCount":100},[],{"trials":5684,"activeCount":100},[],{"intervention":5686,"totalTrials":536,"cells":5687},"sirolimus",{"EARLY_PHASE1":5688,"PHASE1":5690,"PHASE2":5698,"PHASE3":5714,"PHASE4":5716,"NA":5718},{"trials":5689,"activeCount":100},[],{"trials":5691,"activeCount":100},[5692],{"nctId":5693,"briefTitle":5694,"status":139,"phases":5695,"primaryCompletion":2046,"completion":2046,"start":880,"enrollment":313,"conditions":5696,"interventions":5697},"NCT00368914","Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors",[89],[4913],[5686],{"trials":5699,"activeCount":100},[5700,5706,5710],{"nctId":5701,"briefTitle":5702,"status":139,"phases":5703,"primaryCompletion":3211,"completion":2046,"start":989,"enrollment":2037,"conditions":5704,"interventions":5705},"NCT00499486","Sirolimus in Treating Patients With Advanced Pancreatic Cancer",[90],[21],[5686],{"nctId":954,"briefTitle":955,"status":219,"phases":5707,"primaryCompletion":957,"completion":957,"start":958,"enrollment":19,"conditions":5708,"interventions":5709},[90],[960],[82,676,874,962,963,964],{"nctId":2511,"briefTitle":2512,"status":139,"phases":5711,"primaryCompletion":2514,"completion":2514,"start":2515,"enrollment":1099,"conditions":5712,"interventions":5713},[89,90],[2517],[676,1732,677,962,854],{"trials":5715,"activeCount":100},[],{"trials":5717,"activeCount":100},[],{"trials":5719,"activeCount":100},[],{"intervention":894,"totalTrials":536,"cells":5721},{"EARLY_PHASE1":5722,"PHASE1":5724,"PHASE2":5726,"PHASE3":5744,"PHASE4":5746,"NA":5748},{"trials":5723,"activeCount":100},[],{"trials":5725,"activeCount":100},[],{"trials":5727,"activeCount":100},[5728,5732,5736,5740],{"nctId":885,"briefTitle":886,"status":219,"phases":5729,"primaryCompletion":888,"completion":888,"start":889,"enrollment":118,"conditions":5730,"interventions":5731},[90],[891],[841,82,893,637,894,895,175,896,897],{"nctId":1047,"briefTitle":1048,"status":416,"phases":5733,"primaryCompletion":1050,"completion":1050,"start":802,"enrollment":100,"conditions":5734,"interventions":5735},[90],[1052,1053,192],[82,639,840,854,757,894,1055,1056],{"nctId":1126,"briefTitle":1127,"status":139,"phases":5737,"primaryCompletion":657,"completion":1129,"start":1130,"enrollment":765,"conditions":5738,"interventions":5739},[90],[27,30],[840,841,82,1133,1134,894,1135,637,1136],{"nctId":1168,"briefTitle":1169,"status":139,"phases":5741,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":384,"conditions":5742,"interventions":5743},[90],[30],[692,883,693,1175,650,1176,704,715,926,1177,1178],{"trials":5745,"activeCount":100},[],{"trials":5747,"activeCount":100},[],{"trials":5749,"activeCount":100},[],{"intervention":579,"totalTrials":536,"cells":5751},{"EARLY_PHASE1":5752,"PHASE1":5754,"PHASE2":5756,"PHASE3":5781,"PHASE4":5783,"NA":5785},{"trials":5753,"activeCount":100},[],{"trials":5755,"activeCount":100},[],{"trials":5757,"activeCount":100},[5758,5766,5770,5777],{"nctId":5759,"briefTitle":5760,"status":139,"phases":5761,"primaryCompletion":5762,"completion":5762,"start":5763,"enrollment":241,"conditions":5764,"interventions":5765},"NCT00894413","A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract",[90],"2012-03","2007-05-08",[268],[579],{"nctId":571,"briefTitle":572,"status":139,"phases":5767,"primaryCompletion":574,"completion":575,"start":576,"enrollment":143,"conditions":5768,"interventions":5769},[90],[21],[579,580,123,341],{"nctId":5771,"briefTitle":5772,"status":139,"phases":5773,"primaryCompletion":5774,"completion":5774,"start":2365,"enrollment":5546,"conditions":5775,"interventions":5776},"NCT01697800","A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract",[90],"2014-07-14",[268],[579],{"nctId":2936,"briefTitle":2937,"status":219,"phases":5778,"primaryCompletion":1562,"completion":1562,"start":732,"enrollment":723,"conditions":5779,"interventions":5780},[90],[673],[579,2941,1990,2942],{"trials":5782,"activeCount":100},[],{"trials":5784,"activeCount":100},[],{"trials":5786,"activeCount":100},[],{"intervention":341,"totalTrials":536,"cells":5788},{"EARLY_PHASE1":5789,"PHASE1":5791,"PHASE2":5793,"PHASE3":5811,"PHASE4":5813,"NA":5815},{"trials":5790,"activeCount":100},[],{"trials":5792,"activeCount":100},[],{"trials":5794,"activeCount":100},[5795,5799,5803,5807],{"nctId":571,"briefTitle":572,"status":139,"phases":5796,"primaryCompletion":574,"completion":575,"start":576,"enrollment":143,"conditions":5797,"interventions":5798},[90],[21],[579,580,123,341],{"nctId":1082,"briefTitle":1083,"status":139,"phases":5800,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":5801,"interventions":5802},[90],[566],[1091,580,341,82,376],{"nctId":332,"briefTitle":333,"status":139,"phases":5804,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":5805,"interventions":5806},[90],[339],[341,341,342,343,344],{"nctId":367,"briefTitle":368,"status":139,"phases":5808,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":5809,"interventions":5810},[90],[21],[82,63,123,376,341,341],{"trials":5812,"activeCount":100},[],{"trials":5814,"activeCount":100},[],{"trials":5816,"activeCount":100},[],{"intervention":703,"totalTrials":536,"cells":5818},{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5827,"PHASE3":5841,"PHASE4":5843,"NA":5845},{"trials":5820,"activeCount":100},[],{"trials":5822,"activeCount":100},[5823],{"nctId":695,"briefTitle":696,"status":139,"phases":5824,"primaryCompletion":698,"start":699,"enrollment":700,"conditions":5825,"interventions":5826},[89],[18],[703,650,704],{"trials":5828,"activeCount":100},[5829,5833,5837],{"nctId":1073,"briefTitle":1074,"status":139,"phases":5830,"primaryCompletion":802,"completion":802,"start":1076,"enrollment":1077,"conditions":5831,"interventions":5832},[90],[18],[703,1080,650],{"nctId":1240,"briefTitle":1241,"status":139,"phases":5834,"primaryCompletion":938,"completion":938,"start":1243,"enrollment":439,"conditions":5835,"interventions":5836},[90],[1245],[1247,48,82],{"nctId":1266,"briefTitle":1267,"status":139,"phases":5838,"primaryCompletion":1269,"completion":1269,"start":1142,"enrollment":405,"conditions":5839,"interventions":5840},[90],[18],[703,1080,650],{"trials":5842,"activeCount":100},[],{"trials":5844,"activeCount":100},[],{"trials":5846,"activeCount":100},[],{"intervention":1511,"totalTrials":536,"cells":5848},{"EARLY_PHASE1":5849,"PHASE1":5851,"PHASE2":5853,"PHASE3":5881,"PHASE4":5883,"NA":5885},{"trials":5850,"activeCount":100},[],{"trials":5852,"activeCount":100},[],{"trials":5854,"activeCount":100},[5855,5861,5868,5877],{"nctId":5856,"briefTitle":5857,"status":139,"phases":5858,"primaryCompletion":722,"completion":1494,"start":1130,"enrollment":22,"conditions":5859,"interventions":5860},"NCT00281866","Erlotinib in Treating Patients With Metastatic and\u002For Recurrent Head and Neck Cancer",[90],[36],[1511],{"nctId":5862,"briefTitle":5863,"status":139,"phases":5864,"primaryCompletion":5865,"start":1243,"enrollment":5546,"conditions":5866,"interventions":5867},"NCT00673569","Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment",[90],"2007-07",[1497],[1511,2306,2308],{"nctId":5869,"briefTitle":5870,"status":139,"phases":5871,"primaryCompletion":5872,"completion":5873,"start":5874,"enrollment":452,"conditions":5875,"interventions":5876},"NCT00313560","ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)",[90],"2013-12-27","2019-02-27","2006-03-16",[21],[1511],{"nctId":1502,"briefTitle":1503,"status":139,"phases":5878,"primaryCompletion":1505,"completion":1506,"start":1507,"enrollment":1508,"conditions":5879,"interventions":5880},[90],[1497],[175,1511,176,1511],{"trials":5882,"activeCount":100},[],{"trials":5884,"activeCount":100},[],{"trials":5886,"activeCount":100},[],{"intervention":2941,"totalTrials":536,"cells":5888},{"EARLY_PHASE1":5889,"PHASE1":5891,"PHASE2":5893,"PHASE3":5926,"PHASE4":5928,"NA":5930},{"trials":5890,"activeCount":100},[],{"trials":5892,"activeCount":100},[],{"trials":5894,"activeCount":100},[5895,5906,5914,5922],{"nctId":5896,"briefTitle":5897,"status":219,"phases":5898,"primaryCompletion":5899,"completion":5900,"start":5901,"enrollment":266,"conditions":5902,"interventions":5903},"NCT03376477","Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission",[90],"2024-01-02","2025-05-30","2019-09-23",[673],[5904,2941,5905],"GM-CSF vaccine","Prevnar13",{"nctId":5907,"briefTitle":5908,"status":139,"phases":5909,"primaryCompletion":3283,"completion":2515,"start":3062,"enrollment":439,"conditions":5910,"interventions":5911},"NCT00445484","Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma",[90],[754],[5912,5913],"pneumococcal polyvalent vaccine","lenalidomide",{"nctId":5915,"briefTitle":5916,"status":139,"phases":5917,"primaryCompletion":5918,"completion":5918,"start":687,"enrollment":34,"conditions":5919,"interventions":5920},"NCT01349569","Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission",[90],"2016-10",[673],[2941,1113,5921],"Prevnar-13",{"nctId":2936,"briefTitle":2937,"status":219,"phases":5923,"primaryCompletion":1562,"completion":1562,"start":732,"enrollment":723,"conditions":5924,"interventions":5925},[90],[673],[579,2941,1990,2942],{"trials":5927,"activeCount":100},[],{"trials":5929,"activeCount":100},[],{"trials":5931,"activeCount":100},[],{"intervention":5933,"totalTrials":224,"cells":5934},"MK-3475",{"EARLY_PHASE1":5935,"PHASE1":5937,"PHASE2":5949,"PHASE3":5974,"PHASE4":5976,"NA":5978},{"trials":5936,"activeCount":100},[],{"trials":5938,"activeCount":100},[5939],{"nctId":5940,"briefTitle":5941,"status":139,"phases":5942,"primaryCompletion":5943,"completion":5943,"start":5944,"enrollment":118,"conditions":5945,"interventions":5946},"NCT02512172","A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer",[89],"2021-11-20","2016-02-19",[120],[5947,5948,5933],"Oral CC-486","Romidepsin",{"trials":5950,"activeCount":100},[5951,5962],{"nctId":5952,"briefTitle":5953,"status":139,"phases":5954,"primaryCompletion":5955,"completion":5955,"start":535,"enrollment":5956,"conditions":5957,"interventions":5961},"NCT01876511","Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)",[90],"2019-08",113,[5958,5959,5960],"MSI Positive Colorectal Cancer","MSI Negative Colorectal Cancer","MSI Positive Non-Colorectal Cancers",[5933],{"nctId":5963,"briefTitle":5964,"status":139,"phases":5965,"primaryCompletion":5966,"completion":5967,"start":5968,"enrollment":969,"conditions":5969,"interventions":5973},"NCT04098068","Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)",[90],"2022-05-15","2025-02-05","2018-01-25",[5970,5971,5972],"High Tumor Mutation Burden","High TMB (Tumor Mutation Burden)","MSS (Microsatellite Stable)",[5933],{"trials":5975,"activeCount":100},[],{"trials":5977,"activeCount":100},[],{"trials":5979,"activeCount":100},[],{"intervention":639,"totalTrials":224,"cells":5981},{"EARLY_PHASE1":5982,"PHASE1":5988,"PHASE2":5990,"PHASE3":6000,"PHASE4":6002,"NA":6004},{"trials":5983,"activeCount":100},[5984],{"nctId":628,"briefTitle":629,"status":219,"phases":5985,"primaryCompletion":631,"completion":631,"start":632,"enrollment":231,"conditions":5986,"interventions":5987},[88],[634],[636,637,638,82,639,637],{"trials":5989,"activeCount":100},[],{"trials":5991,"activeCount":100},[5992,5996],{"nctId":843,"briefTitle":844,"status":139,"phases":5993,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":5994,"interventions":5995},[90],[850,851],[853,676,82,639,854,855],{"nctId":1047,"briefTitle":1048,"status":416,"phases":5997,"primaryCompletion":1050,"completion":1050,"start":802,"enrollment":100,"conditions":5998,"interventions":5999},[90],[1052,1053,192],[82,639,840,854,757,894,1055,1056],{"trials":6001,"activeCount":100},[],{"trials":6003,"activeCount":100},[],{"trials":6005,"activeCount":100},[],{"intervention":3066,"totalTrials":224,"cells":6007},{"EARLY_PHASE1":6008,"PHASE1":6010,"PHASE2":6024,"PHASE3":6035,"PHASE4":6037,"NA":6039},{"trials":6009,"activeCount":100},[],{"trials":6011,"activeCount":100},[6012,6020],{"nctId":6013,"briefTitle":6014,"status":139,"phases":6015,"primaryCompletion":6016,"completion":1030,"start":6017,"enrollment":224,"conditions":6018,"interventions":6019},"NCT00401024","Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma",[89],"2008-02-04","2006-10-12",[24],[3066],{"nctId":3059,"briefTitle":3060,"status":139,"phases":6021,"primaryCompletion":3062,"completion":1563,"start":3063,"enrollment":969,"conditions":6022,"interventions":6023},[89],[18],[1901,3066],{"trials":6025,"activeCount":100},[6026],{"nctId":6027,"briefTitle":6028,"status":139,"phases":6029,"primaryCompletion":2313,"completion":6030,"start":6031,"enrollment":6032,"conditions":6033,"interventions":6034},"NCT00010049","Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma",[89,90],"2006-08-15","2001-02-27",105,[24],[3066],{"trials":6036,"activeCount":100},[],{"trials":6038,"activeCount":100},[],{"trials":6040,"activeCount":100},[],{"intervention":6042,"totalTrials":224,"cells":6043},"simvastatin",{"EARLY_PHASE1":6044,"PHASE1":6046,"PHASE2":6048,"PHASE3":6078,"PHASE4":6080,"NA":6082},{"trials":6045,"activeCount":100},[],{"trials":6047,"activeCount":100},[],{"trials":6049,"activeCount":100},[6050,6058,6064],{"nctId":6051,"briefTitle":6052,"status":139,"phases":6053,"primaryCompletion":3055,"completion":2079,"start":6054,"enrollment":623,"conditions":6055,"interventions":6056},"NCT00354640","Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer",[90],"2006-06",[18],[6057,6042],"anastrozole",{"nctId":6059,"briefTitle":6060,"status":139,"phases":6061,"primaryCompletion":2046,"completion":2079,"start":5411,"enrollment":1280,"conditions":6062,"interventions":6063},"NCT00334542","Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer",[90],[18],[6042],{"nctId":6065,"briefTitle":6066,"status":219,"phases":6067,"primaryCompletion":6068,"completion":6069,"start":6070,"enrollment":96,"conditions":6071,"interventions":6075},"NCT02096588","Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin",[90],"2017-04-25","2023-07-26","2014-05-20",[18,6072,6073,6074],"Stage I Breast Cancer","Stage II Breast Cancer","Stage III Breast Cancer",[6076,6077],"Simvastatin","Doxorubicin\u002Fcyclophosphamide",{"trials":6079,"activeCount":100},[],{"trials":6081,"activeCount":100},[],{"trials":6083,"activeCount":100},[],{"intervention":6085,"totalTrials":224,"cells":6086},"18F-DCFBC",{"EARLY_PHASE1":6087,"PHASE1":6089,"PHASE2":6097,"PHASE3":6115,"PHASE4":6117,"NA":6119},{"trials":6088,"activeCount":100},[],{"trials":6090,"activeCount":100},[6091],{"nctId":6092,"briefTitle":6093,"status":139,"phases":6094,"primaryCompletion":473,"completion":473,"start":2515,"enrollment":1609,"conditions":6095,"interventions":6096},"NCT01417182","Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer",[89],[15],[6085],{"trials":6098,"activeCount":100},[6099,6107],{"nctId":6100,"briefTitle":6101,"status":139,"phases":6102,"primaryCompletion":1191,"completion":6103,"start":6104,"enrollment":156,"conditions":6105,"interventions":6106},"NCT01496157","Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer",[89,90],"2017-09-17","2012-09-11",[15],[6085],{"nctId":6108,"briefTitle":6109,"status":139,"phases":6110,"primaryCompletion":6111,"completion":6112,"start":1683,"enrollment":439,"conditions":6113,"interventions":6114},"NCT01815515","Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer",[89,90],"2015-07","2015-11-18",[244],[6085],{"trials":6116,"activeCount":100},[],{"trials":6118,"activeCount":100},[],{"trials":6120,"activeCount":100},[],{"intervention":637,"totalTrials":224,"cells":6122},{"EARLY_PHASE1":6123,"PHASE1":6129,"PHASE2":6131,"PHASE3":6141,"PHASE4":6143,"NA":6145},{"trials":6124,"activeCount":100},[6125],{"nctId":628,"briefTitle":629,"status":219,"phases":6126,"primaryCompletion":631,"completion":631,"start":632,"enrollment":231,"conditions":6127,"interventions":6128},[88],[634],[636,637,638,82,639,637],{"trials":6130,"activeCount":100},[],{"trials":6132,"activeCount":100},[6133,6137],{"nctId":885,"briefTitle":886,"status":219,"phases":6134,"primaryCompletion":888,"completion":888,"start":889,"enrollment":118,"conditions":6135,"interventions":6136},[90],[891],[841,82,893,637,894,895,175,896,897],{"nctId":1126,"briefTitle":1127,"status":139,"phases":6138,"primaryCompletion":657,"completion":1129,"start":1130,"enrollment":765,"conditions":6139,"interventions":6140},[90],[27,30],[840,841,82,1133,1134,894,1135,637,1136],{"trials":6142,"activeCount":100},[],{"trials":6144,"activeCount":100},[],{"trials":6146,"activeCount":100},[],{"intervention":895,"totalTrials":224,"cells":6148},{"EARLY_PHASE1":6149,"PHASE1":6151,"PHASE2":6153,"PHASE3":6167,"PHASE4":6169,"NA":6171},{"trials":6150,"activeCount":100},[],{"trials":6152,"activeCount":100},[],{"trials":6154,"activeCount":100},[6155,6159,6163],{"nctId":885,"briefTitle":886,"status":219,"phases":6156,"primaryCompletion":888,"completion":888,"start":889,"enrollment":118,"conditions":6157,"interventions":6158},[90],[891],[841,82,893,637,894,895,175,896,897],{"nctId":5457,"briefTitle":5458,"status":139,"phases":6160,"primaryCompletion":3055,"completion":827,"start":1192,"enrollment":623,"conditions":6161,"interventions":6162},[90],[280],[692,5462],{"nctId":3229,"briefTitle":3230,"status":219,"phases":6164,"primaryCompletion":3232,"completion":3232,"start":3233,"enrollment":361,"conditions":6165,"interventions":6166},[90],[3235],[895,893],{"trials":6168,"activeCount":100},[],{"trials":6170,"activeCount":100},[],{"trials":6172,"activeCount":100},[],{"intervention":1102,"totalTrials":224,"cells":6174},{"EARLY_PHASE1":6175,"PHASE1":6177,"PHASE2":6179,"PHASE3":6197,"PHASE4":6199,"NA":6201},{"trials":6176,"activeCount":100},[],{"trials":6178,"activeCount":100},[],{"trials":6180,"activeCount":100},[6181,6189,6193],{"nctId":6182,"briefTitle":6183,"status":139,"phases":6184,"primaryCompletion":828,"completion":6185,"start":6186,"enrollment":700,"conditions":6187,"interventions":6188},"NCT00084383","Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas",[90],"2006-07","2002-01",[21],[1102],{"nctId":1093,"briefTitle":1094,"status":139,"phases":6190,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":6191,"interventions":6192},[90],[21],[1102,650],{"nctId":1116,"briefTitle":1117,"status":139,"phases":6194,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":1121,"conditions":6195,"interventions":6196},[90],[21],[82,1124,580],{"trials":6198,"activeCount":100},[],{"trials":6200,"activeCount":100},[],{"trials":6202,"activeCount":100},[],{"intervention":926,"totalTrials":224,"cells":6204},{"EARLY_PHASE1":6205,"PHASE1":6207,"PHASE2":6209,"PHASE3":6223,"PHASE4":6225,"NA":6227},{"trials":6206,"activeCount":100},[],{"trials":6208,"activeCount":100},[],{"trials":6210,"activeCount":100},[6211,6215,6219],{"nctId":919,"briefTitle":920,"status":139,"phases":6212,"primaryCompletion":922,"completion":922,"start":923,"enrollment":25,"conditions":6213,"interventions":6214},[90],[27,754,33],[693,650,926],{"nctId":2379,"briefTitle":2380,"status":219,"phases":6216,"primaryCompletion":2365,"completion":2365,"start":2382,"enrollment":37,"conditions":6217,"interventions":6218},[90],[30],[883,926,2265],{"nctId":1168,"briefTitle":1169,"status":139,"phases":6220,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":384,"conditions":6221,"interventions":6222},[90],[30],[692,883,693,1175,650,1176,704,715,926,1177,1178],{"trials":6224,"activeCount":100},[],{"trials":6226,"activeCount":100},[],{"trials":6228,"activeCount":100},[],{"intervention":5123,"totalTrials":224,"cells":6230},{"EARLY_PHASE1":6231,"PHASE1":6233,"PHASE2":6235,"PHASE3":6257,"PHASE4":6259,"NA":6261},{"trials":6232,"activeCount":100},[],{"trials":6234,"activeCount":100},[],{"trials":6236,"activeCount":100},[6237,6241,6248],{"nctId":5115,"briefTitle":5116,"status":139,"phases":6238,"primaryCompletion":5118,"completion":5118,"start":5119,"enrollment":5120,"conditions":6239,"interventions":6240},[90],[15],[5123,5106],{"nctId":6242,"briefTitle":6243,"status":139,"phases":6244,"primaryCompletion":2382,"completion":2382,"start":6245,"conditions":6246,"interventions":6247},"NCT00005878","Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus",[90],"2000-07",[171],[5123],{"nctId":6249,"briefTitle":6250,"status":219,"phases":6251,"primaryCompletion":6252,"completion":3200,"start":6253,"enrollment":28,"conditions":6254,"interventions":6255},"NCT00068770","Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT",[90],"2005-05","2003-10",[24],[6256],"Celecoxib",{"trials":6258,"activeCount":100},[],{"trials":6260,"activeCount":100},[],{"trials":6262,"activeCount":100},[],{"intervention":2377,"totalTrials":224,"cells":6264},{"EARLY_PHASE1":6265,"PHASE1":6267,"PHASE2":6269,"PHASE3":6294,"PHASE4":6296,"NA":6298},{"trials":6266,"activeCount":100},[],{"trials":6268,"activeCount":100},[],{"trials":6270,"activeCount":100},[6271,6275,6284],{"nctId":2370,"briefTitle":2371,"status":139,"phases":6272,"primaryCompletion":2373,"completion":741,"start":1888,"enrollment":2374,"conditions":6273,"interventions":6274},[90],[227],[2377,2265],{"nctId":6276,"briefTitle":6277,"status":219,"phases":6278,"primaryCompletion":6279,"completion":6280,"start":6281,"enrollment":190,"conditions":6282,"interventions":6283},"NCT00052715","Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[90],"2006-02-25","2009-01-01","2002-10-23",[24],[2377],{"nctId":6285,"briefTitle":6286,"status":139,"phases":6287,"primaryCompletion":6288,"completion":6289,"start":6290,"enrollment":6291,"conditions":6292,"interventions":6293},"NCT00058123","Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma",[90],"2007-10-06","2009-01-02","2003-03-07",55,[24],[2377],{"trials":6295,"activeCount":100},[],{"trials":6297,"activeCount":100},[],{"trials":6299,"activeCount":100},[],{"intervention":329,"totalTrials":224,"cells":6301},{"EARLY_PHASE1":6302,"PHASE1":6304,"PHASE2":6314,"PHASE3":6324,"PHASE4":6326,"NA":6328},{"trials":6303,"activeCount":100},[],{"trials":6305,"activeCount":100},[6306],{"nctId":6307,"briefTitle":6308,"status":139,"phases":6309,"start":6310,"conditions":6311,"interventions":6312},"NCT00015925","MS-275 in Treating Patients With Hematologic Cancer",[89],"2001-02",[27,754,33,711],[6313],"entinostat",{"trials":6315,"activeCount":100},[6316,6320],{"nctId":318,"briefTitle":319,"status":139,"phases":6317,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":6318,"interventions":6319},[90],[325,326],[328,329,63,330],{"nctId":488,"briefTitle":489,"status":139,"phases":6321,"primaryCompletion":491,"completion":491,"start":492,"enrollment":493,"conditions":6322,"interventions":6323},[90],[495,496,21,497,498,499],[329,63,329,63],{"trials":6325,"activeCount":100},[],{"trials":6327,"activeCount":100},[],{"trials":6329,"activeCount":100},[],{"intervention":1687,"totalTrials":224,"cells":6331},{"EARLY_PHASE1":6332,"PHASE1":6334,"PHASE2":6340,"PHASE3":6355,"PHASE4":6357,"NA":6359},{"trials":6333,"activeCount":100},[],{"trials":6335,"activeCount":100},[6336],{"nctId":2310,"briefTitle":2311,"status":139,"phases":6337,"primaryCompletion":2313,"completion":2314,"start":2315,"conditions":6338,"interventions":6339},[89],[24],[1687,2265],{"trials":6341,"activeCount":100},[6342,6351],{"nctId":6343,"briefTitle":6344,"status":139,"phases":6345,"primaryCompletion":6346,"completion":6347,"start":6348,"enrollment":6032,"conditions":6349,"interventions":6350},"NCT00025675","Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors",[90],"2006-07-05","2010-01-02","2001-10-09",[24],[1687],{"nctId":1680,"briefTitle":1681,"status":219,"phases":6352,"primaryCompletion":1683,"completion":1683,"start":1684,"enrollment":34,"conditions":6353,"interventions":6354},[90],[171],[1175,1687,1500],{"trials":6356,"activeCount":100},[],{"trials":6358,"activeCount":100},[],{"trials":6360,"activeCount":100},[],{"intervention":344,"totalTrials":224,"cells":6362},{"EARLY_PHASE1":6363,"PHASE1":6365,"PHASE2":6371,"PHASE3":6381,"PHASE4":6383,"NA":6385},{"trials":6364,"activeCount":100},[],{"trials":6366,"activeCount":100},[6367],{"nctId":3250,"briefTitle":3251,"status":139,"phases":6368,"primaryCompletion":3253,"completion":3253,"start":3254,"enrollment":848,"conditions":6369,"interventions":6370},[89],[1357],[344,343,2636],{"trials":6372,"activeCount":100},[6373,6377],{"nctId":1352,"briefTitle":1353,"status":139,"phases":6374,"primaryCompletion":47,"completion":47,"start":1355,"enrollment":143,"conditions":6375,"interventions":6376},[90],[1357],[344,343,580],{"nctId":332,"briefTitle":333,"status":139,"phases":6378,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":6379,"interventions":6380},[90],[339],[341,341,342,343,344],{"trials":6382,"activeCount":100},[],{"trials":6384,"activeCount":100},[],{"trials":6386,"activeCount":100},[],{"intervention":1522,"totalTrials":224,"cells":6388},{"EARLY_PHASE1":6389,"PHASE1":6391,"PHASE2":6404,"PHASE3":6422,"PHASE4":6424,"NA":6426},{"trials":6390,"activeCount":100},[],{"trials":6392,"activeCount":100},[6393],{"nctId":6394,"briefTitle":6395,"status":139,"phases":6396,"primaryCompletion":6397,"completion":6398,"start":6399,"enrollment":439,"conditions":6400,"interventions":6401},"NCT02048384","A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer",[89],"2018-02","2019-09","2014-06-10",[566],[6402,6403,1904],"metformin alone","metformin",{"trials":6405,"activeCount":100},[6406,6418],{"nctId":6407,"briefTitle":6408,"status":139,"phases":6409,"primaryCompletion":6410,"completion":6410,"start":1096,"enrollment":6411,"conditions":6412,"interventions":6417},"NCT02431676","Survivorship Promotion In Reducing IGF-1 Trial",[90],"2018-12",121,[18,15,1497,6413,6414,6415,817,21,1863,1601,6416],"Colon Cancer","Melanoma of Skin","Endometrial Cancer","Other Solid Malignant Tumors",[1522],{"nctId":1513,"briefTitle":1514,"status":219,"phases":6419,"primaryCompletion":1448,"completion":1448,"start":1183,"enrollment":1516,"conditions":6420,"interventions":6421},[90],[1518,1519],[176,175,1521,1522],{"trials":6423,"activeCount":100},[],{"trials":6425,"activeCount":100},[],{"trials":6427,"activeCount":100},[],{"intervention":1176,"totalTrials":224,"cells":6429},{"EARLY_PHASE1":6430,"PHASE1":6432,"PHASE2":6434,"PHASE3":6455,"PHASE4":6457,"NA":6459},{"trials":6431,"activeCount":100},[],{"trials":6433,"activeCount":100},[],{"trials":6435,"activeCount":100},[6436,6440,6444],{"nctId":1126,"briefTitle":1127,"status":139,"phases":6437,"primaryCompletion":657,"completion":1129,"start":1130,"enrollment":765,"conditions":6438,"interventions":6439},[90],[27,30],[840,841,82,1133,1134,894,1135,637,1136],{"nctId":1168,"briefTitle":1169,"status":139,"phases":6441,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":384,"conditions":6442,"interventions":6443},[90],[30],[692,883,693,1175,650,1176,704,715,926,1177,1178],{"nctId":6445,"briefTitle":6446,"status":139,"phases":6447,"primaryCompletion":686,"completion":1269,"start":1192,"conditions":6448,"interventions":6449},"NCT00276601","Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia",[90],[27],[6450,1176,6451,6452,6453,6454],"arsenic trioxide","daunorubicin hydrochloride","mercaptopurine","methotrexate","tretinoin",{"trials":6456,"activeCount":100},[],{"trials":6458,"activeCount":100},[],{"trials":6460,"activeCount":100},[],{"intervention":2360,"totalTrials":733,"cells":6462},{"EARLY_PHASE1":6463,"PHASE1":6465,"PHASE2":6467,"PHASE3":6481,"PHASE4":6483,"NA":6485},{"trials":6464,"activeCount":100},[],{"trials":6466,"activeCount":100},[],{"trials":6468,"activeCount":100},[6469,6473],{"nctId":2352,"briefTitle":2353,"status":139,"phases":6470,"primaryCompletion":2355,"completion":2356,"start":2357,"enrollment":493,"conditions":6471,"interventions":6472},[90],[24],[2265,2360],{"nctId":6474,"briefTitle":6475,"status":139,"phases":6476,"primaryCompletion":3210,"completion":3210,"start":6477,"enrollment":313,"conditions":6478,"interventions":6479},"NCT00287872","Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma",[90],"2004-09",[673],[6480,2360],"bortezomib",{"trials":6482,"activeCount":100},[],{"trials":6484,"activeCount":100},[],{"trials":6486,"activeCount":100},[],{"intervention":6488,"totalTrials":733,"cells":6489},"Nelfinavir",{"EARLY_PHASE1":6490,"PHASE1":6504,"PHASE2":6506,"PHASE3":6517,"PHASE4":6519,"NA":6521},{"trials":6491,"activeCount":100},[6492],{"nctId":6493,"briefTitle":6494,"status":219,"phases":6495,"primaryCompletion":182,"completion":182,"start":6496,"enrollment":1156,"conditions":6497,"interventions":6503},"NCT02080416","Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors",[88],"2014-07",[6498,5018,6499,170,6500,6501,6502],"Non-Hodgkin Lymphoma","Kaposi Sarcoma","Nasopharyngeal Cancer","EBV","Castleman Disease",[6488],{"trials":6505,"activeCount":100},[],{"trials":6507,"activeCount":100},[6508],{"nctId":6509,"briefTitle":6510,"status":139,"phases":6511,"primaryCompletion":949,"completion":6512,"start":6513,"enrollment":301,"conditions":6514,"interventions":6516},"NCT01728779","Stereotactic Body Radiation With Nelfinavir for Oligometastases",[90],"2020-12","2014-01-08",[6515],"Oligometastases",[6488],{"trials":6518,"activeCount":100},[],{"trials":6520,"activeCount":100},[],{"trials":6522,"activeCount":100},[],{"intervention":853,"totalTrials":733,"cells":6524},{"EARLY_PHASE1":6525,"PHASE1":6527,"PHASE2":6529,"PHASE3":6539,"PHASE4":6541,"NA":6543},{"trials":6526,"activeCount":100},[],{"trials":6528,"activeCount":100},[],{"trials":6530,"activeCount":100},[6531,6535],{"nctId":843,"briefTitle":844,"status":139,"phases":6532,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":6533,"interventions":6534},[90],[850,851],[853,676,82,639,854,855],{"nctId":1065,"briefTitle":1066,"status":139,"phases":6536,"primaryCompletion":1068,"completion":1068,"start":534,"enrollment":108,"conditions":6537,"interventions":6538},[90],[850,1034,1004,1070],[853,676,82,854,874],{"trials":6540,"activeCount":100},[],{"trials":6542,"activeCount":100},[],{"trials":6544,"activeCount":100},[],{"intervention":6057,"totalTrials":733,"cells":6546},{"EARLY_PHASE1":6547,"PHASE1":6549,"PHASE2":6551,"PHASE3":6563,"PHASE4":6565,"NA":6567},{"trials":6548,"activeCount":100},[],{"trials":6550,"activeCount":100},[],{"trials":6552,"activeCount":100},[6553,6557],{"nctId":6051,"briefTitle":6052,"status":139,"phases":6554,"primaryCompletion":3055,"completion":2079,"start":6054,"enrollment":623,"conditions":6555,"interventions":6556},[90],[18],[6057,6042],{"nctId":6558,"briefTitle":6559,"status":139,"phases":6560,"primaryCompletion":1880,"completion":2079,"start":699,"enrollment":2858,"conditions":6561,"interventions":6562},"NCT00244959","Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer",[90],[18],[6057],{"trials":6564,"activeCount":100},[],{"trials":6566,"activeCount":100},[],{"trials":6568,"activeCount":100},[],{"intervention":2308,"totalTrials":733,"cells":6570},{"EARLY_PHASE1":6571,"PHASE1":6573,"PHASE2":6579,"PHASE3":6585,"PHASE4":6587,"NA":6589},{"trials":6572,"activeCount":100},[],{"trials":6574,"activeCount":100},[6575],{"nctId":2299,"briefTitle":2300,"status":139,"phases":6576,"primaryCompletion":2046,"start":2302,"enrollment":1280,"conditions":6577,"interventions":6578},[89],[24],[2305,2265,2306,2307,2308],{"trials":6580,"activeCount":100},[6581],{"nctId":5862,"briefTitle":5863,"status":139,"phases":6582,"primaryCompletion":5865,"start":1243,"enrollment":5546,"conditions":6583,"interventions":6584},[90],[1497],[1511,2306,2308],{"trials":6586,"activeCount":100},[],{"trials":6588,"activeCount":100},[],{"trials":6590,"activeCount":100},[],{"intervention":1091,"totalTrials":733,"cells":6592},{"EARLY_PHASE1":6593,"PHASE1":6595,"PHASE2":6605,"PHASE3":6611,"PHASE4":6613,"NA":6615},{"trials":6594,"activeCount":100},[],{"trials":6596,"activeCount":100},[6597],{"nctId":6598,"briefTitle":6599,"status":219,"phases":6600,"primaryCompletion":6601,"completion":6601,"start":6602,"enrollment":733,"conditions":6603,"interventions":6604},"NCT03471286","A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies",[89],"2021-07-30","2019-06-06",[4740],[1091],{"trials":6606,"activeCount":100},[6607],{"nctId":1082,"briefTitle":1083,"status":139,"phases":6608,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":6609,"interventions":6610},[90],[566],[1091,580,341,82,376],{"trials":6612,"activeCount":100},[],{"trials":6614,"activeCount":100},[],{"trials":6616,"activeCount":100},[],{"intervention":6618,"totalTrials":733,"cells":6619},"Bicalutamide 150 mg",{"EARLY_PHASE1":6620,"PHASE1":6622,"PHASE2":6636,"PHASE3":6648,"PHASE4":6650,"NA":6652},{"trials":6621,"activeCount":100},[],{"trials":6623,"activeCount":100},[6624],{"nctId":6625,"briefTitle":6626,"status":219,"phases":6627,"primaryCompletion":6628,"completion":6628,"start":6629,"enrollment":231,"conditions":6630,"interventions":6634},"NCT04652765","Camostat With Bicalutamide for COVID-19",[89],"2021-09-15","2021-02-03",[6631,6632,6633],"Covid19","SARS-CoV Infection","Coronavirus Infection",[6635,6618],"Camostat Mesilate",{"trials":6637,"activeCount":100},[6638],{"nctId":6639,"briefTitle":6640,"status":416,"phases":6641,"primaryCompletion":6642,"completion":6642,"start":860,"enrollment":100,"conditions":6643,"interventions":6646},"NCT04374279","Trial to Promote Recovery From COVID-19 With Endocrine Therapy",[90],"2022-01",[6644,6645],"COVID-19","SARS-CoV 2",[6647],"Bicalutamide 150 Mg Oral",{"trials":6649,"activeCount":100},[],{"trials":6651,"activeCount":100},[],{"trials":6653,"activeCount":100},[],{"intervention":906,"totalTrials":733,"cells":6655},{"EARLY_PHASE1":6656,"PHASE1":6658,"PHASE2":6666,"PHASE3":6672,"PHASE4":6674,"NA":6676},{"trials":6657,"activeCount":100},[],{"trials":6659,"activeCount":100},[6660],{"nctId":6661,"briefTitle":6662,"status":219,"phases":6663,"primaryCompletion":1528,"completion":1528,"start":1019,"enrollment":1156,"conditions":6664,"interventions":6665},"NCT00469820","Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant",[89],[27,754],[906,2497],{"trials":6667,"activeCount":100},[6668],{"nctId":899,"briefTitle":900,"status":416,"phases":6669,"primaryCompletion":902,"completion":902,"start":903,"enrollment":100,"conditions":6670,"interventions":6671},[90],[27],[906,883,650],{"trials":6673,"activeCount":100},[],{"trials":6675,"activeCount":100},[],{"trials":6677,"activeCount":100},[],{"intervention":6679,"totalTrials":733,"cells":6680},"pyrazoloacridine",{"EARLY_PHASE1":6681,"PHASE1":6683,"PHASE2":6685,"PHASE3":6703,"PHASE4":6705,"NA":6707},{"trials":6682,"activeCount":100},[],{"trials":6684,"activeCount":100},[],{"trials":6686,"activeCount":100},[6687,6697],{"nctId":6688,"briefTitle":6689,"status":139,"phases":6690,"completion":6691,"start":6692,"conditions":6693,"interventions":6696},"NCT00003802","Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma",[90],"2002-10","1999-02",[6694,6695],"Intraocular Melanoma","Melanoma (Skin)",[6679],{"nctId":6698,"briefTitle":6699,"status":139,"phases":6700,"primaryCompletion":1192,"completion":722,"start":4920,"conditions":6701,"interventions":6702},"NCT00006355","Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme",[89,90],[24],[6679],{"trials":6704,"activeCount":100},[],{"trials":6706,"activeCount":100},[],{"trials":6708,"activeCount":100},[],{"intervention":569,"totalTrials":733,"cells":6710},{"EARLY_PHASE1":6711,"PHASE1":6713,"PHASE2":6715,"PHASE3":6725,"PHASE4":6727,"NA":6729},{"trials":6712,"activeCount":100},[],{"trials":6714,"activeCount":100},[],{"trials":6716,"activeCount":100},[6717,6721],{"nctId":559,"briefTitle":560,"status":139,"phases":6718,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":6719,"interventions":6720},[90],[566],[123,568,569],{"nctId":1197,"briefTitle":1198,"status":139,"phases":6722,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":34,"conditions":6723,"interventions":6724},[90],[21],[82,376,569],{"trials":6726,"activeCount":100},[],{"trials":6728,"activeCount":100},[],{"trials":6730,"activeCount":100},[],{"intervention":636,"totalTrials":733,"cells":6732},{"EARLY_PHASE1":6733,"PHASE1":6739,"PHASE2":6741,"PHASE3":6751,"PHASE4":6753,"NA":6755},{"trials":6734,"activeCount":100},[6735],{"nctId":628,"briefTitle":629,"status":219,"phases":6736,"primaryCompletion":631,"completion":631,"start":632,"enrollment":231,"conditions":6737,"interventions":6738},[88],[634],[636,637,638,82,639,637],{"trials":6740,"activeCount":100},[],{"trials":6742,"activeCount":100},[6743],{"nctId":6744,"briefTitle":6745,"status":139,"phases":6746,"primaryCompletion":5865,"start":1130,"enrollment":6747,"conditions":6748,"interventions":6749},"NCT00293280","Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",[90],42,[1497],[6750],"lomustine",{"trials":6752,"activeCount":100},[],{"trials":6754,"activeCount":100},[],{"trials":6756,"activeCount":100},[],{"intervention":1566,"totalTrials":733,"cells":6758},{"EARLY_PHASE1":6759,"PHASE1":6761,"PHASE2":6767,"PHASE3":6776,"PHASE4":6778,"NA":6780},{"trials":6760,"activeCount":100},[],{"trials":6762,"activeCount":100},[6763],{"nctId":1559,"briefTitle":1560,"status":139,"phases":6764,"primaryCompletion":1562,"completion":182,"start":1563,"enrollment":848,"conditions":6765,"interventions":6766},[89],[21],[409,638,73,73,1566],{"trials":6768,"activeCount":100},[6769],{"nctId":6770,"briefTitle":6771,"status":416,"phases":6772,"primaryCompletion":6773,"completion":6773,"start":722,"enrollment":100,"conditions":6774,"interventions":6775},"NCT00386399","Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene",[90],"2008-02",[21],[1566],{"trials":6777,"activeCount":100},[],{"trials":6779,"activeCount":100},[],{"trials":6781,"activeCount":100},[],{"intervention":3076,"totalTrials":733,"cells":6783},{"EARLY_PHASE1":6784,"PHASE1":6786,"PHASE2":6788,"PHASE3":6798,"PHASE4":6800,"NA":6802},{"trials":6785,"activeCount":100},[],{"trials":6787,"activeCount":100},[],{"trials":6789,"activeCount":100},[6790,6794],{"nctId":3070,"briefTitle":3071,"status":139,"phases":6791,"primaryCompletion":1380,"completion":1380,"start":3073,"enrollment":1872,"conditions":6792,"interventions":6793},[90],[15],[3076,3077,1892],{"nctId":3121,"briefTitle":3122,"status":139,"phases":6795,"primaryCompletion":3124,"completion":3124,"start":3125,"enrollment":1872,"conditions":6796,"interventions":6797},[90],[15],[3076,1892,3077,3128],{"trials":6799,"activeCount":100},[],{"trials":6801,"activeCount":100},[],{"trials":6803,"activeCount":100},[],{"intervention":3077,"totalTrials":733,"cells":6805},{"EARLY_PHASE1":6806,"PHASE1":6808,"PHASE2":6810,"PHASE3":6820,"PHASE4":6822,"NA":6824},{"trials":6807,"activeCount":100},[],{"trials":6809,"activeCount":100},[],{"trials":6811,"activeCount":100},[6812,6816],{"nctId":3070,"briefTitle":3071,"status":139,"phases":6813,"primaryCompletion":1380,"completion":1380,"start":3073,"enrollment":1872,"conditions":6814,"interventions":6815},[90],[15],[3076,3077,1892],{"nctId":3121,"briefTitle":3122,"status":139,"phases":6817,"primaryCompletion":3124,"completion":3124,"start":3125,"enrollment":1872,"conditions":6818,"interventions":6819},[90],[15],[3076,1892,3077,3128],{"trials":6821,"activeCount":100},[],{"trials":6823,"activeCount":100},[],{"trials":6825,"activeCount":100},[],{"intervention":6454,"totalTrials":733,"cells":6827},{"EARLY_PHASE1":6828,"PHASE1":6830,"PHASE2":6840,"PHASE3":6846,"PHASE4":6848,"NA":6850},{"trials":6829,"activeCount":100},[],{"trials":6831,"activeCount":100},[6832],{"nctId":6833,"briefTitle":6834,"status":139,"phases":6835,"primaryCompletion":5544,"completion":6836,"start":6837,"conditions":6838,"interventions":6839},"NCT00006239","Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer",[89],"2005-03","2000-12",[27,33,711],[4915,6454],{"trials":6841,"activeCount":100},[6842],{"nctId":6445,"briefTitle":6446,"status":139,"phases":6843,"primaryCompletion":686,"completion":1269,"start":1192,"conditions":6844,"interventions":6845},[90],[27],[6450,1176,6451,6452,6453,6454],{"trials":6847,"activeCount":100},[],{"trials":6849,"activeCount":100},[],{"trials":6851,"activeCount":100},[],{"intervention":6450,"totalTrials":733,"cells":6853},{"EARLY_PHASE1":6854,"PHASE1":6856,"PHASE2":6864,"PHASE3":6870,"PHASE4":6872,"NA":6874},{"trials":6855,"activeCount":100},[],{"trials":6857,"activeCount":100},[6858],{"nctId":6859,"briefTitle":6860,"status":139,"phases":6861,"primaryCompletion":1563,"completion":1563,"start":1507,"enrollment":25,"conditions":6862,"interventions":6863},"NCT00095771","Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas",[89],[24],[6450],{"trials":6865,"activeCount":100},[6866],{"nctId":6445,"briefTitle":6446,"status":139,"phases":6867,"primaryCompletion":686,"completion":1269,"start":1192,"conditions":6868,"interventions":6869},[90],[27],[6450,1176,6451,6452,6453,6454],{"trials":6871,"activeCount":100},[],{"trials":6873,"activeCount":100},[],{"trials":6875,"activeCount":100},[],{"intervention":704,"totalTrials":733,"cells":6877},{"EARLY_PHASE1":6878,"PHASE1":6880,"PHASE2":6886,"PHASE3":6892,"PHASE4":6894,"NA":6896},{"trials":6879,"activeCount":100},[],{"trials":6881,"activeCount":100},[6882],{"nctId":695,"briefTitle":696,"status":139,"phases":6883,"primaryCompletion":698,"start":699,"enrollment":700,"conditions":6884,"interventions":6885},[89],[18],[703,650,704],{"trials":6887,"activeCount":100},[6888],{"nctId":1168,"briefTitle":1169,"status":139,"phases":6889,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":384,"conditions":6890,"interventions":6891},[90],[30],[692,883,693,1175,650,1176,704,715,926,1177,1178],{"trials":6893,"activeCount":100},[],{"trials":6895,"activeCount":100},[],{"trials":6897,"activeCount":100},[],{"intervention":993,"totalTrials":733,"cells":6899},{"EARLY_PHASE1":6900,"PHASE1":6902,"PHASE2":6904,"PHASE3":6914,"PHASE4":6916,"NA":6918},{"trials":6901,"activeCount":100},[],{"trials":6903,"activeCount":100},[],{"trials":6905,"activeCount":100},[6906,6910],{"nctId":984,"briefTitle":985,"status":139,"phases":6907,"primaryCompletion":987,"completion":988,"start":989,"enrollment":990,"conditions":6908,"interventions":6909},[90],[27,30],[993,841,82],{"nctId":3083,"briefTitle":3084,"status":219,"phases":6911,"primaryCompletion":3086,"completion":3086,"start":3087,"enrollment":34,"conditions":6912,"interventions":6913},[90],[18],[3090,1901],{"trials":6915,"activeCount":100},[],{"trials":6917,"activeCount":100},[],{"trials":6919,"activeCount":100},[],{"intervention":2040,"totalTrials":733,"cells":6921},{"EARLY_PHASE1":6922,"PHASE1":6924,"PHASE2":6926,"PHASE3":6936,"PHASE4":6938,"NA":6940},{"trials":6923,"activeCount":100},[],{"trials":6925,"activeCount":100},[],{"trials":6927,"activeCount":100},[6928,6932],{"nctId":2031,"briefTitle":2032,"status":139,"phases":6929,"primaryCompletion":2034,"completion":2035,"start":2036,"enrollment":2037,"conditions":6930,"interventions":6931},[89,90],[566],[58,2040,2041,638,409],{"nctId":2076,"briefTitle":2077,"status":139,"phases":6933,"primaryCompletion":1141,"completion":1141,"start":2079,"enrollment":493,"conditions":6934,"interventions":6935},[90],[21],[58,2040,2041,638],{"trials":6937,"activeCount":100},[],{"trials":6939,"activeCount":100},[],{"trials":6941,"activeCount":100},[],{"intervention":2041,"totalTrials":733,"cells":6943},{"EARLY_PHASE1":6944,"PHASE1":6946,"PHASE2":6948,"PHASE3":6958,"PHASE4":6960,"NA":6962},{"trials":6945,"activeCount":100},[],{"trials":6947,"activeCount":100},[],{"trials":6949,"activeCount":100},[6950,6954],{"nctId":2031,"briefTitle":2032,"status":139,"phases":6951,"primaryCompletion":2034,"completion":2035,"start":2036,"enrollment":2037,"conditions":6952,"interventions":6953},[89,90],[566],[58,2040,2041,638,409],{"nctId":2076,"briefTitle":2077,"status":139,"phases":6955,"primaryCompletion":1141,"completion":1141,"start":2079,"enrollment":493,"conditions":6956,"interventions":6957},[90],[21],[58,2040,2041,638],{"trials":6959,"activeCount":100},[],{"trials":6961,"activeCount":100},[],{"trials":6963,"activeCount":100},[],{"intervention":714,"totalTrials":733,"cells":6965},{"EARLY_PHASE1":6966,"PHASE1":6968,"PHASE2":6974,"PHASE3":6980,"PHASE4":6982,"NA":6984},{"trials":6967,"activeCount":100},[],{"trials":6969,"activeCount":100},[6970],{"nctId":706,"briefTitle":707,"status":139,"phases":6971,"start":709,"conditions":6972,"interventions":6973},[89],[27,30,33,711],[713,692,714,650,715,716],{"trials":6975,"activeCount":100},[6976],{"nctId":5541,"briefTitle":5542,"status":219,"phases":6977,"primaryCompletion":5544,"completion":644,"start":5545,"enrollment":5546,"conditions":6978,"interventions":6979},[90],[27],[1023,714],{"trials":6981,"activeCount":100},[],{"trials":6983,"activeCount":100},[],{"trials":6985,"activeCount":100},[],{"intervention":2497,"totalTrials":733,"cells":6987},{"EARLY_PHASE1":6988,"PHASE1":6990,"PHASE2":6996,"PHASE3":7002,"PHASE4":7004,"NA":7006},{"trials":6989,"activeCount":100},[],{"trials":6991,"activeCount":100},[6992],{"nctId":6661,"briefTitle":6662,"status":219,"phases":6993,"primaryCompletion":1528,"completion":1528,"start":1019,"enrollment":1156,"conditions":6994,"interventions":6995},[89],[27,754],[906,2497],{"trials":6997,"activeCount":100},[6998],{"nctId":2490,"briefTitle":2491,"status":139,"phases":6999,"primaryCompletion":2493,"completion":2493,"start":2494,"enrollment":405,"conditions":7000,"interventions":7001},[90],[27,30,754,33],[2497,757,758],{"trials":7003,"activeCount":100},[],{"trials":7005,"activeCount":100},[],{"trials":7007,"activeCount":100},[],{"intervention":1024,"totalTrials":733,"cells":7009},{"EARLY_PHASE1":7010,"PHASE1":7012,"PHASE2":7014,"PHASE3":7024,"PHASE4":7026,"NA":7028},{"trials":7011,"activeCount":100},[],{"trials":7013,"activeCount":100},[],{"trials":7015,"activeCount":100},[7016,7020],{"nctId":1016,"briefTitle":1017,"status":139,"phases":7017,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":493,"conditions":7018,"interventions":7019},[90],[30],[692,883,1023,1024,650,715],{"nctId":2426,"briefTitle":2427,"status":139,"phases":7021,"primaryCompletion":2429,"completion":2430,"start":2431,"enrollment":2432,"conditions":7022,"interventions":7023},[90],[24],[1024,2265],{"trials":7025,"activeCount":100},[],{"trials":7027,"activeCount":100},[],{"trials":7029,"activeCount":100},[],{"intervention":7031,"totalTrials":733,"cells":7032},"Melphalan hydrochloride",{"EARLY_PHASE1":7033,"PHASE1":7035,"PHASE2":7046,"PHASE3":7056,"PHASE4":7058,"NA":7060},{"trials":7034,"activeCount":100},[],{"trials":7036,"activeCount":100},[7037],{"nctId":7038,"briefTitle":7039,"status":139,"phases":7040,"primaryCompletion":3037,"completion":7041,"start":7042,"enrollment":224,"conditions":7043,"interventions":7045},"NCT01688401","Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).",[89],"2018-11-26","2013-03-08",[7044],"Diffuse Intrinsic Pontine Glioma (DIPG)",[7031],{"trials":7047,"activeCount":100},[7048],{"nctId":7049,"briefTitle":7050,"status":219,"phases":7051,"primaryCompletion":7052,"completion":7052,"start":1458,"enrollment":1655,"conditions":7053,"interventions":7055},"NCT01293539","Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma",[90],"2016-08",[7054],"Retinoblastoma",[7031],{"trials":7057,"activeCount":100},[],{"trials":7059,"activeCount":100},[],{"trials":7061,"activeCount":100},[],{"intervention":7063,"totalTrials":733,"cells":7064},"terameprocol",{"EARLY_PHASE1":7065,"PHASE1":7067,"PHASE2":7079,"PHASE3":7088,"PHASE4":7090,"NA":7092},{"trials":7066,"activeCount":100},[],{"trials":7068,"activeCount":100},[7069],{"nctId":7070,"briefTitle":7071,"status":139,"phases":7072,"primaryCompletion":7073,"completion":1742,"start":7074,"enrollment":405,"conditions":7075,"interventions":7077},"NCT02575794","Terameprocol in Treating Patients With Recurrent High Grade Glioma",[89],"2023-09-30","2018-05-03",[7076],"High Grade Glioma (III or IV)",[7078],"Terameprocol",{"trials":7080,"activeCount":100},[7081],{"nctId":7082,"briefTitle":7083,"status":139,"phases":7084,"primaryCompletion":2046,"completion":7085,"start":3062,"enrollment":28,"conditions":7086,"interventions":7087},"NCT00404248","Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma",[89,90],"2012-02",[24],[7063],{"trials":7089,"activeCount":100},[],{"trials":7091,"activeCount":100},[],{"trials":7093,"activeCount":100},[],{"intervention":2636,"totalTrials":733,"cells":7095},{"EARLY_PHASE1":7096,"PHASE1":7098,"PHASE2":7104,"PHASE3":7110,"PHASE4":7112,"NA":7114},{"trials":7097,"activeCount":100},[],{"trials":7099,"activeCount":100},[7100],{"nctId":3250,"briefTitle":3251,"status":139,"phases":7101,"primaryCompletion":3253,"completion":3253,"start":3254,"enrollment":848,"conditions":7102,"interventions":7103},[89],[1357],[344,343,2636],{"trials":7105,"activeCount":100},[7106],{"nctId":2624,"briefTitle":2625,"status":139,"phases":7107,"primaryCompletion":2627,"completion":2627,"start":2628,"enrollment":2629,"conditions":7108,"interventions":7109},[89,90],[2631],[2633,2634,2635,2636,409],{"trials":7111,"activeCount":100},[],{"trials":7113,"activeCount":100},[],{"trials":7115,"activeCount":100},[],{"intervention":7117,"totalTrials":733,"cells":7118},"Radium-223",{"EARLY_PHASE1":7119,"PHASE1":7121,"PHASE2":7123,"PHASE3":7142,"PHASE4":7144,"NA":7146},{"trials":7120,"activeCount":100},[],{"trials":7122,"activeCount":100},[],{"trials":7124,"activeCount":100},[7125,7133],{"nctId":7126,"briefTitle":7127,"status":139,"phases":7128,"primaryCompletion":438,"completion":438,"start":7129,"enrollment":25,"conditions":7130,"interventions":7131},"NCT02463799","Study of Sipuleucel-T W\u002F or W\u002FO Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC",[90],"2016-02-22",[15],[7117,7132],"Sipuleucel-T",{"nctId":7134,"briefTitle":7135,"status":139,"phases":7136,"primaryCompletion":7137,"completion":7137,"start":7138,"enrollment":7139,"conditions":7140,"interventions":7141},"NCT04037358","RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers",[90],"2025-07-15","2019-08-09",64,[15],[7117],{"trials":7143,"activeCount":100},[],{"trials":7145,"activeCount":100},[],{"trials":7147,"activeCount":100},[],{"intervention":1349,"totalTrials":733,"cells":7149},{"EARLY_PHASE1":7150,"PHASE1":7152,"PHASE2":7154,"PHASE3":7170,"PHASE4":7172,"NA":7174},{"trials":7151,"activeCount":100},[],{"trials":7153,"activeCount":100},[],{"trials":7155,"activeCount":100},[7156,7160],{"nctId":1339,"briefTitle":1340,"status":416,"phases":7157,"primaryCompletion":1342,"completion":1343,"start":1344,"enrollment":100,"conditions":7158,"interventions":7159},[89,90],[1346,1347],[580,1349,1350],{"nctId":7161,"briefTitle":7162,"status":219,"phases":7163,"primaryCompletion":7164,"completion":7165,"start":7166,"enrollment":1156,"conditions":7167,"interventions":7169},"NCT06322576","177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma",[90],"2025-11-16","2026-01-20","2025-02-10",[7168],"Adenoid Cystic Carcinoma",[1349],{"trials":7171,"activeCount":100},[],{"trials":7173,"activeCount":100},[],{"trials":7175,"activeCount":100},[],{"intervention":5524,"totalTrials":733,"cells":7177},{"EARLY_PHASE1":7178,"PHASE1":7180,"PHASE2":7182,"PHASE3":7192,"PHASE4":7194,"NA":7196},{"trials":7179,"activeCount":100},[],{"trials":7181,"activeCount":100},[],{"trials":7183,"activeCount":100},[7184,7188],{"nctId":5517,"briefTitle":5518,"status":219,"phases":7185,"primaryCompletion":5520,"completion":1184,"start":5521,"enrollment":452,"conditions":7186,"interventions":7187},[90],[27],[5524,1023],{"nctId":5533,"briefTitle":5534,"status":139,"phases":7189,"primaryCompletion":5536,"completion":5536,"start":5537,"conditions":7190,"interventions":7191},[90],[27],[5524,1023],{"trials":7193,"activeCount":100},[],{"trials":7195,"activeCount":100},[],{"trials":7197,"activeCount":100},[],{"intervention":5387,"totalTrials":733,"cells":7199},{"EARLY_PHASE1":7200,"PHASE1":7202,"PHASE2":7204,"PHASE3":7218,"PHASE4":7220,"NA":7222},{"trials":7201,"activeCount":100},[],{"trials":7203,"activeCount":100},[],{"trials":7205,"activeCount":100},[7206,7210],{"nctId":5374,"briefTitle":5375,"status":139,"phases":7207,"primaryCompletion":5377,"completion":5378,"start":2365,"enrollment":16,"conditions":7208,"interventions":7209},[90],[5380,5381,5382,5383,5384,5385],[5387,841],{"nctId":7211,"briefTitle":7212,"status":219,"phases":7213,"primaryCompletion":7214,"completion":7214,"start":722,"enrollment":1156,"conditions":7215,"interventions":7216},"NCT00390364","Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy",[90],"2007-10",[120],[7217],"everolimus",{"trials":7219,"activeCount":100},[],{"trials":7221,"activeCount":100},[],{"trials":7223,"activeCount":100},[],{"intervention":1732,"totalTrials":733,"cells":7225},{"EARLY_PHASE1":7226,"PHASE1":7228,"PHASE2":7234,"PHASE3":7240,"PHASE4":7242,"NA":7244},{"trials":7227,"activeCount":100},[],{"trials":7229,"activeCount":100},[7230],{"nctId":1725,"briefTitle":1726,"status":219,"phases":7231,"primaryCompletion":1728,"completion":1728,"start":1729,"enrollment":224,"conditions":7232,"interventions":7233},[89],[15],[1732,1733],{"trials":7235,"activeCount":100},[7236],{"nctId":2511,"briefTitle":2512,"status":139,"phases":7237,"primaryCompletion":2514,"completion":2514,"start":2515,"enrollment":1099,"conditions":7238,"interventions":7239},[89,90],[2517],[676,1732,677,962,854],{"trials":7241,"activeCount":100},[],{"trials":7243,"activeCount":100},[],{"trials":7245,"activeCount":100},[],{"intervention":1113,"totalTrials":733,"cells":7247},{"EARLY_PHASE1":7248,"PHASE1":7250,"PHASE2":7252,"PHASE3":7262,"PHASE4":7264,"NA":7266},{"trials":7249,"activeCount":100},[],{"trials":7251,"activeCount":100},[],{"trials":7253,"activeCount":100},[7254,7258],{"nctId":1104,"briefTitle":1105,"status":139,"phases":7255,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":25,"conditions":7256,"interventions":7257},[90],[673],[1112,1113,82,840,1014,1114],{"nctId":5915,"briefTitle":5916,"status":139,"phases":7259,"primaryCompletion":5918,"completion":5918,"start":687,"enrollment":34,"conditions":7260,"interventions":7261},[90],[673],[2941,1113,5921],{"trials":7263,"activeCount":100},[],{"trials":7265,"activeCount":100},[],{"trials":7267,"activeCount":100},[],{"intervention":2942,"totalTrials":733,"cells":7269},{"EARLY_PHASE1":7270,"PHASE1":7272,"PHASE2":7278,"PHASE3":7284,"PHASE4":7286,"NA":7288},{"trials":7271,"activeCount":100},[],{"trials":7273,"activeCount":100},[7274],{"nctId":3043,"briefTitle":3044,"status":219,"phases":7275,"primaryCompletion":3046,"completion":3046,"start":3047,"enrollment":536,"conditions":7276,"interventions":7277},[89],[15],[1892,3050,2942],{"trials":7279,"activeCount":100},[7280],{"nctId":2936,"briefTitle":2937,"status":219,"phases":7281,"primaryCompletion":1562,"completion":1562,"start":732,"enrollment":723,"conditions":7282,"interventions":7283},[90],[673],[579,2941,1990,2942],{"trials":7285,"activeCount":100},[],{"trials":7287,"activeCount":100},[],{"trials":7289,"activeCount":100},[],{"intervention":2760,"totalTrials":733,"cells":7291},{"EARLY_PHASE1":7292,"PHASE1":7294,"PHASE2":7296,"PHASE3":7313,"PHASE4":7315,"NA":7317},{"trials":7293,"activeCount":100},[],{"trials":7295,"activeCount":100},[],{"trials":7297,"activeCount":100},[7298,7309],{"nctId":7299,"briefTitle":7300,"status":219,"phases":7301,"primaryCompletion":7302,"completion":7302,"start":7303,"enrollment":7304,"conditions":7305,"interventions":7307},"NCT01282216","Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide",[90],"2016-01","2011-04",120,[7306],"Transplant-Related Cancer",[7308,2760],"Havrix",{"nctId":2752,"briefTitle":2753,"status":139,"phases":7310,"primaryCompletion":42,"completion":2755,"start":2756,"enrollment":1872,"conditions":7311,"interventions":7312},[89,90],[754],[2759,1014,2760],{"trials":7314,"activeCount":100},[],{"trials":7316,"activeCount":100},[],{"trials":7318,"activeCount":100},[],{"intervention":1904,"totalTrials":733,"cells":7320},{"EARLY_PHASE1":7321,"PHASE1":7323,"PHASE2":7329,"PHASE3":7335,"PHASE4":7337,"NA":7339},{"trials":7322,"activeCount":100},[],{"trials":7324,"activeCount":100},[7325],{"nctId":6394,"briefTitle":6395,"status":139,"phases":7326,"primaryCompletion":6397,"completion":6398,"start":6399,"enrollment":439,"conditions":7327,"interventions":7328},[89],[566],[6402,6403,1904],{"trials":7330,"activeCount":100},[7331],{"nctId":1894,"briefTitle":1895,"status":219,"phases":7332,"primaryCompletion":741,"completion":741,"start":688,"enrollment":1897,"conditions":7333,"interventions":7334},[90],[21],[1900,1875,1901,1902,58,409,1903,1904],{"trials":7336,"activeCount":100},[],{"trials":7338,"activeCount":100},[],{"trials":7340,"activeCount":100},[],{"intervention":1134,"totalTrials":733,"cells":7342},{"EARLY_PHASE1":7343,"PHASE1":7345,"PHASE2":7347,"PHASE3":7357,"PHASE4":7359,"NA":7361},{"trials":7344,"activeCount":100},[],{"trials":7346,"activeCount":100},[],{"trials":7348,"activeCount":100},[7349,7353],{"nctId":1126,"briefTitle":1127,"status":139,"phases":7350,"primaryCompletion":657,"completion":1129,"start":1130,"enrollment":765,"conditions":7351,"interventions":7352},[90],[27,30],[840,841,82,1133,1134,894,1135,637,1136],{"nctId":6445,"briefTitle":6446,"status":139,"phases":7354,"primaryCompletion":686,"completion":1269,"start":1192,"conditions":7355,"interventions":7356},[90],[27],[6450,1176,6451,6452,6453,6454],{"trials":7358,"activeCount":100},[],{"trials":7360,"activeCount":100},[],{"trials":7362,"activeCount":100},[],{"intervention":1136,"totalTrials":733,"cells":7364},{"EARLY_PHASE1":7365,"PHASE1":7367,"PHASE2":7369,"PHASE3":7379,"PHASE4":7381,"NA":7383},{"trials":7366,"activeCount":100},[],{"trials":7368,"activeCount":100},[],{"trials":7370,"activeCount":100},[7371,7375],{"nctId":1126,"briefTitle":1127,"status":139,"phases":7372,"primaryCompletion":657,"completion":1129,"start":1130,"enrollment":765,"conditions":7373,"interventions":7374},[90],[27,30],[840,841,82,1133,1134,894,1135,637,1136],{"nctId":2063,"briefTitle":2064,"status":139,"phases":7376,"primaryCompletion":1796,"completion":2066,"start":1449,"enrollment":118,"conditions":7377,"interventions":7378},[90],[2068,292,170],[1892,1136,2070,638],{"trials":7380,"activeCount":100},[],{"trials":7382,"activeCount":100},[],{"trials":7384,"activeCount":100},[],{"intervention":1162,"totalTrials":733,"cells":7386},{"EARLY_PHASE1":7387,"PHASE1":7389,"PHASE2":7391,"PHASE3":7401,"PHASE4":7403,"NA":7405},{"trials":7388,"activeCount":100},[],{"trials":7390,"activeCount":100},[],{"trials":7392,"activeCount":100},[7393,7397],{"nctId":1150,"briefTitle":1151,"status":219,"phases":7394,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":7395,"interventions":7396},[89,90],[1158,1159],[82,676,854,677,1161,1162],{"nctId":1209,"briefTitle":1210,"status":219,"phases":7398,"primaryCompletion":1212,"completion":1213,"start":1076,"enrollment":1214,"conditions":7399,"interventions":7400},[90],[30,1216,1217,865],[676,82,854,677,841,1219],{"trials":7402,"activeCount":100},[],{"trials":7404,"activeCount":100},[],{"trials":7406,"activeCount":100},[],{"intervention":7408,"totalTrials":733,"cells":7409},"pNGVL4a-Sig\u002FE7(detox)\u002FHSP70 DNA vaccine",{"EARLY_PHASE1":7410,"PHASE1":7412,"PHASE2":7425,"PHASE3":7435,"PHASE4":7437,"NA":7439},{"trials":7411,"activeCount":100},[],{"trials":7413,"activeCount":100},[7414],{"nctId":7415,"briefTitle":7416,"status":139,"phases":7417,"primaryCompletion":7418,"completion":7418,"start":5634,"enrollment":3853,"conditions":7419,"interventions":7422},"NCT00788164","Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia",[89],"2023-08",[4716,5598,7420,7421],"HPV Disease","Human Papilomavirus",[7423,7408,7424],"TA-HPV","imiquimod",{"trials":7426,"activeCount":100},[7427],{"nctId":7428,"briefTitle":7429,"status":139,"phases":7430,"primaryCompletion":7431,"completion":7431,"start":7432,"enrollment":37,"conditions":7433,"interventions":7434},"NCT00121173","Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia",[89,90],"2010-01","2003-11",[4716,5598],[7408],{"trials":7436,"activeCount":100},[],{"trials":7438,"activeCount":100},[],{"trials":7440,"activeCount":100},[],{"intervention":1453,"totalTrials":1156,"cells":7442},{"EARLY_PHASE1":7443,"PHASE1":7445,"PHASE2":7447,"PHASE3":7453,"PHASE4":7455,"NA":7457},{"trials":7444,"activeCount":100},[],{"trials":7446,"activeCount":100},[],{"trials":7448,"activeCount":100},[7449],{"nctId":1445,"briefTitle":1446,"status":219,"phases":7450,"primaryCompletion":1141,"completion":1448,"start":1449,"enrollment":361,"conditions":7451,"interventions":7452},[89,90],[1451],[1453,176,175,638],{"trials":7454,"activeCount":100},[],{"trials":7456,"activeCount":100},[],{"trials":7458,"activeCount":100},[],{"intervention":832,"totalTrials":1156,"cells":7460},{"EARLY_PHASE1":7461,"PHASE1":7463,"PHASE2":7465,"PHASE3":7471,"PHASE4":7473,"NA":7475},{"trials":7462,"activeCount":100},[],{"trials":7464,"activeCount":100},[],{"trials":7466,"activeCount":100},[7467],{"nctId":824,"briefTitle":825,"status":139,"phases":7468,"primaryCompletion":827,"completion":827,"start":828,"enrollment":700,"conditions":7469,"interventions":7470},[90],[21],[831,832,82],{"trials":7472,"activeCount":100},[],{"trials":7474,"activeCount":100},[],{"trials":7476,"activeCount":100},[],{"intervention":1931,"totalTrials":1156,"cells":7478},{"EARLY_PHASE1":7479,"PHASE1":7481,"PHASE2":7483,"PHASE3":7489,"PHASE4":7491,"NA":7493},{"trials":7480,"activeCount":100},[],{"trials":7482,"activeCount":100},[],{"trials":7484,"activeCount":100},[7485],{"nctId":1924,"briefTitle":1925,"status":139,"phases":7486,"primaryCompletion":1927,"completion":1927,"start":1928,"enrollment":156,"conditions":7487,"interventions":7488},[90],[15,243,1780],[1931,258],{"trials":7490,"activeCount":100},[],{"trials":7492,"activeCount":100},[],{"trials":7494,"activeCount":100},[],{"intervention":839,"totalTrials":1156,"cells":7496},{"EARLY_PHASE1":7497,"PHASE1":7499,"PHASE2":7501,"PHASE3":7507,"PHASE4":7509,"NA":7511},{"trials":7498,"activeCount":100},[],{"trials":7500,"activeCount":100},[],{"trials":7502,"activeCount":100},[7503],{"nctId":834,"briefTitle":835,"status":139,"phases":7504,"primaryCompletion":658,"completion":658,"start":742,"enrollment":190,"conditions":7505,"interventions":7506},[89,90],[30],[839,840,841,82],{"trials":7508,"activeCount":100},[],{"trials":7510,"activeCount":100},[],{"trials":7512,"activeCount":100},[],{"intervention":7514,"totalTrials":1156,"cells":7515},"Itraconazole",{"EARLY_PHASE1":7516,"PHASE1":7518,"PHASE2":7520,"PHASE3":7531,"PHASE4":7533,"NA":7535},{"trials":7517,"activeCount":100},[],{"trials":7519,"activeCount":100},[],{"trials":7521,"activeCount":100},[7522],{"nctId":7523,"briefTitle":7524,"status":219,"phases":7525,"primaryCompletion":658,"completion":7526,"start":5634,"enrollment":765,"conditions":7527,"interventions":7529},"NCT00769600","Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC",[90],"2013-02",[7528],"Recurrent Non Small Cell Lung Cancer",[7514,7530],"Pemetrexed",{"trials":7532,"activeCount":100},[],{"trials":7534,"activeCount":100},[],{"trials":7536,"activeCount":100},[],{"intervention":7530,"totalTrials":1156,"cells":7538},{"EARLY_PHASE1":7539,"PHASE1":7541,"PHASE2":7543,"PHASE3":7549,"PHASE4":7551,"NA":7553},{"trials":7540,"activeCount":100},[],{"trials":7542,"activeCount":100},[],{"trials":7544,"activeCount":100},[7545],{"nctId":7523,"briefTitle":7524,"status":219,"phases":7546,"primaryCompletion":658,"completion":7526,"start":5634,"enrollment":765,"conditions":7547,"interventions":7548},[90],[7528],[7514,7530],{"trials":7550,"activeCount":100},[],{"trials":7552,"activeCount":100},[],{"trials":7554,"activeCount":100},[],{"intervention":855,"totalTrials":1156,"cells":7556},{"EARLY_PHASE1":7557,"PHASE1":7559,"PHASE2":7561,"PHASE3":7567,"PHASE4":7569,"NA":7571},{"trials":7558,"activeCount":100},[],{"trials":7560,"activeCount":100},[],{"trials":7562,"activeCount":100},[7563],{"nctId":843,"briefTitle":844,"status":139,"phases":7564,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":7565,"interventions":7566},[90],[850,851],[853,676,82,639,854,855],{"trials":7568,"activeCount":100},[],{"trials":7570,"activeCount":100},[],{"trials":7572,"activeCount":100},[],{"intervention":7574,"totalTrials":1156,"cells":7575},"oral azacitidine",{"EARLY_PHASE1":7576,"PHASE1":7578,"PHASE2":7580,"PHASE3":7591,"PHASE4":7593,"NA":7595},{"trials":7577,"activeCount":100},[],{"trials":7579,"activeCount":100},[],{"trials":7581,"activeCount":100},[7582],{"nctId":7583,"briefTitle":7584,"status":139,"phases":7585,"primaryCompletion":7586,"completion":7586,"start":7587,"enrollment":7588,"conditions":7589,"interventions":7590},"NCT01845805","Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)",[90],"2021-04-09","2014-01-10",49,[21],[7574],{"trials":7592,"activeCount":100},[],{"trials":7594,"activeCount":100},[],{"trials":7596,"activeCount":100},[],{"intervention":1462,"totalTrials":1156,"cells":7598},{"EARLY_PHASE1":7599,"PHASE1":7601,"PHASE2":7603,"PHASE3":7609,"PHASE4":7611,"NA":7613},{"trials":7600,"activeCount":100},[],{"trials":7602,"activeCount":100},[],{"trials":7604,"activeCount":100},[7605],{"nctId":1455,"briefTitle":1456,"status":219,"phases":7606,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":361,"conditions":7607,"interventions":7608},[89,90],[36],[1462,831,638,175],{"trials":7610,"activeCount":100},[],{"trials":7612,"activeCount":100},[],{"trials":7614,"activeCount":100},[],{"intervention":7616,"totalTrials":1156,"cells":7617},"Adagrasib",{"EARLY_PHASE1":7618,"PHASE1":7620,"PHASE2":7622,"PHASE3":7635,"PHASE4":7637,"NA":7639},{"trials":7619,"activeCount":100},[],{"trials":7621,"activeCount":100},[],{"trials":7623,"activeCount":100},[7624],{"nctId":7625,"briefTitle":7626,"status":416,"phases":7627,"primaryCompletion":7628,"completion":7629,"start":7630,"enrollment":100,"conditions":7631,"interventions":7633},"NCT05472623","Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab",[90],"2025-06-01","2025-09-01","2023-03-21",[7632],"Resectable Non-Small Cell Lung Cancer",[7616,7634],"Adagrasib\u002FNivolumab",{"trials":7636,"activeCount":100},[],{"trials":7638,"activeCount":100},[],{"trials":7640,"activeCount":100},[],{"intervention":7634,"totalTrials":1156,"cells":7642},{"EARLY_PHASE1":7643,"PHASE1":7645,"PHASE2":7647,"PHASE3":7653,"PHASE4":7655,"NA":7657},{"trials":7644,"activeCount":100},[],{"trials":7646,"activeCount":100},[],{"trials":7648,"activeCount":100},[7649],{"nctId":7625,"briefTitle":7626,"status":416,"phases":7650,"primaryCompletion":7628,"completion":7629,"start":7630,"enrollment":100,"conditions":7651,"interventions":7652},[90],[7632],[7616,7634],{"trials":7654,"activeCount":100},[],{"trials":7656,"activeCount":100},[],{"trials":7658,"activeCount":100},[],{"intervention":7660,"totalTrials":1156,"cells":7661},"Neoadjuvant treatment",{"EARLY_PHASE1":7662,"PHASE1":7664,"PHASE2":7666,"PHASE3":7676,"PHASE4":7678,"NA":7680},{"trials":7663,"activeCount":100},[],{"trials":7665,"activeCount":100},[],{"trials":7667,"activeCount":100},[7668],{"nctId":7669,"briefTitle":7670,"status":416,"phases":7671,"primaryCompletion":7672,"completion":1755,"start":7673,"enrollment":100,"conditions":7674,"interventions":7675},"NCT05574712","A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer",[90],"2025-01","2024-01-01",[15],[7660],{"trials":7677,"activeCount":100},[],{"trials":7679,"activeCount":100},[],{"trials":7681,"activeCount":100},[],{"intervention":7683,"totalTrials":1156,"cells":7684},"Ex vivo expansion of cord blood",{"EARLY_PHASE1":7685,"PHASE1":7687,"PHASE2":7689,"PHASE3":7702,"PHASE4":7704,"NA":7706},{"trials":7686,"activeCount":100},[],{"trials":7688,"activeCount":100},[],{"trials":7690,"activeCount":100},[7691],{"nctId":7692,"briefTitle":7693,"status":219,"phases":7694,"primaryCompletion":7695,"completion":7695,"start":7696,"enrollment":224,"conditions":7697,"interventions":7701},"NCT00539656","Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers",[89,90],"2009-10-20","2007-12-20",[779,7698,7699,7700],"Leukemia, Lymphoblastic, Acute","Leukemia, Bilineage, Acute","Leukemia, Myeloid, Chronic",[7683],{"trials":7703,"activeCount":100},[],{"trials":7705,"activeCount":100},[],{"trials":7707,"activeCount":100},[],{"intervention":7709,"totalTrials":1156,"cells":7710},"suramin",{"EARLY_PHASE1":7711,"PHASE1":7713,"PHASE2":7715,"PHASE3":7724,"PHASE4":7726,"NA":7728},{"trials":7712,"activeCount":100},[],{"trials":7714,"activeCount":100},[],{"trials":7716,"activeCount":100},[7717],{"nctId":7718,"briefTitle":7719,"status":139,"phases":7720,"primaryCompletion":7721,"completion":939,"start":752,"enrollment":2858,"conditions":7722,"interventions":7723},"NCT00004073","Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[90],"2003-05",[24],[7709],{"trials":7725,"activeCount":100},[],{"trials":7727,"activeCount":100},[],{"trials":7729,"activeCount":100},[],{"intervention":7731,"totalTrials":1156,"cells":7732},"fenretinide",{"EARLY_PHASE1":7733,"PHASE1":7735,"PHASE2":7737,"PHASE3":7748,"PHASE4":7750,"NA":7752},{"trials":7734,"activeCount":100},[],{"trials":7736,"activeCount":100},[],{"trials":7738,"activeCount":100},[7739],{"nctId":7740,"briefTitle":7741,"status":139,"phases":7742,"primaryCompletion":7743,"completion":7744,"start":7745,"conditions":7746,"interventions":7747},"NCT00006080","Fenretinide in Treating Patients With Recurrent Malignant Glioma",[90],"2004-09-14","2004-11-01","2000-09-25",[24],[7731],{"trials":7749,"activeCount":100},[],{"trials":7751,"activeCount":100},[],{"trials":7753,"activeCount":100},[],{"intervention":7755,"totalTrials":1156,"cells":7756},"Encorafenib",{"EARLY_PHASE1":7757,"PHASE1":7759,"PHASE2":7761,"PHASE3":7780,"PHASE4":7782,"NA":7784},{"trials":7758,"activeCount":100},[],{"trials":7760,"activeCount":100},[],{"trials":7762,"activeCount":100},[7763],{"nctId":7764,"briefTitle":7765,"status":219,"phases":7766,"primaryCompletion":7767,"completion":7768,"start":7769,"enrollment":1609,"conditions":7770,"interventions":7776},"NCT03973918","Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG",[90],"2022-04-30","2023-10-01","2019-07-29",[2367,7771,7772,7773,7774,7775,226],"BRAF V600E","BRAF V600K","Anaplastic Astrocytoma","Anaplastic Pleomorphic Xanthoastrocytoma","Gliosarcoma",[7755,7777,7778,7779],"Binimetinib","Research Bloods","Tumor Tissue",{"trials":7781,"activeCount":100},[],{"trials":7783,"activeCount":100},[],{"trials":7785,"activeCount":100},[],{"intervention":7777,"totalTrials":1156,"cells":7787},{"EARLY_PHASE1":7788,"PHASE1":7790,"PHASE2":7792,"PHASE3":7798,"PHASE4":7800,"NA":7802},{"trials":7789,"activeCount":100},[],{"trials":7791,"activeCount":100},[],{"trials":7793,"activeCount":100},[7794],{"nctId":7764,"briefTitle":7765,"status":219,"phases":7795,"primaryCompletion":7767,"completion":7768,"start":7769,"enrollment":1609,"conditions":7796,"interventions":7797},[90],[2367,7771,7772,7773,7774,7775,226],[7755,7777,7778,7779],{"trials":7799,"activeCount":100},[],{"trials":7801,"activeCount":100},[],{"trials":7803,"activeCount":100},[],{"intervention":7778,"totalTrials":1156,"cells":7805},{"EARLY_PHASE1":7806,"PHASE1":7808,"PHASE2":7810,"PHASE3":7816,"PHASE4":7818,"NA":7820},{"trials":7807,"activeCount":100},[],{"trials":7809,"activeCount":100},[],{"trials":7811,"activeCount":100},[7812],{"nctId":7764,"briefTitle":7765,"status":219,"phases":7813,"primaryCompletion":7767,"completion":7768,"start":7769,"enrollment":1609,"conditions":7814,"interventions":7815},[90],[2367,7771,7772,7773,7774,7775,226],[7755,7777,7778,7779],{"trials":7817,"activeCount":100},[],{"trials":7819,"activeCount":100},[],{"trials":7821,"activeCount":100},[],{"intervention":7779,"totalTrials":1156,"cells":7823},{"EARLY_PHASE1":7824,"PHASE1":7826,"PHASE2":7828,"PHASE3":7834,"PHASE4":7836,"NA":7838},{"trials":7825,"activeCount":100},[],{"trials":7827,"activeCount":100},[],{"trials":7829,"activeCount":100},[7830],{"nctId":7764,"briefTitle":7765,"status":219,"phases":7831,"primaryCompletion":7767,"completion":7768,"start":7769,"enrollment":1609,"conditions":7832,"interventions":7833},[90],[2367,7771,7772,7773,7774,7775,226],[7755,7777,7778,7779],{"trials":7835,"activeCount":100},[],{"trials":7837,"activeCount":100},[],{"trials":7839,"activeCount":100},[],{"intervention":897,"totalTrials":1156,"cells":7841},{"EARLY_PHASE1":7842,"PHASE1":7844,"PHASE2":7846,"PHASE3":7852,"PHASE4":7854,"NA":7856},{"trials":7843,"activeCount":100},[],{"trials":7845,"activeCount":100},[],{"trials":7847,"activeCount":100},[7848],{"nctId":885,"briefTitle":886,"status":219,"phases":7849,"primaryCompletion":888,"completion":888,"start":889,"enrollment":118,"conditions":7850,"interventions":7851},[90],[891],[841,82,893,637,894,895,175,896,897],{"trials":7853,"activeCount":100},[],{"trials":7855,"activeCount":100},[],{"trials":7857,"activeCount":100},[],{"intervention":7859,"totalTrials":1156,"cells":7860},"Sm-EDTMP",{"EARLY_PHASE1":7861,"PHASE1":7863,"PHASE2":7865,"PHASE3":7876,"PHASE4":7878,"NA":7880},{"trials":7862,"activeCount":100},[],{"trials":7864,"activeCount":100},[],{"trials":7866,"activeCount":100},[7867],{"nctId":7868,"briefTitle":7869,"status":219,"phases":7870,"primaryCompletion":1419,"completion":7871,"start":7872,"enrollment":536,"conditions":7873,"interventions":7875},"NCT01886105","Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma",[90],"2017-06-11","2013-08-19",[7874],"Metastatic Osteosarcoma",[7859],{"trials":7877,"activeCount":100},[],{"trials":7879,"activeCount":100},[],{"trials":7881,"activeCount":100},[],{"intervention":6480,"totalTrials":1156,"cells":7883},{"EARLY_PHASE1":7884,"PHASE1":7886,"PHASE2":7888,"PHASE3":7894,"PHASE4":7896,"NA":7898},{"trials":7885,"activeCount":100},[],{"trials":7887,"activeCount":100},[],{"trials":7889,"activeCount":100},[7890],{"nctId":6474,"briefTitle":6475,"status":139,"phases":7891,"primaryCompletion":3210,"completion":3210,"start":6477,"enrollment":313,"conditions":7892,"interventions":7893},[90],[673],[6480,2360],{"trials":7895,"activeCount":100},[],{"trials":7897,"activeCount":100},[],{"trials":7899,"activeCount":100},[],{"intervention":3203,"totalTrials":1156,"cells":7901},{"EARLY_PHASE1":7902,"PHASE1":7904,"PHASE2":7906,"PHASE3":7912,"PHASE4":7914,"NA":7916},{"trials":7903,"activeCount":100},[],{"trials":7905,"activeCount":100},[],{"trials":7907,"activeCount":100},[7908],{"nctId":3196,"briefTitle":3197,"status":139,"phases":7909,"primaryCompletion":3199,"completion":3199,"start":3200,"enrollment":1581,"conditions":7910,"interventions":7911},[90],[30],[3203,841,3204,893,3205],{"trials":7913,"activeCount":100},[],{"trials":7915,"activeCount":100},[],{"trials":7917,"activeCount":100},[],{"intervention":3204,"totalTrials":1156,"cells":7919},{"EARLY_PHASE1":7920,"PHASE1":7922,"PHASE2":7924,"PHASE3":7930,"PHASE4":7932,"NA":7934},{"trials":7921,"activeCount":100},[],{"trials":7923,"activeCount":100},[],{"trials":7925,"activeCount":100},[7926],{"nctId":3196,"briefTitle":3197,"status":139,"phases":7927,"primaryCompletion":3199,"completion":3199,"start":3200,"enrollment":1581,"conditions":7928,"interventions":7929},[90],[30],[3203,841,3204,893,3205],{"trials":7931,"activeCount":100},[],{"trials":7933,"activeCount":100},[],{"trials":7935,"activeCount":100},[],{"intervention":3205,"totalTrials":1156,"cells":7937},{"EARLY_PHASE1":7938,"PHASE1":7940,"PHASE2":7942,"PHASE3":7948,"PHASE4":7950,"NA":7952},{"trials":7939,"activeCount":100},[],{"trials":7941,"activeCount":100},[],{"trials":7943,"activeCount":100},[7944],{"nctId":3196,"briefTitle":3197,"status":139,"phases":7945,"primaryCompletion":3199,"completion":3199,"start":3200,"enrollment":1581,"conditions":7946,"interventions":7947},[90],[30],[3203,841,3204,893,3205],{"trials":7949,"activeCount":100},[],{"trials":7951,"activeCount":100},[],{"trials":7953,"activeCount":100},[],{"intervention":7955,"totalTrials":1156,"cells":7956},"Hodgkin's antigens-GM-CSF-expressing cell vaccine",{"EARLY_PHASE1":7957,"PHASE1":7959,"PHASE2":7961,"PHASE3":7970,"PHASE4":7972,"NA":7974},{"trials":7958,"activeCount":100},[],{"trials":7960,"activeCount":100},[],{"trials":7962,"activeCount":100},[7963],{"nctId":7964,"briefTitle":7965,"status":219,"phases":7966,"primaryCompletion":7967,"completion":7967,"start":1019,"enrollment":1156,"conditions":7968,"interventions":7969},"NCT00478062","Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma",[89,90],"2008-06",[30],[7955],{"trials":7971,"activeCount":100},[],{"trials":7973,"activeCount":100},[],{"trials":7975,"activeCount":100},[],{"intervention":568,"totalTrials":1156,"cells":7977},{"EARLY_PHASE1":7978,"PHASE1":7980,"PHASE2":7982,"PHASE3":7988,"PHASE4":7990,"NA":7992},{"trials":7979,"activeCount":100},[],{"trials":7981,"activeCount":100},[],{"trials":7983,"activeCount":100},[7984],{"nctId":559,"briefTitle":560,"status":139,"phases":7985,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":7986,"interventions":7987},[90],[566],[123,568,569],{"trials":7989,"activeCount":100},[],{"trials":7991,"activeCount":100},[],{"trials":7993,"activeCount":100},[],{"intervention":7995,"totalTrials":1156,"cells":7996},"Pemigatinib",{"EARLY_PHASE1":7997,"PHASE1":7999,"PHASE2":8001,"PHASE3":8014,"PHASE4":8016,"NA":8018},{"trials":7998,"activeCount":100},[],{"trials":8000,"activeCount":100},[],{"trials":8002,"activeCount":100},[8003],{"nctId":8004,"briefTitle":8005,"status":139,"phases":8006,"primaryCompletion":8007,"completion":8007,"start":8008,"enrollment":313,"conditions":8009,"interventions":8013},"NCT03914794","A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors",[90],"2025-09-30","2020-10-02",[1334,8010,8011,8012],"NMIBC","Non-Muscle Invasive Bladder Cancer","Urothelial Carcinoma Recurrent",[7995],{"trials":8015,"activeCount":100},[],{"trials":8017,"activeCount":100},[],{"trials":8019,"activeCount":100},[],{"intervention":8021,"totalTrials":1156,"cells":8022},"I-131 Tositumomab therapeutic regimen",{"EARLY_PHASE1":8023,"PHASE1":8025,"PHASE2":8027,"PHASE3":8036,"PHASE4":8038,"NA":8040},{"trials":8024,"activeCount":100},[],{"trials":8026,"activeCount":100},[],{"trials":8028,"activeCount":100},[8029],{"nctId":8030,"briefTitle":8031,"status":139,"phases":8032,"primaryCompletion":1562,"completion":8033,"start":646,"enrollment":969,"conditions":8034,"interventions":8035},"NCT00484874","Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed\u002FRefractory Hodgkin's Lymphoma",[89,90],"2015-11",[5384],[8021],{"trials":8037,"activeCount":100},[],{"trials":8039,"activeCount":100},[],{"trials":8041,"activeCount":100},[],{"intervention":3215,"totalTrials":1156,"cells":8043},{"EARLY_PHASE1":8044,"PHASE1":8046,"PHASE2":8048,"PHASE3":8054,"PHASE4":8056,"NA":8058},{"trials":8045,"activeCount":100},[],{"trials":8047,"activeCount":100},[],{"trials":8049,"activeCount":100},[8050],{"nctId":3207,"briefTitle":3208,"status":219,"phases":8051,"primaryCompletion":2515,"completion":3210,"start":3211,"enrollment":536,"conditions":8052,"interventions":8053},[90],[280,3213],[3215,893],{"trials":8055,"activeCount":100},[],{"trials":8057,"activeCount":100},[],{"trials":8059,"activeCount":100},[],{"intervention":8061,"totalTrials":1156,"cells":8062},"Muscadine Plus Grape Skin Extract",{"EARLY_PHASE1":8063,"PHASE1":8065,"PHASE2":8067,"PHASE3":8077,"PHASE4":8079,"NA":8081},{"trials":8064,"activeCount":100},[],{"trials":8066,"activeCount":100},[],{"trials":8068,"activeCount":100},[8069],{"nctId":8070,"briefTitle":8071,"status":139,"phases":8072,"primaryCompletion":8033,"completion":8033,"start":988,"enrollment":323,"conditions":8073,"interventions":8074},"NCT01317199","Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer",[89,90],[15],[8061,8075,8076],"Low-dose MPX","High-dose MPX",{"trials":8078,"activeCount":100},[],{"trials":8080,"activeCount":100},[],{"trials":8082,"activeCount":100},[],{"intervention":8075,"totalTrials":1156,"cells":8084},{"EARLY_PHASE1":8085,"PHASE1":8087,"PHASE2":8089,"PHASE3":8095,"PHASE4":8097,"NA":8099},{"trials":8086,"activeCount":100},[],{"trials":8088,"activeCount":100},[],{"trials":8090,"activeCount":100},[8091],{"nctId":8070,"briefTitle":8071,"status":139,"phases":8092,"primaryCompletion":8033,"completion":8033,"start":988,"enrollment":323,"conditions":8093,"interventions":8094},[89,90],[15],[8061,8075,8076],{"trials":8096,"activeCount":100},[],{"trials":8098,"activeCount":100},[],{"trials":8100,"activeCount":100},[],{"intervention":8076,"totalTrials":1156,"cells":8102},{"EARLY_PHASE1":8103,"PHASE1":8105,"PHASE2":8107,"PHASE3":8113,"PHASE4":8115,"NA":8117},{"trials":8104,"activeCount":100},[],{"trials":8106,"activeCount":100},[],{"trials":8108,"activeCount":100},[8109],{"nctId":8070,"briefTitle":8071,"status":139,"phases":8110,"primaryCompletion":8033,"completion":8033,"start":988,"enrollment":323,"conditions":8111,"interventions":8112},[89,90],[15],[8061,8075,8076],{"trials":8114,"activeCount":100},[],{"trials":8116,"activeCount":100},[],{"trials":8118,"activeCount":100},[],{"intervention":8120,"totalTrials":1156,"cells":8121},"letrozole",{"EARLY_PHASE1":8122,"PHASE1":8124,"PHASE2":8126,"PHASE3":8142,"PHASE4":8144,"NA":8146},{"trials":8123,"activeCount":100},[],{"trials":8125,"activeCount":100},[],{"trials":8127,"activeCount":100},[8128],{"nctId":8129,"briefTitle":8130,"status":139,"phases":8131,"primaryCompletion":1562,"completion":1562,"start":8132,"enrollment":1077,"conditions":8133,"interventions":8140},"NCT01194440","Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms",[90],"2011-02",[8134,8135,8136,6072,6073,8137,8138,8139],"Ductal Carcinoma in Situ","Estrogen Receptor-positive Breast Cancer","Progesterone Receptor-positive Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[8120,8141],"zoledronic acid",{"trials":8143,"activeCount":100},[],{"trials":8145,"activeCount":100},[],{"trials":8147,"activeCount":100},[],{"intervention":8141,"totalTrials":1156,"cells":8149},{"EARLY_PHASE1":8150,"PHASE1":8152,"PHASE2":8154,"PHASE3":8160,"PHASE4":8162,"NA":8164},{"trials":8151,"activeCount":100},[],{"trials":8153,"activeCount":100},[],{"trials":8155,"activeCount":100},[8156],{"nctId":8129,"briefTitle":8130,"status":139,"phases":8157,"primaryCompletion":1562,"completion":1562,"start":8132,"enrollment":1077,"conditions":8158,"interventions":8159},[90],[8134,8135,8136,6072,6073,8137,8138,8139],[8120,8141],{"trials":8161,"activeCount":100},[],{"trials":8163,"activeCount":100},[],{"trials":8165,"activeCount":100},[],{"intervention":952,"totalTrials":1156,"cells":8167},{"EARLY_PHASE1":8168,"PHASE1":8170,"PHASE2":8172,"PHASE3":8178,"PHASE4":8180,"NA":8182},{"trials":8169,"activeCount":100},[],{"trials":8171,"activeCount":100},[],{"trials":8173,"activeCount":100},[8174],{"nctId":945,"briefTitle":946,"status":416,"phases":8175,"primaryCompletion":948,"completion":949,"start":473,"enrollment":100,"conditions":8176,"interventions":8177},[90],[18],[893,82,952],{"trials":8179,"activeCount":100},[],{"trials":8181,"activeCount":100},[],{"trials":8183,"activeCount":100},[],{"intervention":963,"totalTrials":1156,"cells":8185},{"EARLY_PHASE1":8186,"PHASE1":8188,"PHASE2":8190,"PHASE3":8196,"PHASE4":8198,"NA":8200},{"trials":8187,"activeCount":100},[],{"trials":8189,"activeCount":100},[],{"trials":8191,"activeCount":100},[8192],{"nctId":954,"briefTitle":955,"status":219,"phases":8193,"primaryCompletion":957,"completion":957,"start":958,"enrollment":19,"conditions":8194,"interventions":8195},[90],[960],[82,676,874,962,963,964],{"trials":8197,"activeCount":100},[],{"trials":8199,"activeCount":100},[],{"trials":8201,"activeCount":100},[],{"intervention":964,"totalTrials":1156,"cells":8203},{"EARLY_PHASE1":8204,"PHASE1":8206,"PHASE2":8208,"PHASE3":8214,"PHASE4":8216,"NA":8218},{"trials":8205,"activeCount":100},[],{"trials":8207,"activeCount":100},[],{"trials":8209,"activeCount":100},[8210],{"nctId":954,"briefTitle":955,"status":219,"phases":8211,"primaryCompletion":957,"completion":957,"start":958,"enrollment":19,"conditions":8212,"interventions":8213},[90],[960],[82,676,874,962,963,964],{"trials":8215,"activeCount":100},[],{"trials":8217,"activeCount":100},[],{"trials":8219,"activeCount":100},[],{"intervention":8221,"totalTrials":1156,"cells":8222},"temsirolimus plus liposomal doxorubicin",{"EARLY_PHASE1":8223,"PHASE1":8225,"PHASE2":8227,"PHASE3":8236,"PHASE4":8238,"NA":8240},{"trials":8224,"activeCount":100},[],{"trials":8226,"activeCount":100},[],{"trials":8228,"activeCount":100},[8229],{"nctId":8230,"briefTitle":8231,"status":139,"phases":8232,"primaryCompletion":2365,"completion":2365,"start":8233,"enrollment":266,"conditions":8234,"interventions":8235},"NCT00949325","Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma",[89,90],"2009-09",[280],[8221],{"trials":8237,"activeCount":100},[],{"trials":8239,"activeCount":100},[],{"trials":8241,"activeCount":100},[],{"intervention":8243,"totalTrials":1156,"cells":8244},"MEDI-551 Maintenance",{"EARLY_PHASE1":8245,"PHASE1":8247,"PHASE2":8249,"PHASE3":8259,"PHASE4":8261,"NA":8263},{"trials":8246,"activeCount":100},[],{"trials":8248,"activeCount":100},[],{"trials":8250,"activeCount":100},[8251],{"nctId":8252,"briefTitle":8253,"status":219,"phases":8254,"primaryCompletion":8255,"completion":8255,"start":8256,"enrollment":1156,"conditions":8257,"interventions":8258},"NCT03218163","MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma",[90],"2018-04-15","2017-09-27",[673],[8243],{"trials":8260,"activeCount":100},[],{"trials":8262,"activeCount":100},[],{"trials":8264,"activeCount":100},[],{"intervention":982,"totalTrials":1156,"cells":8266},{"EARLY_PHASE1":8267,"PHASE1":8269,"PHASE2":8271,"PHASE3":8277,"PHASE4":8279,"NA":8281},{"trials":8268,"activeCount":100},[],{"trials":8270,"activeCount":100},[],{"trials":8272,"activeCount":100},[8273],{"nctId":973,"briefTitle":974,"status":139,"phases":8274,"primaryCompletion":948,"completion":976,"start":977,"enrollment":978,"conditions":8275,"interventions":8276},[89,90],[980],[982,82,343],{"trials":8278,"activeCount":100},[],{"trials":8280,"activeCount":100},[],{"trials":8282,"activeCount":100},[],{"intervention":8284,"totalTrials":1156,"cells":8285},"Androgen Deprivation Therapy",{"EARLY_PHASE1":8286,"PHASE1":8288,"PHASE2":8290,"PHASE3":8300,"PHASE4":8302,"NA":8304},{"trials":8287,"activeCount":100},[],{"trials":8289,"activeCount":100},[],{"trials":8291,"activeCount":100},[8292],{"nctId":8293,"briefTitle":8294,"status":139,"phases":8295,"primaryCompletion":429,"completion":8296,"start":8297,"enrollment":241,"conditions":8298,"interventions":8299},"NCT01517451","Radiation and Androgen Ablation for Prostate Cancer",[89,90],"2025-12-31","2013-05-22",[1972],[8284],{"trials":8301,"activeCount":100},[],{"trials":8303,"activeCount":100},[],{"trials":8305,"activeCount":100},[],{"intervention":8307,"totalTrials":1156,"cells":8308},"Fish oil supplement",{"EARLY_PHASE1":8309,"PHASE1":8311,"PHASE2":8313,"PHASE3":8325,"PHASE4":8327,"NA":8329},{"trials":8310,"activeCount":100},[],{"trials":8312,"activeCount":100},[],{"trials":8314,"activeCount":100},[8315],{"nctId":8316,"briefTitle":8317,"status":139,"phases":8318,"primaryCompletion":1880,"completion":1880,"start":939,"enrollment":1516,"conditions":8319,"interventions":8324},"NCT00094562","A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss",[90],[648,8320,8321,8322,8323],"Cancer Cachexia","Chronic Obstructive Pulmonary Disease","Chronic Heart Failure","Rheumatoid Arthritis",[8307],{"trials":8326,"activeCount":100},[],{"trials":8328,"activeCount":100},[],{"trials":8330,"activeCount":100},[],{"intervention":5513,"totalTrials":1156,"cells":8332},{"EARLY_PHASE1":8333,"PHASE1":8335,"PHASE2":8337,"PHASE3":8343,"PHASE4":8345,"NA":8347},{"trials":8334,"activeCount":100},[],{"trials":8336,"activeCount":100},[],{"trials":8338,"activeCount":100},[8339],{"nctId":5506,"briefTitle":5507,"status":139,"phases":8340,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":1872,"conditions":8341,"interventions":8342},[90],[27,33,711],[1023,5513,5514,5515],{"trials":8344,"activeCount":100},[],{"trials":8346,"activeCount":100},[],{"trials":8348,"activeCount":100},[],{"intervention":5514,"totalTrials":1156,"cells":8350},{"EARLY_PHASE1":8351,"PHASE1":8353,"PHASE2":8355,"PHASE3":8361,"PHASE4":8363,"NA":8365},{"trials":8352,"activeCount":100},[],{"trials":8354,"activeCount":100},[],{"trials":8356,"activeCount":100},[8357],{"nctId":5506,"briefTitle":5507,"status":139,"phases":8358,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":1872,"conditions":8359,"interventions":8360},[90],[27,33,711],[1023,5513,5514,5515],{"trials":8362,"activeCount":100},[],{"trials":8364,"activeCount":100},[],{"trials":8366,"activeCount":100},[],{"intervention":5515,"totalTrials":1156,"cells":8368},{"EARLY_PHASE1":8369,"PHASE1":8371,"PHASE2":8373,"PHASE3":8379,"PHASE4":8381,"NA":8383},{"trials":8370,"activeCount":100},[],{"trials":8372,"activeCount":100},[],{"trials":8374,"activeCount":100},[8375],{"nctId":5506,"briefTitle":5507,"status":139,"phases":8376,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":1872,"conditions":8377,"interventions":8378},[90],[27,33,711],[1023,5513,5514,5515],{"trials":8380,"activeCount":100},[],{"trials":8382,"activeCount":100},[],{"trials":8384,"activeCount":100},[],{"intervention":1055,"totalTrials":1156,"cells":8386},{"EARLY_PHASE1":8387,"PHASE1":8389,"PHASE2":8391,"PHASE3":8397,"PHASE4":8399,"NA":8401},{"trials":8388,"activeCount":100},[],{"trials":8390,"activeCount":100},[],{"trials":8392,"activeCount":100},[8393],{"nctId":1047,"briefTitle":1048,"status":416,"phases":8394,"primaryCompletion":1050,"completion":1050,"start":802,"enrollment":100,"conditions":8395,"interventions":8396},[90],[1052,1053,192],[82,639,840,854,757,894,1055,1056],{"trials":8398,"activeCount":100},[],{"trials":8400,"activeCount":100},[],{"trials":8402,"activeCount":100},[],{"intervention":6077,"totalTrials":1156,"cells":8404},{"EARLY_PHASE1":8405,"PHASE1":8407,"PHASE2":8409,"PHASE3":8415,"PHASE4":8417,"NA":8419},{"trials":8406,"activeCount":100},[],{"trials":8408,"activeCount":100},[],{"trials":8410,"activeCount":100},[8411],{"nctId":6065,"briefTitle":6066,"status":219,"phases":8412,"primaryCompletion":6068,"completion":6069,"start":6070,"enrollment":96,"conditions":8413,"interventions":8414},[90],[18,6072,6073,6074],[6076,6077],{"trials":8416,"activeCount":100},[],{"trials":8418,"activeCount":100},[],{"trials":8420,"activeCount":100},[],{"intervention":2633,"totalTrials":1156,"cells":8422},{"EARLY_PHASE1":8423,"PHASE1":8425,"PHASE2":8427,"PHASE3":8433,"PHASE4":8435,"NA":8437},{"trials":8424,"activeCount":100},[],{"trials":8426,"activeCount":100},[],{"trials":8428,"activeCount":100},[8429],{"nctId":2624,"briefTitle":2625,"status":139,"phases":8430,"primaryCompletion":2627,"completion":2627,"start":2628,"enrollment":2629,"conditions":8431,"interventions":8432},[89,90],[2631],[2633,2634,2635,2636,409],{"trials":8434,"activeCount":100},[],{"trials":8436,"activeCount":100},[],{"trials":8438,"activeCount":100},[],{"intervention":2634,"totalTrials":1156,"cells":8440},{"EARLY_PHASE1":8441,"PHASE1":8443,"PHASE2":8445,"PHASE3":8451,"PHASE4":8453,"NA":8455},{"trials":8442,"activeCount":100},[],{"trials":8444,"activeCount":100},[],{"trials":8446,"activeCount":100},[8447],{"nctId":2624,"briefTitle":2625,"status":139,"phases":8448,"primaryCompletion":2627,"completion":2627,"start":2628,"enrollment":2629,"conditions":8449,"interventions":8450},[89,90],[2631],[2633,2634,2635,2636,409],{"trials":8452,"activeCount":100},[],{"trials":8454,"activeCount":100},[],{"trials":8456,"activeCount":100},[],{"intervention":2635,"totalTrials":1156,"cells":8458},{"EARLY_PHASE1":8459,"PHASE1":8461,"PHASE2":8463,"PHASE3":8469,"PHASE4":8471,"NA":8473},{"trials":8460,"activeCount":100},[],{"trials":8462,"activeCount":100},[],{"trials":8464,"activeCount":100},[8465],{"nctId":2624,"briefTitle":2625,"status":139,"phases":8466,"primaryCompletion":2627,"completion":2627,"start":2628,"enrollment":2629,"conditions":8467,"interventions":8468},[89,90],[2631],[2633,2634,2635,2636,409],{"trials":8470,"activeCount":100},[],{"trials":8472,"activeCount":100},[],{"trials":8474,"activeCount":100},[],{"intervention":8476,"totalTrials":1156,"cells":8477},"Dupilumab",{"EARLY_PHASE1":8478,"PHASE1":8480,"PHASE2":8482,"PHASE3":8492,"PHASE4":8494,"NA":8496},{"trials":8479,"activeCount":100},[],{"trials":8481,"activeCount":100},[],{"trials":8483,"activeCount":100},[8484],{"nctId":8485,"briefTitle":8486,"status":219,"phases":8487,"primaryCompletion":8488,"completion":8488,"start":8489,"enrollment":689,"conditions":8490,"interventions":8491},"NCT03886493","Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer",[90],"2020-10-06","2019-08-28",[15],[8476],{"trials":8493,"activeCount":100},[],{"trials":8495,"activeCount":100},[],{"trials":8497,"activeCount":100},[],{"intervention":8499,"totalTrials":1156,"cells":8500},"Busulfan, Fludarabine, Cytoxan",{"EARLY_PHASE1":8501,"PHASE1":8503,"PHASE2":8505,"PHASE3":8513,"PHASE4":8515,"NA":8517},{"trials":8502,"activeCount":100},[],{"trials":8504,"activeCount":100},[],{"trials":8506,"activeCount":100},[8507],{"nctId":8508,"briefTitle":8509,"status":139,"phases":8510,"primaryCompletion":5596,"completion":5596,"start":1506,"enrollment":2421,"conditions":8511,"interventions":8512},"NCT00809276","Allo BMT Using Matched Related\u002FUnrelated Donors With FluBu and HiCY",[89,90],[30,673,27,778],[8499],{"trials":8514,"activeCount":100},[],{"trials":8516,"activeCount":100},[],{"trials":8518,"activeCount":100},[],{"intervention":7132,"totalTrials":1156,"cells":8520},{"EARLY_PHASE1":8521,"PHASE1":8523,"PHASE2":8525,"PHASE3":8531,"PHASE4":8533,"NA":8535},{"trials":8522,"activeCount":100},[],{"trials":8524,"activeCount":100},[],{"trials":8526,"activeCount":100},[8527],{"nctId":7126,"briefTitle":7127,"status":139,"phases":8528,"primaryCompletion":438,"completion":438,"start":7129,"enrollment":25,"conditions":8529,"interventions":8530},[90],[15],[7117,7132],{"trials":8532,"activeCount":100},[],{"trials":8534,"activeCount":100},[],{"trials":8536,"activeCount":100},[],{"intervention":1350,"totalTrials":1156,"cells":8538},{"EARLY_PHASE1":8539,"PHASE1":8541,"PHASE2":8543,"PHASE3":8549,"PHASE4":8551,"NA":8553},{"trials":8540,"activeCount":100},[],{"trials":8542,"activeCount":100},[],{"trials":8544,"activeCount":100},[8545],{"nctId":1339,"briefTitle":1340,"status":416,"phases":8546,"primaryCompletion":1342,"completion":1343,"start":1344,"enrollment":100,"conditions":8547,"interventions":8548},[89,90],[1346,1347],[580,1349,1350],{"trials":8550,"activeCount":100},[],{"trials":8552,"activeCount":100},[],{"trials":8554,"activeCount":100},[],{"intervention":8556,"totalTrials":1156,"cells":8557},"Contrave",{"EARLY_PHASE1":8558,"PHASE1":8560,"PHASE2":8562,"PHASE3":8574,"PHASE4":8576,"NA":8578},{"trials":8559,"activeCount":100},[],{"trials":8561,"activeCount":100},[],{"trials":8563,"activeCount":100},[8564],{"nctId":8565,"briefTitle":8566,"status":139,"phases":8567,"primaryCompletion":8568,"completion":8568,"start":8569,"enrollment":8570,"conditions":8571,"interventions":8573},"NCT04499950","Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study",[90],"2024-01-10","2021-02-08",53,[18,8572],"Overweight or Obesity",[8556],{"trials":8575,"activeCount":100},[],{"trials":8577,"activeCount":100},[],{"trials":8579,"activeCount":100},[],{"intervention":8581,"totalTrials":1156,"cells":8582},"capecitabine and IMRT",{"EARLY_PHASE1":8583,"PHASE1":8585,"PHASE2":8587,"PHASE3":8599,"PHASE4":8601,"NA":8603},{"trials":8584,"activeCount":100},[],{"trials":8586,"activeCount":100},[],{"trials":8588,"activeCount":100},[8589],{"nctId":8590,"briefTitle":8591,"status":139,"phases":8592,"primaryCompletion":8593,"completion":8594,"start":8595,"enrollment":361,"conditions":8596,"interventions":8597},"NCT02017704","Chemoradiation or Brachytherapy for Rectal Cancer",[90],"2021-09-30","2023-01-31","2014-06-12",[1863],[8581,8598],"FOLFOX6",{"trials":8600,"activeCount":100},[],{"trials":8602,"activeCount":100},[],{"trials":8604,"activeCount":100},[],{"intervention":8598,"totalTrials":1156,"cells":8606},{"EARLY_PHASE1":8607,"PHASE1":8609,"PHASE2":8611,"PHASE3":8617,"PHASE4":8619,"NA":8621},{"trials":8608,"activeCount":100},[],{"trials":8610,"activeCount":100},[],{"trials":8612,"activeCount":100},[8613],{"nctId":8590,"briefTitle":8591,"status":139,"phases":8614,"primaryCompletion":8593,"completion":8594,"start":8595,"enrollment":361,"conditions":8615,"interventions":8616},[90],[1863],[8581,8598],{"trials":8618,"activeCount":100},[],{"trials":8620,"activeCount":100},[],{"trials":8622,"activeCount":100},[],{"intervention":8624,"totalTrials":1156,"cells":8625},"Lenalidomide 50 mg",{"EARLY_PHASE1":8626,"PHASE1":8628,"PHASE2":8630,"PHASE3":8639,"PHASE4":8641,"NA":8643},{"trials":8627,"activeCount":100},[],{"trials":8629,"activeCount":100},[],{"trials":8631,"activeCount":100},[8632],{"nctId":8633,"briefTitle":8634,"status":219,"phases":8635,"primaryCompletion":4292,"completion":4292,"start":1076,"enrollment":168,"conditions":8636,"interventions":8637},"NCT00867308","Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia",[90],[778],[8624,8638],"Lenalidomide 15 mg",{"trials":8640,"activeCount":100},[],{"trials":8642,"activeCount":100},[],{"trials":8644,"activeCount":100},[],{"intervention":8638,"totalTrials":1156,"cells":8646},{"EARLY_PHASE1":8647,"PHASE1":8649,"PHASE2":8651,"PHASE3":8657,"PHASE4":8659,"NA":8661},{"trials":8648,"activeCount":100},[],{"trials":8650,"activeCount":100},[],{"trials":8652,"activeCount":100},[8653],{"nctId":8633,"briefTitle":8634,"status":219,"phases":8654,"primaryCompletion":4292,"completion":4292,"start":1076,"enrollment":168,"conditions":8655,"interventions":8656},[90],[778],[8624,8638],{"trials":8658,"activeCount":100},[],{"trials":8660,"activeCount":100},[],{"trials":8662,"activeCount":100},[],{"intervention":330,"totalTrials":1156,"cells":8664},{"EARLY_PHASE1":8665,"PHASE1":8667,"PHASE2":8669,"PHASE3":8675,"PHASE4":8677,"NA":8679},{"trials":8666,"activeCount":100},[],{"trials":8668,"activeCount":100},[],{"trials":8670,"activeCount":100},[8671],{"nctId":318,"briefTitle":319,"status":139,"phases":8672,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":8673,"interventions":8674},[90],[325,326],[328,329,63,330],{"trials":8676,"activeCount":100},[],{"trials":8678,"activeCount":100},[],{"trials":8680,"activeCount":100},[],{"intervention":1800,"totalTrials":1156,"cells":8682},{"EARLY_PHASE1":8683,"PHASE1":8685,"PHASE2":8687,"PHASE3":8693,"PHASE4":8695,"NA":8697},{"trials":8684,"activeCount":100},[],{"trials":8686,"activeCount":100},[],{"trials":8688,"activeCount":100},[8689],{"nctId":1793,"briefTitle":1794,"status":139,"phases":8690,"primaryCompletion":1796,"completion":1796,"start":658,"enrollment":1797,"conditions":8691,"interventions":8692},[90],[353],[246,1800,1801],{"trials":8694,"activeCount":100},[],{"trials":8696,"activeCount":100},[],{"trials":8698,"activeCount":100},[],{"intervention":1801,"totalTrials":1156,"cells":8700},{"EARLY_PHASE1":8701,"PHASE1":8703,"PHASE2":8705,"PHASE3":8711,"PHASE4":8713,"NA":8715},{"trials":8702,"activeCount":100},[],{"trials":8704,"activeCount":100},[],{"trials":8706,"activeCount":100},[8707],{"nctId":1793,"briefTitle":1794,"status":139,"phases":8708,"primaryCompletion":1796,"completion":1796,"start":658,"enrollment":1797,"conditions":8709,"interventions":8710},[90],[353],[246,1800,1801],{"trials":8712,"activeCount":100},[],{"trials":8714,"activeCount":100},[],{"trials":8716,"activeCount":100},[],{"intervention":8718,"totalTrials":1156,"cells":8719},"temsirolimus",{"EARLY_PHASE1":8720,"PHASE1":8722,"PHASE2":8724,"PHASE3":8735,"PHASE4":8737,"NA":8739},{"trials":8721,"activeCount":100},[],{"trials":8723,"activeCount":100},[],{"trials":8725,"activeCount":100},[8726],{"nctId":8727,"briefTitle":8728,"status":139,"phases":8729,"primaryCompletion":8730,"completion":8731,"start":8732,"enrollment":7588,"conditions":8733,"interventions":8734},"NCT00022724","CCI-779 in Treating Patients With Malignant Glioma",[89,90],"2006-05-04","2007-12-15","2001-08-27",[24],[8718],{"trials":8736,"activeCount":100},[],{"trials":8738,"activeCount":100},[],{"trials":8740,"activeCount":100},[],{"intervention":2222,"totalTrials":1156,"cells":8742},{"EARLY_PHASE1":8743,"PHASE1":8745,"PHASE2":8747,"PHASE3":8753,"PHASE4":8755,"NA":8757},{"trials":8744,"activeCount":100},[],{"trials":8746,"activeCount":100},[],{"trials":8748,"activeCount":100},[8749],{"nctId":2214,"briefTitle":2215,"status":139,"phases":8750,"primaryCompletion":2217,"completion":2218,"start":2219,"enrollment":1516,"conditions":8751,"interventions":8752},[90],[497],[1855,2222],{"trials":8754,"activeCount":100},[],{"trials":8756,"activeCount":100},[],{"trials":8758,"activeCount":100},[],{"intervention":8760,"totalTrials":1156,"cells":8761},"penicillamine",{"EARLY_PHASE1":8762,"PHASE1":8764,"PHASE2":8766,"PHASE3":8775,"PHASE4":8777,"NA":8779},{"trials":8763,"activeCount":100},[],{"trials":8765,"activeCount":100},[],{"trials":8767,"activeCount":100},[8768],{"nctId":8769,"briefTitle":8770,"status":139,"phases":8771,"primaryCompletion":939,"completion":1130,"start":8772,"enrollment":5546,"conditions":8773,"interventions":8774},"NCT00003751","Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma",[90],"1999-03",[24],[8760],{"trials":8776,"activeCount":100},[],{"trials":8778,"activeCount":100},[],{"trials":8780,"activeCount":100},[],{"intervention":8782,"totalTrials":1156,"cells":8783},"valproic acid",{"EARLY_PHASE1":8784,"PHASE1":8786,"PHASE2":8788,"PHASE3":8796,"PHASE4":8798,"NA":8800},{"trials":8785,"activeCount":100},[],{"trials":8787,"activeCount":100},[],{"trials":8789,"activeCount":100},[8790],{"nctId":8791,"briefTitle":8792,"status":219,"phases":8793,"primaryCompletion":517,"completion":517,"start":1474,"enrollment":156,"conditions":8794,"interventions":8795},"NCT00670046","Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer",[90],[15],[8782],{"trials":8797,"activeCount":100},[],{"trials":8799,"activeCount":100},[],{"trials":8801,"activeCount":100},[],{"intervention":8803,"totalTrials":1156,"cells":8804},"Rucaparib",{"EARLY_PHASE1":8805,"PHASE1":8807,"PHASE2":8809,"PHASE3":8821,"PHASE4":8823,"NA":8825},{"trials":8806,"activeCount":100},[],{"trials":8808,"activeCount":100},[],{"trials":8810,"activeCount":100},[8811],{"nctId":8812,"briefTitle":8813,"status":139,"phases":8814,"primaryCompletion":8815,"completion":8816,"start":8817,"enrollment":969,"conditions":8818,"interventions":8820},"NCT03413995","Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations",[90],"2023-11-08","2024-09-12","2018-09-10",[8819],"Prostate Cancer Metastatic",[8803],{"trials":8822,"activeCount":100},[],{"trials":8824,"activeCount":100},[],{"trials":8826,"activeCount":100},[],{"intervention":8828,"totalTrials":1156,"cells":8829},"olaratumab",{"EARLY_PHASE1":8830,"PHASE1":8832,"PHASE2":8834,"PHASE3":8847,"PHASE4":8849,"NA":8851},{"trials":8831,"activeCount":100},[],{"trials":8833,"activeCount":100},[],{"trials":8835,"activeCount":100},[8836],{"nctId":8837,"briefTitle":8838,"status":139,"phases":8839,"primaryCompletion":8840,"completion":8841,"start":644,"enrollment":8842,"conditions":8843,"interventions":8845},"NCT00895180","Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme",[90],"2012-06-22","2014-03-04",80,[8844],"Adult Glioblastoma Multiforme",[8828,8846],"ramucirumab",{"trials":8848,"activeCount":100},[],{"trials":8850,"activeCount":100},[],{"trials":8852,"activeCount":100},[],{"intervention":8846,"totalTrials":1156,"cells":8854},{"EARLY_PHASE1":8855,"PHASE1":8857,"PHASE2":8859,"PHASE3":8865,"PHASE4":8867,"NA":8869},{"trials":8856,"activeCount":100},[],{"trials":8858,"activeCount":100},[],{"trials":8860,"activeCount":100},[8861],{"nctId":8837,"briefTitle":8838,"status":139,"phases":8862,"primaryCompletion":8840,"completion":8841,"start":644,"enrollment":8842,"conditions":8863,"interventions":8864},[90],[8844],[8828,8846],{"trials":8866,"activeCount":100},[],{"trials":8868,"activeCount":100},[],{"trials":8870,"activeCount":100},[],{"intervention":1112,"totalTrials":1156,"cells":8872},{"EARLY_PHASE1":8873,"PHASE1":8875,"PHASE2":8877,"PHASE3":8883,"PHASE4":8885,"NA":8887},{"trials":8874,"activeCount":100},[],{"trials":8876,"activeCount":100},[],{"trials":8878,"activeCount":100},[8879],{"nctId":1104,"briefTitle":1105,"status":139,"phases":8880,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":25,"conditions":8881,"interventions":8882},[90],[673],[1112,1113,82,840,1014,1114],{"trials":8884,"activeCount":100},[],{"trials":8886,"activeCount":100},[],{"trials":8888,"activeCount":100},[],{"intervention":1114,"totalTrials":1156,"cells":8890},{"EARLY_PHASE1":8891,"PHASE1":8893,"PHASE2":8895,"PHASE3":8901,"PHASE4":8903,"NA":8905},{"trials":8892,"activeCount":100},[],{"trials":8894,"activeCount":100},[],{"trials":8896,"activeCount":100},[8897],{"nctId":1104,"briefTitle":1105,"status":139,"phases":8898,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":25,"conditions":8899,"interventions":8900},[90],[673],[1112,1113,82,840,1014,1114],{"trials":8902,"activeCount":100},[],{"trials":8904,"activeCount":100},[],{"trials":8906,"activeCount":100},[],{"intervention":2694,"totalTrials":1156,"cells":8908},{"EARLY_PHASE1":8909,"PHASE1":8911,"PHASE2":8913,"PHASE3":8919,"PHASE4":8921,"NA":8923},{"trials":8910,"activeCount":100},[],{"trials":8912,"activeCount":100},[],{"trials":8914,"activeCount":100},[8915],{"nctId":2685,"briefTitle":2686,"status":139,"phases":8916,"primaryCompletion":2688,"completion":2689,"start":2690,"enrollment":1609,"conditions":8917,"interventions":8918},[90],[2692],[2660,2694],{"trials":8920,"activeCount":100},[],{"trials":8922,"activeCount":100},[],{"trials":8924,"activeCount":100},[],{"intervention":8926,"totalTrials":1156,"cells":8927},"semaxanib",{"EARLY_PHASE1":8928,"PHASE1":8930,"PHASE2":8932,"PHASE3":8943,"PHASE4":8945,"NA":8947},{"trials":8929,"activeCount":100},[],{"trials":8931,"activeCount":100},[],{"trials":8933,"activeCount":100},[8934],{"nctId":8935,"briefTitle":8936,"status":139,"phases":8937,"primaryCompletion":8938,"completion":8939,"start":8940,"conditions":8941,"interventions":8942},"NCT00004868","SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy",[89,90],"2004-09-15","2005-09-15","2000-03-24",[24],[8926],{"trials":8944,"activeCount":100},[],{"trials":8946,"activeCount":100},[],{"trials":8948,"activeCount":100},[],{"intervention":8950,"totalTrials":1156,"cells":8951},"Liposomal Doxorubicin",{"EARLY_PHASE1":8952,"PHASE1":8954,"PHASE2":8956,"PHASE3":8964,"PHASE4":8966,"NA":8968},{"trials":8953,"activeCount":100},[],{"trials":8955,"activeCount":100},[],{"trials":8957,"activeCount":100},[8958],{"nctId":8959,"briefTitle":8960,"status":219,"phases":8961,"primaryCompletion":1076,"completion":1076,"start":2382,"enrollment":733,"conditions":8962,"interventions":8963},"NCT00465673","Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer",[90],[18],[8950],{"trials":8965,"activeCount":100},[],{"trials":8967,"activeCount":100},[],{"trials":8969,"activeCount":100},[],{"intervention":2132,"totalTrials":1156,"cells":8971},{"EARLY_PHASE1":8972,"PHASE1":8974,"PHASE2":8976,"PHASE3":8982,"PHASE4":8984,"NA":8986},{"trials":8973,"activeCount":100},[],{"trials":8975,"activeCount":100},[],{"trials":8977,"activeCount":100},[8978],{"nctId":2123,"briefTitle":2124,"status":219,"phases":8979,"primaryCompletion":2126,"completion":2127,"start":2128,"enrollment":231,"conditions":8980,"interventions":8981},[90],[2130],[58,1892,2132],{"trials":8983,"activeCount":100},[],{"trials":8985,"activeCount":100},[],{"trials":8987,"activeCount":100},[],{"intervention":8989,"totalTrials":1156,"cells":8990},"Bicalutamide plus Finasteride- Combination therapy",{"EARLY_PHASE1":8991,"PHASE1":8993,"PHASE2":8995,"PHASE3":9006,"PHASE4":9008,"NA":9010},{"trials":8992,"activeCount":100},[],{"trials":8994,"activeCount":100},[],{"trials":8996,"activeCount":100},[8997],{"nctId":8998,"briefTitle":8999,"status":416,"phases":9000,"primaryCompletion":9001,"completion":9001,"start":9002,"enrollment":100,"conditions":9003,"interventions":9005},"NCT02146937","A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance",[90],"2015-03","2014-03",[9004],"Detectable Prostate Nodules",[8989],{"trials":9007,"activeCount":100},[],{"trials":9009,"activeCount":100},[],{"trials":9011,"activeCount":100},[],{"intervention":5556,"totalTrials":1156,"cells":9013},{"EARLY_PHASE1":9014,"PHASE1":9016,"PHASE2":9018,"PHASE3":9024,"PHASE4":9026,"NA":9028},{"trials":9015,"activeCount":100},[],{"trials":9017,"activeCount":100},[],{"trials":9019,"activeCount":100},[9020],{"nctId":5550,"briefTitle":5551,"status":139,"phases":9021,"primaryCompletion":5553,"completion":5553,"start":1243,"enrollment":25,"conditions":9022,"interventions":9023},[90],[27],[5556,5557,4936],{"trials":9025,"activeCount":100},[],{"trials":9027,"activeCount":100},[],{"trials":9029,"activeCount":100},[],{"intervention":5557,"totalTrials":1156,"cells":9031},{"EARLY_PHASE1":9032,"PHASE1":9034,"PHASE2":9036,"PHASE3":9042,"PHASE4":9044,"NA":9046},{"trials":9033,"activeCount":100},[],{"trials":9035,"activeCount":100},[],{"trials":9037,"activeCount":100},[9038],{"nctId":5550,"briefTitle":5551,"status":139,"phases":9039,"primaryCompletion":5553,"completion":5553,"start":1243,"enrollment":25,"conditions":9040,"interventions":9041},[90],[27],[5556,5557,4936],{"trials":9043,"activeCount":100},[],{"trials":9045,"activeCount":100},[],{"trials":9047,"activeCount":100},[],{"intervention":7308,"totalTrials":1156,"cells":9049},{"EARLY_PHASE1":9050,"PHASE1":9052,"PHASE2":9054,"PHASE3":9060,"PHASE4":9062,"NA":9064},{"trials":9051,"activeCount":100},[],{"trials":9053,"activeCount":100},[],{"trials":9055,"activeCount":100},[9056],{"nctId":7299,"briefTitle":7300,"status":219,"phases":9057,"primaryCompletion":7302,"completion":7302,"start":7303,"enrollment":7304,"conditions":9058,"interventions":9059},[90],[7306],[7308,2760],{"trials":9061,"activeCount":100},[],{"trials":9063,"activeCount":100},[],{"trials":9065,"activeCount":100},[],{"intervention":9067,"totalTrials":1156,"cells":9068},"aMIL",{"EARLY_PHASE1":9069,"PHASE1":9071,"PHASE2":9073,"PHASE3":9084,"PHASE4":9086,"NA":9088},{"trials":9070,"activeCount":100},[],{"trials":9072,"activeCount":100},[],{"trials":9074,"activeCount":100},[9075],{"nctId":9076,"briefTitle":9077,"status":139,"phases":9078,"primaryCompletion":9079,"completion":9079,"start":535,"enrollment":9080,"conditions":9081,"interventions":9082},"NCT01858558","Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma",[90],"2019-06-19",102,[673],[9067,9083],"No aMIL",{"trials":9085,"activeCount":100},[],{"trials":9087,"activeCount":100},[],{"trials":9089,"activeCount":100},[],{"intervention":9083,"totalTrials":1156,"cells":9091},{"EARLY_PHASE1":9092,"PHASE1":9094,"PHASE2":9096,"PHASE3":9102,"PHASE4":9104,"NA":9106},{"trials":9093,"activeCount":100},[],{"trials":9095,"activeCount":100},[],{"trials":9097,"activeCount":100},[9098],{"nctId":9076,"briefTitle":9077,"status":139,"phases":9099,"primaryCompletion":9079,"completion":9079,"start":535,"enrollment":9080,"conditions":9100,"interventions":9101},[90],[673],[9067,9083],{"trials":9103,"activeCount":100},[],{"trials":9105,"activeCount":100},[],{"trials":9107,"activeCount":100},[],{"intervention":9109,"totalTrials":1156,"cells":9110},"Nivolumab 480mg and surgical resection",{"EARLY_PHASE1":9111,"PHASE1":9113,"PHASE2":9115,"PHASE3":9126,"PHASE4":9128,"NA":9130},{"trials":9112,"activeCount":100},[],{"trials":9114,"activeCount":100},[],{"trials":9116,"activeCount":100},[9117],{"nctId":9118,"briefTitle":9119,"status":139,"phases":9120,"primaryCompletion":9121,"completion":9121,"start":9122,"enrollment":1872,"conditions":9123,"interventions":9125},"NCT03878979","Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent\u002FMetastatic SCCHN",[90],"2023-10-17","2019-07-08",[268,36,9124],"Head and Neck Cancer Metastatic",[9109],{"trials":9127,"activeCount":100},[],{"trials":9129,"activeCount":100},[],{"trials":9131,"activeCount":100},[],{"intervention":1135,"totalTrials":1156,"cells":9133},{"EARLY_PHASE1":9134,"PHASE1":9136,"PHASE2":9138,"PHASE3":9144,"PHASE4":9146,"NA":9148},{"trials":9135,"activeCount":100},[],{"trials":9137,"activeCount":100},[],{"trials":9139,"activeCount":100},[9140],{"nctId":1126,"briefTitle":1127,"status":139,"phases":9141,"primaryCompletion":657,"completion":1129,"start":1130,"enrollment":765,"conditions":9142,"interventions":9143},[90],[27,30],[840,841,82,1133,1134,894,1135,637,1136],{"trials":9145,"activeCount":100},[],{"trials":9147,"activeCount":100},[],{"trials":9149,"activeCount":100},[],{"intervention":2415,"totalTrials":1156,"cells":9151},{"EARLY_PHASE1":9152,"PHASE1":9154,"PHASE2":9156,"PHASE3":9162,"PHASE4":9164,"NA":9166},{"trials":9153,"activeCount":100},[],{"trials":9155,"activeCount":100},[],{"trials":9157,"activeCount":100},[9158],{"nctId":2403,"briefTitle":2404,"status":139,"phases":9159,"primaryCompletion":2406,"completion":2406,"start":2407,"enrollment":1383,"conditions":9160,"interventions":9161},[89,90],[2409,2410,2411,2412,2413],[2415,2276],{"trials":9163,"activeCount":100},[],{"trials":9165,"activeCount":100},[],{"trials":9167,"activeCount":100},[],{"intervention":1161,"totalTrials":1156,"cells":9169},{"EARLY_PHASE1":9170,"PHASE1":9172,"PHASE2":9174,"PHASE3":9180,"PHASE4":9182,"NA":9184},{"trials":9171,"activeCount":100},[],{"trials":9173,"activeCount":100},[],{"trials":9175,"activeCount":100},[9176],{"nctId":1150,"briefTitle":1151,"status":219,"phases":9177,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":9178,"interventions":9179},[89,90],[1158,1159],[82,676,854,677,1161,1162],{"trials":9181,"activeCount":100},[],{"trials":9183,"activeCount":100},[],{"trials":9185,"activeCount":100},[],{"intervention":9187,"totalTrials":1156,"cells":9188},"tipifarnib",{"EARLY_PHASE1":9189,"PHASE1":9191,"PHASE2":9193,"PHASE3":9205,"PHASE4":9207,"NA":9209},{"trials":9190,"activeCount":100},[],{"trials":9192,"activeCount":100},[],{"trials":9194,"activeCount":100},[9195],{"nctId":9196,"briefTitle":9197,"status":139,"phases":9198,"primaryCompletion":9199,"completion":9200,"start":9201,"enrollment":9202,"conditions":9203,"interventions":9204},"NCT00005859","Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma",[89,90],"2005-07-01","2006-08-01","2000-05-16",136,[24],[9187],{"trials":9206,"activeCount":100},[],{"trials":9208,"activeCount":100},[],{"trials":9210,"activeCount":100},[],{"intervention":1178,"totalTrials":1156,"cells":9212},{"EARLY_PHASE1":9213,"PHASE1":9215,"PHASE2":9217,"PHASE3":9223,"PHASE4":9225,"NA":9227},{"trials":9214,"activeCount":100},[],{"trials":9216,"activeCount":100},[],{"trials":9218,"activeCount":100},[9219],{"nctId":1168,"briefTitle":1169,"status":139,"phases":9220,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":384,"conditions":9221,"interventions":9222},[90],[30],[692,883,693,1175,650,1176,704,715,926,1177,1178],{"trials":9224,"activeCount":100},[],{"trials":9226,"activeCount":100},[],{"trials":9228,"activeCount":100},[],{"intervention":6451,"totalTrials":1156,"cells":9230},{"EARLY_PHASE1":9231,"PHASE1":9233,"PHASE2":9235,"PHASE3":9241,"PHASE4":9243,"NA":9245},{"trials":9232,"activeCount":100},[],{"trials":9234,"activeCount":100},[],{"trials":9236,"activeCount":100},[9237],{"nctId":6445,"briefTitle":6446,"status":139,"phases":9238,"primaryCompletion":686,"completion":1269,"start":1192,"conditions":9239,"interventions":9240},[90],[27],[6450,1176,6451,6452,6453,6454],{"trials":9242,"activeCount":100},[],{"trials":9244,"activeCount":100},[],{"trials":9246,"activeCount":100},[],{"intervention":6452,"totalTrials":1156,"cells":9248},{"EARLY_PHASE1":9249,"PHASE1":9251,"PHASE2":9253,"PHASE3":9259,"PHASE4":9261,"NA":9263},{"trials":9250,"activeCount":100},[],{"trials":9252,"activeCount":100},[],{"trials":9254,"activeCount":100},[9255],{"nctId":6445,"briefTitle":6446,"status":139,"phases":9256,"primaryCompletion":686,"completion":1269,"start":1192,"conditions":9257,"interventions":9258},[90],[27],[6450,1176,6451,6452,6453,6454],{"trials":9260,"activeCount":100},[],{"trials":9262,"activeCount":100},[],{"trials":9264,"activeCount":100},[],{"intervention":9266,"totalTrials":1156,"cells":9267},"Cisplatin + Gemcitabine with SUBATM-itraconazole",{"EARLY_PHASE1":9268,"PHASE1":9270,"PHASE2":9272,"PHASE3":9282,"PHASE4":9284,"NA":9286},{"trials":9269,"activeCount":100},[],{"trials":9271,"activeCount":100},[],{"trials":9273,"activeCount":100},[9274],{"nctId":9275,"briefTitle":9276,"status":219,"phases":9277,"primaryCompletion":888,"completion":888,"start":1683,"enrollment":224,"conditions":9278,"interventions":9280},"NCT01752023","A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.",[90],[9279],"Non-small Cell Lung Cancer Metastatic",[9266,9281],"Cisplatin + Gemcitabine",{"trials":9283,"activeCount":100},[],{"trials":9285,"activeCount":100},[],{"trials":9287,"activeCount":100},[],{"intervention":9281,"totalTrials":1156,"cells":9289},{"EARLY_PHASE1":9290,"PHASE1":9292,"PHASE2":9294,"PHASE3":9300,"PHASE4":9302,"NA":9304},{"trials":9291,"activeCount":100},[],{"trials":9293,"activeCount":100},[],{"trials":9295,"activeCount":100},[9296],{"nctId":9275,"briefTitle":9276,"status":219,"phases":9297,"primaryCompletion":888,"completion":888,"start":1683,"enrollment":224,"conditions":9298,"interventions":9299},[90],[9279],[9266,9281],{"trials":9301,"activeCount":100},[],{"trials":9303,"activeCount":100},[],{"trials":9305,"activeCount":100},[],{"intervention":5904,"totalTrials":1156,"cells":9307},{"EARLY_PHASE1":9308,"PHASE1":9310,"PHASE2":9312,"PHASE3":9318,"PHASE4":9320,"NA":9322},{"trials":9309,"activeCount":100},[],{"trials":9311,"activeCount":100},[],{"trials":9313,"activeCount":100},[9314],{"nctId":5896,"briefTitle":5897,"status":219,"phases":9315,"primaryCompletion":5899,"completion":5900,"start":5901,"enrollment":266,"conditions":9316,"interventions":9317},[90],[673],[5904,2941,5905],{"trials":9319,"activeCount":100},[],{"trials":9321,"activeCount":100},[],{"trials":9323,"activeCount":100},[],{"intervention":5905,"totalTrials":1156,"cells":9325},{"EARLY_PHASE1":9326,"PHASE1":9328,"PHASE2":9330,"PHASE3":9336,"PHASE4":9338,"NA":9340},{"trials":9327,"activeCount":100},[],{"trials":9329,"activeCount":100},[],{"trials":9331,"activeCount":100},[9332],{"nctId":5896,"briefTitle":5897,"status":219,"phases":9333,"primaryCompletion":5899,"completion":5900,"start":5901,"enrollment":266,"conditions":9334,"interventions":9335},[90],[673],[5904,2941,5905],{"trials":9337,"activeCount":100},[],{"trials":9339,"activeCount":100},[],{"trials":9341,"activeCount":100},[],{"intervention":2714,"totalTrials":1156,"cells":9343},{"EARLY_PHASE1":9344,"PHASE1":9346,"PHASE2":9348,"PHASE3":9354,"PHASE4":9356,"NA":9358},{"trials":9345,"activeCount":100},[],{"trials":9347,"activeCount":100},[],{"trials":9349,"activeCount":100},[9350],{"nctId":2704,"briefTitle":2705,"status":416,"phases":9351,"primaryCompletion":2707,"completion":2707,"start":2708,"enrollment":100,"conditions":9352,"interventions":9353},[90],[2710,2711,2712],[2714,2660],{"trials":9355,"activeCount":100},[],{"trials":9357,"activeCount":100},[],{"trials":9359,"activeCount":100},[],{"intervention":2070,"totalTrials":1156,"cells":9361},{"EARLY_PHASE1":9362,"PHASE1":9364,"PHASE2":9366,"PHASE3":9372,"PHASE4":9374,"NA":9376},{"trials":9363,"activeCount":100},[],{"trials":9365,"activeCount":100},[],{"trials":9367,"activeCount":100},[9368],{"nctId":2063,"briefTitle":2064,"status":139,"phases":9369,"primaryCompletion":1796,"completion":2066,"start":1449,"enrollment":118,"conditions":9370,"interventions":9371},[90],[2068,292,170],[1892,1136,2070,638],{"trials":9373,"activeCount":100},[],{"trials":9375,"activeCount":100},[],{"trials":9377,"activeCount":100},[],{"intervention":9379,"totalTrials":1156,"cells":9380},"Nivolumab 10 MG\u002FML Intravenous Solution [OPDIVO]",{"EARLY_PHASE1":9381,"PHASE1":9383,"PHASE2":9385,"PHASE3":9396,"PHASE4":9398,"NA":9400},{"trials":9382,"activeCount":100},[],{"trials":9384,"activeCount":100},[],{"trials":9386,"activeCount":100},[9387],{"nctId":9388,"briefTitle":9389,"status":416,"phases":9390,"primaryCompletion":9391,"completion":9392,"start":9391,"enrollment":100,"conditions":9393,"interventions":9395},"NCT04042506","SBRT as a Vaccination for Metastatic Melanoma",[90],"2019-11-26","2021-01-26",[9394],"Metastatic Melanoma",[9379],{"trials":9397,"activeCount":100},[],{"trials":9399,"activeCount":100},[],{"trials":9401,"activeCount":100},[],{"intervention":9403,"totalTrials":1156,"cells":9404},"HIF-2alpha Inhibitor PT2385",{"EARLY_PHASE1":9405,"PHASE1":9407,"PHASE2":9409,"PHASE3":9420,"PHASE4":9422,"NA":9424},{"trials":9406,"activeCount":100},[],{"trials":9408,"activeCount":100},[],{"trials":9410,"activeCount":100},[9411],{"nctId":9412,"briefTitle":9413,"status":139,"phases":9414,"primaryCompletion":9415,"completion":9416,"start":9417,"enrollment":266,"conditions":9418,"interventions":9419},"NCT03216499","HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma",[90],"2019-08-31","2020-06-05","2017-09-14",[2411],[9403],{"trials":9421,"activeCount":100},[],{"trials":9423,"activeCount":100},[],{"trials":9425,"activeCount":100},[],{"intervention":1387,"totalTrials":1156,"cells":9427},{"EARLY_PHASE1":9428,"PHASE1":9430,"PHASE2":9432,"PHASE3":9438,"PHASE4":9440,"NA":9442},{"trials":9429,"activeCount":100},[],{"trials":9431,"activeCount":100},[],{"trials":9433,"activeCount":100},[9434],{"nctId":1377,"briefTitle":1378,"status":139,"phases":9435,"primaryCompletion":1380,"completion":1381,"start":1382,"enrollment":1383,"conditions":9436,"interventions":9437},[90],[779],[1386,1387],{"trials":9439,"activeCount":100},[],{"trials":9441,"activeCount":100},[],{"trials":9443,"activeCount":100},[],{"intervention":5912,"totalTrials":1156,"cells":9445},{"EARLY_PHASE1":9446,"PHASE1":9448,"PHASE2":9450,"PHASE3":9456,"PHASE4":9458,"NA":9460},{"trials":9447,"activeCount":100},[],{"trials":9449,"activeCount":100},[],{"trials":9451,"activeCount":100},[9452],{"nctId":5907,"briefTitle":5908,"status":139,"phases":9453,"primaryCompletion":3283,"completion":2515,"start":3062,"enrollment":439,"conditions":9454,"interventions":9455},[90],[754],[5912,5913],{"trials":9457,"activeCount":100},[],{"trials":9459,"activeCount":100},[],{"trials":9461,"activeCount":100},[],{"intervention":9463,"totalTrials":1156,"cells":9464},"Paclitaxel, Carboplatin and Irinotecan",{"EARLY_PHASE1":9465,"PHASE1":9467,"PHASE2":9469,"PHASE3":9478,"PHASE4":9480,"NA":9482},{"trials":9466,"activeCount":100},[],{"trials":9468,"activeCount":100},[],{"trials":9470,"activeCount":100},[9471],{"nctId":9472,"briefTitle":9473,"status":219,"phases":9474,"primaryCompletion":659,"completion":9475,"start":7721,"enrollment":689,"conditions":9476,"interventions":9477},"NCT00465907","Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer",[90],"2014-02",[1497],[9463],{"trials":9479,"activeCount":100},[],{"trials":9481,"activeCount":100},[],{"trials":9483,"activeCount":100},[],{"intervention":9485,"totalTrials":1156,"cells":9486},"INCMGA00012",{"EARLY_PHASE1":9487,"PHASE1":9489,"PHASE2":9491,"PHASE3":9503,"PHASE4":9505,"NA":9507},{"trials":9488,"activeCount":100},[],{"trials":9490,"activeCount":100},[],{"trials":9492,"activeCount":100},[9493],{"nctId":9494,"briefTitle":9495,"status":139,"phases":9496,"primaryCompletion":9497,"completion":9498,"start":9499,"enrollment":1516,"conditions":9500,"interventions":9502},"NCT04116073","INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer",[90],"2024-08-06","2024-12-03","2020-04-09",[9501,4378],"Pancreatic Cancer Non-resectable",[9485],{"trials":9504,"activeCount":100},[],{"trials":9506,"activeCount":100},[],{"trials":9508,"activeCount":100},[],{"intervention":9510,"totalTrials":1156,"cells":9511},"Venetoclax Oral Tablet [Venclexta]",{"EARLY_PHASE1":9512,"PHASE1":9514,"PHASE2":9516,"PHASE3":9526,"PHASE4":9528,"NA":9530},{"trials":9513,"activeCount":100},[],{"trials":9515,"activeCount":100},[],{"trials":9517,"activeCount":100},[9518],{"nctId":9519,"briefTitle":9520,"status":219,"phases":9521,"primaryCompletion":9522,"completion":9522,"start":9523,"enrollment":689,"conditions":9524,"interventions":9525},"NCT05025423","Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma",[90],"2025-05-14","2022-06-21",[5381],[9510],{"trials":9527,"activeCount":100},[],{"trials":9529,"activeCount":100},[],{"trials":9531,"activeCount":100},[],{"intervention":423,"totalTrials":1156,"cells":9533},{"EARLY_PHASE1":9534,"PHASE1":9536,"PHASE2":9538,"PHASE3":9544,"PHASE4":9546,"NA":9548},{"trials":9535,"activeCount":100},[],{"trials":9537,"activeCount":100},[],{"trials":9539,"activeCount":100},[9540],{"nctId":414,"briefTitle":415,"status":416,"phases":9541,"primaryCompletion":418,"completion":418,"start":419,"enrollment":100,"conditions":9542,"interventions":9543},[90],[421],[63,423],{"trials":9545,"activeCount":100},[],{"trials":9547,"activeCount":100},[],{"trials":9549,"activeCount":100},[],{"intervention":1499,"totalTrials":1156,"cells":9551},{"EARLY_PHASE1":9552,"PHASE1":9554,"PHASE2":9556,"PHASE3":9562,"PHASE4":9564,"NA":9566},{"trials":9553,"activeCount":100},[],{"trials":9555,"activeCount":100},[],{"trials":9557,"activeCount":100},[9558],{"nctId":1491,"briefTitle":1492,"status":139,"phases":9559,"primaryCompletion":1494,"start":1130,"enrollment":1495,"conditions":9560,"interventions":9561},[90],[1497],[43,1499,1500],{"trials":9563,"activeCount":100},[],{"trials":9565,"activeCount":100},[],{"trials":9567,"activeCount":100},[],{"intervention":1521,"totalTrials":1156,"cells":9569},{"EARLY_PHASE1":9570,"PHASE1":9572,"PHASE2":9574,"PHASE3":9580,"PHASE4":9582,"NA":9584},{"trials":9571,"activeCount":100},[],{"trials":9573,"activeCount":100},[],{"trials":9575,"activeCount":100},[9576],{"nctId":1513,"briefTitle":1514,"status":219,"phases":9577,"primaryCompletion":1448,"completion":1448,"start":1183,"enrollment":1516,"conditions":9578,"interventions":9579},[90],[1518,1519],[176,175,1521,1522],{"trials":9581,"activeCount":100},[],{"trials":9583,"activeCount":100},[],{"trials":9585,"activeCount":100},[],{"intervention":1902,"totalTrials":1156,"cells":9587},{"EARLY_PHASE1":9588,"PHASE1":9590,"PHASE2":9592,"PHASE3":9598,"PHASE4":9600,"NA":9602},{"trials":9589,"activeCount":100},[],{"trials":9591,"activeCount":100},[],{"trials":9593,"activeCount":100},[9594],{"nctId":1894,"briefTitle":1895,"status":219,"phases":9595,"primaryCompletion":741,"completion":741,"start":688,"enrollment":1897,"conditions":9596,"interventions":9597},[90],[21],[1900,1875,1901,1902,58,409,1903,1904],{"trials":9599,"activeCount":100},[],{"trials":9601,"activeCount":100},[],{"trials":9603,"activeCount":100},[],{"intervention":1903,"totalTrials":1156,"cells":9605},{"EARLY_PHASE1":9606,"PHASE1":9608,"PHASE2":9610,"PHASE3":9616,"PHASE4":9618,"NA":9620},{"trials":9607,"activeCount":100},[],{"trials":9609,"activeCount":100},[],{"trials":9611,"activeCount":100},[9612],{"nctId":1894,"briefTitle":1895,"status":219,"phases":9613,"primaryCompletion":741,"completion":741,"start":688,"enrollment":1897,"conditions":9614,"interventions":9615},[90],[21],[1900,1875,1901,1902,58,409,1903,1904],{"trials":9617,"activeCount":100},[],{"trials":9619,"activeCount":100},[],{"trials":9621,"activeCount":100},[],{"intervention":9623,"totalTrials":1156,"cells":9624},"Lupron",{"EARLY_PHASE1":9625,"PHASE1":9627,"PHASE2":9629,"PHASE3":9639,"PHASE4":9641,"NA":9643},{"trials":9626,"activeCount":100},[],{"trials":9628,"activeCount":100},[],{"trials":9630,"activeCount":100},[9631],{"nctId":9632,"briefTitle":9633,"status":416,"phases":9634,"primaryCompletion":7418,"completion":9635,"start":2219,"enrollment":100,"conditions":9636,"interventions":9638},"NCT04331717","Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer",[90],"2023-12",[1988,9637],"Obesity, Morbid",[9623],{"trials":9640,"activeCount":100},[],{"trials":9642,"activeCount":100},[],{"trials":9644,"activeCount":100},[],{"intervention":2424,"totalTrials":1156,"cells":9646},{"EARLY_PHASE1":9647,"PHASE1":9649,"PHASE2":9651,"PHASE3":9657,"PHASE4":9659,"NA":9661},{"trials":9648,"activeCount":100},[],{"trials":9650,"activeCount":100},[],{"trials":9652,"activeCount":100},[9653],{"nctId":2417,"briefTitle":2418,"status":139,"phases":9654,"primaryCompletion":1269,"completion":1562,"start":2420,"enrollment":2421,"conditions":9655,"interventions":9656},[89,90],[24],[2424,2265],{"trials":9658,"activeCount":100},[],{"trials":9660,"activeCount":100},[],{"trials":9662,"activeCount":100},[],{"intervention":9664,"totalTrials":1156,"cells":9665},"Vorinostat and Tamoxifen",{"EARLY_PHASE1":9666,"PHASE1":9668,"PHASE2":9670,"PHASE3":9679,"PHASE4":9681,"NA":9683},{"trials":9667,"activeCount":100},[],{"trials":9669,"activeCount":100},[],{"trials":9671,"activeCount":100},[9672],{"nctId":9673,"briefTitle":9674,"status":219,"phases":9675,"primaryCompletion":2079,"completion":2079,"start":1458,"enrollment":733,"conditions":9676,"interventions":9678},"NCT01194427","A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer",[90],[6072,6073,6074,9677],"Invasive Breast Cancer",[9664],{"trials":9680,"activeCount":100},[],{"trials":9682,"activeCount":100},[],{"trials":9684,"activeCount":100},[],{"intervention":2724,"totalTrials":1156,"cells":9686},{"EARLY_PHASE1":9687,"PHASE1":9689,"PHASE2":9691,"PHASE3":9697,"PHASE4":9699,"NA":9701},{"trials":9688,"activeCount":100},[],{"trials":9690,"activeCount":100},[],{"trials":9692,"activeCount":100},[9693],{"nctId":2716,"briefTitle":2717,"status":219,"phases":9694,"primaryCompletion":2719,"completion":2720,"start":2721,"enrollment":361,"conditions":9695,"interventions":9696},[90],[325],[2660,1557,2724],{"trials":9698,"activeCount":100},[],{"trials":9700,"activeCount":100},[],{"trials":9702,"activeCount":100},[],{"intervention":9704,"totalTrials":1156,"cells":9705},"Gemcitabine, nab-Paclitaxel, GDC-0449",{"EARLY_PHASE1":9706,"PHASE1":9708,"PHASE2":9710,"PHASE3":9722,"PHASE4":9724,"NA":9726},{"trials":9707,"activeCount":100},[],{"trials":9709,"activeCount":100},[],{"trials":9711,"activeCount":100},[9712],{"nctId":9713,"briefTitle":9714,"status":139,"phases":9715,"primaryCompletion":9716,"completion":9717,"start":9718,"enrollment":9719,"conditions":9720,"interventions":9721},"NCT01088815","Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas",[90],"2017-12-01","2018-02-17","2010-09-17",98,[497],[9704],{"trials":9723,"activeCount":100},[],{"trials":9725,"activeCount":100},[],{"trials":9727,"activeCount":100},[],{"intervention":9729,"totalTrials":1156,"cells":9730},"Gemcitabine\u002FGemzar",{"EARLY_PHASE1":9731,"PHASE1":9733,"PHASE2":9735,"PHASE3":9743,"PHASE4":9745,"NA":9747},{"trials":9732,"activeCount":100},[],{"trials":9734,"activeCount":100},[],{"trials":9736,"activeCount":100},[9737],{"nctId":9738,"briefTitle":9739,"status":416,"phases":9740,"enrollment":100,"conditions":9741,"interventions":9742},"NCT01045941","Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma",[90],[1837],[9729],{"trials":9744,"activeCount":100},[],{"trials":9746,"activeCount":100},[],{"trials":9748,"activeCount":100},[],{"intervention":1238,"totalTrials":1156,"cells":9750},{"EARLY_PHASE1":9751,"PHASE1":9753,"PHASE2":9755,"PHASE3":9761,"PHASE4":9763,"NA":9765},{"trials":9752,"activeCount":100},[],{"trials":9754,"activeCount":100},[],{"trials":9756,"activeCount":100},[9757],{"nctId":1231,"briefTitle":1232,"status":139,"phases":9758,"primaryCompletion":1234,"completion":1234,"start":1235,"conditions":9759,"interventions":9760},[90],[27],[650,1238],{"trials":9762,"activeCount":100},[],{"trials":9764,"activeCount":100},[],{"trials":9766,"activeCount":100},[],{"intervention":5921,"totalTrials":1156,"cells":9768},{"EARLY_PHASE1":9769,"PHASE1":9771,"PHASE2":9773,"PHASE3":9779,"PHASE4":9781,"NA":9783},{"trials":9770,"activeCount":100},[],{"trials":9772,"activeCount":100},[],{"trials":9774,"activeCount":100},[9775],{"nctId":5915,"briefTitle":5916,"status":139,"phases":9776,"primaryCompletion":5918,"completion":5918,"start":687,"enrollment":34,"conditions":9777,"interventions":9778},[90],[673],[2941,1113,5921],{"trials":9780,"activeCount":100},[],{"trials":9782,"activeCount":100},[],{"trials":9784,"activeCount":100},[],{"intervention":444,"totalTrials":1156,"cells":9786},{"EARLY_PHASE1":9787,"PHASE1":9789,"PHASE2":9791,"PHASE3":9797,"PHASE4":9799,"NA":9801},{"trials":9788,"activeCount":100},[],{"trials":9790,"activeCount":100},[],{"trials":9792,"activeCount":100},[9793],{"nctId":434,"briefTitle":435,"status":139,"phases":9794,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":9795,"interventions":9796},[89,90],[441,442],[63,444,343],{"trials":9798,"activeCount":100},[],{"trials":9800,"activeCount":100},[],{"trials":9802,"activeCount":100},[],{"intervention":9804,"totalTrials":1156,"cells":9805},"Rapamycin 3mg",{"EARLY_PHASE1":9806,"PHASE1":9808,"PHASE2":9810,"PHASE3":9820,"PHASE4":9822,"NA":9824},{"trials":9807,"activeCount":100},[],{"trials":9809,"activeCount":100},[],{"trials":9811,"activeCount":100},[9812],{"nctId":9813,"briefTitle":9814,"status":139,"phases":9815,"primaryCompletion":9816,"completion":5404,"start":903,"enrollment":168,"conditions":9817,"interventions":9818},"NCT00311623","Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer",[89,90],"2008-01",[15],[9804,9819],"Rapamycin 6mg",{"trials":9821,"activeCount":100},[],{"trials":9823,"activeCount":100},[],{"trials":9825,"activeCount":100},[],{"intervention":9819,"totalTrials":1156,"cells":9827},{"EARLY_PHASE1":9828,"PHASE1":9830,"PHASE2":9832,"PHASE3":9838,"PHASE4":9840,"NA":9842},{"trials":9829,"activeCount":100},[],{"trials":9831,"activeCount":100},[],{"trials":9833,"activeCount":100},[9834],{"nctId":9813,"briefTitle":9814,"status":139,"phases":9835,"primaryCompletion":9816,"completion":5404,"start":903,"enrollment":168,"conditions":9836,"interventions":9837},[89,90],[15],[9804,9819],{"trials":9839,"activeCount":100},[],{"trials":9841,"activeCount":100},[],{"trials":9843,"activeCount":100},[],{"intervention":457,"totalTrials":1156,"cells":9845},{"EARLY_PHASE1":9846,"PHASE1":9848,"PHASE2":9850,"PHASE3":9856,"PHASE4":9858,"NA":9860},{"trials":9847,"activeCount":100},[],{"trials":9849,"activeCount":100},[],{"trials":9851,"activeCount":100},[9852],{"nctId":446,"briefTitle":447,"status":139,"phases":9853,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":9854,"interventions":9855},[89,90],[454,455],[457,63],{"trials":9857,"activeCount":100},[],{"trials":9859,"activeCount":100},[],{"trials":9861,"activeCount":100},[],{"intervention":2759,"totalTrials":1156,"cells":9863},{"EARLY_PHASE1":9864,"PHASE1":9866,"PHASE2":9868,"PHASE3":9874,"PHASE4":9876,"NA":9878},{"trials":9865,"activeCount":100},[],{"trials":9867,"activeCount":100},[],{"trials":9869,"activeCount":100},[9870],{"nctId":2752,"briefTitle":2753,"status":139,"phases":9871,"primaryCompletion":42,"completion":2755,"start":2756,"enrollment":1872,"conditions":9872,"interventions":9873},[89,90],[754],[2759,1014,2760],{"trials":9875,"activeCount":100},[],{"trials":9877,"activeCount":100},[],{"trials":9879,"activeCount":100},[],{"intervention":9881,"totalTrials":1156,"cells":9882},"Digoxin",{"EARLY_PHASE1":9883,"PHASE1":9885,"PHASE2":9887,"PHASE3":9896,"PHASE4":9898,"NA":9900},{"trials":9884,"activeCount":100},[],{"trials":9886,"activeCount":100},[],{"trials":9888,"activeCount":100},[9889],{"nctId":9890,"briefTitle":9891,"status":139,"phases":9892,"primaryCompletion":9893,"completion":9893,"start":658,"enrollment":231,"conditions":9894,"interventions":9895},"NCT01763931","DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer",[90],"2016-04-01",[18],[9881],{"trials":9897,"activeCount":100},[],{"trials":9899,"activeCount":100},[],{"trials":9901,"activeCount":100},[],{"intervention":9903,"totalTrials":1156,"cells":9904},"Revlimid",{"EARLY_PHASE1":9905,"PHASE1":9907,"PHASE2":9909,"PHASE3":9919,"PHASE4":9921,"NA":9923},{"trials":9906,"activeCount":100},[],{"trials":9908,"activeCount":100},[],{"trials":9910,"activeCount":100},[9911],{"nctId":9912,"briefTitle":9913,"status":139,"phases":9914,"primaryCompletion":9915,"completion":9915,"start":2356,"enrollment":9916,"conditions":9917,"interventions":9918},"NCT00348595","Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer",[89,90],"2016-06-29",77,[15],[9903],{"trials":9920,"activeCount":100},[],{"trials":9922,"activeCount":100},[],{"trials":9924,"activeCount":100},[],{"intervention":2153,"totalTrials":1156,"cells":9926},{"EARLY_PHASE1":9927,"PHASE1":9929,"PHASE2":9931,"PHASE3":9937,"PHASE4":9939,"NA":9941},{"trials":9928,"activeCount":100},[],{"trials":9930,"activeCount":100},[],{"trials":9932,"activeCount":100},[9933],{"nctId":2146,"briefTitle":2147,"status":219,"phases":9934,"primaryCompletion":2149,"completion":2149,"start":2150,"enrollment":765,"conditions":9935,"interventions":9936},[89,90],[442],[2153,58,2154,2155,2156],{"trials":9938,"activeCount":100},[],{"trials":9940,"activeCount":100},[],{"trials":9942,"activeCount":100},[],{"intervention":2155,"totalTrials":1156,"cells":9944},{"EARLY_PHASE1":9945,"PHASE1":9947,"PHASE2":9949,"PHASE3":9955,"PHASE4":9957,"NA":9959},{"trials":9946,"activeCount":100},[],{"trials":9948,"activeCount":100},[],{"trials":9950,"activeCount":100},[9951],{"nctId":2146,"briefTitle":2147,"status":219,"phases":9952,"primaryCompletion":2149,"completion":2149,"start":2150,"enrollment":765,"conditions":9953,"interventions":9954},[89,90],[442],[2153,58,2154,2155,2156],{"trials":9956,"activeCount":100},[],{"trials":9958,"activeCount":100},[],{"trials":9960,"activeCount":100},[],{"intervention":2156,"totalTrials":1156,"cells":9962},{"EARLY_PHASE1":9963,"PHASE1":9965,"PHASE2":9967,"PHASE3":9973,"PHASE4":9975,"NA":9977},{"trials":9964,"activeCount":100},[],{"trials":9966,"activeCount":100},[],{"trials":9968,"activeCount":100},[9969],{"nctId":2146,"briefTitle":2147,"status":219,"phases":9970,"primaryCompletion":2149,"completion":2149,"start":2150,"enrollment":765,"conditions":9971,"interventions":9972},[89,90],[442],[2153,58,2154,2155,2156],{"trials":9974,"activeCount":100},[],{"trials":9976,"activeCount":100},[],{"trials":9978,"activeCount":100},[],{"intervention":9980,"totalTrials":1156,"cells":9981},"Broccoli sprout extract",{"EARLY_PHASE1":9982,"PHASE1":9984,"PHASE2":9986,"PHASE3":9995,"PHASE4":9997,"NA":9999},{"trials":9983,"activeCount":100},[],{"trials":9985,"activeCount":100},[],{"trials":9987,"activeCount":100},[9988],{"nctId":9989,"briefTitle":9990,"status":139,"phases":9991,"primaryCompletion":563,"completion":563,"start":3283,"enrollment":96,"conditions":9992,"interventions":9993},"NCT00982319","Study to Evaluate the Effect of Sulforaphane in Broccoli Sprout Extract on Breast Tissue",[90],[18],[9980,9994],"Mango juice",{"trials":9996,"activeCount":100},[],{"trials":9998,"activeCount":100},[],{"trials":10000,"activeCount":100},[],{"intervention":9994,"totalTrials":1156,"cells":10002},{"EARLY_PHASE1":10003,"PHASE1":10005,"PHASE2":10007,"PHASE3":10013,"PHASE4":10015,"NA":10017},{"trials":10004,"activeCount":100},[],{"trials":10006,"activeCount":100},[],{"trials":10008,"activeCount":100},[10009],{"nctId":9989,"briefTitle":9990,"status":139,"phases":10010,"primaryCompletion":563,"completion":563,"start":3283,"enrollment":96,"conditions":10011,"interventions":10012},[90],[18],[9980,9994],{"trials":10014,"activeCount":100},[],{"trials":10016,"activeCount":100},[],{"trials":10018,"activeCount":100},[],{"intervention":4915,"totalTrials":224,"cells":10020},{"EARLY_PHASE1":10021,"PHASE1":10023,"PHASE2":10037,"PHASE3":10039,"PHASE4":10041,"NA":10043},{"trials":10022,"activeCount":100},[],{"trials":10024,"activeCount":100},[10025,10029,10033],{"nctId":4907,"briefTitle":4908,"status":139,"phases":10026,"primaryCompletion":1130,"completion":1130,"start":4910,"enrollment":96,"conditions":10027,"interventions":10028},[89],[30,4912,4913],[328,4915],{"nctId":6833,"briefTitle":6834,"status":139,"phases":10030,"primaryCompletion":5544,"completion":6836,"start":6837,"conditions":10031,"interventions":10032},[89],[27,33,711],[4915,6454],{"nctId":4917,"briefTitle":4918,"status":139,"phases":10034,"start":4920,"conditions":10035,"interventions":10036},[89],[27,33,711],[4923,4915],{"trials":10038,"activeCount":100},[],{"trials":10040,"activeCount":100},[],{"trials":10042,"activeCount":100},[],{"trials":10044,"activeCount":100},[],{"intervention":7424,"totalTrials":733,"cells":10046},{"EARLY_PHASE1":10047,"PHASE1":10049,"PHASE2":10067,"PHASE3":10069,"PHASE4":10071,"NA":10073},{"trials":10048,"activeCount":100},[],{"trials":10050,"activeCount":100},[10051,10063],{"nctId":10052,"briefTitle":10053,"status":139,"phases":10054,"primaryCompletion":1382,"completion":1382,"start":8233,"enrollment":10055,"conditions":10056,"interventions":10059},"NCT00988559","Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2\u002F3)",[89],132,[10057,10058],"HPV16 Positive","Cervical Intraepithelial Neoplasia (CIN 2\u002F3)",[10060,10061,10062,7424],"DNA vaccination","intramuscular vaccination","intra-lesional vaccine administration",{"nctId":7415,"briefTitle":7416,"status":139,"phases":10064,"primaryCompletion":7418,"completion":7418,"start":5634,"enrollment":3853,"conditions":10065,"interventions":10066},[89],[4716,5598,7420,7421],[7423,7408,7424],{"trials":10068,"activeCount":100},[],{"trials":10070,"activeCount":100},[],{"trials":10072,"activeCount":100},[],{"trials":10074,"activeCount":100},[],{"intervention":5627,"totalTrials":733,"cells":10076},{"EARLY_PHASE1":10077,"PHASE1":10079,"PHASE2":10092,"PHASE3":10094,"PHASE4":10096,"NA":10098},{"trials":10078,"activeCount":100},[],{"trials":10080,"activeCount":100},[10081,10085],{"nctId":5621,"briefTitle":5622,"status":139,"phases":10082,"primaryCompletion":5624,"start":5536,"enrollment":313,"conditions":10083,"interventions":10084},[89],[4913],[5627,2297],{"nctId":10086,"briefTitle":10087,"status":139,"phases":10088,"start":10089,"conditions":10090,"interventions":10091},"NCT00003289","UCN-01 in Treating Patients With Advanced Cancer",[89],"1998-06",[27,30,4913],[5627],{"trials":10093,"activeCount":100},[],{"trials":10095,"activeCount":100},[],{"trials":10097,"activeCount":100},[],{"trials":10099,"activeCount":100},[],{"intervention":747,"totalTrials":733,"cells":10101},{"EARLY_PHASE1":10102,"PHASE1":10104,"PHASE2":10114,"PHASE3":10116,"PHASE4":10118,"NA":10120},{"trials":10103,"activeCount":100},[],{"trials":10105,"activeCount":100},[10106,10110],{"nctId":738,"briefTitle":739,"status":139,"phases":10107,"primaryCompletion":741,"start":742,"enrollment":743,"conditions":10108,"interventions":10109},[89],[745,27,711],[747,650],{"nctId":772,"briefTitle":773,"status":219,"phases":10111,"primaryCompletion":775,"completion":775,"start":776,"enrollment":28,"conditions":10112,"interventions":10113},[89],[778,779,780,781,782,783,784,785,786,787],[789,82],{"trials":10115,"activeCount":100},[],{"trials":10117,"activeCount":100},[],{"trials":10119,"activeCount":100},[],{"trials":10121,"activeCount":100},[],{"intervention":10123,"totalTrials":733,"cells":10124},"motexafin gadolinium",{"EARLY_PHASE1":10125,"PHASE1":10127,"PHASE2":10145,"PHASE3":10147,"PHASE4":10149,"NA":10151},{"trials":10126,"activeCount":100},[],{"trials":10128,"activeCount":100},[10129,10136],{"nctId":10130,"briefTitle":10131,"status":139,"phases":10132,"start":10133,"enrollment":241,"conditions":10134,"interventions":10135},"NCT00003798","Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery",[89],"2000-04",[21],[10123],{"nctId":10137,"briefTitle":10138,"status":139,"phases":10139,"primaryCompletion":10140,"completion":10141,"start":10142,"enrollment":231,"conditions":10143,"interventions":10144},"NCT00006452","Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme",[89],"2003-05-09","2004-03-16","2002-04-10",[24],[10123],{"trials":10146,"activeCount":100},[],{"trials":10148,"activeCount":100},[],{"trials":10150,"activeCount":100},[],{"trials":10152,"activeCount":100},[],{"intervention":10154,"totalTrials":733,"cells":10155},"Mebendazole",{"EARLY_PHASE1":10156,"PHASE1":10158,"PHASE2":10182,"PHASE3":10184,"PHASE4":10186,"NA":10188},{"trials":10157,"activeCount":100},[],{"trials":10159,"activeCount":100},[10160,10169],{"nctId":10161,"briefTitle":10162,"status":139,"phases":10163,"primaryCompletion":534,"completion":10164,"start":10165,"enrollment":266,"conditions":10166,"interventions":10168},"NCT01729260","Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide",[89],"2021-04-16","2013-04-04",[10167],"Newly Diagnosed High-Grade Glioma",[10154],{"nctId":10170,"briefTitle":10171,"status":139,"phases":10172,"primaryCompletion":10173,"completion":10173,"start":10174,"enrollment":37,"conditions":10175,"interventions":10181},"NCT02644291","Phase I Study of Mebendazole Therapy for Recurrent\u002FProgressive Pediatric Brain Tumors",[89],"2022-06-09","2016-05",[634,10176,226,7773,10177,10178,10179,10180],"Astrocytoma, Grade III","Brain Stem Neoplasms, Malignant","Oligodendroblastoma","Anaplastic Oligodendroglioma","Malignant Glioma",[10154],{"trials":10183,"activeCount":100},[],{"trials":10185,"activeCount":100},[],{"trials":10187,"activeCount":100},[],{"trials":10189,"activeCount":100},[],{"intervention":5664,"totalTrials":1156,"cells":10191},{"EARLY_PHASE1":10192,"PHASE1":10194,"PHASE2":10200,"PHASE3":10202,"PHASE4":10204,"NA":10206},{"trials":10193,"activeCount":100},[],{"trials":10195,"activeCount":100},[10196],{"nctId":5659,"briefTitle":5660,"status":139,"phases":10197,"start":699,"conditions":10198,"interventions":10199},[89],[27,33,711],[756,5664],{"trials":10201,"activeCount":100},[],{"trials":10203,"activeCount":100},[],{"trials":10205,"activeCount":100},[],{"trials":10207,"activeCount":100},[],{"intervention":10209,"totalTrials":1156,"cells":10210},"RIC alloBMT w PTCy in refractory SSc",{"EARLY_PHASE1":10211,"PHASE1":10213,"PHASE2":10225,"PHASE3":10227,"PHASE4":10229,"NA":10231},{"trials":10212,"activeCount":100},[],{"trials":10214,"activeCount":100},[10215],{"nctId":10216,"briefTitle":10217,"status":219,"phases":10218,"primaryCompletion":10219,"completion":10220,"start":10221,"enrollment":1156,"conditions":10222,"interventions":10224},"NCT05298358","RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis",[89],"2024-11-13","2024-11-21","2022-11-18",[10223],"Systemic Sclerosis",[10209],{"trials":10226,"activeCount":100},[],{"trials":10228,"activeCount":100},[],{"trials":10230,"activeCount":100},[],{"trials":10232,"activeCount":100},[],{"intervention":5947,"totalTrials":1156,"cells":10234},{"EARLY_PHASE1":10235,"PHASE1":10237,"PHASE2":10243,"PHASE3":10245,"PHASE4":10247,"NA":10249},{"trials":10236,"activeCount":100},[],{"trials":10238,"activeCount":100},[10239],{"nctId":5940,"briefTitle":5941,"status":139,"phases":10240,"primaryCompletion":5943,"completion":5943,"start":5944,"enrollment":118,"conditions":10241,"interventions":10242},[89],[120],[5947,5948,5933],{"trials":10244,"activeCount":100},[],{"trials":10246,"activeCount":100},[],{"trials":10248,"activeCount":100},[],{"trials":10250,"activeCount":100},[],{"intervention":5948,"totalTrials":1156,"cells":10252},{"EARLY_PHASE1":10253,"PHASE1":10255,"PHASE2":10261,"PHASE3":10263,"PHASE4":10265,"NA":10267},{"trials":10254,"activeCount":100},[],{"trials":10256,"activeCount":100},[10257],{"nctId":5940,"briefTitle":5941,"status":139,"phases":10258,"primaryCompletion":5943,"completion":5943,"start":5944,"enrollment":118,"conditions":10259,"interventions":10260},[89],[120],[5947,5948,5933],{"trials":10262,"activeCount":100},[],{"trials":10264,"activeCount":100},[],{"trials":10266,"activeCount":100},[],{"trials":10268,"activeCount":100},[],{"intervention":521,"totalTrials":1156,"cells":10270},{"EARLY_PHASE1":10271,"PHASE1":10273,"PHASE2":10279,"PHASE3":10281,"PHASE4":10283,"NA":10285},{"trials":10272,"activeCount":100},[],{"trials":10274,"activeCount":100},[10275],{"nctId":514,"briefTitle":515,"status":139,"phases":10276,"primaryCompletion":517,"completion":517,"start":518,"enrollment":313,"conditions":10277,"interventions":10278},[89],[21],[123,521],{"trials":10280,"activeCount":100},[],{"trials":10282,"activeCount":100},[],{"trials":10284,"activeCount":100},[],{"trials":10286,"activeCount":100},[],{"intervention":10288,"totalTrials":1156,"cells":10289},"IRX5183",{"EARLY_PHASE1":10290,"PHASE1":10292,"PHASE2":10304,"PHASE3":10306,"PHASE4":10308,"NA":10310},{"trials":10291,"activeCount":100},[],{"trials":10293,"activeCount":100},[10294],{"nctId":10295,"briefTitle":10296,"status":219,"phases":10297,"primaryCompletion":10298,"completion":10298,"start":10299,"enrollment":212,"conditions":10300,"interventions":10303},"NCT02749708","Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome",[89],"2018-08-14","2017-01-30",[5015,10301,10302],"Myelodysplastic Syndrome (MDS)","Chronic Myelomonocytic Leukemia (CMML)",[10288],{"trials":10305,"activeCount":100},[],{"trials":10307,"activeCount":100},[],{"trials":10309,"activeCount":100},[],{"trials":10311,"activeCount":100},[],{"intervention":2305,"totalTrials":1156,"cells":10313},{"EARLY_PHASE1":10314,"PHASE1":10316,"PHASE2":10322,"PHASE3":10324,"PHASE4":10326,"NA":10328},{"trials":10315,"activeCount":100},[],{"trials":10317,"activeCount":100},[10318],{"nctId":2299,"briefTitle":2300,"status":139,"phases":10319,"primaryCompletion":2046,"start":2302,"enrollment":1280,"conditions":10320,"interventions":10321},[89],[24],[2305,2265,2306,2307,2308],{"trials":10323,"activeCount":100},[],{"trials":10325,"activeCount":100},[],{"trials":10327,"activeCount":100},[],{"trials":10329,"activeCount":100},[],{"intervention":10331,"totalTrials":1156,"cells":10332},"NT-I7",{"EARLY_PHASE1":10333,"PHASE1":10335,"PHASE2":10346,"PHASE3":10348,"PHASE4":10350,"NA":10352},{"trials":10334,"activeCount":100},[],{"trials":10336,"activeCount":100},[10337],{"nctId":10338,"briefTitle":10339,"status":219,"phases":10340,"primaryCompletion":10341,"completion":10342,"start":5132,"enrollment":969,"conditions":10343,"interventions":10345},"NCT02659800","Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas",[89],"2022-03-30","2023-10-03",[10344,10180],"Lymphopenia",[10331],{"trials":10347,"activeCount":100},[],{"trials":10349,"activeCount":100},[],{"trials":10351,"activeCount":100},[],{"trials":10353,"activeCount":100},[],{"intervention":6635,"totalTrials":1156,"cells":10355},{"EARLY_PHASE1":10356,"PHASE1":10358,"PHASE2":10364,"PHASE3":10366,"PHASE4":10368,"NA":10370},{"trials":10357,"activeCount":100},[],{"trials":10359,"activeCount":100},[10360],{"nctId":6625,"briefTitle":6626,"status":219,"phases":10361,"primaryCompletion":6628,"completion":6628,"start":6629,"enrollment":231,"conditions":10362,"interventions":10363},[89],[6631,6632,6633],[6635,6618],{"trials":10365,"activeCount":100},[],{"trials":10367,"activeCount":100},[],{"trials":10369,"activeCount":100},[],{"trials":10371,"activeCount":100},[],{"intervention":10373,"totalTrials":1156,"cells":10374},"benzoylphenylurea",{"EARLY_PHASE1":10375,"PHASE1":10377,"PHASE2":10386,"PHASE3":10388,"PHASE4":10390,"NA":10392},{"trials":10376,"activeCount":100},[],{"trials":10378,"activeCount":100},[10379],{"nctId":10380,"briefTitle":10381,"status":139,"phases":10382,"primaryCompletion":2047,"completion":1243,"start":10383,"enrollment":34,"conditions":10384,"interventions":10385},"NCT00016354","Benzoylphenylurea in Treating Patients With Advanced Solid Tumors",[89],"2001-03",[4913],[10373],{"trials":10387,"activeCount":100},[],{"trials":10389,"activeCount":100},[],{"trials":10391,"activeCount":100},[],{"trials":10393,"activeCount":100},[],{"intervention":10395,"totalTrials":1156,"cells":10396},"Flotetuzumab",{"EARLY_PHASE1":10397,"PHASE1":10399,"PHASE2":10410,"PHASE3":10412,"PHASE4":10414,"NA":10416},{"trials":10398,"activeCount":100},[],{"trials":10400,"activeCount":100},[10401],{"nctId":10402,"briefTitle":10403,"status":139,"phases":10404,"primaryCompletion":10405,"completion":10405,"start":10406,"enrollment":224,"conditions":10407,"interventions":10409},"NCT05506956","Post-transplant Flotetuzumab for AML",[89],"2024-06-18","2022-10-20",[10408],"Leukemia, Myeloid, Acute",[10395],{"trials":10411,"activeCount":100},[],{"trials":10413,"activeCount":100},[],{"trials":10415,"activeCount":100},[],{"trials":10417,"activeCount":100},[],{"intervention":663,"totalTrials":1156,"cells":10419},{"EARLY_PHASE1":10420,"PHASE1":10422,"PHASE2":10428,"PHASE3":10430,"PHASE4":10432,"NA":10434},{"trials":10421,"activeCount":100},[],{"trials":10423,"activeCount":100},[10424],{"nctId":654,"briefTitle":655,"status":139,"phases":10425,"primaryCompletion":657,"completion":658,"start":659,"enrollment":361,"conditions":10426,"interventions":10427},[89],[120,661],[663,650],{"trials":10429,"activeCount":100},[],{"trials":10431,"activeCount":100},[],{"trials":10433,"activeCount":100},[],{"trials":10435,"activeCount":100},[],{"intervention":10060,"totalTrials":1156,"cells":10437},{"EARLY_PHASE1":10438,"PHASE1":10440,"PHASE2":10446,"PHASE3":10448,"PHASE4":10450,"NA":10452},{"trials":10439,"activeCount":100},[],{"trials":10441,"activeCount":100},[10442],{"nctId":10052,"briefTitle":10053,"status":139,"phases":10443,"primaryCompletion":1382,"completion":1382,"start":8233,"enrollment":10055,"conditions":10444,"interventions":10445},[89],[10057,10058],[10060,10061,10062,7424],{"trials":10447,"activeCount":100},[],{"trials":10449,"activeCount":100},[],{"trials":10451,"activeCount":100},[],{"trials":10453,"activeCount":100},[],{"intervention":10061,"totalTrials":1156,"cells":10455},{"EARLY_PHASE1":10456,"PHASE1":10458,"PHASE2":10464,"PHASE3":10466,"PHASE4":10468,"NA":10470},{"trials":10457,"activeCount":100},[],{"trials":10459,"activeCount":100},[10460],{"nctId":10052,"briefTitle":10053,"status":139,"phases":10461,"primaryCompletion":1382,"completion":1382,"start":8233,"enrollment":10055,"conditions":10462,"interventions":10463},[89],[10057,10058],[10060,10061,10062,7424],{"trials":10465,"activeCount":100},[],{"trials":10467,"activeCount":100},[],{"trials":10469,"activeCount":100},[],{"trials":10471,"activeCount":100},[],{"intervention":10062,"totalTrials":1156,"cells":10473},{"EARLY_PHASE1":10474,"PHASE1":10476,"PHASE2":10482,"PHASE3":10484,"PHASE4":10486,"NA":10488},{"trials":10475,"activeCount":100},[],{"trials":10477,"activeCount":100},[10478],{"nctId":10052,"briefTitle":10053,"status":139,"phases":10479,"primaryCompletion":1382,"completion":1382,"start":8233,"enrollment":10055,"conditions":10480,"interventions":10481},[89],[10057,10058],[10060,10061,10062,7424],{"trials":10483,"activeCount":100},[],{"trials":10485,"activeCount":100},[],{"trials":10487,"activeCount":100},[],{"trials":10489,"activeCount":100},[],{"intervention":678,"totalTrials":1156,"cells":10491},{"EARLY_PHASE1":10492,"PHASE1":10494,"PHASE2":10500,"PHASE3":10502,"PHASE4":10504,"NA":10506},{"trials":10493,"activeCount":100},[],{"trials":10495,"activeCount":100},[10496],{"nctId":665,"briefTitle":666,"status":139,"phases":10497,"primaryCompletion":668,"completion":668,"start":657,"enrollment":669,"conditions":10498,"interventions":10499},[89],[671,27,672,673,674],[82,676,677,678,679,680,681],{"trials":10501,"activeCount":100},[],{"trials":10503,"activeCount":100},[],{"trials":10505,"activeCount":100},[],{"trials":10507,"activeCount":100},[],{"intervention":679,"totalTrials":1156,"cells":10509},{"EARLY_PHASE1":10510,"PHASE1":10512,"PHASE2":10518,"PHASE3":10520,"PHASE4":10522,"NA":10524},{"trials":10511,"activeCount":100},[],{"trials":10513,"activeCount":100},[10514],{"nctId":665,"briefTitle":666,"status":139,"phases":10515,"primaryCompletion":668,"completion":668,"start":657,"enrollment":669,"conditions":10516,"interventions":10517},[89],[671,27,672,673,674],[82,676,677,678,679,680,681],{"trials":10519,"activeCount":100},[],{"trials":10521,"activeCount":100},[],{"trials":10523,"activeCount":100},[],{"trials":10525,"activeCount":100},[],{"intervention":680,"totalTrials":1156,"cells":10527},{"EARLY_PHASE1":10528,"PHASE1":10530,"PHASE2":10536,"PHASE3":10538,"PHASE4":10540,"NA":10542},{"trials":10529,"activeCount":100},[],{"trials":10531,"activeCount":100},[10532],{"nctId":665,"briefTitle":666,"status":139,"phases":10533,"primaryCompletion":668,"completion":668,"start":657,"enrollment":669,"conditions":10534,"interventions":10535},[89],[671,27,672,673,674],[82,676,677,678,679,680,681],{"trials":10537,"activeCount":100},[],{"trials":10539,"activeCount":100},[],{"trials":10541,"activeCount":100},[],{"trials":10543,"activeCount":100},[],{"intervention":681,"totalTrials":1156,"cells":10545},{"EARLY_PHASE1":10546,"PHASE1":10548,"PHASE2":10554,"PHASE3":10556,"PHASE4":10558,"NA":10560},{"trials":10547,"activeCount":100},[],{"trials":10549,"activeCount":100},[10550],{"nctId":665,"briefTitle":666,"status":139,"phases":10551,"primaryCompletion":668,"completion":668,"start":657,"enrollment":669,"conditions":10552,"interventions":10553},[89],[671,27,672,673,674],[82,676,677,678,679,680,681],{"trials":10555,"activeCount":100},[],{"trials":10557,"activeCount":100},[],{"trials":10559,"activeCount":100},[],{"trials":10561,"activeCount":100},[],{"intervention":10563,"totalTrials":1156,"cells":10564},"Ad5CMV-p53 gene",{"EARLY_PHASE1":10565,"PHASE1":10567,"PHASE2":10578,"PHASE3":10580,"PHASE4":10582,"NA":10584},{"trials":10566,"activeCount":100},[],{"trials":10568,"activeCount":100},[10569],{"nctId":10570,"briefTitle":10571,"status":139,"phases":10572,"primaryCompletion":10573,"completion":10574,"start":10575,"conditions":10576,"interventions":10577},"NCT00004041","Gene Therapy in Treating Patients With Recurrent Malignant Gliomas",[89],"2002-07-22","2003-07-01","1999-02-25",[24],[10563],{"trials":10579,"activeCount":100},[],{"trials":10581,"activeCount":100},[],{"trials":10583,"activeCount":100},[],{"trials":10585,"activeCount":100},[],{"intervention":10587,"totalTrials":1156,"cells":10588},"LDE225",{"EARLY_PHASE1":10589,"PHASE1":10591,"PHASE2":10600,"PHASE3":10602,"PHASE4":10604,"NA":10606},{"trials":10590,"activeCount":100},[],{"trials":10592,"activeCount":100},[10593],{"nctId":10594,"briefTitle":10595,"status":139,"phases":10596,"primaryCompletion":10597,"completion":10597,"start":888,"enrollment":723,"conditions":10598,"interventions":10599},"NCT02111187","A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer",[89],"2017-01-18",[15],[10587],{"trials":10601,"activeCount":100},[],{"trials":10603,"activeCount":100},[],{"trials":10605,"activeCount":100},[],{"trials":10607,"activeCount":100},[],{"intervention":10609,"totalTrials":1156,"cells":10610},"Inactivated EBV-infected vaccine",{"EARLY_PHASE1":10611,"PHASE1":10613,"PHASE2":10624,"PHASE3":10626,"PHASE4":10628,"NA":10630},{"trials":10612,"activeCount":100},[],{"trials":10614,"activeCount":100},[10615],{"nctId":10616,"briefTitle":10617,"status":219,"phases":10618,"primaryCompletion":10619,"completion":10619,"start":10620,"enrollment":765,"conditions":10621,"interventions":10623},"NCT00278200","Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD",[89],"2012-08","2003-01",[10622],"Lymphoproliferative Disorder",[10609],{"trials":10625,"activeCount":100},[],{"trials":10627,"activeCount":100},[],{"trials":10629,"activeCount":100},[],{"trials":10631,"activeCount":100},[],{"intervention":10633,"totalTrials":1156,"cells":10634},"Red blood cell transfusion",{"EARLY_PHASE1":10635,"PHASE1":10637,"PHASE2":10648,"PHASE3":10650,"PHASE4":10652,"NA":10654},{"trials":10636,"activeCount":100},[],{"trials":10638,"activeCount":100},[10639],{"nctId":10640,"briefTitle":10641,"status":139,"phases":10642,"primaryCompletion":1984,"completion":1984,"start":888,"enrollment":5281,"conditions":10643,"interventions":10647},"NCT02086773","Red Cell Transfusion Goals in Patients With Acute Leukemias",[89],[2917,10644,10645,10646],"Acute Lymphocytic Leukemia (ALL)","Acute Myelogenous Leukemia (AML)","Acute Promyelocytic Leukemia (APL)",[10633],{"trials":10649,"activeCount":100},[],{"trials":10651,"activeCount":100},[],{"trials":10653,"activeCount":100},[],{"trials":10655,"activeCount":100},[],{"intervention":3040,"totalTrials":1156,"cells":10657},{"EARLY_PHASE1":10658,"PHASE1":10660,"PHASE2":10666,"PHASE3":10668,"PHASE4":10670,"NA":10672},{"trials":10659,"activeCount":100},[],{"trials":10661,"activeCount":100},[10662],{"nctId":3034,"briefTitle":3035,"status":219,"phases":10663,"primaryCompletion":3037,"completion":3037,"start":1382,"enrollment":224,"conditions":10664,"interventions":10665},[89],[15],[3040,1892,3041],{"trials":10667,"activeCount":100},[],{"trials":10669,"activeCount":100},[],{"trials":10671,"activeCount":100},[],{"trials":10673,"activeCount":100},[],{"intervention":3041,"totalTrials":1156,"cells":10675},{"EARLY_PHASE1":10676,"PHASE1":10678,"PHASE2":10684,"PHASE3":10686,"PHASE4":10688,"NA":10690},{"trials":10677,"activeCount":100},[],{"trials":10679,"activeCount":100},[10680],{"nctId":3034,"briefTitle":3035,"status":219,"phases":10681,"primaryCompletion":3037,"completion":3037,"start":1382,"enrollment":224,"conditions":10682,"interventions":10683},[89],[15],[3040,1892,3041],{"trials":10685,"activeCount":100},[],{"trials":10687,"activeCount":100},[],{"trials":10689,"activeCount":100},[],{"trials":10691,"activeCount":100},[],{"intervention":716,"totalTrials":1156,"cells":10693},{"EARLY_PHASE1":10694,"PHASE1":10696,"PHASE2":10702,"PHASE3":10704,"PHASE4":10706,"NA":10708},{"trials":10695,"activeCount":100},[],{"trials":10697,"activeCount":100},[10698],{"nctId":706,"briefTitle":707,"status":139,"phases":10699,"start":709,"conditions":10700,"interventions":10701},[89],[27,30,33,711],[713,692,714,650,715,716],{"trials":10703,"activeCount":100},[],{"trials":10705,"activeCount":100},[],{"trials":10707,"activeCount":100},[],{"trials":10709,"activeCount":100},[],{"intervention":726,"totalTrials":1156,"cells":10711},{"EARLY_PHASE1":10712,"PHASE1":10714,"PHASE2":10720,"PHASE3":10722,"PHASE4":10724,"NA":10726},{"trials":10713,"activeCount":100},[],{"trials":10715,"activeCount":100},[10716],{"nctId":718,"briefTitle":719,"status":219,"phases":10717,"primaryCompletion":721,"completion":721,"start":722,"enrollment":723,"conditions":10718,"interventions":10719},[89],[27,33],[82,726],{"trials":10721,"activeCount":100},[],{"trials":10723,"activeCount":100},[],{"trials":10725,"activeCount":100},[],{"trials":10727,"activeCount":100},[],{"intervention":160,"totalTrials":1156,"cells":10729},{"EARLY_PHASE1":10730,"PHASE1":10732,"PHASE2":10738,"PHASE3":10740,"PHASE4":10742,"NA":10744},{"trials":10731,"activeCount":100},[],{"trials":10733,"activeCount":100},[10734],{"nctId":150,"briefTitle":151,"status":139,"phases":10735,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":10736,"interventions":10737},[89],[158],[160,63],{"trials":10739,"activeCount":100},[],{"trials":10741,"activeCount":100},[],{"trials":10743,"activeCount":100},[],{"trials":10745,"activeCount":100},[],{"intervention":10747,"totalTrials":1156,"cells":10748},"HPV 16 TA-CIN",{"EARLY_PHASE1":10749,"PHASE1":10751,"PHASE2":10762,"PHASE3":10764,"PHASE4":10766,"NA":10768},{"trials":10750,"activeCount":100},[],{"trials":10752,"activeCount":100},[10753],{"nctId":10754,"briefTitle":10755,"status":416,"phases":10756,"primaryCompletion":10757,"completion":10757,"start":10758,"enrollment":100,"conditions":10759,"interventions":10761},"NCT05132803","TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers",[89],"2022-01-18","2021-08",[10760],"Recurrent Human Papillomavirus Type 16 Associated Cancer",[10747],{"trials":10763,"activeCount":100},[],{"trials":10765,"activeCount":100},[],{"trials":10767,"activeCount":100},[],{"trials":10769,"activeCount":100},[],{"intervention":736,"totalTrials":1156,"cells":10771},{"EARLY_PHASE1":10772,"PHASE1":10774,"PHASE2":10780,"PHASE3":10782,"PHASE4":10784,"NA":10786},{"trials":10773,"activeCount":100},[],{"trials":10775,"activeCount":100},[10776],{"nctId":728,"briefTitle":729,"status":219,"phases":10777,"primaryCompletion":731,"completion":731,"start":732,"enrollment":733,"conditions":10778,"interventions":10779},[89],[36],[736,82],{"trials":10781,"activeCount":100},[],{"trials":10783,"activeCount":100},[],{"trials":10785,"activeCount":100},[],{"trials":10787,"activeCount":100},[],{"intervention":10789,"totalTrials":1156,"cells":10790},"Tasquinimod",{"EARLY_PHASE1":10791,"PHASE1":10793,"PHASE2":10802,"PHASE3":10804,"PHASE4":10806,"NA":10808},{"trials":10792,"activeCount":100},[],{"trials":10794,"activeCount":100},[10795],{"nctId":10796,"briefTitle":10797,"status":416,"phases":10798,"primaryCompletion":5335,"completion":5335,"start":9001,"enrollment":100,"conditions":10799,"interventions":10801},"NCT02396368","A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer",[89],[15,10800],"Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)",[10789],{"trials":10803,"activeCount":100},[],{"trials":10805,"activeCount":100},[],{"trials":10807,"activeCount":100},[],{"trials":10809,"activeCount":100},[],{"intervention":10811,"totalTrials":1156,"cells":10812},"Oral MRX-1024",{"EARLY_PHASE1":10813,"PHASE1":10815,"PHASE2":10826,"PHASE3":10828,"PHASE4":10830,"NA":10832},{"trials":10814,"activeCount":100},[],{"trials":10816,"activeCount":100},[10817],{"nctId":10818,"briefTitle":10819,"status":219,"phases":10820,"completion":5865,"start":3062,"conditions":10821,"interventions":10824},"NCT00427102","MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and Neck",[89],[3855,36,10822,10823],"Resected Head and Neck Cancer","Mucositis",[10811,10825],"High-Dose Cisplatin Chemotherapy",{"trials":10827,"activeCount":100},[],{"trials":10829,"activeCount":100},[],{"trials":10831,"activeCount":100},[],{"trials":10833,"activeCount":100},[],{"intervention":10825,"totalTrials":1156,"cells":10835},{"EARLY_PHASE1":10836,"PHASE1":10838,"PHASE2":10844,"PHASE3":10846,"PHASE4":10848,"NA":10850},{"trials":10837,"activeCount":100},[],{"trials":10839,"activeCount":100},[10840],{"nctId":10818,"briefTitle":10819,"status":219,"phases":10841,"completion":5865,"start":3062,"conditions":10842,"interventions":10843},[89],[3855,36,10822,10823],[10811,10825],{"trials":10845,"activeCount":100},[],{"trials":10847,"activeCount":100},[],{"trials":10849,"activeCount":100},[],{"trials":10851,"activeCount":100},[],{"intervention":10853,"totalTrials":1156,"cells":10854},"Activated PTCy-MILs",{"EARLY_PHASE1":10855,"PHASE1":10857,"PHASE2":10869,"PHASE3":10871,"PHASE4":10873,"NA":10875},{"trials":10856,"activeCount":100},[],{"trials":10858,"activeCount":100},[10859],{"nctId":10860,"briefTitle":10861,"status":139,"phases":10862,"primaryCompletion":10863,"completion":10864,"start":10865,"enrollment":168,"conditions":10866,"interventions":10868},"NCT02342613","Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation",[89],"2023-11-29","2024-03-31","2015-05-28",[2517,10867],"Graft-Versus-Host Disease",[10853],{"trials":10870,"activeCount":100},[],{"trials":10872,"activeCount":100},[],{"trials":10874,"activeCount":100},[],{"trials":10876,"activeCount":100},[],{"intervention":10878,"totalTrials":1156,"cells":10879},"PD 0332991",{"EARLY_PHASE1":10880,"PHASE1":10882,"PHASE2":10894,"PHASE3":10896,"PHASE4":10898,"NA":10900},{"trials":10881,"activeCount":100},[],{"trials":10883,"activeCount":100},[10884],{"nctId":10885,"briefTitle":10886,"status":219,"phases":10887,"primaryCompletion":10888,"completion":10888,"start":2365,"enrollment":733,"conditions":10889,"interventions":10893},"NCT01701375","A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia",[89],"2013-04",[10890,10891,10892],"Relapsed Acute Leukemia","Refractory Acute Leukemia","High-Risk Myelodysplasia",[10878],{"trials":10895,"activeCount":100},[],{"trials":10897,"activeCount":100},[],{"trials":10899,"activeCount":100},[],{"trials":10901,"activeCount":100},[],{"intervention":3050,"totalTrials":1156,"cells":10903},{"EARLY_PHASE1":10904,"PHASE1":10906,"PHASE2":10912,"PHASE3":10914,"PHASE4":10916,"NA":10918},{"trials":10905,"activeCount":100},[],{"trials":10907,"activeCount":100},[10908],{"nctId":3043,"briefTitle":3044,"status":219,"phases":10909,"primaryCompletion":3046,"completion":3046,"start":3047,"enrollment":536,"conditions":10910,"interventions":10911},[89],[15],[1892,3050,2942],{"trials":10913,"activeCount":100},[],{"trials":10915,"activeCount":100},[],{"trials":10917,"activeCount":100},[],{"trials":10919,"activeCount":100},[],{"intervention":10921,"totalTrials":1156,"cells":10922},"Retrograde venous infusion of gemcitabine\u002Flipiodol",{"EARLY_PHASE1":10923,"PHASE1":10925,"PHASE2":10936,"PHASE3":10938,"PHASE4":10940,"NA":10942},{"trials":10924,"activeCount":100},[],{"trials":10926,"activeCount":100},[10927],{"nctId":10928,"briefTitle":10929,"status":416,"phases":10930,"primaryCompletion":10931,"completion":846,"start":10932,"enrollment":100,"conditions":10933,"interventions":10935},"NCT03865563","Selective Transvenous Chemoembolization of Primary Pancreatic Tumors",[89],"2021-06","2019-07",[10934],"Pancreatic Adenocarcinoma",[10921],{"trials":10937,"activeCount":100},[],{"trials":10939,"activeCount":100},[],{"trials":10941,"activeCount":100},[],{"trials":10943,"activeCount":100},[],{"intervention":2011,"totalTrials":1156,"cells":10945},{"EARLY_PHASE1":10946,"PHASE1":10948,"PHASE2":10954,"PHASE3":10956,"PHASE4":10958,"NA":10960},{"trials":10947,"activeCount":100},[],{"trials":10949,"activeCount":100},[10950],{"nctId":2006,"briefTitle":2007,"status":219,"phases":10951,"primaryCompletion":182,"completion":182,"start":1076,"enrollment":439,"conditions":10952,"interventions":10953},[89],[36],[831,2011,638],{"trials":10955,"activeCount":100},[],{"trials":10957,"activeCount":100},[],{"trials":10959,"activeCount":100},[],{"trials":10961,"activeCount":100},[],{"intervention":10963,"totalTrials":1156,"cells":10964},"penclomedine",{"EARLY_PHASE1":10965,"PHASE1":10967,"PHASE2":10976,"PHASE3":10978,"PHASE4":10980,"NA":10982},{"trials":10966,"activeCount":100},[],{"trials":10968,"activeCount":100},[10969],{"nctId":10970,"briefTitle":10971,"status":139,"phases":10972,"start":10973,"conditions":10974,"interventions":10975},"NCT00002915","Penclomedine in Treating Patients With Advanced Solid Tumors",[89],"1996-12",[4913],[10963],{"trials":10977,"activeCount":100},[],{"trials":10979,"activeCount":100},[],{"trials":10981,"activeCount":100},[],{"trials":10983,"activeCount":100},[],{"intervention":10985,"totalTrials":1156,"cells":10986},"Allogeneic Human Mesenchymal Stem Cells",{"EARLY_PHASE1":10987,"PHASE1":10989,"PHASE2":10999,"PHASE3":11001,"PHASE4":11003,"NA":11005},{"trials":10988,"activeCount":100},[],{"trials":10990,"activeCount":100},[10991],{"nctId":10992,"briefTitle":10993,"status":219,"phases":10994,"primaryCompletion":10995,"completion":10995,"start":10996,"enrollment":689,"conditions":10997,"interventions":10998},"NCT01983709","Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer",[89],"2017-06","2013-10",[15],[10985],{"trials":11000,"activeCount":100},[],{"trials":11002,"activeCount":100},[],{"trials":11004,"activeCount":100},[],{"trials":11006,"activeCount":100},[],{"intervention":6402,"totalTrials":1156,"cells":11008},{"EARLY_PHASE1":11009,"PHASE1":11011,"PHASE2":11017,"PHASE3":11019,"PHASE4":11021,"NA":11023},{"trials":11010,"activeCount":100},[],{"trials":11012,"activeCount":100},[11013],{"nctId":6394,"briefTitle":6395,"status":139,"phases":11014,"primaryCompletion":6397,"completion":6398,"start":6399,"enrollment":439,"conditions":11015,"interventions":11016},[89],[566],[6402,6403,1904],{"trials":11018,"activeCount":100},[],{"trials":11020,"activeCount":100},[],{"trials":11022,"activeCount":100},[],{"trials":11024,"activeCount":100},[],{"intervention":4381,"totalTrials":1156,"cells":11026},{"EARLY_PHASE1":11027,"PHASE1":11029,"PHASE2":11035,"PHASE3":11037,"PHASE4":11039,"NA":11041},{"trials":11028,"activeCount":100},[],{"trials":11030,"activeCount":100},[11031],{"nctId":4373,"briefTitle":4374,"status":416,"phases":11032,"primaryCompletion":4376,"completion":4376,"start":4376,"enrollment":100,"conditions":11033,"interventions":11034},[89],[4378,4379],[4381,2348],{"trials":11036,"activeCount":100},[],{"trials":11038,"activeCount":100},[],{"trials":11040,"activeCount":100},[],{"trials":11042,"activeCount":100},[],{"intervention":2326,"totalTrials":1156,"cells":11044},{"EARLY_PHASE1":11045,"PHASE1":11047,"PHASE2":11053,"PHASE3":11055,"PHASE4":11057,"NA":11059},{"trials":11046,"activeCount":100},[],{"trials":11048,"activeCount":100},[11049],{"nctId":2319,"briefTitle":2320,"status":139,"phases":11050,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":266,"conditions":11051,"interventions":11052},[89],[24],[2265,2326,2327,2306,2307,2328],{"trials":11054,"activeCount":100},[],{"trials":11056,"activeCount":100},[],{"trials":11058,"activeCount":100},[],{"trials":11060,"activeCount":100},[],{"intervention":2328,"totalTrials":1156,"cells":11062},{"EARLY_PHASE1":11063,"PHASE1":11065,"PHASE2":11071,"PHASE3":11073,"PHASE4":11075,"NA":11077},{"trials":11064,"activeCount":100},[],{"trials":11066,"activeCount":100},[11067],{"nctId":2319,"briefTitle":2320,"status":139,"phases":11068,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":266,"conditions":11069,"interventions":11070},[89],[24],[2265,2326,2327,2306,2307,2328],{"trials":11072,"activeCount":100},[],{"trials":11074,"activeCount":100},[],{"trials":11076,"activeCount":100},[],{"trials":11078,"activeCount":100},[],{"intervention":11080,"totalTrials":1156,"cells":11081},"Clostridium novyi-NT spores",{"EARLY_PHASE1":11082,"PHASE1":11084,"PHASE2":11093,"PHASE3":11095,"PHASE4":11097,"NA":11099},{"trials":11083,"activeCount":100},[],{"trials":11085,"activeCount":100},[11086],{"nctId":11087,"briefTitle":11088,"status":219,"phases":11089,"primaryCompletion":3211,"completion":3211,"start":6185,"enrollment":733,"conditions":11090,"interventions":11092},"NCT00358397","One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy",[89],[11091],"Tumors",[11080],{"trials":11094,"activeCount":100},[],{"trials":11096,"activeCount":100},[],{"trials":11098,"activeCount":100},[],{"trials":11100,"activeCount":100},[],{"intervention":11102,"totalTrials":1156,"cells":11103},"TA-CIN",{"EARLY_PHASE1":11104,"PHASE1":11106,"PHASE2":11118,"PHASE3":11120,"PHASE4":11122,"NA":11124},{"trials":11105,"activeCount":100},[],{"trials":11107,"activeCount":100},[11108],{"nctId":11109,"briefTitle":11110,"status":139,"phases":11111,"primaryCompletion":11112,"completion":11113,"start":11114,"enrollment":156,"conditions":11115,"interventions":11117},"NCT02405221","Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer",[89],"2024-12-31","2025-01-31","2019-04-04",[11116],"HPV16 Associated Cervical Cancer",[11102,11102],{"trials":11119,"activeCount":100},[],{"trials":11121,"activeCount":100},[],{"trials":11123,"activeCount":100},[],{"trials":11125,"activeCount":100},[],{"intervention":11127,"totalTrials":1156,"cells":11128},"FBnTP",{"EARLY_PHASE1":11129,"PHASE1":11131,"PHASE2":11140,"PHASE3":11142,"PHASE4":11144,"NA":11146},{"trials":11130,"activeCount":100},[],{"trials":11132,"activeCount":100},[11133],{"nctId":11134,"briefTitle":11135,"status":219,"phases":11136,"primaryCompletion":2228,"completion":2228,"start":11137,"enrollment":536,"conditions":11138,"interventions":11139},"NCT02204462","FBnTP Imaging of Breast Cancer",[89],"2015-03-12",[18],[11127],{"trials":11141,"activeCount":100},[],{"trials":11143,"activeCount":100},[],{"trials":11145,"activeCount":100},[],{"trials":11147,"activeCount":100},[],{"intervention":11149,"totalTrials":1156,"cells":11150},"18F-DCFPyL PET\u002FCT",{"EARLY_PHASE1":11151,"PHASE1":11153,"PHASE2":11164,"PHASE3":11166,"PHASE4":11168,"NA":11170},{"trials":11152,"activeCount":100},[],{"trials":11154,"activeCount":100},[11155],{"nctId":11156,"briefTitle":11157,"status":219,"phases":11158,"primaryCompletion":11159,"completion":11159,"start":11160,"enrollment":224,"conditions":11161,"interventions":11162},"NCT03619655","Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy",[89],"2022-11-14","2019-11-15",[15],[11149,11163],"18F-NaF PET\u002FCT",{"trials":11165,"activeCount":100},[],{"trials":11167,"activeCount":100},[],{"trials":11169,"activeCount":100},[],{"trials":11171,"activeCount":100},[],{"intervention":11163,"totalTrials":1156,"cells":11173},{"EARLY_PHASE1":11174,"PHASE1":11176,"PHASE2":11182,"PHASE3":11184,"PHASE4":11186,"NA":11188},{"trials":11175,"activeCount":100},[],{"trials":11177,"activeCount":100},[11178],{"nctId":11156,"briefTitle":11157,"status":219,"phases":11179,"primaryCompletion":11159,"completion":11159,"start":11160,"enrollment":224,"conditions":11180,"interventions":11181},[89],[15],[11149,11163],{"trials":11183,"activeCount":100},[],{"trials":11185,"activeCount":100},[],{"trials":11187,"activeCount":100},[],{"trials":11189,"activeCount":100},[],{"intervention":11191,"totalTrials":1156,"cells":11192},"Artesunate Suppositories",{"EARLY_PHASE1":11193,"PHASE1":11195,"PHASE2":11207,"PHASE3":11209,"PHASE4":11211,"NA":11213},{"trials":11194,"activeCount":100},[],{"trials":11196,"activeCount":100},[11197],{"nctId":11198,"briefTitle":11199,"status":139,"phases":11200,"primaryCompletion":11201,"completion":11202,"start":2036,"enrollment":313,"conditions":11203,"interventions":11206},"NCT02354534","Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2\u002F3)",[89],"2018-07","2018-11-06",[11204,11205],"Cervical Intraepithelial Neoplasia Grade 2\u002F3","High-risk HPV (Any Strain)",[11191],{"trials":11208,"activeCount":100},[],{"trials":11210,"activeCount":100},[],{"trials":11212,"activeCount":100},[],{"trials":11214,"activeCount":100},[],{"intervention":11216,"totalTrials":1156,"cells":11217},"[18F]FLOR (FC303)",{"EARLY_PHASE1":11218,"PHASE1":11220,"PHASE2":11230,"PHASE3":11232,"PHASE4":11234,"NA":11236},{"trials":11219,"activeCount":100},[],{"trials":11221,"activeCount":100},[11222],{"nctId":11223,"briefTitle":11224,"status":219,"phases":11225,"primaryCompletion":11226,"completion":11226,"start":11227,"enrollment":9,"conditions":11228,"interventions":11229},"NCT04528199","[18F]FLOR (FC303) PET\u002FCT Imaging in Patients With Prostate Cancer",[89],"2023-04-21","2021-02-01",[244],[11216],{"trials":11231,"activeCount":100},[],{"trials":11233,"activeCount":100},[],{"trials":11235,"activeCount":100},[],{"trials":11237,"activeCount":100},[],{"intervention":11239,"totalTrials":1156,"cells":11240},"Intraductal arm",{"EARLY_PHASE1":11241,"PHASE1":11243,"PHASE2":11253,"PHASE3":11255,"PHASE4":11257,"NA":11259},{"trials":11242,"activeCount":100},[],{"trials":11244,"activeCount":100},[11245],{"nctId":11246,"briefTitle":11247,"status":139,"phases":11248,"primaryCompletion":721,"completion":11249,"start":742,"enrollment":405,"conditions":11250,"interventions":11251},"NCT00290732","Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer",[89],"2011-10",[18],[11239,11252],"Intravenous arm",{"trials":11254,"activeCount":100},[],{"trials":11256,"activeCount":100},[],{"trials":11258,"activeCount":100},[],{"trials":11260,"activeCount":100},[],{"intervention":11252,"totalTrials":1156,"cells":11262},{"EARLY_PHASE1":11263,"PHASE1":11265,"PHASE2":11271,"PHASE3":11273,"PHASE4":11275,"NA":11277},{"trials":11264,"activeCount":100},[],{"trials":11266,"activeCount":100},[11267],{"nctId":11246,"briefTitle":11247,"status":139,"phases":11268,"primaryCompletion":721,"completion":11249,"start":742,"enrollment":405,"conditions":11269,"interventions":11270},[89],[18],[11239,11252],{"trials":11272,"activeCount":100},[],{"trials":11274,"activeCount":100},[],{"trials":11276,"activeCount":100},[],{"trials":11278,"activeCount":100},[],{"intervention":4287,"totalTrials":1156,"cells":11280},{"EARLY_PHASE1":11281,"PHASE1":11283,"PHASE2":11289,"PHASE3":11291,"PHASE4":11293,"NA":11295},{"trials":11282,"activeCount":100},[],{"trials":11284,"activeCount":100},[11285],{"nctId":4280,"briefTitle":4281,"status":139,"phases":11286,"primaryCompletion":4283,"completion":4283,"start":4284,"enrollment":1516,"conditions":11287,"interventions":11288},[89],[244],[4254,4287],{"trials":11290,"activeCount":100},[],{"trials":11292,"activeCount":100},[],{"trials":11294,"activeCount":100},[],{"trials":11296,"activeCount":100},[],{"intervention":11298,"totalTrials":1156,"cells":11299},"[18F]F-AraG",{"EARLY_PHASE1":11300,"PHASE1":11302,"PHASE2":11312,"PHASE3":11314,"PHASE4":11316,"NA":11318},{"trials":11301,"activeCount":100},[],{"trials":11303,"activeCount":100},[11304],{"nctId":11305,"briefTitle":11306,"status":219,"phases":11307,"primaryCompletion":11308,"completion":11308,"start":11227,"enrollment":536,"conditions":11309,"interventions":11311},"NCT04524195","PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)",[89],"2023-11-27",[11310],"Non-small Cell Lung Cancer (NSCLC)",[11298],{"trials":11313,"activeCount":100},[],{"trials":11315,"activeCount":100},[],{"trials":11317,"activeCount":100},[],{"trials":11319,"activeCount":100},[],{"intervention":807,"totalTrials":1156,"cells":11321},{"EARLY_PHASE1":11322,"PHASE1":11324,"PHASE2":11330,"PHASE3":11332,"PHASE4":11334,"NA":11336},{"trials":11323,"activeCount":100},[],{"trials":11325,"activeCount":100},[11326],{"nctId":799,"briefTitle":800,"status":139,"phases":11327,"primaryCompletion":658,"completion":802,"start":803,"enrollment":108,"conditions":11328,"interventions":11329},[89],[805],[807,82],{"trials":11331,"activeCount":100},[],{"trials":11333,"activeCount":100},[],{"trials":11335,"activeCount":100},[],{"trials":11337,"activeCount":100},[],{"intervention":2338,"totalTrials":1156,"cells":11339},{"EARLY_PHASE1":11340,"PHASE1":11342,"PHASE2":11348,"PHASE3":11350,"PHASE4":11352,"NA":11354},{"trials":11341,"activeCount":100},[],{"trials":11343,"activeCount":100},[11344],{"nctId":2330,"briefTitle":2331,"status":139,"phases":11345,"primaryCompletion":2333,"completion":2334,"start":2335,"enrollment":31,"conditions":11346,"interventions":11347},[89],[24],[2265,2338],{"trials":11349,"activeCount":100},[],{"trials":11351,"activeCount":100},[],{"trials":11353,"activeCount":100},[],{"trials":11355,"activeCount":100},[],{"intervention":11357,"totalTrials":1156,"cells":11358},"oral 5-azacitidine in combination with romidepsin",{"EARLY_PHASE1":11359,"PHASE1":11361,"PHASE2":11371,"PHASE3":11373,"PHASE4":11375,"NA":11377},{"trials":11360,"activeCount":100},[],{"trials":11362,"activeCount":100},[11363],{"nctId":11364,"briefTitle":11365,"status":139,"phases":11366,"primaryCompletion":802,"completion":534,"start":7085,"enrollment":848,"conditions":11367,"interventions":11370},"NCT01537744","A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma",[89],[11368,11369],"Solid Tumors","Virally Mediated Cancers and Liposarcoma",[11357],{"trials":11372,"activeCount":100},[],{"trials":11374,"activeCount":100},[],{"trials":11376,"activeCount":100},[],{"trials":11378,"activeCount":100},[],{"intervention":11380,"totalTrials":1156,"cells":11381},"Fostamatinib 100 mg bid and Paclitaxel",{"EARLY_PHASE1":11382,"PHASE1":11384,"PHASE2":11397,"PHASE3":11399,"PHASE4":11401,"NA":11403},{"trials":11383,"activeCount":100},[],{"trials":11385,"activeCount":100},[11386],{"nctId":11387,"briefTitle":11388,"status":139,"phases":11389,"primaryCompletion":11390,"completion":11391,"start":11392,"enrollment":28,"conditions":11393,"interventions":11394},"NCT03246074","Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer",[89],"2022-08-09","2023-04-03","2018-04-03",[768],[11380,11395,11396],"Fostamatinib 150 mg bid and Paclitaxel","Fostamatinib 200 mg bid and Paclitaxel",{"trials":11398,"activeCount":100},[],{"trials":11400,"activeCount":100},[],{"trials":11402,"activeCount":100},[],{"trials":11404,"activeCount":100},[],{"intervention":11395,"totalTrials":1156,"cells":11406},{"EARLY_PHASE1":11407,"PHASE1":11409,"PHASE2":11415,"PHASE3":11417,"PHASE4":11419,"NA":11421},{"trials":11408,"activeCount":100},[],{"trials":11410,"activeCount":100},[11411],{"nctId":11387,"briefTitle":11388,"status":139,"phases":11412,"primaryCompletion":11390,"completion":11391,"start":11392,"enrollment":28,"conditions":11413,"interventions":11414},[89],[768],[11380,11395,11396],{"trials":11416,"activeCount":100},[],{"trials":11418,"activeCount":100},[],{"trials":11420,"activeCount":100},[],{"trials":11422,"activeCount":100},[],{"intervention":11396,"totalTrials":1156,"cells":11424},{"EARLY_PHASE1":11425,"PHASE1":11427,"PHASE2":11433,"PHASE3":11435,"PHASE4":11437,"NA":11439},{"trials":11426,"activeCount":100},[],{"trials":11428,"activeCount":100},[11429],{"nctId":11387,"briefTitle":11388,"status":139,"phases":11430,"primaryCompletion":11390,"completion":11391,"start":11392,"enrollment":28,"conditions":11431,"interventions":11432},[89],[768],[11380,11395,11396],{"trials":11434,"activeCount":100},[],{"trials":11436,"activeCount":100},[],{"trials":11438,"activeCount":100},[],{"trials":11440,"activeCount":100},[],{"intervention":11442,"totalTrials":1156,"cells":11443},"Helixor® M",{"EARLY_PHASE1":11444,"PHASE1":11446,"PHASE2":11456,"PHASE3":11458,"PHASE4":11460,"NA":11462},{"trials":11445,"activeCount":100},[],{"trials":11447,"activeCount":100},[11448],{"nctId":11449,"briefTitle":11450,"status":139,"phases":11451,"primaryCompletion":11452,"completion":11453,"start":1580,"enrollment":108,"conditions":11454,"interventions":11455},"NCT03051477","Trial of Mistletoe Extract in Patients With Advanced Solid Tumors",[89],"2021-01-29","2022-08-05",[4740],[11442],{"trials":11457,"activeCount":100},[],{"trials":11459,"activeCount":100},[],{"trials":11461,"activeCount":100},[],{"trials":11463,"activeCount":100},[],{"intervention":11465,"totalTrials":1156,"cells":11466},"Regadenoson 0.05mg",{"EARLY_PHASE1":11467,"PHASE1":11469,"PHASE2":11485,"PHASE3":11487,"PHASE4":11489,"NA":11491},{"trials":11468,"activeCount":100},[],{"trials":11470,"activeCount":100},[11471],{"nctId":11472,"briefTitle":11473,"status":219,"phases":11474,"primaryCompletion":7767,"completion":11475,"start":11476,"enrollment":689,"conditions":11477,"interventions":11478},"NCT03971734","Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas",[89],"2023-10-02","2019-12-06",[2367,7773,10179,226],[11465,11479,11480,11481,11482,11483,11484],"Regadensoson 0.1mg","Regadensoson 0.2mg","Regadensoson 0.4mg","Regadensoson 0.7mg","Regadensoson 1.0mg","Regadensoson 1.4mg",{"trials":11486,"activeCount":100},[],{"trials":11488,"activeCount":100},[],{"trials":11490,"activeCount":100},[],{"trials":11492,"activeCount":100},[],{"intervention":11479,"totalTrials":1156,"cells":11494},{"EARLY_PHASE1":11495,"PHASE1":11497,"PHASE2":11503,"PHASE3":11505,"PHASE4":11507,"NA":11509},{"trials":11496,"activeCount":100},[],{"trials":11498,"activeCount":100},[11499],{"nctId":11472,"briefTitle":11473,"status":219,"phases":11500,"primaryCompletion":7767,"completion":11475,"start":11476,"enrollment":689,"conditions":11501,"interventions":11502},[89],[2367,7773,10179,226],[11465,11479,11480,11481,11482,11483,11484],{"trials":11504,"activeCount":100},[],{"trials":11506,"activeCount":100},[],{"trials":11508,"activeCount":100},[],{"trials":11510,"activeCount":100},[],{"intervention":11480,"totalTrials":1156,"cells":11512},{"EARLY_PHASE1":11513,"PHASE1":11515,"PHASE2":11521,"PHASE3":11523,"PHASE4":11525,"NA":11527},{"trials":11514,"activeCount":100},[],{"trials":11516,"activeCount":100},[11517],{"nctId":11472,"briefTitle":11473,"status":219,"phases":11518,"primaryCompletion":7767,"completion":11475,"start":11476,"enrollment":689,"conditions":11519,"interventions":11520},[89],[2367,7773,10179,226],[11465,11479,11480,11481,11482,11483,11484],{"trials":11522,"activeCount":100},[],{"trials":11524,"activeCount":100},[],{"trials":11526,"activeCount":100},[],{"trials":11528,"activeCount":100},[],{"intervention":11481,"totalTrials":1156,"cells":11530},{"EARLY_PHASE1":11531,"PHASE1":11533,"PHASE2":11539,"PHASE3":11541,"PHASE4":11543,"NA":11545},{"trials":11532,"activeCount":100},[],{"trials":11534,"activeCount":100},[11535],{"nctId":11472,"briefTitle":11473,"status":219,"phases":11536,"primaryCompletion":7767,"completion":11475,"start":11476,"enrollment":689,"conditions":11537,"interventions":11538},[89],[2367,7773,10179,226],[11465,11479,11480,11481,11482,11483,11484],{"trials":11540,"activeCount":100},[],{"trials":11542,"activeCount":100},[],{"trials":11544,"activeCount":100},[],{"trials":11546,"activeCount":100},[],{"intervention":11482,"totalTrials":1156,"cells":11548},{"EARLY_PHASE1":11549,"PHASE1":11551,"PHASE2":11557,"PHASE3":11559,"PHASE4":11561,"NA":11563},{"trials":11550,"activeCount":100},[],{"trials":11552,"activeCount":100},[11553],{"nctId":11472,"briefTitle":11473,"status":219,"phases":11554,"primaryCompletion":7767,"completion":11475,"start":11476,"enrollment":689,"conditions":11555,"interventions":11556},[89],[2367,7773,10179,226],[11465,11479,11480,11481,11482,11483,11484],{"trials":11558,"activeCount":100},[],{"trials":11560,"activeCount":100},[],{"trials":11562,"activeCount":100},[],{"trials":11564,"activeCount":100},[],{"intervention":11483,"totalTrials":1156,"cells":11566},{"EARLY_PHASE1":11567,"PHASE1":11569,"PHASE2":11575,"PHASE3":11577,"PHASE4":11579,"NA":11581},{"trials":11568,"activeCount":100},[],{"trials":11570,"activeCount":100},[11571],{"nctId":11472,"briefTitle":11473,"status":219,"phases":11572,"primaryCompletion":7767,"completion":11475,"start":11476,"enrollment":689,"conditions":11573,"interventions":11574},[89],[2367,7773,10179,226],[11465,11479,11480,11481,11482,11483,11484],{"trials":11576,"activeCount":100},[],{"trials":11578,"activeCount":100},[],{"trials":11580,"activeCount":100},[],{"trials":11582,"activeCount":100},[],{"intervention":11484,"totalTrials":1156,"cells":11584},{"EARLY_PHASE1":11585,"PHASE1":11587,"PHASE2":11593,"PHASE3":11595,"PHASE4":11597,"NA":11599},{"trials":11586,"activeCount":100},[],{"trials":11588,"activeCount":100},[11589],{"nctId":11472,"briefTitle":11473,"status":219,"phases":11590,"primaryCompletion":7767,"completion":11475,"start":11476,"enrollment":689,"conditions":11591,"interventions":11592},[89],[2367,7773,10179,226],[11465,11479,11480,11481,11482,11483,11484],{"trials":11594,"activeCount":100},[],{"trials":11596,"activeCount":100},[],{"trials":11598,"activeCount":100},[],{"trials":11600,"activeCount":100},[],{"intervention":11602,"totalTrials":1156,"cells":11603},"Anti-LAG-3 Monoclonal Antibody BMS 986016",{"EARLY_PHASE1":11604,"PHASE1":11606,"PHASE2":11618,"PHASE3":11620,"PHASE4":11622,"NA":11624},{"trials":11605,"activeCount":100},[],{"trials":11607,"activeCount":100},[11608],{"nctId":11609,"briefTitle":11610,"status":139,"phases":11611,"primaryCompletion":7767,"completion":10342,"start":11612,"enrollment":1077,"conditions":11613,"interventions":11615},"NCT02658981","Anti-LAG-3 Alone & in Combination w\u002F Nivolumab Treating Patients w\u002F Recurrent GBM (Anti-CD137 Arm Closed 10\u002F16\u002F18)",[89],"2016-08-24",[226,7775,11614],"Recurrent Brain Neoplasm",[11602,11616,11617],"Anti-PD-1","Anti-CD137",{"trials":11619,"activeCount":100},[],{"trials":11621,"activeCount":100},[],{"trials":11623,"activeCount":100},[],{"trials":11625,"activeCount":100},[],{"intervention":11616,"totalTrials":1156,"cells":11627},{"EARLY_PHASE1":11628,"PHASE1":11630,"PHASE2":11636,"PHASE3":11638,"PHASE4":11640,"NA":11642},{"trials":11629,"activeCount":100},[],{"trials":11631,"activeCount":100},[11632],{"nctId":11609,"briefTitle":11610,"status":139,"phases":11633,"primaryCompletion":7767,"completion":10342,"start":11612,"enrollment":1077,"conditions":11634,"interventions":11635},[89],[226,7775,11614],[11602,11616,11617],{"trials":11637,"activeCount":100},[],{"trials":11639,"activeCount":100},[],{"trials":11641,"activeCount":100},[],{"trials":11643,"activeCount":100},[],{"intervention":11617,"totalTrials":1156,"cells":11645},{"EARLY_PHASE1":11646,"PHASE1":11648,"PHASE2":11654,"PHASE3":11656,"PHASE4":11658,"NA":11660},{"trials":11647,"activeCount":100},[],{"trials":11649,"activeCount":100},[11650],{"nctId":11609,"briefTitle":11610,"status":139,"phases":11651,"primaryCompletion":7767,"completion":10342,"start":11612,"enrollment":1077,"conditions":11652,"interventions":11653},[89],[226,7775,11614],[11602,11616,11617],{"trials":11655,"activeCount":100},[],{"trials":11657,"activeCount":100},[],{"trials":11659,"activeCount":100},[],{"trials":11661,"activeCount":100},[],{"intervention":5338,"totalTrials":1156,"cells":11663},{"EARLY_PHASE1":11664,"PHASE1":11666,"PHASE2":11672,"PHASE3":11674,"PHASE4":11676,"NA":11678},{"trials":11665,"activeCount":100},[],{"trials":11667,"activeCount":100},[11668],{"nctId":5332,"briefTitle":5333,"status":219,"phases":11669,"primaryCompletion":5335,"completion":5335,"start":42,"enrollment":231,"conditions":11670,"interventions":11671},[89],[30],[5338,841],{"trials":11673,"activeCount":100},[],{"trials":11675,"activeCount":100},[],{"trials":11677,"activeCount":100},[],{"trials":11679,"activeCount":100},[],{"intervention":7423,"totalTrials":1156,"cells":11681},{"EARLY_PHASE1":11682,"PHASE1":11684,"PHASE2":11690,"PHASE3":11692,"PHASE4":11694,"NA":11696},{"trials":11683,"activeCount":100},[],{"trials":11685,"activeCount":100},[11686],{"nctId":7415,"briefTitle":7416,"status":139,"phases":11687,"primaryCompletion":7418,"completion":7418,"start":5634,"enrollment":3853,"conditions":11688,"interventions":11689},[89],[4716,5598,7420,7421],[7423,7408,7424],{"trials":11691,"activeCount":100},[],{"trials":11693,"activeCount":100},[],{"trials":11695,"activeCount":100},[],{"trials":11697,"activeCount":100},[],{"intervention":11699,"totalTrials":1156,"cells":11700},"artesunate ointment 40%",{"EARLY_PHASE1":11701,"PHASE1":11703,"PHASE2":11716,"PHASE3":11718,"PHASE4":11720,"NA":11722},{"trials":11702,"activeCount":100},[],{"trials":11704,"activeCount":100},[11705],{"nctId":11706,"briefTitle":11707,"status":139,"phases":11708,"primaryCompletion":2345,"completion":9498,"start":4738,"enrollment":156,"conditions":11709,"interventions":11715},"NCT03792516","Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2\u002F3)",[89],[11710,11711,11712,11713,11714],"Vulvar Dysplasia","HPV-Related Vulvar Intraepithelial Neoplasia","Preinvasive Vulvar Disease","Vulva Intraepithelial Neoplasia","Vulvar Diseases",[11699],{"trials":11717,"activeCount":100},[],{"trials":11719,"activeCount":100},[],{"trials":11721,"activeCount":100},[],{"trials":11723,"activeCount":100},[],{"intervention":11725,"totalTrials":1156,"cells":11726},"Idelalisib 100 MG",{"EARLY_PHASE1":11727,"PHASE1":11729,"PHASE2":11744,"PHASE3":11746,"PHASE4":11748,"NA":11750},{"trials":11728,"activeCount":100},[],{"trials":11730,"activeCount":100},[11731],{"nctId":11732,"briefTitle":11733,"status":219,"phases":11734,"primaryCompletion":11735,"completion":11736,"start":11737,"enrollment":37,"conditions":11738,"interventions":11743},"NCT03151057","Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies",[89],"2022-06-20","2022-07-20","2018-07-31",[11739,11740,11741,5381,11742],"B Cells-Tumors","B Cell Chronic Lymphocytic Leukemia","Follicular Lymphoma","Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)",[11725],{"trials":11745,"activeCount":100},[],{"trials":11747,"activeCount":100},[],{"trials":11749,"activeCount":100},[],{"trials":11751,"activeCount":100},[],{"intervention":11753,"totalTrials":1156,"cells":11754},"O6-benzylguanine",{"EARLY_PHASE1":11755,"PHASE1":11757,"PHASE2":11767,"PHASE3":11769,"PHASE4":11771,"NA":11773},{"trials":11756,"activeCount":100},[],{"trials":11758,"activeCount":100},[11759],{"nctId":11760,"briefTitle":11761,"status":139,"phases":11762,"primaryCompletion":11763,"completion":6280,"start":11764,"conditions":11765,"interventions":11766},"NCT00002971","O(6)-Benzylguanine in Treating Patients With Malignant Glioma",[89],"2003-02-20","1997-06-19",[24],[11753],{"trials":11768,"activeCount":100},[],{"trials":11770,"activeCount":100},[],{"trials":11772,"activeCount":100},[],{"trials":11774,"activeCount":100},[],{"intervention":229,"totalTrials":1156,"cells":11776},{"EARLY_PHASE1":11777,"PHASE1":11779,"PHASE2":11785,"PHASE3":11787,"PHASE4":11789,"NA":11791},{"trials":11778,"activeCount":100},[],{"trials":11780,"activeCount":100},[11781],{"nctId":217,"briefTitle":218,"status":219,"phases":11782,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":11783,"interventions":11784},[89],[226,227],[63,229,230,123],{"trials":11786,"activeCount":100},[],{"trials":11788,"activeCount":100},[],{"trials":11790,"activeCount":100},[],{"trials":11792,"activeCount":100},[],{"intervention":230,"totalTrials":1156,"cells":11794},{"EARLY_PHASE1":11795,"PHASE1":11797,"PHASE2":11803,"PHASE3":11805,"PHASE4":11807,"NA":11809},{"trials":11796,"activeCount":100},[],{"trials":11798,"activeCount":100},[11799],{"nctId":217,"briefTitle":218,"status":219,"phases":11800,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":11801,"interventions":11802},[89],[226,227],[63,229,230,123],{"trials":11804,"activeCount":100},[],{"trials":11806,"activeCount":100},[],{"trials":11808,"activeCount":100},[],{"trials":11810,"activeCount":100},[],{"intervention":11812,"totalTrials":1156,"cells":11813},"5-Aminolevulinic Acid",{"EARLY_PHASE1":11814,"PHASE1":11816,"PHASE2":11826,"PHASE3":11828,"PHASE4":11830,"NA":11832},{"trials":11815,"activeCount":100},[],{"trials":11817,"activeCount":100},[11818],{"nctId":11819,"briefTitle":11820,"status":219,"phases":11821,"primaryCompletion":1096,"completion":3073,"start":2365,"enrollment":231,"conditions":11822,"interventions":11825},"NCT01502605","Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas",[89],[11823,11824],"Astrocytoma","Glioma",[11812],{"trials":11827,"activeCount":100},[],{"trials":11829,"activeCount":100},[],{"trials":11831,"activeCount":100},[],{"trials":11833,"activeCount":100},[],{"intervention":11835,"totalTrials":1156,"cells":11836},"Pazopanib",{"EARLY_PHASE1":11837,"PHASE1":11839,"PHASE2":11852,"PHASE3":11854,"PHASE4":11856,"NA":11858},{"trials":11838,"activeCount":100},[],{"trials":11840,"activeCount":100},[11841],{"nctId":11842,"briefTitle":11843,"status":139,"phases":11844,"primaryCompletion":11845,"completion":393,"start":11249,"enrollment":11846,"conditions":11847,"interventions":11850},"NCT01438554","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",[89],"2016-04",89,[11368,11848,11849,496],"Thyroid Cancer","Soft-tissue Sarcoma",[11835,11851],"GSK1120212",{"trials":11853,"activeCount":100},[],{"trials":11855,"activeCount":100},[],{"trials":11857,"activeCount":100},[],{"trials":11859,"activeCount":100},[],{"intervention":11851,"totalTrials":1156,"cells":11861},{"EARLY_PHASE1":11862,"PHASE1":11864,"PHASE2":11870,"PHASE3":11872,"PHASE4":11874,"NA":11876},{"trials":11863,"activeCount":100},[],{"trials":11865,"activeCount":100},[11866],{"nctId":11842,"briefTitle":11843,"status":139,"phases":11867,"primaryCompletion":11845,"completion":393,"start":11249,"enrollment":11846,"conditions":11868,"interventions":11869},[89],[11368,11848,11849,496],[11835,11851],{"trials":11871,"activeCount":100},[],{"trials":11873,"activeCount":100},[],{"trials":11875,"activeCount":100},[],{"trials":11877,"activeCount":100},[],{"intervention":11879,"totalTrials":1156,"cells":11880},"Lenalidomide, Dexamethasone, and MEDI-551",{"EARLY_PHASE1":11881,"PHASE1":11890,"PHASE2":11892,"PHASE3":11894,"PHASE4":11896,"NA":11898},{"trials":11882,"activeCount":100},[11883],{"nctId":11884,"briefTitle":11885,"status":139,"phases":11886,"primaryCompletion":11845,"completion":1382,"start":4292,"enrollment":405,"conditions":11887,"interventions":11889},"NCT01861340","Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma",[88],[11888],"Myeloma",[11879],{"trials":11891,"activeCount":100},[],{"trials":11893,"activeCount":100},[],{"trials":11895,"activeCount":100},[],{"trials":11897,"activeCount":100},[],{"trials":11899,"activeCount":100},[],{"intervention":626,"totalTrials":1156,"cells":11901},{"EARLY_PHASE1":11902,"PHASE1":11908,"PHASE2":11910,"PHASE3":11912,"PHASE4":11914,"NA":11916},{"trials":11903,"activeCount":100},[11904],{"nctId":617,"briefTitle":618,"status":139,"phases":11905,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":11906,"interventions":11907},[88],[21],[82,376,580,626],{"trials":11909,"activeCount":100},[],{"trials":11911,"activeCount":100},[],{"trials":11913,"activeCount":100},[],{"trials":11915,"activeCount":100},[],{"trials":11917,"activeCount":100},[],{"intervention":11919,"totalTrials":1156,"cells":11920},"Enfuvirtide",{"EARLY_PHASE1":11921,"PHASE1":11932,"PHASE2":11934,"PHASE3":11936,"PHASE4":11938,"NA":11940},{"trials":11922,"activeCount":100},[11923],{"nctId":11924,"briefTitle":11925,"status":139,"phases":11926,"primaryCompletion":11927,"completion":11928,"start":1269,"enrollment":623,"conditions":11929,"interventions":11931},"NCT01836068","Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals",[88],"2020-01-22","2021-06-05",[11930],"HIV",[11919],{"trials":11933,"activeCount":100},[],{"trials":11935,"activeCount":100},[],{"trials":11937,"activeCount":100},[],{"trials":11939,"activeCount":100},[],{"trials":11941,"activeCount":100},[],{"intervention":11943,"totalTrials":1156,"cells":11944},"lapatinib",{"EARLY_PHASE1":11945,"PHASE1":11958,"PHASE2":11960,"PHASE3":11962,"PHASE4":11964,"NA":11966},{"trials":11946,"activeCount":100},[11947],{"nctId":11948,"briefTitle":11949,"status":139,"phases":11950,"primaryCompletion":847,"completion":847,"start":2046,"enrollment":1872,"conditions":11951,"interventions":11957},"NCT00863122","Concentration and Activity of Lapatinib in Vestibular Schwannomas",[88],[11952,11953,11954,11955,11956],"Vestibular Schwannoma","NF2","Neurofibromatosis 2","Acoustic Neuroma","Auditory Tumor",[11943],{"trials":11959,"activeCount":100},[],{"trials":11961,"activeCount":100},[],{"trials":11963,"activeCount":100},[],{"trials":11965,"activeCount":100},[],{"trials":11967,"activeCount":100},[],{"intervention":2285,"totalTrials":1156,"cells":11969},{"EARLY_PHASE1":11970,"PHASE1":11976,"PHASE2":11978,"PHASE3":11980,"PHASE4":11982,"NA":11984},{"trials":11971,"activeCount":100},[11972],{"nctId":2278,"briefTitle":2279,"status":139,"phases":11973,"primaryCompletion":182,"completion":2281,"start":2036,"enrollment":231,"conditions":11974,"interventions":11975},[88],[2283],[2285,2276],{"trials":11977,"activeCount":100},[],{"trials":11979,"activeCount":100},[],{"trials":11981,"activeCount":100},[],{"trials":11983,"activeCount":100},[],{"trials":11985,"activeCount":100},[],{"intervention":11987,"totalTrials":1156,"cells":11988},"K562\u002FGM-CSF cell vaccine",{"EARLY_PHASE1":11989,"PHASE1":11997,"PHASE2":11999,"PHASE3":12001,"PHASE4":12003,"NA":12005},{"trials":11990,"activeCount":100},[11991],{"nctId":11992,"briefTitle":11993,"status":219,"phases":11994,"primaryCompletion":1459,"completion":7431,"start":1880,"enrollment":361,"conditions":11995,"interventions":11996},"NCT00361296","Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes",[88],[33],[11987],{"trials":11998,"activeCount":100},[],{"trials":12000,"activeCount":100},[],{"trials":12002,"activeCount":100},[],{"trials":12004,"activeCount":100},[],{"trials":12006,"activeCount":100},[],{"intervention":12008,"totalTrials":1156,"cells":12009},"Pelvic DCFPyL PET-MRI fusion or PET\u002FMRI",{"EARLY_PHASE1":12010,"PHASE1":12022,"PHASE2":12024,"PHASE3":12026,"PHASE4":12028,"NA":12030},{"trials":12011,"activeCount":100},[12012],{"nctId":12013,"briefTitle":12014,"status":139,"phases":12015,"primaryCompletion":12016,"completion":12017,"start":12018,"enrollment":765,"conditions":12019,"interventions":12021},"NCT02420977","Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer",[88],"2024-03-01","2025-03-01","2018-12-06",[12020],"Advanced Prostate Cancer",[12008],{"trials":12023,"activeCount":100},[],{"trials":12025,"activeCount":100},[],{"trials":12027,"activeCount":100},[],{"trials":12029,"activeCount":100},[],{"trials":12031,"activeCount":100},[],{"intervention":12033,"totalTrials":1156,"cells":12034},"Allopurinol",{"EARLY_PHASE1":12035,"PHASE1":12046,"PHASE2":12048,"PHASE3":12050,"PHASE4":12052,"NA":12054},{"trials":12036,"activeCount":100},[12037],{"nctId":12038,"briefTitle":12039,"status":139,"phases":12040,"primaryCompletion":12041,"completion":12041,"start":12042,"enrollment":96,"conditions":12043,"interventions":12045},"NCT02046694","A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL",[88],"2020-04-06","2014-01-06",[12044],"Acute Lymphoblastic Leukemia (ALL)",[12033],{"trials":12047,"activeCount":100},[],{"trials":12049,"activeCount":100},[],{"trials":12051,"activeCount":100},[],{"trials":12053,"activeCount":100},[],{"trials":12055,"activeCount":100},[],{"intervention":12057,"totalTrials":1156,"cells":12058},"Vismodegib",{"EARLY_PHASE1":12059,"PHASE1":12067,"PHASE2":12069,"PHASE3":12071,"PHASE4":12073,"NA":12075},{"trials":12060,"activeCount":100},[12061],{"nctId":12062,"briefTitle":12063,"status":139,"phases":12064,"primaryCompletion":11845,"completion":11845,"start":888,"enrollment":361,"conditions":12065,"interventions":12066},"NCT02115828","A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy",[88],[15],[12057],{"trials":12068,"activeCount":100},[],{"trials":12070,"activeCount":100},[],{"trials":12072,"activeCount":100},[],{"trials":12074,"activeCount":100},[],{"trials":12076,"activeCount":100},[],{"intervention":12078,"totalTrials":1156,"cells":12079},"BGB 324",{"EARLY_PHASE1":12080,"PHASE1":12089,"PHASE2":12091,"PHASE3":12093,"PHASE4":12095,"NA":12097},{"trials":12081,"activeCount":100},[12082],{"nctId":12083,"briefTitle":12084,"status":219,"phases":12085,"primaryCompletion":2406,"completion":2406,"start":12086,"enrollment":1655,"conditions":12087,"interventions":12088},"NCT03965494","AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery",[88],"2020-01-02",[24],[12078,12078],{"trials":12090,"activeCount":100},[],{"trials":12092,"activeCount":100},[],{"trials":12094,"activeCount":100},[],{"trials":12096,"activeCount":100},[],{"trials":12098,"activeCount":100},[],{"intervention":12100,"totalTrials":1156,"cells":12101},"Flutamide",{"EARLY_PHASE1":12102,"PHASE1":12112,"PHASE2":12114,"PHASE3":12116,"PHASE4":12118,"NA":12120},{"trials":12103,"activeCount":100},[12104],{"nctId":12105,"briefTitle":12106,"status":139,"phases":12107,"primaryCompletion":12108,"completion":350,"start":12109,"enrollment":1516,"conditions":12110,"interventions":12111},"NCT03507608","Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression",[88],"2024-09-30","2019-05-10",[15],[12100],{"trials":12113,"activeCount":100},[],{"trials":12115,"activeCount":100},[],{"trials":12117,"activeCount":100},[],{"trials":12119,"activeCount":100},[],{"trials":12121,"activeCount":100},[],{"intervention":12123,"totalTrials":1156,"cells":12124},"Radiolabeled humanized PAM4 IgG",{"EARLY_PHASE1":12125,"PHASE1":12133,"PHASE2":12135,"PHASE3":12137,"PHASE4":12139,"NA":12141},{"trials":12126,"activeCount":100},[12127],{"nctId":12128,"briefTitle":12129,"status":219,"phases":12130,"primaryCompletion":698,"completion":698,"start":902,"enrollment":733,"conditions":12131,"interventions":12132},"NCT00364364","Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.",[88],[21],[12123],{"trials":12134,"activeCount":100},[],{"trials":12136,"activeCount":100},[],{"trials":12138,"activeCount":100},[],{"trials":12140,"activeCount":100},[],{"trials":12142,"activeCount":100},[],{"intervention":12144,"totalTrials":1156,"cells":12145},"Fingolimod",{"EARLY_PHASE1":12146,"PHASE1":12154,"PHASE2":12156,"PHASE3":12158,"PHASE4":12160,"NA":12162},{"trials":12147,"activeCount":100},[12148],{"nctId":12149,"briefTitle":12150,"status":139,"phases":12151,"primaryCompletion":5553,"completion":5553,"start":6111,"enrollment":1609,"conditions":12152,"interventions":12153},"NCT02490930","A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma",[88],[226,7773],[12144],{"trials":12155,"activeCount":100},[],{"trials":12157,"activeCount":100},[],{"trials":12159,"activeCount":100},[],{"trials":12161,"activeCount":100},[],{"trials":12163,"activeCount":100},[],{"intervention":12165,"totalTrials":1156,"cells":12166},"recombinant interferon-α",{"EARLY_PHASE1":12167,"PHASE1":12176,"PHASE2":12178,"PHASE3":12180,"PHASE4":12182,"NA":12184},{"trials":12168,"activeCount":100},[12169],{"nctId":12170,"briefTitle":12171,"status":219,"phases":12172,"primaryCompletion":7431,"completion":7431,"start":7214,"enrollment":224,"conditions":12173,"interventions":12174},"NCT00470093","Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma",[88],[754],[12165,12175],"recombinant interleukin-6",{"trials":12177,"activeCount":100},[],{"trials":12179,"activeCount":100},[],{"trials":12181,"activeCount":100},[],{"trials":12183,"activeCount":100},[],{"trials":12185,"activeCount":100},[],{"intervention":12175,"totalTrials":1156,"cells":12187},{"EARLY_PHASE1":12188,"PHASE1":12194,"PHASE2":12196,"PHASE3":12198,"PHASE4":12200,"NA":12202},{"trials":12189,"activeCount":100},[12190],{"nctId":12170,"briefTitle":12171,"status":219,"phases":12191,"primaryCompletion":7431,"completion":7431,"start":7214,"enrollment":224,"conditions":12192,"interventions":12193},[88],[754],[12165,12175],{"trials":12195,"activeCount":100},[],{"trials":12197,"activeCount":100},[],{"trials":12199,"activeCount":100},[],{"trials":12201,"activeCount":100},[],{"trials":12203,"activeCount":100},[],{"intervention":2306,"totalTrials":536,"cells":12205},{"EARLY_PHASE1":12206,"PHASE1":12208,"PHASE2":12218,"PHASE3":12224,"PHASE4":12226,"NA":12228},{"trials":12207,"activeCount":100},[],{"trials":12209,"activeCount":100},[12210,12214],{"nctId":2299,"briefTitle":2300,"status":139,"phases":12211,"primaryCompletion":2046,"start":2302,"enrollment":1280,"conditions":12212,"interventions":12213},[89],[24],[2305,2265,2306,2307,2308],{"nctId":2319,"briefTitle":2320,"status":139,"phases":12215,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":266,"conditions":12216,"interventions":12217},[89],[24],[2265,2326,2327,2306,2307,2328],{"trials":12219,"activeCount":100},[12220],{"nctId":5862,"briefTitle":5863,"status":139,"phases":12221,"primaryCompletion":5865,"start":1243,"enrollment":5546,"conditions":12222,"interventions":12223},[90],[1497],[1511,2306,2308],{"trials":12225,"activeCount":100},[],{"trials":12227,"activeCount":100},[],{"trials":12229,"activeCount":100},[12230],{"nctId":12231,"briefTitle":12232,"status":139,"phases":12233,"primaryCompletion":1506,"completion":12234,"start":902,"enrollment":12235,"conditions":12236,"interventions":12238},"NCT00897273","Oral HPV Infection in Young Men",[],"2009-05-05",500,[36,12237,5598],"Infection",[2459,2306],{"intervention":2327,"totalTrials":224,"cells":12240},{"EARLY_PHASE1":12241,"PHASE1":12243,"PHASE2":12249,"PHASE3":12251,"PHASE4":12253,"NA":12255},{"trials":12242,"activeCount":100},[],{"trials":12244,"activeCount":100},[12245],{"nctId":2319,"briefTitle":2320,"status":139,"phases":12246,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":266,"conditions":12247,"interventions":12248},[89],[24],[2265,2326,2327,2306,2307,2328],{"trials":12250,"activeCount":100},[],{"trials":12252,"activeCount":100},[],{"trials":12254,"activeCount":100},[],{"trials":12256,"activeCount":100},[12257,12261],{"nctId":4348,"briefTitle":4349,"status":139,"phases":12258,"primaryCompletion":518,"completion":4351,"start":3200,"enrollment":28,"conditions":12259,"interventions":12260},[],[18],[4354,4329,2327,4355],{"nctId":12262,"briefTitle":12263,"status":139,"phases":12264,"primaryCompletion":5404,"completion":5918,"start":3062,"enrollment":12265,"conditions":12266,"interventions":12267},"NCT00899548","DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer",[],182,[18],[2327,12268,12269],"microarray analysis","polymerase chain reaction",{"intervention":2307,"totalTrials":224,"cells":12271},{"EARLY_PHASE1":12272,"PHASE1":12274,"PHASE2":12284,"PHASE3":12286,"PHASE4":12288,"NA":12290},{"trials":12273,"activeCount":100},[],{"trials":12275,"activeCount":100},[12276,12280],{"nctId":2299,"briefTitle":2300,"status":139,"phases":12277,"primaryCompletion":2046,"start":2302,"enrollment":1280,"conditions":12278,"interventions":12279},[89],[24],[2305,2265,2306,2307,2308],{"nctId":2319,"briefTitle":2320,"status":139,"phases":12281,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":266,"conditions":12282,"interventions":12283},[89],[24],[2265,2326,2327,2306,2307,2328],{"trials":12285,"activeCount":100},[],{"trials":12287,"activeCount":100},[],{"trials":12289,"activeCount":100},[],{"trials":12291,"activeCount":100},[12292],{"nctId":12293,"briefTitle":12294,"status":139,"phases":12295,"primaryCompletion":395,"completion":395,"start":6054,"enrollment":1280,"conditions":12296,"interventions":12297},"NCT00899756","Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer",[],[1497],[12298,2307],"molecular diagnostic method",{"intervention":12300,"totalTrials":733,"cells":12301},"graft versus host disease prophylaxis\u002Ftherapy",{"EARLY_PHASE1":12302,"PHASE1":12304,"PHASE2":12306,"PHASE3":12308,"PHASE4":12318,"NA":12320},{"trials":12303,"activeCount":100},[],{"trials":12305,"activeCount":100},[],{"trials":12307,"activeCount":100},[],{"trials":12309,"activeCount":100},[12310],{"nctId":12311,"briefTitle":12312,"status":139,"phases":12313,"primaryCompletion":1505,"completion":1505,"start":12314,"enrollment":12315,"conditions":12316,"interventions":12317},"NCT00265837","Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer",[91],"2002-12",72,[796,27,30,754,33,711],[12300],{"trials":12319,"activeCount":100},[],{"trials":12321,"activeCount":100},[12322],{"nctId":12323,"briefTitle":12324,"status":139,"phases":12325,"primaryCompletion":1278,"completion":1278,"start":12326,"conditions":12327,"interventions":12328},"NCT00003538","Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation",[93],"1997-03",[648],[12300],{"intervention":4354,"totalTrials":733,"cells":12330},{"EARLY_PHASE1":12331,"PHASE1":12333,"PHASE2":12335,"PHASE3":12337,"PHASE4":12339,"NA":12341},{"trials":12332,"activeCount":100},[],{"trials":12334,"activeCount":100},[],{"trials":12336,"activeCount":100},[],{"trials":12338,"activeCount":100},[],{"trials":12340,"activeCount":100},[],{"trials":12342,"activeCount":100},[12343,12347],{"nctId":4348,"briefTitle":4349,"status":139,"phases":12344,"primaryCompletion":518,"completion":4351,"start":3200,"enrollment":28,"conditions":12345,"interventions":12346},[],[18],[4354,4329,2327,4355],{"nctId":12348,"briefTitle":12349,"status":139,"phases":12350,"primaryCompletion":12351,"completion":12351,"start":2150,"enrollment":1797,"conditions":12352,"interventions":12353},"NCT01478854","Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide",[93],"2018-04-25",[227],[12354],"Chemotherapy",{"intervention":12268,"totalTrials":733,"cells":12356},{"EARLY_PHASE1":12357,"PHASE1":12359,"PHASE2":12361,"PHASE3":12363,"PHASE4":12365,"NA":12367},{"trials":12358,"activeCount":100},[],{"trials":12360,"activeCount":100},[],{"trials":12362,"activeCount":100},[],{"trials":12364,"activeCount":100},[],{"trials":12366,"activeCount":100},[],{"trials":12368,"activeCount":100},[12369,12378],{"nctId":12370,"briefTitle":12371,"status":139,"phases":12372,"primaryCompletion":2046,"completion":2046,"start":2047,"enrollment":12373,"conditions":12374,"interventions":12375},"NCT00095589","Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer",[],125,[1334],[12376,12268,12377],"loss of heterozygosity analysis","microsatellite instability analysis",{"nctId":12262,"briefTitle":12263,"status":139,"phases":12379,"primaryCompletion":5404,"completion":5918,"start":3062,"enrollment":12265,"conditions":12380,"interventions":12381},[],[18],[2327,12268,12269],{"intervention":2459,"totalTrials":733,"cells":12383},{"EARLY_PHASE1":12384,"PHASE1":12386,"PHASE2":12388,"PHASE3":12390,"PHASE4":12392,"NA":12394},{"trials":12385,"activeCount":100},[],{"trials":12387,"activeCount":100},[],{"trials":12389,"activeCount":100},[],{"trials":12391,"activeCount":100},[],{"trials":12393,"activeCount":100},[],{"trials":12395,"activeCount":100},[12396,12400],{"nctId":2450,"briefTitle":2451,"status":219,"phases":12397,"primaryCompletion":2453,"completion":2454,"start":2455,"enrollment":1655,"conditions":12398,"interventions":12399},[],[24,2457],[2265,2459,2460],{"nctId":12231,"briefTitle":12232,"status":139,"phases":12401,"primaryCompletion":1506,"completion":12234,"start":902,"enrollment":12235,"conditions":12402,"interventions":12403},[],[36,12237,5598],[2459,2306],{"intervention":4355,"totalTrials":1156,"cells":12405},{"EARLY_PHASE1":12406,"PHASE1":12408,"PHASE2":12410,"PHASE3":12412,"PHASE4":12414,"NA":12416},{"trials":12407,"activeCount":100},[],{"trials":12409,"activeCount":100},[],{"trials":12411,"activeCount":100},[],{"trials":12413,"activeCount":100},[],{"trials":12415,"activeCount":100},[],{"trials":12417,"activeCount":100},[12418],{"nctId":4348,"briefTitle":4349,"status":139,"phases":12419,"primaryCompletion":518,"completion":4351,"start":3200,"enrollment":28,"conditions":12420,"interventions":12421},[],[18],[4354,4329,2327,4355],{"intervention":12423,"totalTrials":1156,"cells":12424},"Disulfiram",{"EARLY_PHASE1":12425,"PHASE1":12427,"PHASE2":12429,"PHASE3":12431,"PHASE4":12433,"NA":12435},{"trials":12426,"activeCount":100},[],{"trials":12428,"activeCount":100},[],{"trials":12430,"activeCount":100},[],{"trials":12432,"activeCount":100},[],{"trials":12434,"activeCount":100},[],{"trials":12436,"activeCount":100},[12437],{"nctId":12438,"briefTitle":12439,"status":139,"phases":12440,"primaryCompletion":12441,"completion":12441,"start":12442,"enrollment":34,"conditions":12443,"interventions":12444},"NCT01118741","Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)",[93],"2012-06","2010-05",[15],[12423],{"intervention":12446,"totalTrials":1156,"cells":12447},"X-PACT",{"EARLY_PHASE1":12448,"PHASE1":12450,"PHASE2":12452,"PHASE3":12454,"PHASE4":12456,"NA":12458},{"trials":12449,"activeCount":100},[],{"trials":12451,"activeCount":100},[],{"trials":12453,"activeCount":100},[],{"trials":12455,"activeCount":100},[],{"trials":12457,"activeCount":100},[],{"trials":12459,"activeCount":100},[12460],{"nctId":12461,"briefTitle":12462,"status":12463,"phases":12464,"conditions":12465,"interventions":12466},"NCT06836648","Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer","AVAILABLE",[],[15],[12446],{"intervention":12376,"totalTrials":1156,"cells":12468},{"EARLY_PHASE1":12469,"PHASE1":12471,"PHASE2":12473,"PHASE3":12475,"PHASE4":12477,"NA":12479},{"trials":12470,"activeCount":100},[],{"trials":12472,"activeCount":100},[],{"trials":12474,"activeCount":100},[],{"trials":12476,"activeCount":100},[],{"trials":12478,"activeCount":100},[],{"trials":12480,"activeCount":100},[12481],{"nctId":12370,"briefTitle":12371,"status":139,"phases":12482,"primaryCompletion":2046,"completion":2046,"start":2047,"enrollment":12373,"conditions":12483,"interventions":12484},[],[1334],[12376,12268,12377],{"intervention":12377,"totalTrials":1156,"cells":12486},{"EARLY_PHASE1":12487,"PHASE1":12489,"PHASE2":12491,"PHASE3":12493,"PHASE4":12495,"NA":12497},{"trials":12488,"activeCount":100},[],{"trials":12490,"activeCount":100},[],{"trials":12492,"activeCount":100},[],{"trials":12494,"activeCount":100},[],{"trials":12496,"activeCount":100},[],{"trials":12498,"activeCount":100},[12499],{"nctId":12370,"briefTitle":12371,"status":139,"phases":12500,"primaryCompletion":2046,"completion":2046,"start":2047,"enrollment":12373,"conditions":12501,"interventions":12502},[],[1334],[12376,12268,12377],{"intervention":12504,"totalTrials":1156,"cells":12505},"gadobenate dimeglumine",{"EARLY_PHASE1":12506,"PHASE1":12508,"PHASE2":12510,"PHASE3":12512,"PHASE4":12514,"NA":12516},{"trials":12507,"activeCount":100},[],{"trials":12509,"activeCount":100},[],{"trials":12511,"activeCount":100},[],{"trials":12513,"activeCount":100},[],{"trials":12515,"activeCount":100},[],{"trials":12517,"activeCount":100},[12518],{"nctId":12519,"briefTitle":12520,"status":139,"phases":12521,"primaryCompletion":1683,"completion":4351,"start":1880,"enrollment":241,"conditions":12522,"interventions":12523},"NCT00539253","Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.",[93],[192],[12504],{"intervention":4252,"totalTrials":1156,"cells":12525},{"EARLY_PHASE1":12526,"PHASE1":12528,"PHASE2":12530,"PHASE3":12532,"PHASE4":12534,"NA":12536},{"trials":12527,"activeCount":100},[],{"trials":12529,"activeCount":100},[],{"trials":12531,"activeCount":100},[],{"trials":12533,"activeCount":100},[],{"trials":12535,"activeCount":100},[],{"trials":12537,"activeCount":100},[12538],{"nctId":4247,"briefTitle":4248,"status":139,"phases":12539,"primaryCompletion":3199,"completion":3199,"start":1528,"enrollment":37,"conditions":12540,"interventions":12541},[93],[15],[4252,896],{"intervention":12543,"totalTrials":1156,"cells":12544},"Reference ultrasound",{"EARLY_PHASE1":12545,"PHASE1":12547,"PHASE2":12549,"PHASE3":12551,"PHASE4":12553,"NA":12555},{"trials":12546,"activeCount":100},[],{"trials":12548,"activeCount":100},[],{"trials":12550,"activeCount":100},[],{"trials":12552,"activeCount":100},[],{"trials":12554,"activeCount":100},[],{"trials":12556,"activeCount":100},[12557],{"nctId":12558,"briefTitle":12559,"status":219,"phases":12560,"primaryCompletion":12561,"completion":12561,"start":10174,"enrollment":733,"conditions":12562,"interventions":12563},"NCT02722616","Ultrasound Monitoring of Abdominal Soft Tissue",[93],"2022-10-28",[21,817],[12543],{"intervention":12565,"totalTrials":1156,"cells":12566},"18F DCFPyL- Radiopharmaceutica",{"EARLY_PHASE1":12567,"PHASE1":12569,"PHASE2":12571,"PHASE3":12573,"PHASE4":12575,"NA":12577},{"trials":12568,"activeCount":100},[],{"trials":12570,"activeCount":100},[],{"trials":12572,"activeCount":100},[],{"trials":12574,"activeCount":100},[],{"trials":12576,"activeCount":100},[],{"trials":12578,"activeCount":100},[12579],{"nctId":12580,"briefTitle":12581,"status":139,"phases":12582,"primaryCompletion":4283,"completion":4283,"start":12583,"enrollment":12584,"conditions":12585,"interventions":12586},"NCT02825875","Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer",[],"2016-06-08",200,[15],[12565],{"intervention":12588,"totalTrials":1156,"cells":12589},"18F DCFPyL- Radiopharmaceutical",{"EARLY_PHASE1":12590,"PHASE1":12592,"PHASE2":12594,"PHASE3":12596,"PHASE4":12598,"NA":12600},{"trials":12591,"activeCount":100},[],{"trials":12593,"activeCount":100},[],{"trials":12595,"activeCount":100},[],{"trials":12597,"activeCount":100},[],{"trials":12599,"activeCount":100},[],{"trials":12601,"activeCount":100},[12602],{"nctId":12603,"briefTitle":12604,"status":139,"phases":12605,"primaryCompletion":12606,"completion":12607,"start":12608,"enrollment":848,"conditions":12609,"interventions":12610},"NCT02856100","Comparison of PSMA-based 18F-DCFPyL PET\u002FCT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer",[],"2019-01","2020-01","2016-08-03",[15],[12588],{"intervention":12612,"totalTrials":1156,"cells":12613},"Lovastatin",{"EARLY_PHASE1":12614,"PHASE1":12616,"PHASE2":12618,"PHASE3":12620,"PHASE4":12622,"NA":12624},{"trials":12615,"activeCount":100},[],{"trials":12617,"activeCount":100},[],{"trials":12619,"activeCount":100},[],{"trials":12621,"activeCount":100},[],{"trials":12623,"activeCount":100},[],{"trials":12625,"activeCount":100},[12626],{"nctId":12627,"briefTitle":12628,"status":219,"phases":12629,"primaryCompletion":12630,"completion":12630,"start":12631,"enrollment":733,"conditions":12632,"interventions":12633},"NCT01478828","Pre-Prostatectomy Lovastatin on Prostate Cancer",[93],"2013-04-08","2012-07-13",[15],[12612],{"intervention":12298,"totalTrials":1156,"cells":12635},{"EARLY_PHASE1":12636,"PHASE1":12638,"PHASE2":12640,"PHASE3":12642,"PHASE4":12644,"NA":12646},{"trials":12637,"activeCount":100},[],{"trials":12639,"activeCount":100},[],{"trials":12641,"activeCount":100},[],{"trials":12643,"activeCount":100},[],{"trials":12645,"activeCount":100},[],{"trials":12647,"activeCount":100},[12648],{"nctId":12293,"briefTitle":12294,"status":139,"phases":12649,"primaryCompletion":395,"completion":395,"start":6054,"enrollment":1280,"conditions":12650,"interventions":12651},[],[1497],[12298,2307],{"intervention":12653,"totalTrials":1156,"cells":12654},"testosterone gel applied to skin",{"EARLY_PHASE1":12655,"PHASE1":12657,"PHASE2":12659,"PHASE3":12661,"PHASE4":12663,"NA":12665},{"trials":12656,"activeCount":100},[],{"trials":12658,"activeCount":100},[],{"trials":12660,"activeCount":100},[],{"trials":12662,"activeCount":100},[],{"trials":12664,"activeCount":100},[],{"trials":12666,"activeCount":100},[12667],{"nctId":12668,"briefTitle":12669,"status":219,"phases":12670,"primaryCompletion":3211,"completion":3211,"start":9816,"enrollment":1156,"conditions":12671,"interventions":12673},"NCT00631137","Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma",[93],[24,12672],"Musculoskeletal Complications",[12653],{"intervention":12269,"totalTrials":1156,"cells":12675},{"EARLY_PHASE1":12676,"PHASE1":12678,"PHASE2":12680,"PHASE3":12682,"PHASE4":12684,"NA":12686},{"trials":12677,"activeCount":100},[],{"trials":12679,"activeCount":100},[],{"trials":12681,"activeCount":100},[],{"trials":12683,"activeCount":100},[],{"trials":12685,"activeCount":100},[],{"trials":12687,"activeCount":100},[12688],{"nctId":12262,"briefTitle":12263,"status":139,"phases":12689,"primaryCompletion":5404,"completion":5918,"start":3062,"enrollment":12265,"conditions":12690,"interventions":12691},[],[18],[2327,12268,12269],{"intervention":12693,"totalTrials":1156,"cells":12694},"morphine sulfate",{"EARLY_PHASE1":12695,"PHASE1":12697,"PHASE2":12699,"PHASE3":12701,"PHASE4":12703,"NA":12705},{"trials":12696,"activeCount":100},[],{"trials":12698,"activeCount":100},[],{"trials":12700,"activeCount":100},[],{"trials":12702,"activeCount":100},[],{"trials":12704,"activeCount":100},[],{"trials":12706,"activeCount":100},[12707],{"nctId":12708,"briefTitle":12709,"status":219,"phases":12710,"primaryCompletion":1458,"completion":1458,"start":659,"enrollment":1156,"conditions":12711,"interventions":12712},"NCT00660348","Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer",[93],[5283,21],[12693],{"intervention":12714,"totalTrials":1156,"cells":12715},"fentanyl citrate",{"EARLY_PHASE1":12716,"PHASE1":12718,"PHASE2":12720,"PHASE3":12722,"PHASE4":12724,"NA":12726},{"trials":12717,"activeCount":100},[],{"trials":12719,"activeCount":100},[],{"trials":12721,"activeCount":100},[],{"trials":12723,"activeCount":100},[],{"trials":12725,"activeCount":100},[],{"trials":12727,"activeCount":100},[12728],{"nctId":12729,"briefTitle":12730,"status":219,"phases":12731,"primaryCompletion":1076,"completion":1076,"start":7214,"enrollment":733,"conditions":12732,"interventions":12734},"NCT00899951","Studying Fentanyl in Patients With Cancer",[],[24,745,27,30,10622,754,33,12733,5283,5598,4913],"Myelodysplastic\u002FMyeloproliferative Neoplasms",[12714],{"intervention":12736,"totalTrials":1156,"cells":12737},"Paroxetine controlled-release",{"EARLY_PHASE1":12738,"PHASE1":12740,"PHASE2":12742,"PHASE3":12744,"PHASE4":12746,"NA":12748},{"trials":12739,"activeCount":100},[],{"trials":12741,"activeCount":100},[],{"trials":12743,"activeCount":100},[],{"trials":12745,"activeCount":100},[],{"trials":12747,"activeCount":100},[],{"trials":12749,"activeCount":100},[12750],{"nctId":12751,"briefTitle":12752,"status":219,"phases":12753,"primaryCompletion":5865,"completion":12754,"start":688,"enrollment":1609,"conditions":12755,"interventions":12757},"NCT00249847","Study of PET Scans and Serotonin in Hot Flashes Treatment",[93],"2008-04",[12756],"Hot Flashes",[12736,12758],"Conjugated equine estrogen",{"intervention":12758,"totalTrials":1156,"cells":12760},{"EARLY_PHASE1":12761,"PHASE1":12763,"PHASE2":12765,"PHASE3":12767,"PHASE4":12769,"NA":12771},{"trials":12762,"activeCount":100},[],{"trials":12764,"activeCount":100},[],{"trials":12766,"activeCount":100},[],{"trials":12768,"activeCount":100},[],{"trials":12770,"activeCount":100},[],{"trials":12772,"activeCount":100},[12773],{"nctId":12751,"briefTitle":12752,"status":219,"phases":12774,"primaryCompletion":5865,"completion":12754,"start":688,"enrollment":1609,"conditions":12775,"interventions":12776},[93],[12756],[12736,12758],{"intervention":2460,"totalTrials":1156,"cells":12778},{"EARLY_PHASE1":12779,"PHASE1":12781,"PHASE2":12783,"PHASE3":12785,"PHASE4":12787,"NA":12789},{"trials":12780,"activeCount":100},[],{"trials":12782,"activeCount":100},[],{"trials":12784,"activeCount":100},[],{"trials":12786,"activeCount":100},[],{"trials":12788,"activeCount":100},[],{"trials":12790,"activeCount":100},[12791],{"nctId":2450,"briefTitle":2451,"status":219,"phases":12792,"primaryCompletion":2453,"completion":2454,"start":2455,"enrollment":1655,"conditions":12793,"interventions":12794},[],[24,2457],[2265,2459,2460],{"intervention":1423,"totalTrials":1156,"cells":12796},{"EARLY_PHASE1":12797,"PHASE1":12799,"PHASE2":12801,"PHASE3":12803,"PHASE4":12805,"NA":12807},{"trials":12798,"activeCount":100},[],{"trials":12800,"activeCount":100},[],{"trials":12802,"activeCount":100},[],{"trials":12804,"activeCount":100},[],{"trials":12806,"activeCount":100},[],{"trials":12808,"activeCount":100},[12809],{"nctId":1415,"briefTitle":1416,"status":139,"phases":12810,"primaryCompletion":1418,"completion":1418,"start":1419,"enrollment":969,"conditions":12811,"interventions":12812},[93],[1421],[1423,580]]